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Abstract 
 
Green Synthesis, Biodegradation and Antimicrobial Studies of Ionic Liquids and Their 
Applications in Surfactant Technology 
 
By Andrew Jordan BSc. (Hons) 
 
A series of L-phenylalanine and L-tyrosine ionic liquids (ILs) and tertiary amino analogues have 
been synthesised according to the 12 principles of green chemistry and a benign by design 
concept. The series of ILs are derived from amino acid ethyl esters and a variety of different 
quaternary nitrogen headgroups have been used to give the series of ILs disclosed within. The 
green chemistry metrics have been calculated for a number of the compounds within and give 
insight into the chosen synthetic methodologies potential environmental footprint and how 
improvements to the synthesis pathways may be conducted in the future. 
 
The ILs and tertiary amino compounds have been evaluated for their antimicrobial toxicity in 
collaboration with Dr. Marcel Špulák in Charles University, Czech Republic. A panel of 12 
fungi, 4 gram positive bacteria and 4 gram negative bacteria were used to investigate the 
antimicrobial toxicity of the ILs. The ILs examined showed generally a low antimicrobial 
toxicity whilst the tertiary amino compounds derived from proline appeared overall to be more 
toxic towards both bacteria and fungi. 
 
The biodegradability of the L-phenylalanine and tertiary amino compounds was examined in 
collaboration with Prof. Klaus Kümmerer in Leuphana University of Lüneberg, Germany. The 
test employed was the closed bottle test and a mineraliseable pyridinium derived IL was 
discovered. Furthermore the metabolic products produced from the biodegradation test were 
identified by LCMS/MS and the potential breakdown pathways of the ILs has been proposed. 
Synthesis of the metabolic products was undertaken and further biodegradation and 
antimicrobial evaluation of these metabolites is ongoing. 
 
The information derived from these studies has led to the synthesis of a second generation of 
linear alkyl and bolaform ILs. The 2
nd
 generation of ILs have been assessed for their green 
chemistry metrics, surfactant properties as well as their antimicrobial toxicity and 
biodegradability. The 2
nd
 generation of ILs synthesised were found to possess favourable 
surface active properties and a broad spectrum antimicrobial activity and moderate to poor 
biodegradability.  
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1.1 Introduction 
Are ionic liquids (ILs) green? Do IL based technologies offer an advantage over current best 
practice? What performance and green chemistry metrics are used to substantiate these claims? 
These are questions frequently asked to research groups that promote ILs as a preferred solution 
to existing problems. Indeed, any new methodology which considers green chemistry principles 
as core values, should undergo the same rigorous critique and debate. This chapter does not 
assess the merits of using ILs but rather focuses on one property, biodegradability. The use of 
persistent or non-biodegradable chemicals, especially as solvents, should be avoided, where 
suitable biodegradable alternatives exist. This chapter details the progress made by the IL 
community in their endeavours to invent biodegradable compounds. In the field of ILs, 
substantial efforts to evaluate the biodegradation properties of a wide range of derivatives has 
been expended. This data can be included in the overall evaluation and selection of a specific IL 
for an application. Over the last 15 years various terms have been used to define ILs and their 
properties; <100 °C m.p., non-volatile, robust, inert, stable to a wide electrochemical window 
are just a few. Of concern is the apparent „desirable‟ stability, or resistance to breakdown, 
especially when initiating a research program to develop biodegradable ILs. However, as we 
delve more deeply into this fascinating research area, exceptions to these previously widely 
adopted “classifications” have been found, for example, the negligible vapour pressure has been 
challenged by Rebelo et al. (2005)
2
,  and Earle and Seddon et al. (2006)
3
 in which distillation of 
ILs with minimal decomposition was demonstrated. The non-flammability property has also 
been questioned as some ILs have been reported by Rogers et al. (2006) as being Class IIIB 
combustible materials.
4
 The question must be asked: „Is it possible to design an IL which is 
stable to a wide range of thermal and chemical conditions yet also biodegrades?‟ Can this, at 
first inspection, apparently mutually exclusive conundrum be solved? 
 
Although ILs have been known for over 100 years, it has only been in recent times that chemists 
have studied their biodegradation in detail. Many papers credit Walden (1914)
5
 or some go even 
further back to Gabriel and Weiner (1888)
6
 with their reported synthesis of ethylammonium 
nitrate (1), Figure 1.1. However the first conventional example the author could find of an 
imidazolium IL goes back even further to 1881 with the synthesis of 1-methyl-3-
methylimidazolium iodide (2) by Goldschmidt ,
7
 see Figure 1.2. Biodegradation studies as part 
of the characterisation of these ILs would have been unheard of in those times. 
 
3 
 
 
Figure 1.1. One of the first ILs, ethylammonium nitrate. 
  
Figure 1.2. 1-Methyl-3-methylimidazolium iodide 
It is our ability to update the definitions, to reclassify and to reinvent design strategy that will 
underpin continuing success in the field of IL research. Guidelines that have steered the field of 
IL research over the past two decades have been defined by landmark works such as the creation 
of the twelve principles of green chemistry by Anastas and Warner.
8
 Other examples of 
concepts that promote cleaner synthesis are atom economy (AE) by Trost,
9
 Sheldon's E-
Factor,
10
 and the Andraos reaction mass efficiency (RME).
11
  It is by implementing these 
principles that green chemists strive to develop their target molecules, monitoring their progress 
using green chemistry metrics. However, clean synthesis is not the only area that needs stringent 
protocols in the green chemistry research process. What happens to the molecules when they are 
ultimately released into the environment is also of paramount importance. The parameters of 
biodegradability, toxicity – and recently mutagenicity12 - are becoming more significant.  
 
Wider adoption of ILs by industry and in academia, e.g. BASIL process 
(Biphasic Acid Scavenging utilising Ionic Liquids), biomass dissolution,
13
 metal salt 
dissolution,
14
 lubrication,
15
 surfactants,
16, 17
 catalysts,
18-20
 reaction solvent,
21
 has been observed. 
Over the past decade the potential for (large scale?) accidental release of ILs has become a 
possibility, thus environmental impact studies, including biodegradation are of increasing 
importance. 
The aim of this chapter is to illustrate the advances, successes and problems encountered in the 
field of biodegradation of IL research since the preceding publication by Coleman and 
Gathergood which covered the literature up to 2010.
22
 
 
 
 
 
4 
 
1.2 Biodegradation - The 10th principle of green chemistry 
 
Are biodegradation studies important in the context of green chemistry and ILs? Biodegradation 
is one method of analysis to determine and predict how a molecule (e.g. IL) interacts with the 
environment. The overarching aim is to avoid the introduction of persistent molecules including 
persistent organic pollutants (POPs) into the environment. The issue of environmental 
persistence of chemicals (including surfactants, antibiotics and solvents), once they have 
fulfilled their desired application, has been widely studied with detrimental effects on 
ecosystems observed.
23
 Environmental damage ranges from endocrine disruptors against fish
24
 
to proliferation of bacterial resistance towards important active pharmaceutical ingredients 
(APIs).
25
 Biodegradation is an essential parameter to investigate in ILs, enabling the design of 
safer analogues where required and reducing environmentally persistent molecules in 
ecosystems. In 1998, Anastas and Warner highlighted the importance of biodegradation studies 
for chemists, selecting this as their 10th Principle of Green Chemistry - Design for 
Degradation.
8
 
 
Design strategies to improve the biodegradability of compounds predate Anastas and Warner‟s 
green chemistry principles. Seminal work by Boethling et al.
26, 27
 includes the highly cited "rules 
of thumb" which relates structural features and functional groups to biodegradation properties. 
These rules have been adopted and applied to IL research over the last decade.
22
 Boethling's 
“rules of thumb” propose that a number of factors affect the percentage of mineralisation of 
chemical compounds by microbial degradation. Beneficial factors include: the presence of 
aromatic rings, long unbranched alkyl chains, and hydrolysable groups such as alcohols, 
aldehydes and carboxylic acids.
26, 27
 Factors that are detrimental to biodegradation include the 
presence of halides in the molecule, alkyl chain branching, quaternary carbon atoms, tertiary 
nitrogen atoms, heterocycles and aliphatic ethers. These “rules of thumb” are not absolutes, 
indeed caution must be exercised when applying these rules in the absence of biodegradation 
data of closely related structures and they only suggest general trends in biodegradation 
pathways, as clearly stated by Boethling in his work.
26, 27
 
 
Early generations of ILs, such as the frequently quoted second generation ILs, the butyl-
methylimidazolium [bmim] class, Figure 1.3, were designed to be robust, liquid at room 
temperature (RT) and inert to a range of chemical conditions thus enabling a broad applicability. 
For example, the [bmim] series was envisaged as a replacement for  VOC electrolytes due to 
their inherent electrostability, large electrochemical window,
28
 thermal stability,
29
 low vapour 
pressure and low/non-flammability.
30
 Applications of these stable and low vapour pressure 
5 
 
replacements for electrolytes have been demonstrated in batteries and capacitors.
31
 However, it 
is this lack of reactivity that lead to concern that the molecules could be recalcitrant to 
biodegradation, with limited breakdown in the environment.
22
  Consideration of Boethling‟s 
“rules of thumb” also suggests poor biodegradability for these classes of ILs and biodegradation 
data to confirm the suspicions about this class of compounds was lacking as we entered the new 
millennium. As biodegradation data for [bmim] ILs began to be experimentally determined, it 
was found to be in agreement with predictions based on Boethling‟s work. [Bmim][BF4] (3), 
amongst other early examples of 1-methylimidazolium ILs, did not pass readily biodegradable 
tests, demonstrating the urgent requirement for further work and advances in this area.
21, 32, 33
 
 
 
Figure 1.3. [bmim] ILs 
Recent studies conducted by Mao et al. further highlight the importance of environmental 
studies associated with the second generation of ILs, when [bmim][PF6], Figure 1.3, (4) was 
shown to proliferate and disseminate antibacterial resistance genes in environmental bacteria, 
emphasising the need for biodegradability to be a key requirement in future IL generations.
34
 
  
1.2.1 Biodegradation – standardised tests 
 
The following section provides an overview of the biodegradation tests which are of interest and 
available to IL researchers. The research area of biodegradation is categorised into the following 
terms: 
 
1. Primary biodegradation – the loss of a specific structural moiety, example hydrolysis 
of an ester bond 
2. Inherently biodegradable - if a compound biodegrades ~20%, then the possibility of 
further degradation is assumed 
3. Readily biodegradable - biodegrades a specific % within a given time frame 
4. Ultimately biodegradable - complete breakdown of a compound 
5. Mineralisation -  decomposition of a compound into molecules available to plants 35 
 
6 
 
According to the Organisation of Economic Co-Operation and Development (OECD) and the 
International Organisation for Standardisation (ISO), there are a number of accepted methods 
that, if implemented correctly, will provide definitive biodegradation data. 
35
  
The testing strategy suggested by the OECD is thus:  
1. Examine the aerobic biodegradation to assess if a chemical is readily biodegradable. 
2. If a test for readily biodegradable is failed, then the chemical of interest can be 
examined by other simulation tests (optimised aerobic conditions representing 
conditions potentially found in a sewage treatment plant) to determine biodegradability. 
An inherent biodegradability test can also be performed. 
3. Finally, potential biodegradability can be determined under anaerobic conditions. 35 
 
 The test methods currently supported by the OECD and are as follows: 
35, 36
 
 
1.2.1.1 Fresh water 
Table 1.1. OECD testing guidelines No. 301 
Test Pass Level after 28 Days 
Dissolved Organic Carbon (DOC) Die-Away Test (TG 301A) 70% DOC removal 
CO2 Evolution Test (TG 301B) 60% ThCO2 
Modified MITI Test (I) (TG 301 C) 60% ThOD 
Closed Bottle Test (CBT) (TG 301D) 
ISO 10708* 
60% ThOD 
Modified OECD Screening Test (TG 301E) 70% DOC removal 
Manometric Respirometry Test (TG 301F) 60% ThOD 
 
Note: These pass levels must be achieved within a ten day window within the 28 day test limit. 
The ten day window begins once 10% DOC (Dissolved Organic Carbon), ThCO2 (Theoretical 
CO2) or ThOD (Theoretical Oxygen Demand) has been achieved. 
*The ten day window is not applied for ISO 10708. 
 
Due to the increased size of the oxygen reservoir in the setup of the ISO 10708 bottle compared 
to the method described by the OECD 301D, Table 1.1, a higher test substance concentration 
can be used in the ISO 10708 test as the amount of oxygen in the bottle is less of a limiting 
factor.
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Table 1.2. OECD testing guidelines No. 310 
Test Pass Level after 28 Days 
CO2 headspace test (OECD 310) 
ISO 14593* 
60% ThCO2 evolution 
*The ten day window is not applied for ISO 14593. 
1.2.1.2 Inherent biodegradation 
Table 1.3. OECD testing guidelines No. 302 
Test Pass Level 
Modified Semi-Continuous Activated Sludge (SCAS) 
Test (TG 302A) 
BOD, DOC and/or COD; No pass 
levels assigned 
Zahn-Wellens/EMPA* Test (TG 302B), 
BOD, DOC and/or COD; No pass 
levels assigned 
Modified MITI** Test (II) (TG 302C) 
BOD, DOC and/or COD; No pass 
levels assigned 
Concawe Test (draft TG 302D) 
 
BOD, DOC and/or COD; No pass 
levels assigned 
 
Unlike the readily biodegradable tests described previously in Table 1.1, (OECD 301A-D), the 
inherent biodegradation test has no pass/fail parameters, Table 1.3. If biodegradation is 
measured to be above 20% biochemical oxygen demand (BOD) or chemical oxygen demand 
(COD) or dissolved organic carbon (DOC) then it can be assumed that a chemical can 
inherently undergo primary biodegradation. If biodegradation of more than 70% is achieved, 
then it is possible that a chemical is inherently capable of undergoing ultimate biodegradation. 
 
*EMPA: Swiss Federal Laboratories for Materials Testing and Research. 
**MITI: Ministry of International Trade and Industry, Japan 
1.2.1.3 Aerobic sewage - simulation tests 
Table 1.4. OECD testing guidelines No. 303 
Test Pass Level after 28 Days 
Aerobic Sewage Treatment: Activated Sludge 
Units (TG 303A) and Biofilms (TG 
303B). 
DOC and/or COD No pass levels assigned 
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Similar to OECD 302, using a sewage treatment plant simulation test OECD 303, Table 1.4, no 
specific limits for pass/fail have been prescribed. This is because the specific operating 
conditions of every treatment plant are different. The test does however provide an estimate for 
potential removal of a chemical compound in a sewage treatment plant, thus the quantity of 
compound that can be released into the environment post treatment can be assessed. 
 
1.2.1.4 Seawater 
Table 1.5. OECD testing guidelines No. 306 
Test Pass Level after 28 Days 
Biodegradability in Seawater (TG 306) 
Shake flask and closed bottle variants 
>70% DOC removal >60% ThOD 
 
The biodegradation in seawater test OECD 306, Table 1.5, differs from the standard 301 tests in 
that the only microorganisms present are those found naturally in the seawater test media. The 
flask is not charged with additional inocula, although it is supplemented with nutrients. This test 
is not intended to represent a marine environment, but rather assess biodegradation in seawater 
media. 
1.2.1.5 Soil, sediment and water 
Table 1.6. OECD testing guidelines No. 307-309 
Test Test duration and parameters 
Aerobic and Anaerobic Transformation in Soil 
(TG 307) 
>120 days testing period - Radio labelled 
and unlabelled compounds can be used 
Aerobic and Anaerobic Transformation in 
Aquatic Sediment Systems (TG 308) 
<100 days testing period - Radio labelled 
and unlabelled compounds can be used 
Aerobic Mineralisation in Surface Water – 
Simulation Biodegradation Test (TG 309) 
<60 days testing period - Radio labelled and 
unlabelled compounds can be used 
 
Due to the inherent complexities of using a solid medium for biodegradation and the use of 
radio labelled atoms there are a number of parameters suggested by the OECD that can be used 
to monitor the fate of chemical compounds in a soil or sedimentary environment. 
 
 First order or pseudo-first order rate constant for biodegradation kinetics 
 Degradation half-life (DT50) 
 Half-saturation constant 
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 Maximum specific growth rate 
 Fraction of mineralised 14C, and, if specific analyses are used, the final level of primary 
degradation 
 Identification and concentration of major transformation products - if radio labelled 
compounds are used 
 
 
Table 1.7. Other non-OECD test guidelines for aerobic biodegradability of plastics in soil 
Test Test Parameters 
ASTM D 5988-96 
Standard Test Method for Determining 
Aerobic Biodegradation of Plastic Materials in 
Soil 
 
No pass or fail mark assigned - test method 
only.Degradation measured by CO2 present in 
a trapping solution by titration, over a 6 month 
period. 
 
ISO 17556: 
Determination of the Ultimate Aerobic 
Biodegradability of Plastic Materials in Soil 
by Measuring the Oxygen Demand in a 
Respirometer or the Amount of Carbon 
Dioxide Evolved 
Biodegradation can be determined by CO2 
evolution or O2 demand 
 
One other prescribed test for inherent biodegradation of chemical compounds in soil exists and 
this is the OECD TG 304A. The test however, requires the use of 
14
C labelled compounds. A 
sample of 
14
C treated compound is introduced into the test medium. The evolution of 
14
CO2 is 
then monitored using alkali absorption and a liquid scintillation counter. 
1.2.1.6 Anaerobic biodegradation 
Table 1.8. OECD testing guidelines No. 311 
Test Pass Level after 60 Days 
Anaerobic Biodegradability of Organic Compounds in 
Digested Sludge/Method by Measurement of Gas 
Production (TG 311). 
 
75-80% Theoretical gas evolution = 
complete anaerobic biodegradation 
 
The TG 311 test, Table 1.8, outlines a method of measuring biodegradability in an aerobic 
environment. However, TG311 is limited as it only assesses biodegradability in anaerobic 
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digesters and does not take into account other anaerobic biodegradation pathways possible in 
different environmental compartments. The test measures gas evolution with a band of 75-80% 
of theoretical gas production being used as a sign of complete anaerobic biodegradation. 
 
As can be seen from Tables 1.1-1.8, there exists a number of techniques for determining 
biodegradability with a wide breadth of conditions and scenarios covered. The test methods 
aforementioned are only approximations of the conditions that exist in the extremely complex 
and dynamic conditions present in WWTP‟s and the greater environment and can never truly 
simulate these conditions. However, if they are treated as tools with which to gain insight into 
the potential environmental breakdown of chemicals, then this information can be used as part 
of an environmental impact assessment as well as assisting in the rational design of future 
generations of chemicals. 
 
Currently a number of different methods have been employed to induce degradation (biotically 
and abiotically) in molecules, these include altering the temperature of the degradation vessel, 
inoculating the test media with a specific bacteria, degradation in an advanced oxidation 
system,
37
 degradation in an electrochemical system,
38, 39
 and ultrasonic degradation.
40
 The 
overall aim is to possibly develop a system for treating wastewater before release into the 
environment.  
1.2.1.7 Biodegradation metrics 
 
Currently biodegradation data is categorised by whether a compound passes or fails a test but 
more recently a visual traffic light metric system has been applied by Gathergood et al.
18
 to give 
a colour coded representation of how biodegradation levels compare.
18
 The levels of 
biodegradation are assigned a colour based on the following criteria: 
 Green: ≥60% readily biodegradable 
 Amber: 20–59% 
 Red: 0–19% 
 
This colour coding system allows for libraries of compounds to be compared and categorised 
visually and with ease. Examples of the system in use will be discussed later in this chapter. 
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1.2.2 Biodegradation in soil, compost and other matrices 
1.2.2.1 Biodegradation in soil 
 
Biodegradation of imidazolium-based ILs in soil has been previously reported by Modelli et al. 
41
 Four ILs [bmim][BF4] (3), [bmim][N(CN)2] (5), [MeOCH2CH2mim][BF4] (6) and 
[MeOCH2CH2mim][N(CN)2] (7), Figure 1.4,  were examined for their biodegradability 
according to the ASTM D 5988-96 protocol. In this protocol a pass/fail mark is not assigned and 
biodegradation is merely observed. Under the test conditions the test compound is mixed with 
soil and placed in a large glass vessel with CO2 evolution regularly measured. Soil can be a 
species rich mixture, but it is expected that the activity will be less than an activated sludge so 
the test is run over a 6 month period. In this particular study it was found that the linear alkyl 
[bmim][BF4] example, underwent degradation of 52.1 ± 6.6% with the N(CN)2 derivative being 
less biodegradable than the halide, producing 17.0 ± 4.2% degradation. The oxygenated 
[MeOCH2CH2mim] derivatives both failed to degrade, producing negligible biodegradation 
results of 0.1 ± 4.0%.  
 
Figure 1.4. Imidazolium ILs examined by Modelli et al.
41
 
1.2.2.2 Interactions with soil, compost and other matrices  
 
It is of concern that ILs could reach concentrations high enough in industrial waste water 
treatment plants (WWTPs) to affect their operating conditions. As outlined in a publication by 
Stolte et al. in 2013, it is believed that ILs will never reach a concentration significant enough to 
inhibit the bacteria in a domestic WWTP, however due to the toxic effects of some ILs, 
inhibitory effects on a WWTPs efficacy could be foreseen.
42
 Some ILs possess the ability to 
adsorb onto sewage flocs. This can actually be beneficial in a WWTP environment as it can 
potentially reduce the concentration of ILs in "solution" and therefore reduce the toxic 
inhibitory effects, if indeed the ILs are toxic.
43
 The ILs partition coefficient and adsorption 
coefficients however plays a further role in the ILs interaction with soil vide infra. Whether 
WWTPs treatments are enough to remove residual ionic compounds is also questionable as 
demonstrated by Gomez et al. in 2011 where ionic and non-ionic surfactant molecules in μg l-1 
concentrations were detected in drinking-water treatment plants, including plants with advanced 
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tertiary treatment plans.
44
  This observation poses the question of whether ILs will behave 
similarly due to their comparable structural features to ionic surfactants and further justifies the 
research employed in designing for degradation. Recent evidence for some 1-
methylimidazolium IL derivatives provided by Gendaszewska et al.
45
 demonstrated, using the 
OECD 302B test, the degree of adsorption of a number of ILs in an inoculum. It was observed 
that more lipophilic derivatives adsorbed to the inoculum (~3.5%) whereas the highly polar 
derivatives did not. SDS was adsorbed at a ~35% level. 
 
The interactions of ILs in soils have been examined in a number of recent publications.
41, 46-49
 
The ability of ILs to interact with a soil and adsorb to this matrix poses a number of problems. If 
the ILs are not biodegradable, will they adsorb to the soil indefinitely and if so what are the 
potential consequences and outcomes of these interactions? Furthermore, if the ILs adsorption 
profile allows it to eventually elute from the soil can the IL then enter the aquifer?  
 
A number of studies have been conducted on ILs and their interactions with soil, bacteria and 
plant life, with some generalisations reported: 
 
 The lower the lipophilicity the more mobile the IL 
 Hydrophobic ILs will only migrate a few centimetres into soil 48 
 IL cations bind more weakly to soils that contain less organic matter 48 
 The mineral content of the soil greatly affects the mechanism of sorption 50 
 The more mobile the IL the greater the ability to pass through soil into ground water 
 Sorption of ILs is greatest with strongly exchangeable cations and a high organic 
content 
 The longer the alkyl chain the higher the sorption coefficient and vice versa, see Figure 
1.5 
48
 
 Desorption can be inversely correlated to sorption 48 
 Hydroxylated analogues adsorb  more weakly 43 
 The higher the hydrophobicity of an IL, the greater the phytotoxic effect 51 
 Bacteria from a high salt environment or a high hydrocarbon environment are far better 
able to survive in higher concentrations of ILs 
52
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Figure 1.5. Sorption coefficients (Kd mL g
−1
) for first layer Kd1 and final concentration Kd2 for 
given soil types.
48
  
 
Figure 1.6. Imidazolium compounds (8-14) examined for soil adsorption. 
 
Figure 1.7. Sorption isotherms for a, [bmim][Cl], and b, [hmim][Cl] on soil type R3.
48
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Figure 1.8. Soil elution profiles (breakthrough curves) of ILs [omim][Cl], [bmim][Cl], 
[mbpy][Cl], [emimOH][Cl] and [emim][Cl] in the three different soil types, CA3, R3 and L2.
48
  
1.2.3 Biodegradation of ILs under denitrifying conditions 
 
Biodegradation of ILs under denitrifying conditions remains a largely undocumented pathway 
and has only been reported in one paper. 
53
 Anaerobic biodegradation conditions are prevalent in 
nature in soils, aquatic environments and in wastewater treatment plants and are considered of 
potential significance as IL biodegradation pathways. 
 
1.2.3.1 Anaerobic biodegradation 
 
In the study carried out by Stolte et al. in 2010, nine ILs (8, 13, 15-20) were examined for their 
anaerobic biodegradability including a metabolite study with compound identification by 
HPLC-UV.
53
 The ILs were subjected to the denitrifying conditions for 11 months. 
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IL Screened 
Primary biodegradation as determined by 
HPLC/MS 
 
0% 
 
0% 
 
100% 
Metabolite detected - See Fig. 9 
   
0% 
 
0% 
 
0% 
 
0% 
 
0% 
Table 1.9. Anaerobic degradation of imidazolium and pyridinium ILs reported by Stolte et al. 
53
 
 
Figure 1.9. Metabolite detected at the end of the study. 
The results of the anaerobic study, Table 1.9, showed no reduction in concentration for the ILs 
studied except for the octyl alcohol derivative (15) which broke down completely, within 30-40 
days, to the carboxylic acid metabolite (21), Figure 1.9,  after a period of three months. The 
16 
 
biodegradation pathway and associated metabolite study are further discussed later in this 
review in Section 1.4.2, vide infra. Attempts to induce biodegradation by co-metabolism 
through the addition of an acetate salt failed.
51
 Alkyl substituted imidazolium (8, 13), 
pyridinium (16, 17) and dimethylaminopyridinium (18-20) ILs were not found to be readily 
biodegradable compounds under the anaerobic test conditions (Table 1.9). 
 
1.2.3.2 Anaerobic dehalogenation 
 
Another benefit of investigating the anaerobic biodegradation of ILs is the potential for 
biodegradation of halogenated compounds. Organohalides make up a large proportion of 
compounds used as solvents, biocides, pesticides, refrigerants etc. and many can be classed as 
persistent organic pollutants.
23,54
 With the introduction of halogenated ILs into industrial 
applications, the question of how these compounds will respond to release into the environment 
must be asked. Under the Stockholm Convention on Persistent Organic Pollutants 2004, bans 
and reductions on some of the world‟s most hazardous organic pollutants were put into effect.55 
With a legal and political framework established for the reduction of halogenated and persistent 
organic pollutants in place, the need to provide readily biodegradable organohalide compounds 
is imperative. Halo-respiring bacteria are known and the reductive dechlorination of common 
chlorinated solvents has been reported including trichloroethane, tetrachlorethene and aromatic 
halides.
56-58
 Examination of ILs for anaerobic biodegradation therefore is of importance, 
especially if the IL is not readily biodegradable under aerobic conditions or if a metabolite study 
shows that a halogenated moiety remains after degradation has plateaued. Inorganic halide 
counterions can breakdown with no release of CO2, for example BF4 hydrolysis.
59
 In a 2012 
study conducted by Stolte et al. the biodegradability of fluoro and cyano derived anions was 
assessed.
60
  
 
Under the aerobic and anaerobic degradation test conditions a number of metal salts of the 
anions were examined:  
 
 NaN(CN)2 -sodium N-cyanocyanamide, 
 LiNTf2 – lithium bis(trifluoromethylsulphonyl)amide 
 KC(CN)3 - potassium tricyanomethanide 
 KB(CN)4 - potassium tetracyanoborate  
 K(C2F5)3PF3 – potassium trifluoridotris(pentafluoroethyl)phosphate 
 
17 
 
Under both aerobic and anaerobic test conditions it was noted that the metal salts of these 
anions did not possess any biodegradation potential and were not toxic to the microorganisms in 
the test sludge (at the concentrations used in the test). It was suggested that the ability for the 
anions to undergo de-fluorination was also unlikely.
60
 
1.2.4 Biotreating ILs for enhanced biodegradation – axenic cultures 
 
An investigation into the use of axenic bacterial cultures - cultures of bacteria containing only 
one organism/strain - in enhancing biodegradation was performed by Catalina et al. in 2011. 
61
 
The use of judicially selected bacteria, specifically a Sphingomonas paucimobilis (S. 
Paucomobilis) strain, has demonstrated that modifying the test conditions from the prescribed 
OECD guidelines can heighten biodegradation. The results of these tests are not recognised 
under the OECD or ISO guidelines; however they do give insight into alternate bio-based 
treatment options for ILs. Previously recalcitrant compounds were observed undergoing 
biodegradation under optimised test conditions of 45°C and IL concentrations of 0.5-3.0 g l
-1
. 
Out of 37 commercially available ILs tested, 20 were found to undergo ≥60% biodegradation in 
less than 28 days,(3-5, 22, 23, 27-32, 36-41, 45, 46, 49, 50) see Table 1.10, with the choice of 
anion playing a significant factor in % degradation. Shortening the length of substituted alkyl 
chains increased biodegradability, e.g. for the chloride series of 1-methylimidazole series (8, 9, 
12, 13, 35). The successful application of a specific bacterial strain capable of adapting to higher 
concentrations of ILs shows that a potential wastewater pre-treatment of non-biodegradable ILs 
is possible. It is also important that the concentration of IL used in each test played a major role 
in % biodegradation values, with ~2 mmol l
-1
 giving optimum results. It is stated by Catalina et 
al.
61
 that no clear relationship between toxicity and biodegradation results were observed for the 
compounds tested. 
Table 1.10. Biodegradation results for Sphingomonas paucimobilis at 45°C. 
Name Structure Biodegradation
a
 
[emim][Cl] 
  
 
53* 
 
[emim][PF6] 
  
87 
[emim][NTf2] 
  
67 
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[bmim][CH3CO2] 
  
51 
[bmim][CF3CO2] 
  
20 
[bmim][CF3SO3] 
  
34 
[bmim][Cl] 
  
39* 
[bmim][BF4] 
  
80* 
[bmim][PF6] 
  
65* 
[bmim][Br] 
  
75* 
[bmim][CH3SO3] 
  
75* 
[bmim][DCN] 
  
77 
[bmim][NTf2] 
  
90* 
19 
 
[bmim][C8H17SO4] 
  
>95* 
[hxmim][Cl] 
  
37 
[hxmim][BF4] 
  
40 
[hxmim][PF6] 
  
70 
[hxmim][NTf2] 
  
73 
[omim][PF6] 
  
54 
[omim][Cl] 
  
32 
[omim][BF4] 
  
33 
[dcmim][Cl] 
  
12 
20 
 
[1EtPy][PF6] 
  
>95 
[1BuPy][PF6] 
  
80 
[1BuPy][NTf2] 
  
86 
[1HxPy][PF6] 
  
62 
[1Et3MePy][NTf2] 
  
>95 
[1Et4MePy][NTf2] 
  
>95 
[1Bu3MePy][NTf2] 
  
17 
[1Bu3MePy][BF4] 
  
35 
[1Bu4MePy][NTf2] 
  
30 
21 
 
[1Bu4MePy][PF6] 
  
78 
[1Bu1MePyrr][NTf2] 
  
>95 
[1Bu1MePyrr][BF4] 
  
49 
[PBu4][BF4] 
  
41 
[PBu4][PF6] 
  
66 
[NBu4][NTf2] 
  
64 
a. Colour Coded to traffic light metric system (see Section 1.2.1.7). 
* Compounds previously reported as recalcitrant.
62-63
 
 
Similar success in the use of axenic cultures was observed in the work by Zhang et al. in 2010, 
where it was demonstrated that a Corynebacteria species could effectively metabolise the 
butylpyridinium ILs (52 and 53), Figure 1.10 but not [bmim] PF6 (4).
64
 
 
A proposed degradation pathway determined by ESI/MS/MS is presented in Section 1.4.2, vide 
infra. The potential capabilities of judiciously selected bacterial cultures have shown that 
biodegradation of previously determined recalcitrant IL compounds is possible, subject to 
optimised conditions. 
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Figure 1.10. [PyBu] derivatives (52 and 53) found to degrade and recalcitrant [bmim][PF6] 
derivative (4). 
 
Jungnickel et al. examined the use of axenic cultures of bacteria in the biodegradation of 
[omim][Cl] (13) in 2014 using the manometric respirometry method (OECD 301F). 
65
  Under 
their biodegradation tests, nine bacteria were isolated from an activated sludge and identified by 
16S rDNA PCR (polymerase chain reaction) and compared to genetic data available on 
Genbank. The bacteria were then examined for their biodegradation potential. The bacteria 
isolated were as follows: 
 
 Flavobacterium sp. WB3.2-27 
 Shewanella putrefaciens CN-32 
 Moraxellaceae bacterium MAG 
 Flavobacterium sp. FB7 
 Microbacterium keratanolyticum AO17b 
 Flavobacterium sp. WB 4.4-116 
 Arthrobacter sp. SPC 26 
 Rhodococcus sp. PN8 
 Arthrobacter protophormiae strain DSM 20168 
 
It was found that the individual axenic cultures were inefficient at biodegrading the [omim][Cl] 
exhibiting only ≤ 8% biodegradation. When all 9 bacteria strains were combined into a mixed 
culture biodegradation experiment, only 30% biodegradation could be achieved. Under the same 
experimental conditions, using an activated sludge, degradation of ~60% was observed for 
[omim][Cl] (determined by the manometric respirometry method (OECD 301F)).
65
 Thus it was 
proposed by Jungnickel et al. that isolated organisms may not facilitate biodegradation as 
efficiently as they would in an activated sludge of far greater complexity where the possibility 
of symbiotic relationships of multiple strains of bacteria are present. Another possibility 
23 
 
suggested was that not all of the bacteria required for IL metabolism were isolated for the 
individual and combined culture experiments.
65
 
 
1.2.5 Suitability of biodegradation tests to IL classes – toxicity vs. biodegradability 
 
Not every IL tested for biodegradation by one of the standard OECD methods will be 
compatible with the test procedure and it has been previously reported that a number of issues 
exist including sorption and kinetic parameters of ILs in activated sludge as previously 
described and toxicity of IL to the inoculum.
66
  Other issues then arise such as concentration 
effects of toxic ILs and biodegradation inhibition that may ensue. See Table 1.11 for a general 
compound suitability to biodegradation test methods.  
 
 
Table 1.11. Suitability of organic compounds to biodegradation screening method. 
22,
 
35
 
Adapted from Coleman et al 2010.
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According to current trends from reported biodegradation data, the increase of alkyl side chains 
has shown to directly lead to an increase in biodegradation due to the extra oxidisable carbons 
in the chain. However a design conflict is present and an increase in alkyl chain length has been 
shown to increase antimicrobial toxicity especially around the C12-C14 chain length. Chains of 
C16 and C18 exhibit very poor water solubility and hence have a lower bioavailability.
67
 A design 
optimisation in the addition of ether oxygen in alkyl chains has shown to reduce toxicity but 
maintain levels of biodegradability.
68
 
 
Validation of biodegradation results is of the utmost importance. For example when carrying 
out the CBT sodium acetate is often used as a control. The high biodegradability of sodium 
acetate is known and by comparing biodegradation results to the control it can be determined 
whether the inoculum chosen for the test is effective.  
 
Further validation is required regarding the toxicity of ILs and the sorption characteristics. 
Removal of ILs by sorption can be calculated using the guidelines in OECD 302B Zahn-
24 
 
Wellens test.
35
 Toxicity of ILs to the inoculum can be assessed by including a toxicity control 
series in tandem to the biodegradation test series and a blank sodium acetate + inoculum series. 
The toxicity reference vessel contains IL + sodium acetate + inoculum, the sodium acetate 
control contains sodium acetate + inoculum. Any significant differences in oxygen demand 
between the toxicity control, when compared to the sodium acetate control, can be attributed to 
toxic effects. 
 
While different research groups may prefer to perform one biodegradation test over another, in 
particular with the CO2 headspace test (OECD 310 or ISO 14593), or even primary vs. readily 
biodegradation tests, it is key to note that this data is just a starting point for a more detailed 
investigation about chemical fate in the environment. Regardless of where you start the 
assessment program, the aim is to ultimately complete a thorough (eco)toxicity and 
biodegradation study of chemicals likely to be used on a large scale and where contamination of 
the environment is a possibility. 
 
1.3 Biodegradation data on classes 
 
1.3.1 Ionic liquids: anion and cation effects with regards to biodegradation 
 
There are a number of different perspectives to consider when interpreting biodegradation data 
of ILs. All ILs consist of an anion and cation thus two parts must be considered, albeit as a pair. 
Another consideration is whether the anion or cation is organic or inorganic. For instance if an 
inorganic ion is used, such as a halide or pseudohalide (or positively charged metal halide 
cation), then it does not contribute directly as a carbon source for biodegradation determination. 
Conversely, if an IL contains an anion of high carbon content which is known to have excellent 
biodegradation characteristics (e.g. octyl sulphate anion, Figure 1.12), then one must be careful 
not to assume high biodegradability for the ion pair, and thus infer good biodegradability for the 
other less degradable ion present in the IL.  
 
Within the OECD test regulations a biodegradation level of 60% is usually required within 28 
days. The test treats the IL as a single chemical compound and therefore the outcome is that the 
IL ion pair either passes or fails the biodegradation test. While caution must be exercised when 
utilising this pass or fail result for biodegradation tests to design future biodegradable ILs, the 
pass or fail result for each IL is valid as defined by the regulations of the OECD test criteria.  It 
is our expectation that this review will assist researchers to design and develop ILs which pass 
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ultimate biodegradation and mineralisation assays, which is only possible if both ions 
biodegrade or are mineralised. 
 
1.3.2 Anions 
 
A popular and widespread class of anions are the halides, Figure 1.11. The halide anions and 
pseudohalides (e.g. BF4 and PF6) are not a carbon source for biodegradation and thus 
biodegradation values are dependent on the organic cation. IL [bmim] derivatives have been 
reported to give poor biodegradability, with values in the, 0-5% range.
22
 Anion choice is usually 
directed by function and application (e.g. in many cases, NTf2 for hydrophobic ILs).  In this 
section organic anions in ILs are reviewed and their progress towards the development of 
biodegradable ILs is discussed. 
  
 
Figure 1.11. Some of the most commonly employed halide/pseudohalide anions as their [bmim] 
ILs. 
Organic anions offer a myriad of possibilities when selecting suitable structures to incorporate 
into ILs. Many natural products (e.g. carboxylic acids, amino acids, and carbohydrates) have 
been tested as feedstocks for anions. Other examples have been adopted from the surfactant 
industry, such as the sulphate anions, Figure 1.12. The alkylsulphate anions exhibit good rates 
of biodegradation. Of note, sodium dodecyl sulphate is used frequently as the positive test 
control for activated sludge activity.
18
 Studies by Scammells et al. showed that 
[bmim][C8H17SO4], (30), Figure 1.13, biodegrades 25% in the CBT (OECD 301D),
63
 or up to 
40% in the CO2 headspace test (ISO 14593).
69
 A reasonable assumption is that the anion is 
converted to CO2 with high efficiency and the [bmim] cation is not transformed, however this 
was not confirmed at the time due to the absence of LCMS data and metabolite identification. 
 
Figure 1.12. Sulphate anion core, R = CnH2n+1, n = 8-12. 
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Figure 1.13. [bmim] paired with the biodegradable, octyl sulphate anion failed the CBT and 
CO2 Headspace test.
63
 
 
Formates, acetates and other simple carboxylates, Figure 1.14, have been employed as IL anions 
with very good biodegradation results found when paired with the cholinium cation, Figure 
1.15. Cation modification can lead to significant changes in biodegradability which is discussed 
later in Section 1.3.3, vide infra. 
 
 
 
Figure 1.14. Formate and carboxylate anions. 
 
 
Figure 1.15. Two readily biodegradable protic ethanolaminium carboxylate ILs.
70
 
Biodegradation values assessed by Manometric Respirometry (OECD 301F). 
 
Similar success has been demonstrated in the use of malonates, succinates, tartrates and other 
natural organic acids and sugars, Figure 1.16. However, pairing with an appropriate cation is 
crucial. In the following examples tetrabutylammonium (TBA) cations have been employed 
where only the organic anion is degraded, Figure 1.17. Replacing the TBA cation with a 
dibutyl-dimethyl ammonium cation (DMDBA), Figure 1.18, promotes biodegradation for the 
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lactate derivative (59). The biodegradation values of the TBA derivatives are in good agreement 
with the percentage carbon equivalent of the anion and it is assumed that the cation is persisting 
with only the anion undergoing biodegradation, CBT (OECD 301D).
71, 72
 See Section 1.3.5.5 on 
tetraalkylammonium ILs for more information on TBA and DMDBA ILs. 
 
 
Figure 1.16. Biodegradable organic acids that have been employed as anions in ILs.
71
 
 
 
 
Figure 1.17. TBA carboxylate ILs.
71
 
Biodegradation values assessed by CBT (OECD 301 D). 
 
28 
 
 
Figure 1.18. A readily biodegradable lactate DMDBA IL.
71, 73
 
Biodegradation values assessed by Manometric Respirometry (OECD 301F) 
 
In addition to organic acids and sugar acids, amino acids have been investigated as the anion in 
ILs, Figure 1.19. There are 23 proteinogenic amino acids for prokaryotic organisms and 21 for 
eukaryotes. A recent publication by Zong et al. 
74
 showed the successful combination of 18 
amino acids (Gly, Ala, Val, Leu, Ile, Ser, Thr, Met, Asp, Glu, Asn, Gln, Lys, His, Arg, Pro, Phe, 
Trp) with a cholinium cation. All of the ILs passed the CBT (OECD 301D) (65.3 – 87.1%) and 
the CO2 headspace test (OECD 310), (62.1 – 85.2%) and can be classed as readily 
biodegradable. Selected examples are shown in Figure 1.19, for full list see Appendix 1, 
compounds (310-322). 
 
Figure 1.19. Biodegradable cholinium amino carboxylate ILs.
74
 
Biodegradation values assessed by CO2 Headspace test (OECD 310). 
 
A common structural feature of all these anions is the free carboxylate which, as suggested by 
Boethling, can promote biodegradability.
75
 It was also noted that the amino acids with branched 
side chains were more resistant to biodegradability (69-72% in OECD 301D and OECD 310) 
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compared to >80% biodegradation for unbranched sidechains. The choice of cation will 
inevitably have a determining factor on the overall biodegradability of the organic anions as can 
be seen when comparing cholinium prolinate (62) to the TBA derivative (67), Figure 1.20. TBA 
L-prolinate (67) undergoes levels of 15-20% biodegradation whereas >70% biodegradation was 
observed for the cholinium analogue (62). 
 
 
Figure 1.20. TBA L-prolinate IL.
71
 
Biodegradation values assessed by CO2 Headspace test (OECD 310). 
 
As an overarching design principal, the authors suggest that a halide anion such as chloride or 
bromide can provide the foundation for potentially biodegradable ILs as the halide counterion 
cannot undergo further degradation as it is already in a mineralised form. Thus, an IL formed 
from a Br or Cl anion will only biodegrade according to the carbon content of the cation. 
Perfluorinated anions should be avoided as they have been shown to be recalcitrant or their 
degradation products are more harmful than their parents, e.g. BF4 degrading to HF. 
59
  
 
Overall the organic acid anions appear to be the best selection for promoting biodegradability. 
Biodegradation information provided by the choices of amino acids screened by Zong et al. 
74
 
ILs (61-66, 310-322 Appendix I) suggest that the amino acids all undergo high levels of 
biodegradation in both the CBT (OECD 301D) and the CO2 headspace test (OECD 310)  and 
will not persist under the test conditions. 
 
The natural organic acids (succinic, tartaric, lactic, malonic, malic, pyruvic, glucoronic, 
galacturonic etc.) such as those employed by Ferlin et al. 
70 
and Jérôme
 
et al. 
71
 can be shown to 
promote biodegradability. In these examples, the tetrabutyl ammonium (TBA) ILs (56-59) and 
(168-172), it is assumed that the TBA cation is recalcitrant to biodegradation (OECD 301D), 
and that the organic acid anion is solely breaking down, this is discussed in more detail under 
Section 1.3.5.5 on tetra alkylammonium cations. 
 
The DMDBA examples (60, 175-180) also displayed great success in the choice of organic acid 
anions.
73
 Finally the amino diol and triol examples (161-167)
70
 also have high levels of 
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biodegradability (OECD 301F) when simple carboxylic acid anions such as formate, acetate, 
propanoate, isopropanoate, butanoate and pentanoate feature. 
1.3.3 Cations 
 
The choice of cation is as large and developed as the choice of anion, with the most common 
cations including the heterocycles 1-methylimidazolium, pyridinium and the non-aromatic 
cholinium and tetrabutylammonium. For the majority of ILs synthesised to date, the cation has 
had a higher carbon content than the anion. This higher carbon content can equate to a larger 
contribution towards the overall CO2 evolution/ O2 demand of the IL within biodegradation 
screening methods and potentially higher levels of biodegradation. While a shift from inorganic 
anions to organic anions has been observed, the research conducted towards cation 
biodegradability has seen many investigations carried out on different organic scaffolds and the 
effect of various functional groups that may facilitate biodegradation.  
 
1.3.4 Aromatic Cations – imidazolium, thiazolium, pyridinium 
1.3.4.1 Imidazolium 
 
Derivatives of 1-methylimidazole have long been a choice of cation in IL based technologies 
with considerable research in the past two decades focussed on 2
nd
 and 3
rd
 generation ILs (4, 8, 
9, 12, 29, 68) see Figure 1.21.
76
 Commercial availability of [bmim] and other alkyl derivatives 
has facilitated the popularity of ILs as replacement solvents but as previously discussed, 
identifying readily biodegradable examples has proven difficult.  
 
 
Figure 1.21. Biodegradation data for some 2
nd
 and 3
rd
 generation ILs.
62, 63, 77
 
* Biodegradation values assessed by Manometric Respirometry (OECD 301F) 
**Biodegradation values assessed by CBT (OECD 301D) 
***Biodegradation values assessed by BOD measurement using an OxiDirect kit 
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Since the previous IL biodegradation reviews published by Gathergood et al. 2010 
22
 and Stolte 
et al. 2011 
78
 a number of substituted imidazolium derivatives have been screened for their 
biodegradability. The imidazolium cation has been functionalised in two ways in efforts to 
improve biodegradation: 
 
 
1) modification of the N-substituents  
and/or  
2)  substitution at the C2 and C4/5 positions of the imidazolium ring, Figure 1.22. 
 
 
Figure 1.22. The imidazolium cation and potential sites for derivatisation. 
Aryl derivatives (69-76) screened by Stolte et al. 2013 
79
 (Figure 1.23) show that aryl 
imidazolium derivatives are recalcitrant to biodegradation (OECD 301F) with no greater than 
8% biodegradation achieved for (75) and (76), most likely undergoing primary biodegradation 
via ethyl ester hydrolysis to the carboxylic acid (77), Figure 1.24. The introduction of an oxygen 
atom in the form of the ethyl ether in (71) and (72) did not initiate biodegradation. 
 
 
Figure 1.23. Biodegradation data for imidazole ILs synthesised by Stolte et al.
79
 
Biodegradation values assessed by Manometric Respirometry (OECD 301F) 
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Similar poor levels of biodegradation (0-2% in the CO2 Headspace Test) for ILs containing 
phenyl rings were obtained for the N-benzyl derivatives (78, 79) screened by Gathergood  et al. 
2013 
18
 Figure 1.25. 
 
 
 
Figure 1.24. Aryl imidazolium IL and potential degradation product.
79
 
 
 
Figure 1.25. N-Benzyl imidazolium ILs.
18
 
Biodegradation values assessed by the CO2 Headspace Test (ISO 14593) 
 
Modifications by Gathergood et al. 2013 
18
 of the imidazolium cation to introduce ester groups 
and amide groups at the C2, C4 and C5 positions ILs (80-96) did not succeed in raising 
biodegradation levels (ISO 14593) beyond that which could be explained by ester degradation, 
Figure 1.26 and 1.27. The imidazolium ILs were categorised by the authors according to the 
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aforementioned traffic light metric and are organised according to amber classified ILs, Figure 
1.26 and red classified ILs, Figure 1.27.
18
 
 
Examples of ester modifications at the imidazolium C2 position, ILs (80, 81), Figure 1.26 show 
a moderate amount of biodegradation (30-35%), however this can be attributed to only the 
degradation of the ester, with the imidazolium ring presumably remaining intact.  Imidazolium 
ILs disubstituted at C4,5 (82, 83, 86-88) with ester groups lead to observed biodegradation in 
the CBT in the range of 3-31% and did not pass the test. Low biodegradation for the C4 
substituted analogues (85, 92) was also observed. There is no evidence that the introduction of 
an ester group to the imidazolium ring leads to breakdown of the charged heterocycle. This 
observation is in contrast to the increase in biodegradability observed when modifying some 
pyridinium ILs to nicotinium ILs. Possible reasons for this lack of reactivity for the C4 and C4,5 
is that after hydrolysis the carboxylic acid or carboxylate salt stabilises the ring making 
breakdown difficult. For C2 ester derivatives, hydrolysis forms an unstable intermediate, with 
facile evolution of CO2, and the imidazolium ring intact.
18
 Thus the more stable to hydrolysis 
amide group was examined to investigate the effect of a stable EWG on the imidazolium ring to 
promote breakdown. However, the authors report that with the amide in the C2 (89, 90, 91), C4 
(79) or C4,5 (92) low biodegradation in the range 2-17% was observed. 
 
 
Amide functionalisation at the nitrogen position to give ILs (78, 95, 96, 90, 91), Figure 1.25 and 
1.27, also show a resistance to biodegradation. This is best exemplified by (95) and (96) with 
levels of 3% biodegradation recorded. 
 
Ester functionalisation at the nitrogen positions (82-86, 89, 92-94,) again followed the trend of 
poor biodegradability with levels attributed solely to ester hydrolysis, derivatives (82) and (83) 
undergoing ester hydrolysis at all three ester positions to give Amber classified ILs Figure 1.26 
while the remaining ILs were classified as Red with <20% biodegradation. The monoester 
derivatives (93) and (94) only attained 10-14% biodegradation in the CBT. 
 
The effect of methylation of the C2 position of the imidazolium ring can also be determined 
from compounds (95) and (96), with no difference in biodegradation (3%) observed. This is in 
agreement with previous studies by Scammells et al.
80
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Figure 1.26. Imidazolium ILs classified as Amber.
18-20
 
Biodegradation values assessed by the CO2 Headspace Test (ISO 14593). 
 
Figure 1.27. Imidazolium ILs classified as Red by Gathergood et al.
18-20
 
Biodegradation values assessed by the CO2 Headspace Test (ISO 14593). 
 
The poor biodegradability (OECD 301D) of C2, C4 and C4/5 modified imidazolium ILs was 
further demonstrated by the work carried out by Gendaszewska et al. in 2014 which established 
the poor biodegradability of four peralkylated imidazolium ILs (97-100), Figure 1.28-29. 
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Figure 1.28. Biodegradation data for C-2,4/5 modified imidazolium ILs.
45
 
Biodegradation values assessed by CBT (OECD 301D) 
 
 
Figure 1.29. Biodegradation data for C-4/5 modified imidazolium ILs.
45
 Biodegradation values 
assessed by CBT (OECD 301D) 
 To tackle the problem of poor biodegradability of imidazolium based ionic liquids containing 
amides, Gathergood et al. designed examples in which the amide bond was more „peptide like‟ 
than the „synthetic‟ examples previously screened.81 The rationale was that an amidase enzyme 
would be more likely to accept the former substrate than the latter. Thus, modification of the 
imidazolium core by the incorporation of an amino acid residue into the side chain of the cation 
has been investigated. In 2012 Gathergood et al. disclosed two readily biodegradable amino 
acid derived imidazolium ILs bromides, Figure 1.30. The two ILs, (101, 102) were screened in 
the CO2 headspace test and achieved >60% biodegradation after 28 days and can hence be 
classed as readily biodegradable. Compound (101) an IL based on a butyl ester of L-
phenylalanine provided biodegradation of 61% and compound (102) a dipeptidyl IL based on L-
phenylalanine-L-leucine methyl ester biodegraded 64% under the test conditions. The high 
levels of biodegradation are beyond that which can be explained by ester hydrolysis and alcohol 
oxidation.  
 
The selection of compounds screened has shown that the majority of imidazolium based ILs 
screened are not readily biodegradable with ≤35% biodegradation observed. The rule of thumb 
regarding imidazolium compounds still stands that N-substitution leads to a significant 
reduction on biodegradability, whereas imidazole and neutral C-substituted imidazole 
derivatives (i.e. not charged ILs) are readily biodegradable under the OECD 301D (100%)
62
 and 
302B (83%)
71
 test conditions. While progress has been made to develop readily biodegradable 
imidazolium halide ILs which contain amide groups in the side chain,
81
 no evidence of 
breakdown of the charged core has been presented in a standardized test. 
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Figure 1.30. Biodegradation data for amino acid derived imidazolium ILs.
81
 
Biodegradation values assessed by the CO2 headspace test ISO 14593 
 
1.3.4.2 Thiazolium 
 
A heterocyclic thiazole derivative of the methyl imidazole core has also been screened by 
Scammells et al. in 2010,
69
 however the inclusion of a sulphur atom in the aromatic ring did not 
give any promising biodegradation results with ≤7% biodegradation being achieved in the CO2 
headspace test (ISO 14593), Figure 1.31. 
 
 
Figure 1.31. Biodegradation data for thiazolium ILs synthesised by Scammells et al.
69
 
Biodegradation values assessed by the CO2 Headspace test (ISO 14593) 
 
1.3.4.3 Pyridinium 
 
The popularity of pyridinium and pyridinium based cations from methoxypyridinium and 
nicotinium acids/esters is high with a larger number screened for their biodegradability. Early 
generations of pyridinium ILs showed similar inertness to biodegradation (OECD 301F) as 
imidazolium ILs, with several compounds classified as not readily biodegradable (e.g. 16, 105-
108), Figure 1.32.
62, 82
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Seminal work by Scammells et al. 2010
69
 and Stolte et al. 2014
82
 demonstrated that pyridinium 
derivatives can pass the CO2 headspace test (OECD 310) and Manometric Respirometry test 
(OECD 301F). The primary ethyl alcohol pyridinium derivatives, compound (109-111), Figure 
1.33, have biodegradation levels of 65% and 62%, respectively, in the CO2 headspace test whilst 
the iodide (111) example screened in the Manometric Respirometry test gave 65%. Increasing 
the length of the alcohol substituent from an ethyl alcohol to a propyl alcohol giving derivative 
(112) displayed a reduction in the biodegradability to 51%. 
 
 
Figure 1.32. Alkyl pyridinium ILs classified as not readily biodegradable.
18, 82
 
* Biodegradation values assessed by Manometric Respirometry (OECD 301F) 
**Biodegradation values assessed by the CO2 Headspace test (ISO 14593) 
 
The elevated biodegradation levels can be attributed to the primary alcohol on the alkyl chain 
promoting biodegradation as a potential site for oxidation. The carbon count of compound (109) 
is 7 x C. The biodegradation levels of 65% would therefore suggest that approximately between 
4 and 5 carbon atoms are being mineralised from this compound. With the side chain only 
supplying 2 x C and the inorganic anion not contributing to CO2 values, it may be inferred that 
the pyridinium core is undergoing breakdown under the CO2 headspace test conditions.  
 
Derivatisation of the pyridinium core can have dramatic effects on the biodegradability of the 
ILs produced. The addition of a methoxymethyl or a methoxyethyl group at the 3-position to 
give compounds (113-119), Figure 1.34, showed a reduction of biodegradability. For the NTf2 
derivative (113) a substantial reduction in biodegradation  6% was observed. 
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Figure 1.33. Pyridinium ILs (109-112).
69, 82
 
*Biodegradation values assessed by the CO2 Headspace test (ISO 14593) 
** Biodegradation values assessed by Manometric Respirometry (OECD 301F) 
 
 
 
Figure 1.34. (113-119) Pyridinium ILs ether substituted at the 3-position.
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Biodegradation values assessed by the CO2 Headspace test (ISO 14593). 
 
The 3-position on the pyridinium core appears to be particularly sensitive to its substituent. 
When comparing methoxymethyl IL (113), Figure 1.34, to its pyridinium counterpart (110), 
Figure 1.33, a reduction in biodegradation (ISO 14593) from 62% to just 6% is observed, 
directly attributable to the addition of a methoxymethyl group on the 3-position. The 
ethoxymethyl derivative of N-butyl pyridinium again highlights the recalcitrance of 3-
substituted ILs, with biodegradation of 1% observed for the NTf2 derivative, IL (114) and 36% 
for the octyl sulphate derivative (115), the elevated levels of biodegradation for the latter 
example are attributable to biodegradation of the anion. For derivatives (116, 117) there is no 
evidence of biodegradation of the N-butyl or methoxymethyl sidechain as levels of 
biodegradation of 32% and 31%, respectively, once again implies biodegradation of the anion 
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solely. With the addition of an ester at the N-position to give ILs (118, 119) the elevated levels 
of biodegradation (47-51%) can be attributed to ester hydrolysis plus the degradation of the 
octyl sulphate anion with the methoxymethyl pyridinium core remaining intact. 
 
With 3-position ethers giving such poor results, a progressive examination of sidechain 
functionalities logically leads to inspection of ester and amide functionalities at the 3-positon, 
Figure 1.35. 
 
Figure 1.35. Nicotinium derived ILs.
18,83
 
Biodegradation values assessed by the CO2 Headspace test (ISO 14593). 
 
Ester functionalities on the 3-position, Figure 1.35, to give nicotinium derivatives, appear to 
have moderate to good biodegradability with derivative (120) being considered readily 
biodegradable (ISO 14593). Changing the ester to an amide (121) produced a considerable 
decrease in biodegradation to almost nothing that could be attributed to the cation, as derivative 
(121) is mostly likely undergoing anion degradation. Further substitution of the pyridinium 
core, compound (122), to give an ester at the 3 position and a primary alcohol on the N-position 
has shown to elevate the biodegradability back up to 71%. Modification of the ester derived 
pyridinium ILs with a group other than a terminal alcohol at the N-position, compound (123), 
leads to a reduction in biodegradation to 25%. 
 
The rule of thumb observable for increased pyridinium biodegradation appears to be the 
presence of a primary alcohol attached at the N-position with careful introduction of other 
functionality on the aromatic ring, as required by application. 
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Figure 1.36. A carbamate functionalised pyridinium IL.
69
 
Biodegradation values assessed by the CO2 Headspace test (ISO 14593). 
The last functional transformation attempted was the introduction of a carbamate group with the 
aim that the carbamate would undergo hydrolysis at this site. This synthetic transformation 
leading to compound (124), Figure 1.36, proved to be recalcitrant to biodegradation at 3%.
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1.3.5 Non aromatic cations – morpholinium, DABCO, piperidinium, cholinium, 
quaternary ammonium - quaternary ammonium cations (QAC’s) 
 
1.3.5.1 Morpholinium, DABCO 
 
The non-aromatic headgroups can be further broken down into two subsets, cyclic and acyclic. 
The former set includes data from the morpholinium and DABCO (1,4-
diazabicyclo[2.2.2]octane) series of ILs presented by Pretti et al. 2011, Stepnowski et al. 2011 
and Neumann et al. 2014, see Figure 1.37.
82, 84, 85
 A series of ILs was prepared using morpholine 
and DABCO as headgroups with various extensions of alkyl chains substituted at the N-
position, Figure 1.37, (125-133). The shortest alkyl chain morpholinium ILprepared by Pretti et 
al.  IL (125) displayed biodegradation (ISO 14593) of 30% after 28 days. If the carbon content 
of the alkyl chain is taken into account, 2 x C, and the overall carbon count of the molecule is 7 
then the 30% biodegradation infers mineralisation of just two carbon atoms, perhaps the alkyl 
chain, however a metabolite study will only tell if any other portion of the molecule is being 
metabolised. The original postulation that with an increase in alkyl chain length there is an 
increase in biodegradation is not observed for this series of ILs. This is an example of how one 
of Boethling‟s rules of thumb did not apply to this subset of ILs, as biodegradation is seen to 
decrease with increasing alkyl chain length, N-butyl (126), N-hexyl (127), N-octyl (128) and N-
decyl (129), Figure 1.37. The decreasing biodegradability is in direct correlation with the 
toxicity results published by the same author demonstrating the increase in toxicity with 
increase in alkyl chain.
84
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Figure 1.37. Biodegradation data for morpholinium ILs.
82, 84, 85
 
*Biodegradation values assessed by CO2 Headspace test (ISO 14593). 
** Biodegradation values assessed by Manometric Respirometry (OECD 301F). 
*** Biodegradation values assessed by CBT (OECD 301D). 
 
Further addition of primary ethyl alcohol to the morpholinium headgroup to give IL (130), gave 
very poor biodegradability results (OECD 301F).
82
 This compound, though analogous to the 
readily biodegradable pyridinium derivative, Figure 1.33, (109), only provided ~1% 
biodegradation. Increasing the length of the alcohol from C2 to C3 increased the biodegradability 
by up to 30% (131). This suggests that the rule of thumb of including primary alcohol groups on 
the head group to increase biodegradation is questionable for morpholinium derivatives and 
may be sensitive to chain length. 
 
For the cyano (132) and benzyl (133) derivatives examined, 0% biodegradability (OECD 301F) 
was observed. Biotic hydrolysis of the cyano group was detected for IL (132).
82
 
 
The N-ether derivatives (134-136), Figure 1.38, did not undergo primary biodegradation when 
examined and agree with the rule of thumb that introducing ether groups can reduce 
biodegradation. Readily biodegradable screening was not carried out on these derivatives. 
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Figure 1.38. Morpholinium ILs screened for primary degradation only.
82
 
 
Figure 1.39. Biodegradation data for DABCO ILs (137-141).
82, 84
 
Biodegradation values assessed by Manometric Respirometry (OECD 301F). 
 
Similar results to those observed for the morpholinium ILs were found for the DABCO series of 
ILs synthesised by Pretti et al., Figure 1.39. Decreasing levels of biodegradation (OECD 301F) 
were observed when alkyl chain lengths longer than ethyl (137) were studied for the series (137-
141) Figure 1.39. Similarly, toxicity increase as chain length increased was attributed to the 
reduced levels of biodegradability for these DABCO ILs. As with the ethyl morpholinium IL 
(125), the ethyl substituted DABCO IL (137), showed the highest level of biodegradation within 
its class, with biodegradation of 40% observed for IL (137) after 28 days. However, unlike the 
morpholinium ILs, in this case there exists a possibility that a portion of the DABCO ring is 
undergoing biodegradation. The ethyl side chain of (137) can only contribute 25% of the 
theoretical carbon for biodegradation, and 40% is observed, thus some portion of the ring must 
be undergoing biodegradation. In general, the DABCO derivatives biodegraded to a greater 
extent than the morpholinium derivatives. However, the lowest value observed for DABCO IL 
biodegradation was 23%, for the hexyl derivative (139). In general the range of values for the 
analogues (137-141) is narrow (23-40%). 
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1.3.5.2 Piperidinium ILs 
 
The piperidinium ILs (142-148) screened for biodegradability (OECD 301F) by Stolte et al. 
2014, Figure 1.40, show a similar recalcitrance to biodegradation.
82, 84
 The N-substituted propyl 
alcohol IL, (143), was the only derivative from this group to be classified as readily 
biodegradable. The shorter ethanol substituted piperidinium derivative, (142) proved to 
biodegrade to a lower extent and cannot be classed as readily biodegradable. Although when the 
test time was extended to 60 days (142) had undergone ~85% biodegradation.
82, 84
 As previously 
observed, ILs substituted with a single ether group can reduce biodegradability and this was 
observed for ILs (145) and (146). Removing the oxygen atom from the N-substituted alkyl 
chains, (147) and (148) also gave ILs which exhibited poor biodegradation (<5%) in the 
manometric respirometry test. 
 
 
Figure 1.40. Biodegradation data for Piperidinium ILs (142-148).
82, 84
 
Biodegradation values assessed by Manometric Respirometry (OECD 301F). 
 
1.3.5.3 Pyrrolidinium 
 
Pyrrolidinium IL biodegradation has rarely been examined except for the work carried out by 
Stolte et al. in 2012 and 2014, Figure 1.41.
82, 86
 N-alkyl substituted pyrrolidinium ILs (149, 150, 
152) were observed to be recalcitrant to biodegradation (OECD 301F). Cyano derivative (154) 
also did not undergo biodegradation >2% though the cyano group was observed to undergo 
biotic hydrolysis.
82
 An N-substituted propyl alcohol IL (151) was observed to be readily 
biodegradable 67 ± 3% whereas the ethyl alcohol IL (153) biodegraded <10%. The continuing 
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trend of much greater levels of biodegradation for N-substituted C3 alcohols over C2 alcohols is 
observed here. Ethyl ester derivative (155) only provided 34 ± 11% biodegradation. Upon 
extension of the alkyl substituent to C8, IL (156), a readily biodegradable IL was discovered, 
with 69% biodegradation observed. This ILs structural features are in agreement with the rules 
of thumb regarding longer chain lengths being able to provide greater levels of biodegradability, 
in this case the IL did not inhibit the bacteria of the test medium. The study shows that several 
of the rules of thumb can be accurately applied for the pyrrolidinium derivatives and is a 
significant success for the design for degradation concept. 
 
Figure 1.41. Biodegradation data for pyrrolidinium ILs.
82, 86
 
Biodegradation values assessed by Manometric Respirometry (OECD 301F) 
*Examined for primary biodegradation only 
 
1.3.5.4 Linear ammonium cations 
 
Among the acyclic ammonium cation class are the quaternary ammonium compounds (QAC), 
such as cholinium and tetrabutylammonium and ILs. 
 
The cholinium cation has been selected as a promising choice for the synthesis of biodegradable 
ILs, due to the high biodegradability (OECD 301D) and low toxicity of cholinium halide salts.
87, 
88
 Thus, providing the cation is appropriately paired with an anion that is biodegradable (157, 
Figure 1.42), or an inorganic anion that does not inhibit metabolism, readily biodegradable ILs 
are a reasonable outcome. Anions derived from organic acids, (see Figures 1.14, 1.16) and the 
45 
 
amino acids, (see Figure 1.19) have all proven successful. See Section 1.3.2 on anions for more 
cholinium IL biodegradation data and Appendix I structures (310-322). Similar protic 
derivatives synthesised from aminoethanol, to give protic ILs (54, 55) Figure 1.15, can also be 
classified as readily biodegradable, see Section 1.3.2 for anion choices. 
 
 
Figure 1.42. Readily biodegradable cholinium mesylate (157).
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Biodegradation values assessed by Manometric Respirometry (OECD 301F). 
 
Biodegradation of the cholinium cation, however, is very sensitive to structural modification. 
The linear alkyl chain derivative trimethylbutylammonium TMBA (158), Figure 1.43, maintains 
high levels of biodegradability (OECD 301F) at ~87-88%. However, once the free alcohol is 
converted to a methyl ether (159) a large decrease in biodegradation is observed from 88-90% 
to 27-29%. No inhibitory toxic effects for ILs (157-159) were observed. 
 
 
Figure 1.43. Quaternary ammonium ILs (158, 159).
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Biodegradation values assessed by Manometric Respirometry (OECD 301F) 
 
Protic IL analogies of cholinium salts, with two ethyl alcohol groups (160-165), Figure 1.44 or 
three ethyl alcohol groups (166-167) Figure 1.45, gave favourable biodegradation results (see 
compounds (160-167)) except when the anion employed was a formate anion as in the case of 
IL (160). Carboxylate examples (acetate 161 to pentanoate 165) pass the manometric 
respirometry test, and (166-167) the triol derivatives (despite failing the test) achieve 
biodegradation levels very close to a pass (57-59%). In the study carried out by Peric et al. 2013 
it was shown by LC analysis that the cations had entirely degraded after the 28 day period and 
anion choice was of more concern, with 7 out of 10 compounds (54-55, 161-165) being classed 
as readily biodegradable.
70
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Figure 1.44. Biodegradation data for protic aminodiol derived ILs (160-165).
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Biodegradation values assessed by Manometric Respirometry (OECD 301F) 
 
Figure 1.45. Biodegradation data for protic aminotriol derived ILs (166-167).
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Biodegradation values assessed by Manometric Respirometry (OECD 301F). 
 
Overall the cholinium and the protic quaternary aminoethanol based ILs with 
methylsulphonates, methylsulphates, amino acid carboxylates and some organic carboxylate 
anions have high biodegradability (OECD 301F). 
  
Choline ILs have also been successfully employed as co-substrates in the effective 
biodegradation of azo dyes. 
89
 A number of choline salts (lactate, tartrate, saccharinate, 
dihydrogen phosphate, citrate), were used in conjunction with the bacteria S. lentus under 
optimised conditions to efficiently biodegrade acid blue 113 (92% degradation in 72 h) with 
choline lactate being the most effective. The degradation products were found to be less toxic 
than glucose mediated co-degradation.
89
 
 
1.3.5.5 Tetraalkylammonium 
 
One of the popular alkylammonium cations is the tetraalkylammonium cation, Figure 1.46, with 
widespread use in the surfactant industry,
90
 as antimicrobials,
91
 and other applications including 
47 
 
phase transfer catalysis.
92
 Amongst the QAC‟s employed in IL research the 
tetrabutylammonium (TBA) cation stands out as being one of the most widely used. Recently 
investigations have also been carried out with the dimethyldibutylammonium (DMDBA) cation, 
Figure 1.46.  
 
 
 
Figure 1.46. Tetrabutylammonium cation and [DMDBA] cation. 
 
Figure 1.47. Biodegradation data for selected tetrabutylammonium ILs.
71, 72
 
* Biodegradation values assessed by CBT (OECD 301 D). 
**Biodegradation values assessed by CO2 Headspace test (OECD 310). 
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Biodegradation data (OECD 301D and OECD 310) of TBA ILs has provided no evidence that 
the TBA biodegrades, Figure 1.17. (56-59) and Figure 1.47, (168-172). As can be seen in Figure 
1.47, TBA ILs with anions synthesised from organic acids and amino acids achieve levels of 
biodegradation that can be attributed to anion degradation only, with the TBA cation remaining 
intact. A more detailed metabolite analysis of the breakdown products would be required to 
confirm this assumption. Similarly, the triethylmethylammonium IL (173) examined by Stolte et 
al.
86
 Figure 1.48, did not undergo levels of biodegradation >5% in the manometric respirometry 
test. 
 
 
 
Figure 1.48. Triethylmethylammonium IL.
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Biodegradation values assessed by Manometric Respirometry (OECD 301F). 
A slight modification to the TBA cation produces the DMDBA family of QAC‟s. This 
modification, in stark contrast to other tetraalkylammonium salts, significantly increases the 
biodegradability (OECD 301F) of the QAC‟s, but only when paired with a biodegradable 
organic anion. In the study conducted by Jérôme et al. 2014 it was shown that the 
[DMDBA][Cl] (174) Figure 1.49, gave 5% biodegradation after 28 days, however changing to 
the acetate (175) lead to 77% biodegradation after 28 days, a dramatic overall increase. It is also 
important to note that the acetate anion can contribute only 28% to the overall carbon content of 
the IL. This strongly suggests that the anion has a crucial  effect on the cations biodegradation 
and could be occurring through a co-metabolic pathway; the cation and anion biodegrading 
concomitantly.
73
 The presence or absence of an organic anion appears to promote (60, 175-180) 
or prohibit (173), respectively, biodegradability for this series of compounds. The ILs studied in 
this work also showed excellent ability at dissolving cellulose with high recyclability.
73
  
 
Unfortunately the same effect of promoting biodegradation (OECD 301D) through the use of an 
organic anion is not apparent for the symmetrical tetraalkylammonium cations (56-59) Figure 
1.17, (168-172) Figure 1.47 as the results published by Bouquillon et al. demonstrates the 
robustness of the tetrabutylammonium cation, even when paired with a biodegradable 
carboxylate.
71, 72
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Figure 1.49. Biodegradation data for selected DMDBA ILs.
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Biodegradation values assessed by Manometric Respirometry (OECD 301F). 
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1.3.5.6 Phosphonium ILS 
 
In 2009 Scammels et al.
93
 screened a range of phosphonium ILs for their biodegradability (ISO 
14593) and, to the authors knowledge, represents the only phosphonium ILs to be examined for 
their biodegradability to date. The two cations screened were tricyclohexyl- and trihexyl-
phosphonium, Figure 1.50.
93
 
 
    
Figure 1.50. General structure of phosphonium cations, studied by Scammells.
93
 
 
 
Figure 1.51. Biodegradation data for tricyclohexylphosphonium ILs.
93
 
Biodegradation values assessed by CO2 Headspace test (ISO 14593). 
 
The general trend observed from the tricyclohexyl derived ILs, Figure 1.51, was a high 
resistance to biodegradation even though hydrolysable esters were included as one of the side 
chains. For example, compounds (181-183) gave between 2-4% biodegradation. Similarly with 
the ester bond in a different orientation (190), only a slight improvement in biodegradation to 
9% was observed. It is believed that the steric bulk of the tricyclohexyl rings inhibits access of 
esterase enzymes to the labile ester bond. Further altering the cation to NTf2 did not improve on 
biodegradability 2-9%, (184-186, 191). When the anion was exchanged to octyl sulphate, (187-
51 
 
189, 192), the expected increase in biodegradation (up to 22%) was observed, but can be solely 
attributed to the biodegradation of the anion and not the cation. 
 
 
Figure 1.52. Biodegradation data for trihexylphosphonium ILs.
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Biodegradation values assessed by CO2 Headspace test (ISO 14593). 
 
When examining the analogous trihexyl phosphonium derivatives, Figure 1.52, a similar 
recalcitrance to biodegradation (ISO 14593) was observed. Long alkyl chain ester bromide 
derivatives, (193-195), exhibited poor biodegradation of 4-12%. The reverse orientated ester 
(202), allyl (205), ether (208) and primary alcohol (211) halide analogues did not biodegrade (0-
2%).  The NTf2 derivatives (196-198, 203, 206, 209, 212) and octyl sulphate derivatives (199-
201, 204, 207, 210, 213) were also screened. In agreement with the tricyclohexyl derivatives 
results, exchanging the halide for NTf2 lead to no improvement while the octyl sulphate 
derivatives gave a range of biodegradation values between 5 and 30%. 
1.3.6 C2 symmetric and dicationic ILs – a new class of ILs 
 
Biodegradation studies of pyridinium cations tethered together using acetal linkers was initially 
examined by Scammells et al,
69
 Figure 1.53 (214-216). The design rationale behind this series 
of bis-pyridinium compounds was based on the hypothesis that under biodegradation test 
conditions the acetal could be hydrolysed to a free alcohol, generating the biodegradable 
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compound (109), Figure 1.33. Upon investigation, however poor biodegradation was observed, 
<5% in the CO2 headspace test, for the chloride, bistriflimide and PF6 ILs (214-216).  
 
 
 
Figure 1.53. Bis-pyridinium ILs (214-216).
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Biodegradation values assessed by CO2 Headspace test (ISO 14593) 
 
Other bis or dicationic ILs that have been tested for biodegradability include those synthesised 
and reported by Stolte et al. 2014, Figure 1.54. The C2 symmetrical imidazolium structures 
(217-224) and the pyrrolidinium structures (225, 226) encompass a great diversity and 
complexity in structure; from bis-ILs linked by an alkyl chain (217-222) to less lipophilic poly-
ether moieties bridging the two cations (223-226). Unfortunately, the trend for biodegradability 
(OECD 301F) for these dicationic ILs is the same as for the pyridinium species (214-216). A 
characteristic strong resistance to biodegradation is observed for these species, including 
examples containing butyl or hexyl alkyl chains (221-222). 
94
 Biodegradation for this series of 
compounds by Stolte et al. was observed to be <5%. 
 
A number of trends have been observed when reviewing the biodegradation results for all of the 
ILs encompassed by this review. The trends can be summarised as follows: 
 
 Terminal cyano groups are readily hydrolysable 
 Terminal alcohol groups can lead to an increase in biodegradation and are necessary for 
anaerobic degradation of alkyl chains 
 Length of alcohol substituent is important, some ethanol substituted compounds won‟t 
degrade yet the propyl derivative undergoes a disproportionate increase in 
biodegradability. 
 Ester bonds are readily hydrolysable but can slow down the rate of degradation 
 Amide bonds are far more robust than esters 
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 Long alkyl chains help to increase biodegradation except for morpholinium derivatives 
where it actually decreases 
 Amino acid cations are generally readily biodegradable 
 Organic acid anions are generally readily biodegradable 
 Colonial cations are generally readily biodegradable, but modification leads to a rapid 
drop off in biodegradation 
 Tetrabutylammonium cations are not readily biodegradable, yet the DMDBA cations 
are when paired with an organic anion 
 Hexyl and cyclohexyl substituted phosphonium ILs are too sterically hindered to 
undergo biodegradation 
 Non-aromatic cycles can be classed as readily biodegradable, but only if an N-
substituted alcohol of appropriate length is used or an alkyl chain of >8 carbons 
(however long chains can increase toxicity) 
 Dicationic ILs examined did not undergo biodegradation of >5% 
 
 
Figure 1.54. Biodegradation data for dicationic imidazolium and pyrrolidinium ILs (217-226) 
examined by Manometric Respirometry (OECD 301F),Stolte et al.
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1.4 Metabolite studies 
 
An active area in IL biodegradation research has been metabolite studies. It has been 
acknowledged that a molecule can pass the readily biodegradable threshold, but a portion may 
remain indefinitely in the environment. If a non-biodegradable metabolite (or even a metabolite 
that degrades at a slower pace) is toxic then its release into the environment through 
biodegradation pathways is a detrimental effect in what would otherwise seem to be a green 
process.  The 4th Principle of Green Chemistry tells us that chemicals should be designed to be 
both functional with minimal toxicity; therefore examining the toxicity of metabolites is a 
parameter of consequence.
8
 
 
Multiple methods of metabolite detection have been successfully employed including LC/MS 
techniques
95
, MALDI 
96
, GC/MS 
37
 etc. In the previous review published by Coleman and 
Gathergood in 2008, the metabolite studies of 1-butyl-3-methylpyridinium bromide 
97
 and 1-
octyl-3-methylimidazolium chloride 
62
 were discussed in detail. Since then a number of 
metabolite studies have been performed analysing the breakdown paths of ILs in OECD 
approved biodegradation tests and in more complex systems. Forays into predicting breakdown 
pathways have also been made using computer modelling. 
 
Two of the most common pathways examined in biodegradation and metabolism prediction are 
β-oxidation and/or ω-oxidation of fatty acid or long alkyl chain residues, Scheme 1.1 (227 to 
237) or the hydrolysis of susceptible bonds such as esters and amides followed by the β-
oxidation and/or ω-oxidation of any fatty acid residues, Scheme 1.2 (238-247). ω-Oxidation 
occurs with oxidation occurring on both ends of the alkane residue to form a dicarboxylic acid 
(242).
98
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Scheme 1.1. Potential β-oxidation pathway of an alkyl imidazolium IL. 
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Scheme 1.2. Potential β-oxidation pathway of an ester derived imidazolium IL. 
 
 
Using a combination of IC and LC-MS, pyrrolidinium, morpholinium, piperidinium and 
imidazolium ILs were examined for headgroup biodegradation, by Stolte et al. in 2014.
82
 The 
biodegradation and metabolites are shown in Figure 1.55 for the pyrrolidinium headgroup. 
 
 
Figure 1.55. Biodegradation of pyrrolidinium headgroup. 
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Stolte also showed that a number of cations (pyrrolidinium 1, 154; morpholinium (131); 
piperidinium (142, 143) and pyridinium (111, 112)) could be classified as inherently 
biodegradable after extended periods of time, >28 days, Figure 1.56. For piperidinium (142, 
143) up to 80% biodegradation after 60 days was observed, again classifying these compounds 
as inherently biodegradable. Supporting other aforementioned data on the imidazolium 
headgroup, no biodegradation was observed for these compounds.  
 
 
Figure 1.56. Inherently biodegradable ILs; effect of cations by Stolte.
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For more robust ILs the aerobic degradation process is much longer, as was observed by 
Gendazewska et al. 2014.
45
 After 28 days, limited aerobic oxidation of the 1-methylimidazolium 
hexyl side chain (100), Figure 1.29, to an aldehyde had been detected and a greater proportion 
of the hexyl substituted methyl imidazolium IL was detected by MS-MS showing that the 
biodegradation had progressed along the β-pathway very little (total biodegradation of ~ 9%). 
 
 
1.4.1 Aerobic degradation metabolite studies 
 
Docherty et al. 2010 reported the breakdown of three pyridinium ILs, [bmpyr][Br], 
[hmpyr][Br], [ompyr][Br] into their respective metabolites by GC-MS analysis. The degradation 
pathways were investigated and in this seminal work, metabolites were screened for their 
toxicity against daphnia magnia. The conclusion of this study on IL metabolites showed that the 
metabolites of these particular pyridinium ILs were less toxic than the parent ILs. 
95
 The results 
were discussed in the previous review published by Gathergood et al. 
22
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1.4.2 Pyridinium 
 
The total metabolism of a pyridinium IL [EtPy][BF4] and [EtPy][CF3COO] was successfully 
demonstrated by Zhang et al. in 2010 when an axenic culture of bacteria (Corynebacterium sp) 
demonstrated ring opening of the pyridinium cation (250 or 251) before the ethyl chain 
underwent oxidation to (252), Scheme 1.3. The study also demonstrated that the same bacteria 
could not successfully breakdown a methyl imidazolium IL [bmim][PF6] and would suggest that 
different cultures of bacteria are involved in degrading different classes of ILs. 
64
 
 
 
 
Scheme 1.3. Breakdown pathway of [EtPy][BF4] by an axenic culture of Corynebacterium 
The metabolic breakdown of [EtPy][BF4]  by an axenic culture of Pseudomonas fluorescens (P. 
fluorescens) was successfully analysed by Zhang et al. in 2011, Scheme 1.4, when the following 
breakdown pathway was published (Scheme 1.4). The study suggests that N-ethyl pyridinium 
(249) degrades by oxidation of the ethyl side chain (256 or 257) followed by the elimination of 
a molecule of ethanol and the formation of a pyridinium salt (258).
99
 The choice of bacteria for 
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this biodegradation test appears to have altered the metabolic breakdown pathway. In the first 
test described in Scheme 3, the pyridinium ring is completely mineralised by the 
Corynebacterium strain, yet P. fluorescens cannot completely mineralise the ring within the 48 
hours of the test described in Scheme 1.4. 
 
 
Scheme 1.4. Metabolism of [EtPy][BF4]  by an axenic culture of P. fluorescens.
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1.4.3 Sidechain studies 
 
Other metabolic pathways for ethoxylated molecules include terminal oxidation and hydroxyl 
shift metabolism, Scheme 1.5. Sato et al. 2001 demonstrated with the surfactant octylphenol 
polyethoxylate that the chain could be broken down by two possible pathways. Though these 
molecules are not ILs, a lot can be learned from potential biodegradation pathways of 
ethoxylated chains which have been previously employed in IL synthesis.
68
 The metabolites 
were analysed by MALDI-MS.
96
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Scheme 1.5. Breakdown pathway of a poly ethoxylated sidechain. 
1.4.4 Anaerobic degradation metabolite studies  
 
The 2010 investigation carried out by Neumann et al. on the anaerobic biodegradation of ILs, 
included a GC-MS analysis of an imidazolium IL (228), see anaerobic breakdown pathway 
Scheme 1.6. It is important to note, that under the anaerobic denitrifying conditions, 
biodegradation does not initiate without the presence of the free alcohol site on the alkyl chain. 
The anaerobic degradation pathways differ to the aerobic pathways in that oxygenase enzymes 
cannot insert oxygen into the terminus of alkyl chains under anaerobic conditions. The addition 
of a terminal alcohol could therefore allow some methyl imidazolium ILs an alternate 
biodegradation pathway, however 318 days were required for the last metabolite identified (21) 
to be detected.
53
 Anaerobic degradation can also take place by a fumarate addition mechanism. 
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Scheme 1.6. Anaerobic biodegradation of an imidazolium IL.
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1.5 Computer modelling and predictability and databases available 
containing IL biodegradation data 
 
ADMET - Absorption, Distribution, Metabolism, Excretion, Toxicity  
 
TSAR – Thinking in Structure-Activity Relationships 
 
SBR – Structure Biodegradation Relationships 
 
Aside from the physical aspects of measuring biodegradability of ILs there has emerged a drive 
to predict biodegradation using in silico techniques. Modelling software has been successfully 
used during drug development to screen drug activity and ADMET parameters and it is this 
ideology and technology that has been adapted for use in IL and surfactant biodegradation 
prediction. Current software that is available includes TOPKAT,
101
 META,
102
 BIOWIN, 
103
 
VEGA,
104
 START,
105
  (also part of ToxTree) and CATABOL.
106
 The software suites can have 
mixed results in predicting biodegradation pathways, in part due to the lack of available 
biodegradation data sets. In 2013, Benfenati et al. conducted an in-depth study of a number of 
the most popular biodegradation prediction suites (VEGA, TOPKAT, BIOWIN 5 and 6 and 
START) for the potential use in regulation under the EU REACH legislation or the 
“Registration Evaluation Authorization and Restriction of Chemicals”. A dataset of 722 
62 
 
compounds was chosen and the software packages were examined under the following 
headings: accuracy, sensitivity, specificity and Matthew's correlation coefficient (MCC). 
BIOWIN, TOPKAT and VEGA performed the best out of the examined software. VEGA and 
TOPKAT gave 88 and 87% accuracy in biodegradation prediction with BIOWIN 6 and 5 
performing slightly lower at 83 and 82% and START following up with 70%. Overall it was 
concluded that BIOWIN, TOPKAT and VEGA could be employed for legislative purposes.
107
 
However in a critical review by Rucker et al. 2012 it was demonstrated that there were issues 
present with using prediction software. The major downfalls being the difficulty in reproducing 
biodegradation data due to the inherent issues associated with bacteria and the variability they 
introduce into a system. Other issues include the secrecy behind some of the datasets used due 
to their sensitive nature in industry. Other biodegradation data never sees the light of day and 
remains under industry redaction permanently.
108
 
 
Currently a centralised database of some IL biodegradation data has been established by 
MERCK in association with UFT Bremen. There currently resides an ever growing library of 
data on IL - and other associated materials such as starting materials – biodegradation. With the 
ever increasing datasets available in "UFT / Merck ILs Biological Effects Database" more 
information about potential eco-persistence posed by ILs can potentially be determined before 
their synthesis even begins.
109
  
 
The SBR approach in conjunction with Boethling‟s rules of thumb for designing biodegradable 
compounds
75
 has led to successfully producing some of the first biodegradable ILs. Inspired by 
design strategies successfully implemented by the surfactant industry, the incorporation of ester 
linkages was demonstrated to promote biodegradability in a range of previously recalcitrant 
imidazolium ILs. 
80
 Similar design strategies include adding susceptible hydroxyl groups such 
as aldehydes, carboxylic acids and alcohols have all shown to promote biodegradation. 
Hydrolysable amides, although more stable to chemical hydrolysis than esters, can also 
potentially promote biodegradation. By considering how these molecules and their functional 
groups will interact in the environment and especially in WWTP‟s will allow for a more 
streamlined synthesis that promotes increased biodegradability. Will a particular bond interact 
with an enzyme to enhance breakdown? Or can this particular anion be used as a carbon source 
for aerobic digestion? Will a particular cation adsorb to a sewage floc or into soil and therefore 
be removed from aerobic degradation pathways altogether? These are the types of design 
questions that need to be considered when discussing an ILs structure and its potential 
interactions in the environment. 
 
63 
 
Combining the SBR approach with computer modelling will be the ultimate goal for rational 
design of sustainable and biodegradable green ILs. A well informed and designed synthesis, 
under the 10
th
 principle of green chemistry “Design for Degradation”, in conjunction with 
computer modelling of biodegradation can and will aid the design of the next generation of ILs.  
 
The greatest challenge with using in silico methods to predict biodegradation of ILs is that in 
many cases charged compounds, especially QAC‟s, are not suitable candidates for these models, 
(e.g. BIOWIN). In addition, as the majority of ILs screened up to 2010 did not pass readily 
biodegradable tests, despite the diversity of structures present, they collectively formed a biased 
training set for the model. However, as this review illustrates, the number of readily 
biodegradable ILs is increasing, and more balanced training sets are now potentially available. 
 
 
1.6 Abiotic Degradation - Chemically induced degradation in advanced 
systems 
 
Currently there is interest in the area of abiotic degradation of ILs due to the relatively low 
numbers of ILs passing readily biodegradable tests.
22
 Thus, solving the problem of poor 
biodegradability by investigating alternative methods to biological degradation has been 
examined including: advanced oxidation systems,
37
 peroxide,
40
 UV degradation,
110
 
electrochemical,
38,39
 and ultrasonic degradation.
40
 
 
With the increasing use of ILs in technological applications, the chance of release into the 
environment has grown. Environmental persistence of these compounds has already been 
postulated and current advanced oxidation process (AOP) technology has demonstrated that 
where ILs have failed biodegradation tests, AOP‟s can offer an alternative method of 
degradation. One of the most common AOP‟s that can potentially be used in WWTP‟s is the 
photolysis of hydrogen peroxide. This process involves irradiating H2O2 with 400 nm UV light 
causing rapid generation of hydroxyl radicals.  
 
Stepnowski et al.
35
 showed, by examining the degradation products formed under an advanced 
oxidation system (hydrogen peroxide 0.2% treatment time 2 hrs UV Lamp 254/366 nm), that 
the imidazolium core of ILs (8, 9, 12, 13), Figure 1.57, is the first part of the molecule to be 
affected and not the alkyl chain. It was also shown that the imidazolium ring was cleaved and 
lost its aromatic properties under the test conditions. Other observations include various 
hydroxyl groups inserted on the alkyl chains and carbonyl insertion into the cleaved 
64 
 
imidazolium ring, some of the observed degradation products (266-273) for [emim][Cl] are 
illustrated in Scheme 1.7.
37
 
 
 
Figure 1.57. Commercially available ILs tested under UV/H2O2 oxidation conditions.
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A real, applicable, benefit of an oxidative pre-treatment is that the imidazolium core, which has 
been shown not to break down under standard aerobic biodegradation conditions, has ring 
opened (266), Scheme 1.7. The insertion of carbonyl groups and hydroxyl functionalities also 
potentially allows for more rapid biodegradation as free hydroxyl groups have previously shown 
to enhance biodegradation of alkyl chains.
22
 
 
 
 
Scheme 1.7. Possible breakdown products detected by HPLC/MS for [emim][Cl] IL. Further 
fragmentation was analysed by MS/MS. 
 
 
Apart from UV/H2O2 oxidation, a number of other methods have been successful in the area of 
abiotic degradation. Ultrasonic breakdown of ILs in solution was demonstrated by Tsang et al. 
when they showed that a number of [Rmim] ILs (R = C2H5, C3H7, C4H9, C5H11, C6H13), Figure 
1.58, could be broken down in a H2O2/acetic acid/ultrasonic system at a temperature of 50° C. 
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This system performed to a much higher degree than systems based on the individual 
components used in the final degradation experiment, see Figure 1.59. Under the optimised test 
conditions >74% degradation was achieved for all compounds examined after 3 hours and after 
12 hours of test time >93% degradation of all ILs examined had been reached. >98% 
degradation of all 8 of the commercially available ILs was achieved within 72 h, Table 1.12. 
40
 
 
 
Figure 1.58. Structures of the commercially available ILs screened.
40
 
 
 
Figure 1.59. Radical oxidation of [bmim][BF4] under various oxidising environments. Adapted 
from Li et al 2007.
40
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Table 1.12. Oxidative degradation of alkyl imidazolium ILs assisted by acetic acid and 
ultrasonic irradiation. Adapted from Li et al 2007.
40
 
 Degradation % 
ILs 1 h 3 h 5 h 12 h 24 h 72 h 
C2mim Cl 53.49 76.55 86.62 95.09 96.27 98.35 
C3mim Cl 52.65 74.26 85.71 93.08 96.22 98.13 
C4mim Cl 54.60 76.07 87.45 94.58 97.25 99.16 
C4mim Br 55.35 76.91 87.33 93.66 96.47 98.75 
C4mim 
BF4 
54.78 75.25 86.29 94.18 96.87 98.89 
C4mim 
PF6 
53.26 77.47 87.63 95.38 97.76 98.47 
C5mim Cl 55.11 75.63 86.71 93.54 97.18 99.31 
C6mim 
BF4 
54.38 76.25 87.32 94.61 96.55 98.68 
25 ml solution, ILs: 2.5 mM, H2O2: 21 mM. CH3COOH: 10 mM at 50 °C. 
 
 
Scheme 1.8. Proposed degradation scheme by Li et al.
40
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The degradation pathways were also examined using GC-MS, Scheme 1.8. The proposed 
degradation products (276-283) were similar to a number of those reported by Stepnowski et al., 
Scheme 7.
37
 Two of the end products were determined to be biurea and acetoxyacetic acid, both 
“low-toxicity” molecules.40 
 
Further methods of IL degradation in AOP‟s include ozonolysis111 or employing the Fenton 
reaction.
112
 Ozonolysis results published by Pernak et al. in 2004 demonstrated the effective 
degradation of  98 pyridinium salts by ozonation within 30 minutes, examples of which include 
IL (284) Figure 1.60 and 1.61. The destruction of the IL is rapid and complete (100% 
degradation). 
 
Figure 1.60. Example of a pyridinium salt synthesised by Pernak et al.
111
 and examined for 
degradation in an AOP. 
 
Figure 1.61. Degree of destruction (%) vs time (min.) for a pyridinium salt (284), examined by 
Pernak et al.
111
 
In the Fenton reaction, H2O2 in combination with an iron catalyst, are used to produce hydroxyl 
radicals. However, a strong anion effect was observed on reaction time with the ability of [Cl
-
] 
ions from the IL to form Fe
3+
 chloride complexes and reduce the rate of radical production, 
Figure 1.62. [bmim][CF3SO4] was completely degraded after 45 minutes and its 
tricyanomethide analogue within one hour.
112
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Figure 1.62. Observed rate of degradation for [bmim][Cl] is slower than [bmim][CF3SO4] or 
[bmim][C(CN)3].
112
 
ILs have also been examined for their use in electrochemical systems as electrolytes due to their 
attractive properties as non-volatile tuneable solvents.
28
 The harsh conditions potentially present 
in some electrochemical applications has caused reported breakdowns of some of the ILs used.
38
 
Witkamp et al.
38
 demonstrated in 2006 that the use of semi-empirical PM3 quantum calculations 
allowed for the successful prediction of  IL breakdown in their electrochemical systems, 
including the range of decomposition products. The electrochemical conditions involved 
applying a voltage difference of 8V across the electrodes for 3 hours at room temperature. The 
decomposition products were subsequently detected by GC-MS. ILs examined were 
[bmim][BF4] 3 and [bmpyrrol][NTf2] 47 , Figure 1.63. 
 
 
Figure 1.63. [bmim][BF4] (3) and [bmpyrrol][NTf2] (47). 
 
Pyrrolidinium derivative (47) was observed to break down into a range of products including 
methylpyrrolidine, octanes, octenes, 2-butanol, dibutylmethylamine and butylpyrrolidine, 
Scheme 1.9, whereas with the 1-methylimidazole derivative (3), radicals are formed that react 
with each other in a radical–radical coupling reaction and in a disproportionation reaction.38 The 
successful application of quantum calculations in decomposition products shows the potential 
for predicting IL suitability for task and how the decompositions will affect their usefulness. 
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Scheme 1.9. Example of electrochemical decomposition of a pyrrolidinium IL. 
 
Similarly Van der Bruggen et al. demonstrated the breakdown of choline based ILs in a range of 
electrochemical applications, Scheme 1.10. 
39
 
 
Scheme 1.10. Electrochemical decomposition of a choline chloride (285).
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1.7 Biodegradable Surfactants: An IL by another name. 
 
Current designs of biodegradable ILs are based on mid-20
th
 century successes in the field of 
biodegradable surfactants.
113
 The drive to replace persistent and low biodegradability surfactants 
and fabric softeners has seen some great advances in the past 50 years. For instance, the 
replacement of "DHTDMAC" (di-hydrogenated tallow dimethylammonium chloride) with 
derivatives incorporating hydrolysable amide or ester linkages, example DEEDMAC,
114
 
demonstrated increased biodegradability and reducing foaming in sewage treatment plants. 
There are four major classes of surfactant: non-ionic, anionic, cationic and zwitterionic. ILs hold 
much in common with the ionic derivatives as the cationic surfactants usually are derived from 
quaternised nitrogen salts and the anionic derivatives derive their charge often from sulphonate 
salts. The drive to produce biodegradable surfactants is now cemented by the European 
Detergents Regulation (Regulation (EC) No 648/2004) which came into law on October 8 2005 
and states that “all surfactants used for domestic detergents have to be ultimately 
biodegradable”. An exception is also made for some surfactants for use in the industrial and 
institutional sector “which are primarily but not ultimately biodegradable only for very special 
purposes and after having obtained a derogation based on risk assessment and benefits 
evaluations”.113 With this regulation in place, designing surfactants for use in the European 
market requires that they are biodegradable by law. 
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Since the implementation of the law a number of biocompatible surfactant designs have been 
published. In 2010 Perez et al. published results on arginine based surfactants synthesised using 
enzymatic catalysis. 
115
 Three candidates were screened for their ready biodegradability and all 
three passed the CBT with 79-90% biodegradation values being recorded. All three surfactants 
contain amide and ester bonds and none showed recalcitrance to biodegradation. It is postulated 
that the use of natural building blocks in surfactants and ILs, such as amino acids, allow for 
easier recognition by enzymes and accessibility to a wider range of amino acid specific 
degradation pathways. 
 
Further work carried out on bis-arginine gemini surfactants by Lozano et al. 2011 further 
demonstrated the effectiveness of using natural building blocks in synthesising biocompatible 
surfactants. It was suggested that the high levels of biodegradation may be attributed to the 
formation of biodegradable intermediates during the biodegradation process such as arginine 
and glycerol.
116
 
 
A number of key points regarding surfactants were illustrated in the  review published by Ranke 
et al. 2007
117
 and are summarised as follows: 
 
Cations: 
 Medium alkyl chain length pyridinium cations are potential candidates for producing 
readily biodegradable surfactants 
 Alkylpyridinium surfactants are poorly biodegradable  
 Dialkyldimethyl-ammonium and alkyldimethylbenzyl-ammonium quaternary 
compounds are less biodegradable than monoalkyltrimethyl-ammonium quaternaries 
but more biodegradable than alkyl pyridinium surfactants 
 
Biodegradability: monoalkyltrimethyl-ammonium > dialkyldimethyl-ammonium and 
alkyldimethylbenzyl-ammonium > alkylpyridinium 
 
 
Anions: 
 Linear alkylsulphates exhibit excellent biodegradability 
 Linear alkyl sulphonates and alkylbenzene sulphonates show good biodegradability 
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Surfactants are screened for biodegradation in the same tests that can be employed for ILs, vide 
supra. When released to the environment or indeed to a WWTP, surfactants are not treated as 
single compounds but as complex mixtures. In 2008 Kümmerer et al.
119
 screened mixtures of 
surfactants for their biodegradability and compared the mixtures to the single compound results, 
Table 1.13. It was found that ion pair formation between organic anions and quaternary 
ammonium cations, e.g. between LAS (linear alkylbenzene sulphonate) and BAC 
(benzalkonium chloride) caused a decrease in biodegradation. It was suggested that compounds 
above 500 Da render the molecule impossible to biodegrade and indeed mixtures of BAC:SDS 
or DDMAC (didecyldimethylammonium chloride):LAS are all above this molecular weight. 
 
Substance 
% Biodegradability 
CBT
a
 
 
BAC - benzalkonium chloride 
-8 
 
DDMAC - didecyldimethylammonium chloride 
4 
 
 
EL - Ethacridine lactate 
13 
 
BSA – Benzene sulfonic acid 
25 
 
LAS – Linear alkylbenzene sulfonate 
50 
 
12 
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NSA – Naphthalene sulfonic acid 
 
SDS – Sodium dodecyl sulfate 
69 
BAC:BSA 1:1 45 
BAC:LAS 1:1 13 
BAC:NSA 1:1 45 
BAC: SDS 1:1 39 
DDMAC:LAS 1:1 11 
DDMAC:NSA 1:1 -2 
DDMAC:SDS 1:1 15 
EL:BSA 1:1 1 
EL:LAS 1:1 23 
EL:NSA 1:1 16 
EL:SDS 1:1 36 
Table 1.13. Biodegradation of surfactants and mixtures of surfactants.
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a
Biodegradation values assessed by the CBT OECD (TG 301D) 
 
The biodegradability of tris (286-297) and tetrakis (298-309) imidazolium and benzimidazolium 
IL surfactants, Figure 1.64, using the CBT (OECD 301D) was reported in 2015 by Al-
Mohammed et al.
16,17
 As can be seen from Figure 1.64, a number of tris and tetrakis 
imidazolium and benzimidazolium ILs with various alkyl chain lengths, from C4 to C12 and 
benzyl, were synthesised and evaluated for their surfactant properties and their biodegradability. 
The same trend of increased biodegradation with increased chain length can be observed for 
these series of IL surfactants with C12 (290, 296, 302, 308) degrading the most (45-56%) and C4 
(286, 292, 298, 304) the least (22-35%) and the non-linear N-benzyl derivatives (291, 297, 303, 
309) degrading even less than the C4 derivatives (16-22%). The tetrakis family (298-309)  in 
general appeared to have slightly elevated levels of biodegradability, ~5-10%, when compared 
to the tris family (286-297). The benzimidazolium tris (292-297) and tetrakis (304-309) families 
in turn were observed to have lower levels of biodegradability throughout the homologous 
series of alkyl chains than their respective imidazolium families (286-291, 298-303). A plateau 
in the levels of biodegradability was reached after 16 days and the tests were not run for the full 
28 day period.  
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Figure 1.64. Tris- and tetrakis-imidazolium and benzimidazolium IL surfactants examine for 
their biodegradability. 
 
The scope of this review does not include an in depth discussion on biodegradable surfactants, 
however the author wishes to acknowledge the overlap between IL biodegradation and the 
lessons that can be learned from biodegradable surfactant research. 
1.8 Outlook and recommendations 
 
To date a number of readily biodegradable ILs have been synthesised, ILs (54, 55, 60-66, 101, 
102, 109, 110, 120, 122, 151, 156-158, 161-165, 175, 176, 178, 180, 310-322). Nearly 50%, of 
the readily biodegradable ILs have been comprised of a cholinium cation and organic acid 
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anion. (61-66, 157, 310-322). The cholinium cation was shown to be highly sensitive to 
modification, with most modifications reducing biodegradability. The cholinium family of ILs 
present the most effective route to readily biodegradable compounds examined to date. 
 
Protic analogues of the cholinium core also proved to be good candidates for synthesising 
biodegradable ILs with seven considered readily biodegradable (54, 55, 161-165) 
 
Efforts to prepare a readily biodegradable imidazolium IL have demonstrated that the 
imidazolium core does not degrade under standardised ISO or OECD test conditions. Chemical 
oxidation is the most effective method to degrade these compounds. Substitution at the 
imidazolium rings C2 and C4/5 positions with electron withdrawing groups and readily 
hydrolysable groups such as esters and amides did not significantly improve biodegradation. It 
is the recommendation of this review that further studies into imidazolium ILs biodegradation 
are required. 
 
Biodegradable pyridinium ILs have been synthesised (109, 110, 120, 122). Three examples 
(109, 110, 122) critically include a primary alcohol terminated chain on the N-position. 
Pyridinium ILs are very sensitive to modification on the ring with many derivatives which fail 
the CBT and CO2 headspace test known including 3-position and N-substituted ethers . 
 
Most tetra alkylammonium cations do not undergo high levels of biodegradation with the 
exceptions of TMBA IL (158) and 5 DMDBA examples (60, 175, 176, 178, 180). The DMDBA 
ILs all required a carboxylate counterion for biodegradation to be high enough to pass readily 
biodegradation tests. The chloride DMDBA derivative (174) was found to undergo just 5% 
biodegradation.  
 
Hexyl and cyclohexyl phosphonium cations appear to sterically hinder enzymatic degradation 
and further studies in this area are required. It is proposed that shorter, less bulky, alkyl chain 
substituted phosphonium cations or an asymmetrically substituted cation paired with an organic 
acid anion may undergo a higher level of biodegradation similar to the DMDBA series.  
 
Non-aromatic 6 membered cyclic compounds examined, such as the morpholinium, DABCO 
and piperidinium ILs are in general not readily biodegradable. One exception is the derivative 
(143), which degraded 79%. The primary structural feature of (143) enabling biodegradation 
was the presence of an N-substituted propyl alcohol terminated chain. The chain length was also 
of importance, with an ethyl derivative (142) undergoing a considerably lower 29% 
biodegradation. 
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The 5 membered non-aromatic pyrrolidinium heterocycles underwent similar levels of 
biodegradation to the 6 membered cycles with the exception of derivatives (151) and (156), both 
achieving greater than 60% biodegradation. The key structural feature of (156) was an N-
substituted octyl chain while the critical feature of (151) was the presence of an N-substituted 
propyl alcohol. Once more it was observed that the shorter ethyl alcohol substituted IL (153) did 
not undergo biodegradation >6%. 
 
Biodegradation screening of symmetrical ILs has been undertaken since Coleman and 
Gathergood‟s review in 2010 with a number of imidazolium, pyridinium, pyrrolidinium ILs 
studied. The dicationic ILs screened all failed to achieve > 5% biodegradation under their 
respective test conditions and it has been surmised that the compounds are resistant to 
biodegrading due to inability of enzymes to access hydrolysable sites, whether this is due to 
steric effects or electronic considerations is unknown. 
 
Metabolite identification as part of biodegradation studies provides useful data to allow 
researchers to design ILs which can not only pass readily biodegradable tests but reduce the 
build-up of persistent breakdown products. 
 
1.9 Conclusion 
To conclude this IL biodegradation review it is necessary to examine the guidelines with which 
potentially biodegradable ILs are designed. Often, Boethling‟s rules of thumb are quoted for 
designing biodegradable ILs but just how compatible are these rules with the ILs that have been 
synthesised in the past decade?  
 
When the trends in IL biodegradation are taken as a whole it can be observed that a number of 
the rules of thumb hold true. Longer unbranched alkyl chains promote biodegradability and the 
presence of hydrolysable groups (i.e. esters) and groups easily oxidised (i.e. alcohols) and 
carboxylic acids are noted as being amongst the prominent features of the readily biodegradable 
ILs in this chapter. The use of natural building blocks for instance, choline and nicotinic acid for 
the cation can lead to biodegradable derivatives. However, even modest changes to the structure 
can in some cases greatly inhibit access to biodegradation pathways. Detrimental factors that 
have been observed, that are in agreement with the rules of thumb, include the presence of 
aliphatic ethers. It is stated in the rules of thumb that heterocycles are best avoided, making the 
task of producing heterocyclic ILs a challenge from the very beginning, although every 
compound is unique and requires careful consideration of all structural features. 
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The goal of making task specific yet biodegradable low toxicity ILs is a daunting one. Can ILs 
which are robust under a wide range of applications (e.g. chemical reactions, thermal, 
biocatalysis etc.), yet are suitable substrates for breakdown pathways in the environment, 
leading to ultimate biodegradation be designed? While this task is challenging, from the data 
collated in this review the author believes that great progress is being made towards this goal. 
 
To undergo a full eco(toxicity) life cycle assessment is the ultimate goal for any IL that has 
potential industrial application. The hazard of using the IL versus the benefits must be carefully 
reviewed as ILs move from academic curiosities to large scale industrial applications. Further 
studies on metabolic pathways and breakdown products for ILs will be required to stimulate 
advances that are required in producing readily biodegradable ILs. Ultimately (eco)toxicity 
analysis of these metabolites will also be required, for after all, what is the benefit of nowadays 
producing a readily biodegradable IL if its persistent breakdown products are more toxic than 
the parent compound? Intense debate, of this very issue, at green chemistry, IL and 
environmental toxicology meetings, conferences and in research papers has raised awareness of 
the limitations of standardised biodegradation tests. It is proposed that the outcome from this 
process is that current biodegradation studies of ILs are now at the forefront of new initiatives in 
biodegradation assays and reinterpretation of results. Chemists working together with experts in 
environmental science and (eco)toxicology can work towards the common interest of the design 
of safer chemicals.  Indeed, although the number of possible cation and anion combinations 
which lead to salts classed as ILs seems mindbogglingly large (frequently >10
18
), this is a small 
subset of possible simple organic molecules. The journey which scientists who study 
biodegradation of ILs have travelled is a roadmap to enable other researchers to reduce the 
potential problems of emergence of persistent chemicals in the environment. 
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Chapter 2 
Synthesis of 1st Generation Amino Acid Ionic 
Liquids 
 
 
 
 
 
 
 
Sections of Chapter 2 have been published in Green Chemistry as part of two back to back 
publications in collaboration with Prof. Klaus Kümmerer and are as follows: 
Synthesis of a Series of Amino Acid Derived Ionic Liquids and Tertiary Amines: Green 
chemistry metrics including microbial toxicity and preliminary biodegradation data analysis. A. 
Jordan, Haiß, M. Spulak, Y. Karpichev, K. Kummerer and N. Gathergood, Green Chem., 2016, 
DOI: 10.1039/C6GC00415F.
1
 
 
On the way to greener ionic liquids. Identification of a fully mineralizable phenylalanine-based 
ionic liquid. Hai, A. Jordan, J. Westphal, E. Logunova, N. Gathergood and K. Kummerer, 
Green Chem., 2016, DOI: 10.1039/C6GC00417B.
2
 
 
Reproduced by permission of The Royal Society of Chemistry 
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2.1 Aim 
The aim of this investigation was to synthesise a series of amino acid derived ILs, henceforth 
referred to as the 1st generation amino acid ILs, with respect to the principles of green 
chemistry and Boethling‟s rules of thumb for designing biodegradable compounds,3 the 12 
principles of green chemistry,
4
 and preceding generations of research conducted within the 
Gathergood research group.
5-10
 Antimicrobial toxicity and biodegradability of the compounds 
was also to be investigated as part of the assessment of the ILs potential “greenness”. Data 
provided by such studies can contribute to defining structure activity relationships (SAR) and 
structure activity biodegradation relationships (SABR) of the series of ILs and aid in rationally 
designing subsequent generations of ILs. Searching for applications suited to the ILs that are 
designed within the Gathergood group is not the foremost concern, (although model studies for 
future surfactant compounds is a long term research theme). The primary goal is to synthesise 
low toxicity, biodegradable ILs and then search for suitable applications after this assessment 
has been carried out. This design strategy ensures that even if no useful application can be found 
then the data collected on the toxicity and biodegradability can be utilised in rationally 
designing next generation ILs. Toxicity and biodegradability assessments are completely 
independent of application. This design strategy can be visually summarised in Figure 2.1. 
 
Figure 2.1. IL design strategy 
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2.2 Introduction 
A series of L-phenylalanine ILs, L-tyrosine ILs and L-phenylalanine tertiary amines was 
synthesised to investigate their antimicrobial toxicity and biodegradability. The general 
structure of the ILs consisted of an ethyl ester of an amino acid as a backbone (Figure 2.2). An 
ethyl chain length for the ester moiety was chosen as ethanol is available as a bio-renewable 
starting material for the esterification and will not contribute disproportionate amounts of 
carbon towards the overall biodegradability of the molecule, see Chapter 1 for ester 
biodegradation of ILs (e.g. 75, 76, 82, 83). Additional carbon in the alkyl sidechain can increase 
biodegradability but may not accurately represent whether the entire molecule is degrading or 
whether the ester is only degrading. A short ester chain length should also help in avoiding the 
associated toxicity that comes with longer alkyl chain cationic molecules.
11, 12
 Phenylalanine 
was chosen as the amino acid backbone as this is also available from potentially bio-renewable 
sources
13
 and results in the introduction of an amide functionality into the IL with the aim of 
inducing biodegradation by enzyme recognition by amidase enzymes.
14
 Phenylalanine‟s 
aromatic side chain also allows for additional lipophilicity in the molecule without extending 
the ester chain length, significantly increasing the melting point and enhancing stability. The 
headgroup is linked to the amino acid using an amide linker. Ester chain length and counter-ion 
were not varied in this study and only the headgroup chosen was alternated allowing this study 
to demonstrate the effect of headgroup on biodegradability and toxicity. A subseries of tertiary 
amino derived compounds was synthesised to investigate the effect of the presence of a 
quaternary nitrogen atom on the toxicity and biodegradability and if the presence or absence of 
a positive charge would promote or retard biodegradability and toxicity. Furthermore the 
enzyme phenylalanine hydroxylase (PheOH) can convert phenylalanine into tyrosine by an 
oxidative insertion mechanism
15
 and there exists the possibility that phenylalanine ILs could be 
converted in vivo to the tyrosine derivatives before undergoing biodegradation thus a number of 
L-tyrosine derived ILs were synthesised to investigate whether the presence of a phenolic OH 
group would affect the toxicity and biodegradability. 
 
 
Figure 2.2. General structure of L-phenylalanine (left) and L-tyrosine (right) ILs synthesised. 
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2.2.1 The twelve principles of green chemistry and green chemistry metrics 
 
ILs presented within this chapter were synthesised according to the 12 Principles of Green 
Chemistry. The following is an excerpt from a review published by Gathergood and Jordan  
(2013) entitled Designing Safer and Greener Antibiotics in which the 12 Principles are 
discussed.
16
 
 
The twelve principles of green chemistry are a set of guidelines which “have directed green 
chemists in their research endeavours since the late 1990's and were proposed by Anastas and 
Warner. The principles provide a framework that when adhered to can lead to synthetically 
useful molecules that are conceived, used, and disposed of, in a more environmentally friendly 
manner
17”.16 ILs discussed within this chapter, and subsequently Chapter 3, were synthesised 
according to the following principles outlined by Anastas and Warner: 
 
The twelve principles defined are as follows: 
1. Prevention 
It is better to prevent waste than treating waste after it is produced.
18
 
2. Atom Economy 
Synthetic methods should be employed so as to maximise incorporation of all reagents used, 
in the final product.
19
 
3. Less Hazardous Chemical Syntheses 
When possible, reagents and synthetic methods less toxic to human health and the 
environment should be used.
20
 
4. Designing Safer Chemicals 
Chemicals should be designed, fit for purpose, with minimum toxicity to humans and the 
environment.
21
 
5. Safer Solvents and Auxiliaries 
The use of auxiliary substances such as solvents, drying agents etc. should be reduced when 
possible.
22
 
6. Design for Energy Efficiency 
The energy required to perform a chemical process should be kept to a minimum, e.g. 
temperature and pressure conditions of reactions.
23
 
7. Use of Renewable Feedstocks 
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Raw materials should be from a renewable source if possible.
24
 
8. Reduce Derivatives 
Unnecessary use of protecting groups and structural modifications should be avoided to 
minimise waste production and energy consumption.
25
  
9. Catalysis 
Employing catalysts reduces waste and energy requirements and should be used when 
possible and appropriate, i.e. selectivity.
26
 
10. Design for Degradation 
Synthetic molecules should be designed to breakdown in the environment after use to avoid 
chronic build-up effects. Eventual fate in the environment must be considered.
27
 
11. Real-time analysis for Pollution Prevention 
Real-time process monitoring to control and prevent the production of potentially hazardous 
materials should be employed.
28
 
12. Inherently Safer Chemistry for Accident Prevention 
Safer reagents, procedures and processes should be employed to reduce the chance of 
accidents and exposure of chemicals to the environment and people.
29
 
 
 “By incorporating the design principles outlined above, chemists from academia and industry 
can effectively produce molecules that are fit for purpose and pose far less of a risk to the 
environment. By including biodegradation, toxicity, sustainability and life cycle assessment in 
design criteria, ranges of safer compounds can be effectively produced with reduced impact on 
ecosystems.”16 
 “To analyse a pharmaceutical process or a research project one must first produce a set of 
standards, tests or a scale with which to measure the projects “greenness”. Pioneers of green 
chemistry metrics in the early 1990s established concepts such as “Atom Economy (Trost) 19, “E-
factor(Sheldon),
18
 “Andraos Reaction Mass Efficiency”,30 “GSK Reaction Mass Efficiency”, 
“Process Mass Intensity”, “Solvent Intensity”31-33. The concept is that every chemical process 
can be analysed and its greenness determined, compared and improved. 
In recent years, there has been a drive in the pharmaceutical industry to produce an API with a 
minimum amount of waste. There is often an economic incentive as well as benefit to the 
environment. The largest materials usage in the pharmaceutical industry is solvents, which make 
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up to 90% of material usage producing bulk API 
34
. This makes solvent choice of paramount 
importance. Pharmaceutical companies have reported solvent selection guides, which illustrate 
pros and cons of common solvents used in their processes, including common chlorinated solvents 
and their alternatives.
25
 
The atom economy of a reaction represents the percentage incorporation of starting materials 
into the final product, so a reaction with 100% atom economy will have complete incorporation 
of all starting materials into the product. For example, a Diels-Alder reaction can have up to 
100% atom economy, whereas a Wittig reaction in general is rated with a very low value. 
However, percentage yield is not a consideration when calculating the atom economy. In 
addition, atom economy, which can be very easily calculated from a reaction scheme, does not 
take into account solvent and bulk materials used in the process (e.g., product isolation). The 
Sheldon “Environmental Factor”, or E-factor, does include solvents and waste parameters and 
is a simple calculation of waste quantity divided by product quantity; the lower the number the 
more environmentally acceptable the process.” 
 
The equations associated with the green chemistry metrics are outlined as follows:  
 
Atom Economy
19
, E-factor
18
, Andraos Reaction Mass Efficiency
30
, GSK Reaction Mass 
Efficiency
35
, Mass Intensity
36
, Solvent Intensity
36
, Stoichiometric Factor
30
  and Material 
Recovery Parameter.
33
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Two variations of atom economy (AE) are reported in the literature. The outlined AE above 
includes the molecular weights of all reagents. This inclusion means that auxiliary bases and 
acids etc. that take part in the reaction but are not incorporated into the final product are 
considered in the calculation. The other reported AE calculation only takes the sum of the 
molecular weights of all reactants i.e. chemicals in the reaction that some portion of which are 
incorporated into the final product.
37
 The AE calculation that is employed in this chapter 
includes all reagents as it was felt that this equation better represents the synthetic 
methodologies employed. The replacement of a high molecular weight auxiliary base with a 
lower molecular weight auxiliary base could reduce the overall mass of the reaction and can 
lead to greener synthesis and lower mass intensive processes. 
2.2.2 Synthesis 
2.2.2.1 Targets 
 
As previously stated in Section 2.1 and 2.2 the series of ILs (Figure 2.3) were designed with 
respect to Boethling‟s rules of thumb for designing biodegradable compounds,36 the 12 
principles of green chemistry,
17
 and the preceding generations of research conducted within the 
Gathergood research group.
5-10
  Ester group substituent was maintained as an ethyl ester for all 
compounds synthesised in this chapter to allow this study to demonstrate the effect of the 
headgroup on biodegradability and toxicity. Scope of headgroups includes cationic aromatic 
heterocycles, non-aromatic heterocycles and linear quaternary amines. 
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Figure 2.3. Target L-phenylalanine ILs synthesised. 
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2.2.2.2 Synthesis of L-phenylalanine ILs 
A series of L-phenylalanine ILs (324-335) (Figure 2.3), were synthesised in a high yielding, 
three step synthesis outlined below in Scheme 2.1 
 
 
Scheme 2.1. General synthetic route employed for L-phenylalanine bromide ILs (324-335). 
Step 1:  Fischer-Speier esterification of L-phenylalanine was carried out using thionyl chloride 
(to produce dry HCl in situ) and an excess of ethanol to furnish (336) as a HCl salt which was 
then subsequently neutralised to the free base amine (336). 
 
Step 2: L-Phenylalanine derivative (336) from step 1 was acylated to form the α-bromoamide 
(337). No column chromatography was required for purification at this stage. 
 
Step 3: α-Bromoamide alkylating reagent (337) was reacted with the nitrogen heterocycle/ 
tertiary amine of choice, usually in diethyl ether at room temperature for 24 hours, to yield ILs 
(324-326, 328-330). IL (327) required reflux conditions in THF for 48 hours and ILs (332-335) 
required reflux conditions in ethyl acetate to achieve satisfactory yields. Alkylating reagent 
(337) is the key to this series of compounds as it represents a modular building block that acts as 
a platform to numerous other targets. 
 
The synthesis outlined in Scheme 2.1 is a modification of that employed by Coleman and 
Gathergood
5
 and presents an overall improvement in the formation of the alkylating reagent 
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(337). The method outlined for the formation of (337) in the literature involves the reaction of 
an amino acid ester hydrochloride with an excess of K2CO3 or TEA, and bromoacetyl bromide 
carried out at -78 °C, conditions (A) (Table 2.1). This method results in the formation of 
coloured impurities if using TEA, possibly due to the Menschutkin reaction,
38
 or TEA-Br 
having partial solubility in the organic layer that is not removed during an aqueous workup step. 
Changing the base for Na2CO3 as in conditions (B) demonstrated that impurities were also 
present at the end of the reaction time due to the rate of neutralisation of the ester hydrochloride 
being too slow, thus encouraging the formation of side products. The synthesis route was 
modified so that the amino acid ester was neutralised to the free base form before being used in 
the reaction. An excess of Na2CO3 was used as an auxiliary base to remove the HBr formed 
during the reaction. This pre-neutralisation step allowed the primary amine of the amino acid 
ester to rapidly and cleanly react with the bromoacetyl bromide subsequently added to the 
reaction and avoided the formation of unwanted side products. Room temperature reaction 
conditions were also employed with no formation of side products detected by TLC. Reaction 
conditions (C) resulted in a reaction mixture that could be purified by filtration to remove the 
Na2CO3 followed by aqueous bicarbonate solution washings of the organic layer to remove any 
HBr and bromoacetic acid. Removal of the organic solvent in vacuo furnished the desired 
alkylating reagent in high yields as a white solid with no further purification required. 
Percentage yields from the various reaction conditions are summarised in Table 2.1. THF was 
also trialled as a replacement reaction solvent resulting in a good yield (74%) with a five hour 
reaction time and no chromatography required for purification, conditions (D). Similarly ethyl 
acetate was assessed as reaction solvent, conditions (E), however this time multiple impurities 
were detected by TLC after a five hour reaction time and no further work was carried out with 
this solvent. 
 
Table 2.1. Summary of yields obtained for compound (337) acylation reaction optimisation. 
Conditions A B C D E 
Yield (337) 64%
5
 61% 89% 74% N/A** 
Starting Material 336.HCl 336.HCl 336 336 336 
Base TEA Na2CO3 Na2CO3 Na2CO3 Na2CO3 
Reaction time 5 h 5 h 3 h 5 h 5 h 
Solvent DCM DCM DCM THF 
Ethyl 
Acetate 
Colum Chromatography Required? Yes No
*
 No No Yes 
*Bromoacetic acid detected by 
1
H-NMR, even after aqueous bicarbonate workup. 
** Multiple spots detected by TLC, no further work carried out. 
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Figure 2.4. 
1
H-NMR of alkylating reagent (337) in CDCl3 after aqueous workup and drying. 
 
From the 
1
H-NMR of alkylating reagent (337) (Figure 2.4) it can be seen that the L-
phenylalanine sidechain appears as a 5 proton multiplet 5-9 in the aromatic region (7.33-7.10 
ppm). The amide proton 2 appears as a doublet at 6.86 ppm coupling to the proton at the 
stereogenic centre at position 3 with J = 7.8 Hz. At 4.83 ppm a doublet of triplets (dt) is visible 
with J = 7.8, 5.8 Hz and can be attributed to the proton at stereogenic centre 3 coupling to the 
amide proton and the protons on the benzylic position of the L-phenylalanine sidechain 4. One 
may expect to observe that the benzylic protons are inequivalent due to diastereotopic effects 
(i.e. the proton on the stereogenic centre 3 should be coupling to three inequivalent protons), 
giving rise to a doublet of doublet of doublets (ddd). However, when the two smaller coupling 
constants are the same in the ddd and overlap occurs then the ddd appears as a dt instead.
39
 At 
4.19 ppm the -CO2CH2- protons on the alkyl chain 10 are present, coupling to the neighbouring 
CH3 terminus 11 of the chain to give a quartet with J = 7.1 Hz. Further upfield at 3.87 ppm and 
3.83 ppm there are two doublets present which can be assigned as the protons 1’ and 1” α to the 
bromide atom. The presence of two doublets infers that these protons are not chemically 
equivalent and exhibit geminal coupling due to the protons diastereotopic nature. The protons 4’ 
and 4” on the benzylic position of the L-phenylalanine sidechain occur as diastereotopic 
protons, coupling to the chiral proton 3 and to each other to give rise to two doublets of doublets 
at 3.17 ppm and 3.13 ppm with J = 6.0, 3.1 Hz. Lastly the CH3 terminus of the alkyl chain 11 is 
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present at 1.25 ppm as a triplet, coupling to the neighbouring CH2 protons on the alkyl chain 
with J = 7.1 Hz. 
2.2.2.3 Synthesis of nitrogen heterocycles 
Not all nitrogen heterocycles were commercially available and examples (338-343) were 
synthesised as outlined in Scheme 2.2. Synthesis of proline esters was accomplished as 
described for L-phenylalanine ester (336). Synthesis of N-methyl proline was by reductive 
amination of formaldehyde, using an excess of aqueous formaldehyde solution under a H2 
atmosphere in the presence of 1-5 mol% of Pd/C. The mechanism is outlined in Scheme 2.3. 
and the reaction was carried out according to the literature procedure of Lin et al.
40
 
 
 
 
Scheme 2.2. General scheme for the synthesis of D- and L-Proline heterocycles (338-343). 
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Scheme 2.3. Reaction mechanism for the reductive alkylation of L-proline. 
 
 
Scheme 2.4. Alkylation of tertiary amines with (337) to give ILs (324-335). 
The reaction of (337) with amines of choice gave ILs (324-335), in up to excellent yield (e.g. 
ILs 325, 330 98%) although a wide range of yields (13-98%) was observed (Table 2.2). 
Reactivity of the amines used and the ease in which the target precipitated can be directly 
compared to the range in yields observed. Reduced yields for ILs (327, 331-335) is most likely 
due to the presence of electron withdrawing groups on the 3-position of a number of the 
heterocycles, specifically the ethyl esters present on the ethyl nicotinium IL (327) and on the 
prolinium derivatives (332-335), which reduce the overall nucleophilicity of the nitrogen 
heteroatom. Reduced yield for (329) is attributed to the slower rate of precipitation observed. 
No purification was required for the majority of the compounds except for final purification of 
(327) from unreacted ethyl nicotinate. Separation of the epimers (332-333) and (334-335) was 
carried out by silica gel chromatography. Separation of the epimers (332-333) and (334-335) 
was carried out by silica gel chromatography. For the reaction that produced epimer pair (332, 
333) a ratio of 5:2 (IL 332: IL 333) was estimated by 
1
H-NMR before purification. Similarly for 
epimers (334, 335) a ratio of 5:2 was also observed (IL 335: IL 334). Determination of absolute 
stereochemistry for these derivatives is discussed in Section 2.2.2.4. 
 
 
94 
 
Table 2.2. Yields under different conditions for L-phenylalanine ILs (324-335). 
*No product detected by TLC 10% MeOH:DCM 
 
From Table 2.3 a wide range of melting points for the ILs synthesised can also be observed (60-
164 °C). Under the classical definition of an IL existing as a liquid below 100 °C all examples 
with the exception of (328, 329, 331) conform, though (325, 330) have melting points very 
close to 100 °C. 
 
Table 2.3. Melting points (uncorrected) obtained for L-phenylalanine ILs (324-335). 
 
 
Compound Reaction Conditions Yield % 
324 Diethyl Ether, rt, 24 h, 89 
325 Diethyl Ether, rt, 24 h, 98 
326 Diethyl Ether, rt, 24 h, 96 
327 Diethyl Ether, rt, 24 h, 0* 
327 THF, reflux, 48 h 56 
328 Diethyl Ether, rt, 24 h, 88 
329 Diethyl Ether, rt, 24 h, 34 
330 Diethyl Ether, rt, 24 h, 99 
331 Diethyl Ether, rt, 24 h, 91 
332 Ethyl Acetate, reflux, 48 h 37 
332 Diethyl Ether, rt, 24 h, 0* 
333 Ethyl Acetate, reflux, 48 h 13 
333 Diethyl Ether, rt, 24 h, 0* 
334 Ethyl Acetate, reflux, 48 h 25 
335 Ethyl Acetate, reflux, 48 h 34 
Compound Melting Point °C 
324 77-79 
325 98-100 
326 72-74 
327 60-62 
328 135-137 
329 162-164 
330 97-99 
331 102-104 
332 Liquid at RT 
333 Liquid at RT 
334 Liquid at RT 
335 Liquid at RT 
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Figure 2.5. 
1
H-NMR of Imidazolium IL (324) in CDCl3 . 
From the 
1
H-NMR of (324) (Figure 2.5) it can be seen that the single C-H proton on the 
imidazolium ring C2 position 2 appears as a singlet far downfield at 9.80 ppm. Amide proton 6 
is present as a doublet at 8.90 ppm with a coupling constant J = 1.7 Hz, coupling to the proton 
on the stereogenic position 7. The aromatic region of 7.42-7.11 ppm contains 7 protons, two 
methine protons from the imidazolium ring are present 3, 4, and the protons on the phenyl ring 
of the L-phenylalanine group 9-13. CH2 protons, α to the carbonyl group of the amide linker 5’, 
5” are present at 5.37 ppm and 5.31 ppm as two sets of doublets due to their diastereotopicity. It 
is proposed that the presence of the doublets could also be due to hydrogen bonding of the 
protons 5’, 5” to the bromide counterion introducing an inequivalency and hence geminal 
coupling of the protons with J = 15.0 Hz. The mode of bonding is proposed in Figure 2.6. 
Protons 5’, 5” are present as two doublets at 3.87 ppm and 3.85 ppm in the alkylating reagent 
(337), α to the bromide atom, and are shifted downfield  in the 1H-NMR of (324) by 1.5 ppm 
due to the much higher electron withdrawing effect of the imidazolium group compared to the 
bromine. The proton at the stereogenic centre 7 is present as a doublet of doublet of doublets at 
4.67 ppm due to the coupling of proton 7 to amide proton 6 and the inequivalent protons on the 
benzylic position of the phenylalanine sidechain 8’, 8”. At 4.11 ppm a quartet is observed due to 
the α-protons of the ester group 14 coupling to the terminal CH3 15 with J = 7.2 Hz. The singlet 
peak at 3.98 ppm is attributed to the N-methyl group on the imidazolium ring 1. Diastereotopic 
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protons 8’, 8” of the phenylalanine side chain are present at 3.23 ppm and 3.17 ppm as two sets 
of doublet of doublets with J  = 14.0, 6.0 Hz, due to each protons vicinal coupling to proton 7 
and geminal coupling. Lastly the terminal CH3 group appears as a triplet at 1.18 ppm with J = 
7.2 Hz. 
 
 
Figure 2.6. Proposed hydrogen bonding interaction between the imidazolium headgroup, amide 
linker and bromide counterion. 
 
Figure 2.7. X-ray crystal structure and CH-Br contacts for [bmim][Br]. 
The proposed mode of binding to the proton attached to carbon C2 and also to the sidechain 
protons is supported by the x-ray crystal structures of a series of ILs published by Shaplov et al., 
see [bmim][Br] (Figure 2.7).
41
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Figure 2.8. 
1
H-NMR of C2 Symmetric IL (331). 
 
When a C2 symmetric derivative (331) was analysed, a very different 
1
H-NMR is observed 
(Figure 2.8). CH2 protons, α to the carbonyl group of the amide linker 11’, 11” are now present 
as two distinct doublets, J = 15.6 Hz, with much larger ppm separation than that present in 
(324). The roofing effect is also visible (Figure 2.9). It is proposed that the counterion is 
hydrogen bonding to the C2 proton on the imidazolium ring 12 and the two –CH2 protons on the 
amide linker (Figure 2.10). Benzylic protons 4’, 4” are visible as two sets of doublets of 
doublets at 3.14 ppm and 3.20 ppm due to their diastereotopicity, coupling geminally to give a 
doublet and vicinally with the stereogenic centre protons 3, 17 to give another doublet, i.e. a 
doublet of doublets with J = 15.6 Hz. Protons 3, are visible as a triplet of doublets at 4.69 ppm 
with J = 8.2 and 6.0 Hz, coupling to the amide protons 10 to give a doublet which in turn is 
further split by the coupling to the diastereotopic protons 4’, 4”. 
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Figure 2.9. Doublets and the roofing effect. 
Proposed counterion binding modes are illustrated in Figure 2.10. The bromide anion could 
potentially hydrogen bond to the acidic C2 proton on the imidazole ring or to the N-H protons 
on the amide linker. Chemical shifts of the CH2 protons observed, α to the carbonyl groups, also 
suggests that hydrogen bonding to the anion could be taking place, as per Figure 2.6, 2.7. 
Furthermore a combination of each of the proposed binding modes could be taking place. 
 
Figure 2.10. Proposed possible counter ion binding of C2 symmetric IL (331). 
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2.2.2.4 NOESY assignments of prolinium ILs 
The absolute stereochemistry of prolinium derivatives (332-335) was determined by 2-
dimensional NMR by utilising the nuclear overhauser effect i.e. a NOESY experiment. Under 
the experiments parameters, cross relaxation between individual nuclear spins is used to provide 
correlations between atoms that are spatially close, rather than through the sigma bond network. 
This type of experiment thus allows the determination of stereochemistry as groups that are 
close to each other on the same face, or cis, will exhibit a NOESY correlation and groups that 
are trans may not.
42
 To determine the stereochemistry of the epimer pair (332-333) the alpha 
proton at the stereogenic centre of the N-methyl-L-prolinium headgroup was identified, as were 
the protons belonging to the N-methyl group on the same headgroup (Figure 2.11). Derivative 
(332) should therefore not provide a signal by NOESY and derivative (333) should. 
 
 
 
 
Figure 2.11. H to CH3 NOESY rationale. 
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Figure 2.12. Example of a full NOESY spectra of (332). 
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Figure 2.13. Close up of NOESY spectra of (332), note there is no NOESY signal correlating to 
the N-CH3 and the H alpha to the carbonyl on the prolinium headgroup. 
Chiral Centre 
Proton 
N-CH3 
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Figure 2.14. NOESY spectra of (333), note the NOESY signal produce at the intersection of the 
two green lines. 
 
From the comparison of the two NOESY spectra produced (Figures 2.13-2.14) it can be 
concluded that (332) and (333) possessed the absolute stereochemistry as depicted in Figure 
2.15. 
 
 
Figure 2.15. Absolute stereochemistry for (332-333) as determined by NOESY. 
 
Chiral Centre 
Proton 
N-CH3 
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332 = (1S,2S)‐1‐({[(2S)‐1‐ethoxy‐1‐oxo‐3‐phenylpropan‐2‐yl]carbamoyl}methyl)‐2‐
(ethoxycarbonyl)‐1‐methylpyrrolidin‐1‐ium bromide 
333 = (1R,2S)‐1‐({[(2S)‐1‐ethoxy‐1‐oxo‐3‐phenylpropan‐2‐yl]carbamoyl}methyl)‐2‐
(ethoxycarbonyl)‐1‐methylpyrrolidin‐1‐ium bromide 
 
Similarly the absolute stereochemistry for (334-335) was determined as shown in Figure 2.16. 
 
 
Figure 2.16. Absolute stereochemistry of ILs (334-335) as confirmed by NOESY experiments. 
334 = (1S,2R)‐1‐({[(2S)‐1‐ethoxy‐1‐oxo‐3‐phenylpropan‐2‐yl]carbamoyl}methyl)‐2‐
(ethoxycarbonyl)‐1‐methylpyrrolidin‐1‐ium bromide. 
335 = (1R,2R)‐1‐({[(2S)‐1‐ethoxy‐1‐oxo‐3‐phenylpropan‐2‐yl]carbamoyl}methyl)‐2‐
(ethoxycarbonyl)‐1‐methylpyrrolidin‐1‐ium bromide. 
2.2.2.5 Synthesis of L-phenylalanine tertiary amino analogues 
In parallel to the ILs synthesised in Section 2.2.2.2, a number of neutral tertiary amino 
derivatives (344-348) of the ILs were synthesised to investigate whether the charge on the 
quaternary amine affected the toxicity and biodegradability of the ILs (Figure 2.17). The neutral 
derivatives were synthesised according to modified routes (see Chapter 5, Section 5.3) than that 
in Scheme 2.1 and all were derived from alkylating reagent (337) to give compounds (344-348). 
 
Figure 2.17: Tertiary amino derivatives synthesised. 
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Scheme 2.5. Alkylation of secondary amines with (337) to give ILs (344-348). 
The neutral derivatives (344-348) (Figure 2.17) represented a slightly more challenging 
synthesis as quaternisation of the tertiary amines formed during the reaction was possible, 
though unlikely for some of the more sterically hindered compounds (347-348) (Scheme 2.5). 
Also, as one equivalent of HBr is produced for every equivalent of product produced solid 
Na2CO3 was stirred into the crude reaction products for ILs (346-348) for 1 hour to furnish the 
targets as their free base amines. Purification by column chromatography was employed for 
these compounds and in general the yields were lower than for their respective ILs (Table 2.4). 
One reason for this is that the driving force present in most IL formation reactions is 
precipitation of the product as soon as it is formed. Unfortunately the reactions did not proceed 
rapidly in diethyl ether and the products did not precipitate. Reaction conditions were altered to 
refluxing in ethyl acetate for 24-48 hours and no precipitation occurred under these conditions 
either, the products staying in solution. All of the neutral analogues synthesised were liquids at 
room temperature. 
 
The yield for (345), 33%, is lower than that observed for the other tertiary amines (53-58%). 
This may be due to quaternisation of the tertiary amine with two equivalents of alkylating 
reagent (337). Another possible reason may be that a proportion of the target product was in 
HBr salt form and was not liberated to the free base form before purification, hence trapping a 
significant proportion on the silica gel utilised.  
 
Table 2.4. Percentage yields obtained for for L-phenylalanine tertiary amino analogues. 
Compound Yield % 
344 55 
345 34 
346 57 
347 53 
348 58 
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Figure 2.18. 
1
H-NMR of neutral imidazole analogue (344) in CDCl3. 
From the 
1
H-NMR of (344) (Figure 2.18) it can be seen that the –CH2 protons α to the carbonyl 
group of the amide linker 4’, 4” are not as shifted downfield as those present in the typical ILs 
present in Section 2.2.2.2 and are present as two doublets at 4.57 ppm and 4.56 ppm 
respectively with J = 17.2 Hz. It can also be observed that the C2 proton of the imidazole ring 1 
at 7.42 ppm is no longer shifted so far downfield in comparison to imidazolium IL (324) due to 
the reduced electron withdrawing environment present. Amide proton 5 is also shifted upfield 
considerably from 8.90 ppm in IL (324) to 5.94 ppm in this tertiary amino example. 
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2.2.2.6 Synthesis of L-tyrosine analogues 
 
Figure 2.19. L-Tyrosine ILs (349-353) synthesised. 
A subseries of ILs derived from L-tyrosine was also prepared (Figure 2.19) the aim of which 
was to investigate whether the additional –OH functionality in the tyrosine side chain would 
affect biodegradability and/or toxicity. As previously discussed, the enzyme PheOH can convert 
phenylalanine into tyrosine by an oxidative insertion mechanism
15
 and there exists the 
possibility that the phenylalanine ILs studied in Section 2.2.2.2 could be converted in vivo to the 
tyrosine derivatives before undergoing biodegradation. The tyrosine derivatives were therefore 
synthesised to investigate the possibility of any enhanced biodegradation due to the presence of 
the phenolic –OH group. 
 
The ILs were synthesised according to the route outlined in Scheme 2.6, a modification of 
Scheme 2.1 discussed previously in Section 2.2.2.2. Step 1 of the synthesis was carried out as 
per Scheme 2.1 with an esterification reaction, this time with L-tyrosine and SOCl2 to give L-
tyrosine ethyl ester hydrochloride salt (354). Acylation of the ester (354) in step 2 produced 
target α-bromoamide (356) and over acylated phenolic ester (355) (Figure 2.20). Phenolic ester 
(355) was easily converted to (356) by acid hydrolysis in ethanol in step 3 and a facile 
purification by precipitation furnished the desired compound in 54% yield. α-Bromoamide 
(356) was then reacted with the nitrogen heterocycle of choice or dimethylamino ethanol 
(Scheme 2.6) in step 4 to afford the series of L-tyrosine ILs (349-353). 
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Scheme 2.6. Synthetic route employed for the synthesis of L-tyrosine ILs. 
 
 
Figure 2.20. L-Tyrosine alkylating reagents synthesised. 
    
Table 2.5. Percentage yields and melting points for L-tyrosine ILs synthesised. 
Compound Yield % Melting Point °C 
349 83 38-40 
350 99 30-32 
351 99 117-119 
352 71 53-55 
353 79 141-143 
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The yields for the final tyrosine ILs (349-353) were in general moderate (e.g. 71%, 352) to high 
(e.g. 99%, 350, 351). Derivative (352) was isolated in lower yields due to the harsher conditions 
and column chromatography required for final purification. Derivative (349) and (353) 
precipitated more slowly than expected and a longer reaction time or a solvent switch to ethyl 
acetate/THF and reflux conditions may aid in improving the yields (Table 2.5). 
 
A broad range of melting points (30-32 to 141-143 °C) were observed for the tyrosine 
derivatives with the imidazolium IL (349) 38-40 °C, and pyridinium IL (350) 30-32 °C, the 
lowest. Introduction of an ester group to the pyridinium ring gave an increase in melting point 
(350 vs 352) to  53-55 °C and much higher melting points were observed for the 3-methoxy 
pyridinium derivative (351) 117-119 °C and the cholinium derivative (353) 141-143°C. The 
presence of the –OH group on the tyrosine ring greatly reduces the melting points of several of 
the ILs (349, 350 and 352) when compared to their L-phenylalanine counterparts. A decrease of 
40°C was observed for the imidazolium IL (349 vs 324), 68°C for pyridinium IL (350 vs 325), 
and a modest decrease in melting point of 7 °C for ethyl nicotinium (352 vs 327). Exceptions to 
this trend are the 3-methoxypyridinium IL (326) where an increase in melting point of 45 °C 
was observed and cholinium IL (353) with an increase of 40 °C when compared to their 
phenylalanine counterparts, 325 and 330 respectively.  
2.2.2.7 Green chemistry metrics 
A number of green chemistry metrics were calculated for the amino acid esters (336, 338, 339, 
341, 343, 354), reductive alkylation products (340, 342), alkylating reagents (337, 356), L-
phenylalanine ILs (324-348), neutral tertiary amino L-phenylalanine derivatives (344-348) and 
L-tyrosine ILs (349-353). The parameters calculated are as defined in Section 2.2.1. The metrics 
are presented in Table 2.6 
 
It can be seen from the generated metrics that the synthesis of all the ILs had a 100% atom 
economy, a high E-factor, high GSK RME and a high stoichiometric factor. The Andraos RME 
is lower as it takes into account all solvent used in the IL washing steps. For the IL products that 
required purification by column chromatography (327, 332-335, 352), a much higher solvent 
intensity and mass intensity is also observed due to the amount of solvent required. Trituration 
and chromatography solvent should therefore be recycled in the future or if this process were to 
be scaled up in order to reduce the mass/solvent intensity, E-factor and material recovery 
parameters. Metrics generated for tertiary amino derivatives (344-348) are less desirable as 
lower yields and a higher consumption of solvent due to the purification by column 
chromatography was required.  
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Alkylating reagents (337, 356) were both synthesised with moderate atom economy and a 
generally lower E-factor than the ILs. Moderate atom economy is observed due to the use of 
bromoacetyl bromide which is not fully incorporated into the product as one bromine atom is 
lost in the form of HBr. The presence of an auxiliary base also reduces the atom economy. 
Lower E-factor, which is desirable, is present due to the minimum amount of solvent employed 
when compared to the ILs, no column chromatography and no solvent washes are required. 
 
Overall, the target ILs were all synthesised in sufficient quantities to undergo further 
investigations into their antimicrobial toxicity and biodegradability. 
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Table 2.6. Summary of green chemistry metrics for compounds synthesised in Section 2.2.2. 
Compound 
Atom 
Economy 
Sheldon 
E-factor 
GSK RME 
Andraos 
RME 
Mass 
Intensity 
Solvent 
Intensity 
Stoichiometric 
factor 
Material 
Recovery 
Parameter 
Yield % 
Amino Acid Esters 
336 59% 20.8 0.425 0.046 21.8 11.8 0.735 0.108 99 
338 81% 5.6 0.636 0.152 6.6 5.0 0.788 0.239 99 
339 81% 5.8 0.635 0.147 6.8 5.2 0.788 0.231 99 
341 90% 40.3 0.444 0.024 41.3 38.2 0.596 0.055 83 
343 53% 29.5 0.231 0.033 30.5 24.5 1.000 0.142 43 
354 71% 3.7 0.620 0.211 4.7 3.1 1.000 0.340 87 
Reductive Alkylation 
340 89% 8.1 0.824 .123 8.1 6.9 0.958 0.148 98 
342 89% 16.0 0.309 0.062 16.0 12.8 0.980 0.200 36 
Alkylating Reagents 
337 63% 10.1 0.470 0.090 11.1 7.4 0.843 0.192 89 
356 50% 55.1 0.281 0.018 56.1 17.9 0.873 0.063 54 
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Compound 
Atom 
Economy 
Sheldon E-
factor 
GSK RME 
Andraos 
RME 
Mass 
Intensity 
Solvent 
Intensity 
Stoichiometric 
factor 
Material Recovery 
Parameter 
Yield % 
L-Phenylalanine ILs 
324 100 % 96.7 0.830 0.010 97.7 96.5 0.920 0.012 89 
325 100 % 93.4 0.964 0.011 94.4 93.3 0.991 0.011 98 
326 100 % 108.8 0.689 0.009 109.8 108.3 0.922 0.013 75 
327 100 % 1081.5 0.523 0.001 1082.5 1080.6 0.934 0.002 56 
328 100 % 120.7 0.812 0.008 121.7 120.5 0.918 0.010 88 
329 100 % 126.5 0.335 0.008 127.5 124.5 0.991 0.023 34 
330 100 % 88.1 0.901 0.011 89.1 88.0 0.917 0.012 99 
331 80 % 33.0 0.718 0.029 34.0 32.6 0.986 0.041 91 
332 100 % 1416.6 0.335 0.001 1417.6 1414.7 0.921 0.002 37 
333 100 % 4088.3 0.122 0.001 4089.3 4081.1 0.921 0.002 13 
334 100 % 1119.0 0.254 0.001 1120.0 1116.1 1.000 0.004 25 
335 100 % 833.3 0.341 0.001 834.3 831.3 1.000 0.004 34 
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Compound 
Atom 
Economy 
Sheldon E-
factor 
GSK RME 
Andraos 
RME 
Mass 
Intensity 
Solvent 
Intensity 
Stoichiometric 
factor 
Material Recovery 
Parameter 
Yield % 
Neutral L-Phenylalanine derivatives 
344 66% 1035.4 0.288 0.001 1036.4 1032.9 0.783 0.003 55 
345 79% 2754.1 0.242 0.001 2755.1 2750.9 0.923 0.001 34 
346 80% 476.6 0.433 0.002 477.6 474.6 0.958 0.005 56 
347 53% 770.3 0.266 0.001 771.3 767.6 0.946 0.005 53 
348 54% 463.4 0.305 0.002 464.4 461.1 0.966 0.007 58 
L-Tyrosine ILs 
349 100% 294.0 0.819 0.003 295.0 293.8 0.979 0.004 83 
350 100% 117.1 0.980 0.008 118.1 117.1 0.982 0.009 99 
351 100% 120.7 0.971 0.008 121.7 120.7 0.982 0.008 99 
352 100% 420.3 0.699 0.002 421.3 419.9 0.986 0.003 71 
353 100% 150.7 0.773 0.007 151.7 150.4 0.985 0.009 79 
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2.3 Antimicrobial screening and biodegradation studies of 1st generation 
amino acid ILs and 3° amino analogues 
2.3.1 Antimicrobial screening aim 
The aim of the antimicrobial toxicity investigations was to determine the toxicity of the series of 
ILs and 3° amino compounds synthesised in this chapter. Information obtained from this 
investigation would then enable a rational design of “next generation” ILs based on any 
observed structure activity relationships (SAR) within the antimicrobial results. By keeping the 
amino acid backbone as either L-phenylalanine ethyl ester or L-tyrosine ethyl ester, any 
antimicrobial activity differences between compounds could tentatively be attributed to the 
headgroups effect on the overall molecule. 
 
As previously discussed in Chapter 1, Section 1.2.5, toxicity is a parameter that must be 
investigated when determining the environmental compatibility and “greenness” of ILs. ILs 
have been described as possessing “green” properties, a description which has been repeated ad 
nauseam, often without any considerable investigation into the properties that will determine an 
ILs environmental impact. Exhibiting a negligible vapour pressure or non-flammability does not 
automatically classify an IL as being “green” since the toxicity and bioaccumulation that can 
occur from resistance to biodegradation is unknown. Antimicrobial toxicity and cytotoxicity 
properties of ILs have thus become a necessary parameter for investigation if ILs are to be 
considered benign. To date investigations have been carried out on the toxicity of ILs towards 
bacteria,
43
 fungi,
44
 invertebrates,
45
 aquatic species,
46
 plants,
47
 and algae
48
.  
 
Within the following section the antimicrobial activity of a number of ILs is presented. The ILs 
were screened against eight strains of bacteria, four gram positive and four gram negative, and 
12 strains of fungi. Antimicrobial screening was carried out in collaboration with Dr. Marcel 
Špulák of the Department of Biological and Medical Sciences, Faculty of Pharmacy, Charles 
University, Hradec Králové, Czech Republic. 
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2.3.2 Antibacterial screening  
To investigate the in vitro antibacterial activity of the aforementioned compounds, the following 
eight strains of bacteria from the collection available at Charles University, Czech Republic, 
were screened against: 
 
Gram Positive:  
 S. aureus (ATCC 65382) (SA) 
 Methicillin-res.S.a (HK5996/08) (MRSA) 
 S. epidermidis (HK6966/084 ) (SE) 
 Enterococcus sp. (HK14365/085) (EF) 
Gram Negative: 
 E. coli (ATCC 87396) (EC) 
 K. pneumoniae (HK11750/087) (KP) 
 K. pneumoniae (HK14368/08) (KP-E) 
 P. aeruginosa (ATCC 9027) (PA) 
2.3.2.1 Experimental Method 
The experimental method is as described in Chapter 5, Section 5.8.1. 
2.3.2.2 Antibacterial results – L-phenylalanine ILs 
 
From the results obtained in Table 2.7 for the L-phenylalanine ILs screened (Figure 2.21 
depicting the same selection of ILs as Figure 2.3), it can be seen that in general a moderate to 
low antibacterial toxicity can be observed for the majority of the compounds screened. Where 
>500 (etc.) µmol/L is observed this is due to solubility of the compound being no greater than 
500 µmol/L, therefore any toxicity at higher concentrations cannot be observed. Where >2000 
µmol/L is observed then no discernible toxic effect has been demonstrated up to the screening 
concentration limit of 2000 µmol/L. 
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Figure 2.21. L-Phenylalanine ILs screened for antimicrobial activity. 
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Table 2.7. Antibacterial results obtained for L-phenylalanine ILs. 
Microorganism Time (h) 
IL IC95 µmol 
324 325 326 327 328 329 330 331 332 333 334 335 
 
Gram Positive 
 
             
SA 
24h 
48h 
2000, 
>2000 
2000, 
>2000 
>500, 
>500 
1000, 
1000 
>500, 
>500 
2000, 
2000 
2000, 
>2000 
500, 
500 
>2000, 
>2000 
1000, 
1000 
>2000, 
>2000 
1000, 
1000 
MRSA 
24h 
48h 
>2000, 
>2000 
>2000, 
>2000 
>500, 
>500 
1000, 
1000 
>500, 
>500 
2000, 
2000 
>2000, 
>2000 
1000, 
1000 
>2000, 
>2000 
>1000, 
>1000 
>2000, 
>2000 
>2000, 
>2000 
SE 
24h 
48h 
>2000, 
>2000 
>2000, 
>2000 
>500, 
>500 
1000, 
1000 
>500, 
>500 
>2000, 
>2000 
>2000, 
>2000 
500, 
500 
2000, 
2000 
1000, 
1000 
>2000, 
>2000 
1000, 
1000 
EF 
24h 
48h 
>2000, 
>2000 
>2000, 
>2000 
>500, 
>500 
>1000, 
>1000 
>500, 
>500 
>2000, 
>2000 
>2000, 
>2000 
1000, 
1000 
>2000, 
>2000 
>1000, 
>1000 
>2000, 
>2000 
>2000, 
>2000 
 
Gram Negative 
 
             
EC 
24h 
48h 
>2000, 
>2000 
>2000, 
>2000 
>500, 
>500 
>1000, 
>1000 
>500, 
>500 
>2000, 
>2000 
>2000, 
>2000 
2000, 
2000 
>2000, 
>2000 
>1000, 
>1000 
>2000, 
>2000 
>2000, 
>2000 
KP 
24h 
48h 
>2000, 
>2000 
>2000, 
>2000 
>500, 
>500 
>1000, 
>1000 
>500, 
>500 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
>1000, 
>1000 
>2000, 
>2000 
>2000, 
>2000 
KP-E 
24h 
48h 
>2000, 
>2000 
>2000, 
>2000 
>500, 
>500 
>1000, 
>1000 
>500, 
>500 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
>1000, 
>1000 
>2000, 
>2000 
>2000, 
>2000 
PA 
24h 
48h 
>2000, 
>2000 
>2000, 
>2000 
>500, 
>500 
>1000, 
>1000 
>500, 
>500 
>2000, 
>2000 
>2000, 
>2000 
2000, 
2000 
>2000, 
>2000 
>1000, 
>1000 
>2000, 
>2000 
>2000, 
>2000 
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Figure 2.22. Diastereomeric pairs of N-methyl-prolinium ILs (332-335). 
The lowest IC95 observed was 500 µmol/L for (331) which is the C2 symmetric bromide IL 
towards S.A and S.E. with a higher IC95 observed for MRSA and E. sp. The next highest 
toxicity observed was 1000 µmol/L for derivatives (327, 333, 335) towards some gram positive 
bacteria. The prolinium derivatives, with N-methyl group orientated away from the observer, 
(333, 335) displayed higher levels of toxicity than their respective epimers (332, 334), see 
Figure 2.22. 
There was no selectivity observed towards any of the bacterial strains, however the gram 
negative bacteria appeared more resilient towards the test compounds than the gram positive, as 
expected due to their double membrane cell wall composition.
49
 
2.3.2.3 Antibacterial results – 3° amino compounds 
 
Figure 2.23. 3° Amino compounds screened for antimicrobial activity. 
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Table 2.8. Antibacterial results obtained for 3° amino compounds. 
Microorganism Time 
(h) 
IL IC95 µmol 
344 345 346 347 348 
 
Gram Positive 
 
      
SA 24h  
48h 
1000, 
1000 
1000, 
1000 
2000, 
2000 
125,  
125 
125,  
125 
MRSA 24h 
48h 
1000, 
1000 
2000, 
2000 
2000, 
2000 
500,  
500 
1000, 
>2000 
SE 24h 
48h 
1000, 
1000 
500,  
500 
>2000, 
>2000 
250,  
250 
>2000, 
>2000 
EF 24h 
 48h 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
>1000, 
>1000 
>2000, 
>2000 
 
Gram Negative 
 
      
EC 24h  
48h 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
>1000, 
>1000 
>2000, 
>2000 
KP 24h 
48h 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
>1000, 
>1000 
>2000, 
>2000 
KP-E 24h 
48h 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
>1000, 
>1000 
>2000, 
>2000 
PA 24h 
48h 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
>1000, 
>1000 
>2000, 
>2000 
 
From the results obtained for the tertiary amino compounds (Figure 2.23 depicting the same 
tertiary amines as Figure 2.17), it can be observed that they possessed, in general, a higher 
toxicity than their L-phenylalanine IL counterparts. Imidazole derivative (344) was found to 
possess IC95 of 1000 µmol/L towards SA, MRSA and SE, compared to 2000 µmol/L for the 1-
methylimidazolium derivative (324) (Table 2.8). Tertiary amine (344) was also found to be less 
toxic than the C2 symmetrical imidazolium IL (331). Methylethanolamine derivative (345) was 
observed to be more toxic when compared to cholinium counterpart (330) when screened 
against SA and an IC95 four times greater towards to SE was also observed. Tertiary amino 
morpholine derivative (346) exhibited the same low antimicrobial toxicity as IL counterpart 
(329). L-Proline tertiary amino compounds (347, 348) displayed IC95 values an order of 
magnitude greater than the N-methyl-L-prolinium derivatives (332-335) with IC95 values of 125 
µmol/L observed towards S. aureus and a moderate toxicity towards MRSA and S. epidermidis 
observed for derivative (347). The higher levels of toxicity associated with the tertiary amines is 
most likely due to the presence of reactive basic tertiary nitrogen groups. 
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2.3.2.4 Antibacterial results – L-tyrosine ILs 
 
 
Figure 2.24. L-tyrosine ILs screened for antimicrobial activity. 
Table 2.9. Antibacterial results obtained for L-tyrosine ILs. 
Microorganism Time 
(h) 
IL IC95 µmol 
349 350 351 352 353 
 
Gram Positive 
 
      
SA 24h  
48h 
1000, 
1000 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
2000,  
2000 
MRSA 24h 
48h 
2000, 
>2000 
2000, 
2000 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
SE 24h 
48h 
500,  
1000 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
1000,  
2000 
EF 24h 
 48h 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
 
Gram Negative 
 
 
     
EC 24h  
48h 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
KP 
 
24h 
48h 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
KP-E 24h 
48h 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
PA 24h 
48h 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
 
From the results illustrated in Table 2.9 it can be seen that the L-tyrosine ILs examined (Figure 
2.24 depicting the same ILs as Figure 2.19), had in general a low to moderate toxicity. The L-
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tyrosine imidazolium IL (349) displayed greater toxicity than that of L-phenylalanine analogue 
(324) towards S. aureus, 1000 µmol/L vs 2000 µmol/L. A greater toxicity towards S. 
epidermidis was also observed, 500 µmol/L vs. 2000 µmol/L. Of all the L-tyrosine derivatives 
screened, the 1-methylimidazolium compound (349) displayed the highest level of toxicity, 500-
1000 µmol/L for three of the four gram positive bacteria and had no discernible toxic effect 
towards the gram negative strains. No selectivity effects were observed for the L-tyrosine ILs. 
2.3.2.5 Antibacterial screening conclusions 
In conclusion to the antibacterial screening a moderate to low toxicity was observed for the 
majority of the ILs screened, with the suggestion that stereochemistry plays a role in the toxicity 
results observed, especially with prolinium derivatives (332-335). The presence of a quaternary 
nitrogen centre appears to lower the toxicity significantly, with the tertiary amino derivatives 
exhibiting a much higher toxicity than their quaternary IL counterparts. An exception to this 
trend was observed for the morpholine derivatives (329 and 346) which had the same levels of 
toxicity towards the same strains of bacteria. The most toxic derivative IL screened was the C2 
symmetrical IL (331) which exhibited an IC95 of 500 µmol/L towards SA and SE, see Table 2.7. 
This result may be due to the added lipophilicity of the molecule and is somewhat in 
disagreement with the observations of Fatemi et al.
50
 who suggested that increasing the 
symmetrical properties of an IL can reduce toxicity. However the toxicity measured in their case 
was measured towards Leukaemia rat cell lines and not bacteria and does not make for a direct 
comparison. The generally low toxicity observed for the ILs allows them to be considered 
potential green candidates. 
2.3.3 Antifungal screening 
To investigate the in vitro anti-fungal activity of the ILs, the aforementioned compounds were 
screened against the following strains of fungi, available from the repository at Charles 
University, Czech Republic: 
 
9 Yeasts 
 Candida albicans (ATCC 448597) (CA1) 
 Candida albicans (ATCC 900288) (CA2) 
 Candida parapsilosis (ATCC 220199 ) (CP) 
 Candida krusei (ATCC 62581) (CK1) 
 Candida krusei (E2811) (CK2) 
 Candida tropicalis (156) (CT) 
 Candida glabrata (20/I2) (CG) 
 Candida lusitaniae (2446/I3 ) (CL) 
121 
 
 Trichosporon asahii (11884) (TA) 
3 Filamentous fungi: 
 Aspergillus fumigatus (2315) (AF) 
 Absidia corymbifera (2726) (AC) 
 Trichophyton mentagrophytes (445) (TM) 
2.3.3.1 Experimental Method 
The experimental method is as described in Chapter 5, Section 5.8.2. 
2.3.3.2 Antifungal results – L-phenylalanine ILs  
From the results obtained in Table 2.10, it can be seen that in general low antifungal toxicity can 
be observed for the majority of the compounds screened, with only three compounds (329, 331, 
332) having IC80/50 values lower than 2000 µmol/L(Figure 2.25). IL (329) showed an IC of 2000 
µmol/L towards 6 of the fungi, see Table 2.10. IL (331) similarly displayed and an IC of 2000 
µmol/L towards 5 of the fungi. IL (332) displayed an IC of 2000 µmol/L towards only one of 
the fungi.  No discernible toxic effect was observed for any of the other phenylalanine ILs 
examined. From this antifungal screening panel, it can be seen overall that the L-phenylalanine 
ILs had low toxic effect, at the concentrations screened at, towards any of the fungi. 
 
Figure 2.25. ILs (329, 331, 332) were the only ILs to have any discernible toxic effect. 
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Table 2.10. L-Phenylalanine ILs screened for antifungal activity. 
* 
IC50 values were assessed for AF, AC and TM and IC80 for all other strains. 
Microorganism Time (h) IL IC80/50 µmol* 
324 325 326 327 328 329 330 331 332 333 334 335 
CA1 
24h  
48h 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
> 1000, 
>1000 
> 500, 
>500 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
CA2 
24h 
48h 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
> 1000, 
>1000 
> 500, 
>500 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
CP 
24h 
48h 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
> 1000, 
>1000 
> 500, 
>500 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
CK1 
24h 
 48h 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
> 1000, 
>1000 
> 500, 
>500 
2000, 
2000 
>2000, 
>2000 
2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
CK2 
24h  
48h 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
> 1000, 
>1000 
> 500, 
>500 
2000, 
2000 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
CT 
24h 
48h 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
> 1000, 
>1000 
> 500, 
>500 
>2000, 
>2000 
>2000, 
>2000 
2000, 
2000 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
CG 
24h 
48h 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
> 1000, 
>1000 
> 500, 
>500 
2000, 
2000 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
CL 
24h 
48h 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
> 1000, 
>1000 
> 500, 
>500 
>2000, 
>2000 
>2000, 
>2000 
2000, 
2000 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
TA 
24h 
48h 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
> 1000, 
>1000 
> 500, 
>500 
2000, 
2000 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
AF 
24h 
48h 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
> 1000, 
>1000 
> 500, 
>500 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
AC 
24h 
48h 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
> 1000, 
>1000 
> 500, 
>500 
2000,  
>2000 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
TM 
72h 
120h 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
> 1000, 
>1000 
> 500, 
>500 
2000, 
2000 
>2000, 
>2000 
2000, 
2000 
2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
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2.3.3.3 Antifungal results – 3° amino compounds 
From the results obtained in Table 2.11, it can be seen that the 3° amino derivatives screened 
had in general low toxicity with only one derivative, D-proline tertiary amine (348), having an 
IC80 of less than 2000 µmol/L. D-proline derivative (348) was also more toxic towards some 
fungi than its L-proline epimer (347), suggesting a relationship between stereochemistry and 
toxicity (Figure 2.26). When the tertiary amino D-proline derivative (348) is compared to IL 
counterparts (334, 335 - 2000 µmol/L for all fungi) it can be seen that the tertiary amino 
derivative has a greater toxic effect towards a number of fungi, specifically CA1, CA2, CP, 
CK1 and TM. For the remaining tertiary amino derivatives no discernible toxic effect was 
observed, up to the screening concentration limit of 2000 µmol/L, towards any of the fungi.  
 
Table 2.11. Antifungal results obtained for L-phenylalanine tertiary amino derivatives. 
Microorganism Time 
(h) 
IL IC80/50 µmol* 
344 345 346 347 348 
CA1 
24h  
48h 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
> 1000, 
>1000 
1000, 
>2000 
CA2 
24h 
48h 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
> 1000, 
>1000 
1000,  
2000 
CP 
24h 
48h 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
> 1000, 
>1000 
1000,  
1000 
CK1 
24h 
 48h 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
> 1000, 
>1000 
1000,  
1000 
CK2 
24h  
48h 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
> 1000, 
>1000 
2000,  
2000 
CT 
24h 
48h 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
> 1000, 
>1000 
>2000, 
>2000 
CG 
24h 
48h 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
> 1000, 
>1000 
>2000, 
>2000 
CL 
24h 
48h 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
> 1000, 
>1000 
>2000, 
>2000 
TA 
24h 
48h 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
> 1000, 
>1000 
>2000, 
>2000 
AF 
24h 
48h 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
> 1000, 
>1000 
>2000, 
>2000 
AC 
24h 
48h 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
> 1000, 
>1000 
>2000, 
>2000 
TM 
72h 
120h 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
> 1000, 
>1000 
2000,  
2000 
* 
IC50 values were assessed for AF, AC and TM and IC80 for all other strains. 
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Figure 2.26. Comparison of stereochemistry and toxicity for tertiary amino derivatives (347  ¸
348). 
2.3.3.4 Antifungal results – L-tyrosine ILs  
 
Table 2.12. Antifungal results obtained for L-tyrosine ILs. 
Microorganism Time 
(h) 
IL IC80/50 µmol* 
349 350 351 352 353 
CA1 
24h  
48h 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
CA2 
24h 
48h 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
CP 
24h 
48h 
2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
CK1 
24h 
 48h 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
CK2 
24h  
48h 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
CT 
24h 
48h 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
CG 
24h 
48h 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
CL 
24h 
48h 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
TA 
24h 
48h 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
AF 
24h 
48h 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
AC 
24h 
48h 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
TM 
72h 
120h 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
* 
IC50 values were assessed for AF, AC and TM and IC80 for all other strains. 
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As can be seen from Table 2.12, the L-tyrosine ILs screened had no discernible toxic effect 
towards the 12 strains of fungi, with the single exception of the imidazolium derivative (349) 
which had an IC80 of 2000 µmol/L towards one strain of fungi, the Candida parapsilosis, after 
24 hours. After 48 hours no inhibition was observed as the fungi had recovered. 
 
2.3.3.5 Antifungal screening conclusions 
In conclusion to the antifungal screening a general low toxicity was observed for all the ILs 
screened. Of the tertiary amino derivatives (344-348) screened one derivative (348) exhibited 
moderate toxicity. In total only five compounds screened exhibited any toxic effect whatsoever 
towards the fungi. L-Phenylalanine ILs (329, 331, 332), tertiary amino (348) and L-tyrosine IL 
(349) showed activity of  2000 µmol/L or lower. As an overall trend, it appears that the 
derivatives examined are generally not toxic towards the panel of fungi, at the concentrations 
screened.  
2.3.4 Antimicrobial screening conclusions 
In conclusion to the antimicrobial and antifungal screening it can be observed that the L-
phenylalanine and L-tyrosine ILs had moderate to little toxic effect towards any of the bacteria 
and fungi screened against. Tertiary amino derivatives appeared to have a greater toxicity 
towards the same strains of bacteria and fungi. The presence of a quaternary nitrogen appears to 
have a reduction in the toxicity, though with such a small sample size it cannot be definitively 
said as to whether this is a general trend or an isolated incident. Stereochemistry of the 
prolinium derivatives also appeared to play an important part in the toxicity assessment with the 
orientation of the quaternary nitrogen‟s N-methyl group affecting the toxicity. Overall the 
generally low levels of toxicity support the proposal of a number of the ILs screened as green 
chemicals. In conjunction with the green synthesis metrics in Section 2.2.2.7 and the 
biodegradation studies carried out in Section 2.4, a full assessment of the ILs “greenness” can 
be made. 
2.4 Biodegradation studies of amino acid ILs and 3° amino analogues  
The aim of the work within this section was to investigate the biodegradability of the series of 
L-phenylalanine ILs, tertiary amino compounds and L-tyrosine ILs synthesised in this chapter. 
Necessity for investigating biodegradability of ILs has been thoroughly discussed in Chapter 1. 
Biodegradation screening was carried out using the Closed Bottle Test (CBT). The CBT is one 
of the methods of examining organic compounds for their aerobic biodegradability and is a 
simulation of the environment expected in surface ground water. Test conditions are designed to 
represent surface water conditions, such as low bacterial concentrations and low nutrient 
concentrations. See Chapter 1, Section1.2.1.1 for description of CBT OECD 301D and Chapter 
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5, Section 5.9.1 for experimental method used. The first series of compounds to be screened was 
the L-phenylalanine series. As discussed previously, the backbone of L-phenylalanine ethyl ester 
was kept constant throughout this series so as to determine the effect of the headgroup on 
biodegradability. A second series of compounds, the tertiary amino derivatives, was prepared to 
investigate whether the absence of a positively charge quaternary nitrogen would affect the 
biodegradability. Lastly a series of L-tyrosine ILs was prepared to investigate whether the 
addition of the –OH group at the para position of the tyrosine side chain could affect the 
biodegradability. Results for each of the series are presented herein. Additionally, a subset of 
the L-phenylalanine ILs underwent further analysis. Samples from the beginning and the end of 
the CBTs were taken to determine primary elimination of the phenylalanine ethyl ester 
derivatives (ILs and tertiary amino derivatives) and to identify transformation products (TPs) 
via liquid chromatography/high resolution mass spectrometry (LC-orbitrap HRMS). A number 
of metabolite compounds were observed and their structures and breakdown pathways have 
been proposed. See Chapter 5, Section 5.9.2 for LC/MS method used. 
2.4.1 Biodegradation screening of L-phenylalanine ILs 
 
As can be seen from Table 2.13, of the ILs screened only one of the ILs, pyridinium IL (325), 
gave 63% biodegradation within the 28 day period (Figure 2.27). However IL (325) cannot be 
considered readily biodegradable as it did not reach the pass level of 60%, ten days after 10% 
biodegradation was observed (see Chapter 1, Section1.2.1 for OECD 301D test specifications). 
The allotted test time was extended for IL (325) to 42 days, after which 76% biodegradation 
was observed suggesting IL (325) is inherently ultimately biodegradable.The next highest IL 
biodegradability was the 3-methoxy pyridinium IL (326, 52%) followed by 1-
methylimdazolium (324, 47%) with a further reduction in biodegradability observed for the 
DMAP derivative (328, 33%) and ethyl nicotinium (327, 32%). It appears from the initial data 
that the pyridinium core is very sensitive to modification as the introduction of substituents on 
the 3 and 4 positions appears to greatly reduce biodegradability. C2 symmetrical imidazolium IL 
(331) was also shown to be recalcitrant to biodegradation. Non-aromatic derivatives 
(morpholinium 329, cholinium 330) failed to degrade more than 17 and 24% respectively. For 
the prolinium derivatives (332-335) 21-24% biodegradation was observed. It can be further 
postulated that only the ester functionalities are undergoing biodegradation as the theoretical 
percentage biodegradation attributable to total ester degradation is 19%, a difference of 2-5% 
than that observed. Stereochemistry was not observed to play a role in the levels of 
biodegradation observed for the four prolinium derivatives.  
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Figure 2.27. L-phenylalanine ILs with the highest levels of biodegradability. 
Table 2.13. Biodegradability and carbon distribution of examined L-phenylalanine IL 
compounds, colour coded according to the traffic light classification.
51
 
IL % Biodegradation 
Amino Acid  
Ester Carbon % 
Ester Carbon % 
L-Phenylalanine ILs    
324 47 65 12 
325 63 61 11 
326 52 58 11 
327 32 52 19 
328 33 55 10 
329 17 61 11 
330 24 65 12 
331 40 76 14 
332 24 52 19 
333 22 52 19 
334 23 52 19 
335 21 52 19 
 
 
Figure 2.28. Carbon atom distribution of amino acid IL (324). 
Figure 2.28 depicts the percentage distribution of carbon in imidazolium IL (324). By 
considering the carbon distribution over the various regions of the molecule and comparing the 
percentage biodegradation to the carbon distribution, a number of insights into the breakdown 
pathways of each IL can be considered. As can be seen for IL (324), total ester degradation of 
all IL in the CBT would provide 12% biodegradation, whilst total ester and amino acid 
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degradation would give 65% biodegradation. If biodegradation is observed to be higher than 
total ester degradation but lower than total ester and amino acid degradation then the compound 
may be undergoing different rates of biodegradation within the CBT. A certain proportion of the 
parent compound may undergo ester/amide hydrolysis and the rest of the parent compound 
remaining intact. Another possibility is that other portions of the molecule are undergoing 
biodegradation. All of the L-phenylalanine ILs except (332-335) undergo levels of 
biodegradation greater than total ester degradation, but less than total amino acid plus ester 
degradation. 
2.4.2 Biodegradation screening of 3° amino analogues 
 
A similar resistance to biodegradability was observed for the tertiary amino derivatives screened 
(Table 2.14). When the tertiary amino derivatives are compared to their IL counterparts it can be 
seen that imidazole derivative (344) underwent 40% biodegradation, 7% less than its IL 
counterpart (324, 47%). Tertiary amino derivative (345) underwent higher levels of 
biodegradation (+23%) than IL analogue (330) (Figure 2.29). Tertiary amino L-proline 
derivative (347) was also shown to undergo higher levels (+20-22%) of biodegradability than IL 
counterparts (332, 333) (Figure 2.29). Similarly morpholine derivative (346, 28%) underwent 
11% more biodegradation than the morpholinium derivative (329,  17%).  Elevated levels of 
biodegradation suggest that the presence of a quaternary nitrogen atom can in some cases 
impede the biodegradation process thus tertiary amines can exhibit higher levels of 
biodegradation, an observation which is in agreement with the literature.
3
 However, a larger 
sample size of tertiary amino compounds would need to be examined to draw any definite 
conclusions from any trends observed. 
 
Table 2.14. Biodegradability and carbon distribution of examined tertiary amino compounds. 
IL % Biodegradation 
Amino Acid 
Ester Carbon % 
Ester Carbon % 
Tertiary Amine    
344 40 69 13 
345 47 69 13 
346 28 65 12 
347 44 55 20 
 
Test extensions were applied for tertiary amines (344, 345). After 42 days amine (344) had 
undergone 59% biodegradation and (345) had undergone 78%. It can be suggested that tertiary 
amines (345) could be inherently ultimately biodegradable. 
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Figure 2.29. Comparison of IL biodegradation to tertiary amino biodegradation. 
2.4.3 Biodegradation screening of L-tyrosine analogues 
 
The presence of an additional –OH group on the L-tyrosine derived ILs appears to hinder 
biodegradation. When comparing L-phenylalanine derivative (324) to L-tyrosine derivative 
(349) the L-phenylalanine derivative displayed 7% more biodegradability than the L-tyrosine 
compound (Figure 2.30). A similar trend was observed for all L-tyrosine compounds with 5-
13% less biodegradability. A 1% difference was observed between L-phenylalanine and L-
tyrosine nicotinium (327) and (352). 
 
Table 2.15. Biodegradability and carbon distribution of examined L-tyrosine compounds. 
IL % Biodegradation 
Amino Acid 
Ester Carbon % 
Ester Carbon % 
L-Tyrosine ILs    
349 40 65 12 
350 49 61 11 
351 46 58 11 
352 31 52 19 
353 20 65 12 
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Figure 2.30. L-tyrosine IL biodegradation compared to L-phenylalanine for ILs. 
2.4.4 Summary of IL and tertiary amino biodegradation 
 
For all of the ILs and tertiary amines the percentage biodegradation observed is greater than that 
which can be attributed to ester degradation (though derivatives 332-335 are only 2-5% above 
this level). When the carbon content of the amino acid plus the ester is considered - and the 
assumption that the entire amino acid can undergo biodegradation is made - then the predicted 
levels of biodegradation suggest that a number of the ILs and tertiary amines (324, 325, 329-
331, 344-346, 349, 350, 353) could undergo >60% biodegradation. All of the ILs except 
pyridinium IL (325) and the prolinium derivatives (332-335) are observed to have levels of 
biodegradation greater than full ester degradation but less than full amino acid degradation (324, 
326-331, 344-347, 349-353). Pyridinium IL (325) was observed to biodegrade 2% higher than 
the predicted levels attributable to total ester and amino acid degradation (61% predicted, 63% 
observed). However this rough approximation of carbon distribution and attributable 
degradation cannot be fully substantiated without a metabolite analysis of the closed bottle test. 
What exactly is breaking down? Is the rate of biodegradation such that some of the compound 
in the test undergoes high levels of mineralisation after a particular biochemical transformation? 
Is there some rate limiting step that once complete, allows the IL to biodegrade? Is ester 
hydrolysis occurring preferentially to amide bond hydrolysis or are both happening at the same 
time? Is there fully intact parent compound present in the closed bottle test vessel after the 28 
day period? To answer these questions a detailed LCMS/MS analysis of a selection of ILs and 
3° amino derived compounds was carried out. 
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2.4.5 LCMS/MS analysis of transformation products 
 
In conjunction to the biodegradation screening conducted, an LCMS/MS analysis of the 
biodegradation transformation products was carried out after the 28 day test period by the 
research group of  Prof. Klaus Kümmerer, Faculty for Sustainability, University of Lüneburg, 
Germany. Information gained from this test allowed for some initial elucidation into the 
breakdown pathways of the ILs examined. See Chapter 5, Section 5.9.2 for experimental 
conditions. The transformation products for the ILs and tertiary amines are presented in 
Schemes 2.7 and 2.10 respectively. 
 
Based on the transformation products and percentage biodegradation for pyridinium IL (325), it 
can be inferred that the IL is breaking down by amide bond cleavage to a highly biodegradable 
L-phenylalanine residue and pyridinium acetic acid (357) (Scheme 2.8). It was observed that no 
transformation product was detected at the end of the test suggesting that  pyridinium acetic acid 
is not accumulating. Pyridinium acetic acid can potentially undergo further levels of 
biodegradation as was observed by Besse-Hoggan et al. 2015.
52
 It is currently unknown as to 
whether ester hydrolysis occurs before the amide bond is cleaved. To determine if pyridinium 
acetic acid was accumulating, a second CBT was conducted with a time extension beyond 28 
days. After 42 days 76% biodegradation had occurred suggesting that the pyridinium ring is 
undergoing further degradation towards complete mineralisation. 
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Scheme 2.7. Transformation products detected by LCMS for L-phenylalanine ILs. 
 
 
Scheme 2.8. Potential biodegradation pathway for IL (325). 
 
For ILs (327, 330, 332) (Scheme 2.7), ester hydrolysed products were discovered at the end of 
the 28 day test. No amide hydrolysed products were detected for these compounds. However for 
IL (327) 31% biodegradation was observed. Ester hydrolysis alone cannot account for the levels 
of biodegradation. Ester hydrolysis and mineralisation would theoretically produce 9% 
biodegradation. Therefore some other part of the molecule must be degrading rapidly and thus 
avoiding detection by LCMS/MS. A similar observation is made for IL (330, 332). For 
prolinium derivatives (332-335) only one diastereomer (332) was analysed for metabolic 
breakdown products. However it can be inferred from the biodegradation percentages (21-23% 
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for all four derivatives) that ester hydrolysis is occurring, which is reinforced by the detection of 
TPs (364, 365). At the end of the 28 day test, completely intact parent compound was also 
observed for each of the ILs screened.  
 
 
 
Scheme 2.9. Potential biodegradation pathway of IL (326). 
As can be seen from the potential biodegradation pathway of IL (326) (Scheme 2.9), there is not 
enough carbon in the sidechain to undergo a ≥60% mineralisation within the 28 day period. The 
aim of producing readily biodegradable ILs is not to just pass the test but rather produce readily 
biodegradable ILs that do not present a persistent transformation product. If simply passing the 
test was all that was required then a slightly longer ester chain length such as a butyl ester could 
be employed to predictably increase the levels of biodegradability whilst keeping toxicity at an 
acceptably low level.
8, 53
 
 
Transformation products for the tertiary amino derivatives analysed are outlined in Scheme 
2.10. Imidazole derivative (344) can be seen to breakdown by amide hydrolysis into imidazole 
acetic acid (366). Similarly the methylethanolamine derivative (345) can be seen to also 
undergo amide hydrolysis to (367) as does L-proline derivative (347) to (368). The lack of 
quaternisation on the nitrogen headgroup appears to allow for amide bond hydrolysis in all three 
examples. Of note is the presence of the ethyl ester in (368), after 28 days the ester remained 
intact on this TP. As with the ILs examined, completely intact parent compound was also 
observed for each of the tertiary amino derivatives screened.  
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Scheme 2.10. Transformation products detected for L-phenylalanine tertiary amino derivatives. 
2.4.6 Synthesis of transformation products 
 
The final challenge in the unambiguous elucidation of the TP structures was the synthesis of the 
proposed products. Furthermore, authentic samples for further study, including TP antimicrobial 
toxicity and biodegradation were desired. Antimicrobial toxicity of the metabolic products 
would allow for a far more complete picture of the ILs overall toxicity. The question must be 
asked: what is the point in producing a biodegradable molecule if the transformation products 
are going to be more toxic than the parent compound? In addition it is also possible to assign 
structure, and tentatively stereochemistry, to the TPs if an authentic sample is available. The 
concept of submitting the transformation products of organic chemicals for further 
biodegradation screening has been carried out previously in the literature,
54
 though to the 
authors knowledge, never with ILs. In 2015, Chaintreau et al. performed biodegradation 
screening (OECD 301D and OECD 301F) on a number of ketones.  After the 28 day test period 
had elapsed, a number of persistent TPs were identified and the test duration was extended to 60 
days. When the TPs were identified a number of them were synthesised and submitted for 
biodegradation screening themselves. Results from this screening showed that although the TPs 
were persistent in the original biodegradation screening (even though the test was extended 
beyond 28 days) when submitted for further screening (OECD 301D and OECD 301F) the 
persistent products underwent further biodegradation that was not observed in the original test. 
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The synthesis of the TPs detected in Section 2.4.5 is outlined herein. From the structures 
previously identified in Schemes 2.7 and 2.10, a number of synthetic routes to the target TPs 
were determined as follows: 
2.4.6.1 Ester acid hydrolysis – Route A 
For TPs (357, 358, 361) the route involved synthesis of an ester of the target heterocycle 
followed by acid hydrolysis to give the carboxylic acid TP in a two step synthesis (Scheme 
2.11). It was decided not to react the amine with bromoacetic acid to give the target in one step 
as the amines are nucleophilic bases and can compete with the acid base reaction to give lower 
yields.
55
 The synthetic procedure is as outlined by Pukitis et al. who originally synthesised (361) 
from (371).
56
 TP (358) has been previously reported by Oldfield et al.
57
 
 
Scheme 2.11. Acid hydrolysis - Route A. 
Target TPs were synthesised in good (e.g. 357, 73%) to excellent yields (e.g. 361, 92%)  by 
route A as shown in Scheme 2.11. 
2.4.6.2 Ester base hydrolysis – Route B 
Base hydrolysis of cholinium IL (330) was chosen to furnish TP (362) in a one-step reaction 
providing the amide bond did not cleave under the conditions chosen. NaOH mediated 
hydrolysis cleaved the amide bond as did the use of HCl. To overcome this problem a LiOH 
mediated base hydrolysis procedure that is normally employed in ester deprotection in peptide 
synthesis was used (Route B, Scheme 2.12).
58
 Target TP (362) was synthesised in 85% yield.  
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Scheme 2.12. Base hydrolysis, Route B. 
2.4.6.3 Benzyl ester hydrogenolysis – Route C 
For ILs (327, 331, 332) and tertiary amino derivative (347), a benzyl ester of the parent 
compound was synthesised followed by a deprotection hydrogenolysis reaction to the equivalent 
carboxylic acid TPs. For ILs (327, 332) two possible TPs for each parent compound, one for 
each regioisomer, were proposed and thus two different benzyl ester parent molecules had to be 
synthesised in order to selectively deprotect the ester position of choice. For parent nicotinium 
IL (327) potential TPs were (359, 360) thus the regioisomer benzyl esters (373, 376) were 
synthesised as outlined in Scheme 2.13 and 2.14. 
 
Scheme 2.13. Benzyl ester hydrogenolysis pathway for prolinium TP (359). 
Benzyl nicotinate (372) was synthesised according to the procedure outlined by Khalafi-Nezhad 
et al.
59
 Intermediate (373) was synthesised by the convergent synthesis of benzyl nicotinate 
(372) with alkylating reagent (337) in moderate yield (44%, Scheme 2.13). The initial synthesis 
plan proposed hydrogenolysis of the benzyl ester to give target TP (359). 
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Figure 2.31. 
1
H-NMR spectra of benzyl ester (373) in red and crude material recovered after 
hydrogenolysis reaction in blue. 
Benzyl deprotection by hydrogenolysis did not occur cleanly and gave multiple reduction 
products (as determined by TLC (10% MeOH:DCM and 
1
H-NMR spectra). Reactions solvents 
trialled included EtOH, MeOH and DCM, none of which facilitated a deprotection free of 
impurities and lead to what appeared to be reduction of the ethyl nicotinium ring (Figure 2.31). 
A redesigned synthesis route for IL (359) is further discussed in Section 2.4.6.4. 
 
For TP (360) the proposed synthetic route (Scheme 2.14) was a linear synthesis beginning with 
the L-phenylalanine benzyl ester (374) prepared according to Baggett et al.
60
 Reacting ester 
(374) with bromoacetyl bromide formed alkylating reagent (375) in good yields (69%). Though 
alkylating reagent (375) was previously reported by Toshifumi et al.
61
 it was decided that the 
synthesis would be carried out as per the synthesis of (337) using Na2CO3 instead of 
Toshifumi‟s et al.use of triethylamine. 1H-NMR and 13C-NMR of alkylating reagent (375) were 
in agreement with the literature.
62
 Alkylating reagent (375) was subsequently reacted with ethyl 
nicotinate to give IL intermediate (376) in excellent yield (89%) after purification by column 
chromatography. Deprotection of IL (376) was attempted by hydrogenolysis to give target IL 
(360). However the hydrogenolysis reaction did not occur cleanly as per the previous benzyl IL 
(373) and gave a mixture of spots by TLC (10% MeOH:DCM). Analysis by 
1
H-NMR did not 
show the hydrogenolysis occurring cleanly. Analysis of the crude reaction mixture by LCMS 
identified a peak with m/z of 385.1735 m/z corresponding to a diethyl ester cation (Figure 2.32) 
with the same m/z detected for IL (327). A redesigned synthesis route for IL (360) is further 
discussed in Section 2.4.6.4. 
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Scheme 2.14. Benzyl ester hydrogenolysis pathway for prolinium TPs (360). 
 
 
 
Figure 2.32. Transesterified product produced from the hydrogenolysis reaction of (376). 
For L-prolinium IL (332) the potential TPs were determined to be ILs (364, 365) thus benzyl 
esters were targeted for synthesis as per Scheme 2.15, 2.16. However due to stereochemical 
ambiguity reported during the biodegradation LC/MS analysis of L-prolinium IL (332) the D-
prolinium benzyl esters and metabolite targets were synthesised as stereochemistry was not of 
concern to the LC/MS analysts. TP (380) was synthesised in place of (364) and (382) was 
synthesised in place of (365). 
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Scheme 2.15. Benzyl ester hydrogenolysis pathway for prolinium TP (364/380). 
Synthesis of (380) began with the formation of D-proline benzyl ester hydrochloride (377) in 
good yield (72%) by Fischer-Speier esterification according to the method of Gagné et al.
63
 
(377) then underwent N-methylation by reductive alkylation using sodium borohydride and 
formaldehyde (and not with methyl iodide as carried out by Morphy et al.)
64
 to give the N-
methylated product (378) in moderate yield (31%). Reductive alkylation could not be carried 
out using Pd/C and H2 as the benzyl ester would immediately undergo hydrogenolysis. 
Convergent synthesis of (378) and alkylation with (337) gave a mixture of IL epimers (379) 
which although purified from the reaction mixture could not be separated themselves by silica 
gel chromatography (Rf < 0.01, 10% MeOH:DCM). The mixture of epimers then underwent 
hydrogenolysis to give TP (380) as a mixture of epimers (Scheme 2.15). 
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Scheme 2.16. Benzyl ester hydrogenolysis pathway for prolinium TP (365/ 382). 
Similarly for L-prolinium TP (365) (Scheme 2.16), the D-prolinium derivative (382) was 
synthesised instead. A convergent synthesis from N-methyl-D-proline ethyl ester (343) with 
alkylating reagent (375) provided a mixture of IL epimers (381) in poor yield (27%). As per IL 
(379) the epimers could not be separated but were purified together by silica gel 
chromatography. Removal of the benzyl group by hydrogenolysis furnished TP (382) as a 
mixture of epimers.  
For the synthesis of TPs (380, 382) the benzyl ester hydrogenolysis strategy worked well for 
both compounds and could be applied to an L-prolinium synthesis in future if required. However 
due to the inseparable mixture of diastereomers present in both reactions, no definitive 
biodegradation or antimicrobial studies can be conducted with any certainty as to which 
diastereomer(s) may or may not be more biodegradable or may or may not have more or less 
toxic effect (if any). 
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Scheme 2.17. Synthesis of TP (363). 
TP (363) was also synthesised according to a benzyl ester hydrogenolysis route (Scheme 2.17). 
TMS-imidazole and benzylbromoacetate were reacted to form the IL intermediate (383) which 
rapidly precipitates as a white solid. Removal of solvent in vacuo and redissolving the 
intermediate in water (to remove the silyl protecting group) furnished intermediate (384) in 
moderate yield (44%) after purification by silica gel chromatography. Intermediate (384) was 
synthesised without the need to use a strong base to deprotonate imidazole before alkylation, as 
was the case with the synthesis outlined by Cerdan et al. using KOH to give the target (384)
65
. 
A convergent synthesis with (337) gave intermediate IL (385) in high yields (97%). 
Deprotection by hydrogenolysis afforded target TP (363) in high yield (87%). The synthesis 
was rapid, clean and efficient and required silica gel chromatography at only one stage, the 
purification of (384).  
 
Scheme 2.18. Synthesis of TP (387). 
For the synthesis of L- target metabolite (368), once more due to the stereochemical ambiguity 
aforementioned, the target metabolite (368) was synthesised as the D-prolinium derivative 
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(387). Tertiary amino derivative (387) was similarly synthesised from monoalkylation of D-
proline ethyl ester hydrochloride (339) to give the benzyl bromoacetate derivative (386) in good 
yield (74%). Debenzylation of (386) by hydrogenolysis gave target TP (387) in high yield 
(86%) (Scheme 2.18). 
2.4.6.4 Nicotinate TP synthesis redesign – route D 
As the deprotection reaction by hydrogenolysis to remove the benzyl esters to give target 
compounds (359, 360) (Scheme 2.19), did not proceed as expected, and clean deprotection 
could not be detected by 
1
H-NMR, a new route had to be considered.  
 
Scheme 2.19. Failed benzyl deprotection reaction. 
It was decided that instead of utilising benzyl esters as carboxylic acid protecting groups that 
utilising the target carboxylic acid from the very first stage of the reaction would be attempted. 
The redesigned synthesis is outlined in Scheme 2.20. 
 
 
Scheme 2.20. Redesigned synthesis for TPs (359, 360). 
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For the redesigned synthesis of (359) alkylating reagent (337) was reacted with sodium 
nicotinate (388) in refluxing DMF for 72 hours. After 72 hours the reaction mixture was 
acidified and purified by silica gel chromatography, to give the target product in moderate 
yields (37%) (Scheme 2.20). For the synthesis of TP (360) alkylating reagent (389) was 
synthesised according to the method outlined by Qin et al.
66
 Alkylating reagent (389) was then 
reacted with ethyl nicotinate followed by purification by silica gel chromatography to give TP 
(360) in good yield (57%) (Scheme 2.20). The new synthetic route for (359, 360) gave the 
desired TPs, however a difficult separation by silica gel chromatography was required for the 
final purification. Carboxylic acid IL TPs are very polar and movement on normal phase silica 
gel made for a very slow purification. 
2.4.6.5 Imidazole acetic acid 
TP (366) was commercially available and was purchased from TCI Europe. 
2.4.6.6 Formation of TP (367) – route E 
TP (367) was formed through the 1 step  reaction of glyoxal with 2-(methylamino)ethanol, 
according to the literature procedure outline by Farfán et al. Scheme 2.21,
67
 in moderate yield 
(51%). 
 
 
Scheme 2.21. Formation of TP (367). 
2.4.6.7 Yield data for intermediate transformation product synthesis 
 
As can be seen from Table 2.16, the ester yields observed ranged from good (e.g. (372, 97%) to 
moderate (e.g. 374, 48%). N-methylation of D-proline benzyl ester (378) proceeded with 
moderate yield (31%) whilst the N-alkylation of D-proline ethyl ester hydrochloride (339) with 
benzyl bromoacetate proceeded with 74% yield (386). The intermediate benzyl acetate of 
imidazole, (384), was produced in moderate yields (44%) potentially due to slow precipitation 
of the silyl IL intermediate (383) during the reaction. Synthesis of alkylating reagents (375, 389) 
proceeded in good yields (69%, 58% respectively). TP intermediate ILs were synthesised in 
poor (e.g. 381, 27%) to excellent yields (385, 97%). Poor yields associated with ILs (373, 379, 
381) can be directly associated with the requirement for silica gel chromatography on these 
compounds to separate them from crude products containing multiple impurities by TLC. 
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Table 2.16. Percentage yields for intermediates synthesised. 
Intermediate Compounds Yield 
Esters  
372 97% 
374 48% 
377 72% 
N-alkylated products  
378 31% 
384 44% 
386 74% 
Alkylating reagents  
375 69% 
389 58% 
IL TP intermediates  
369 63% 
370 87% 
371 97% 
373 44% 
376 89% 
379 47% 
381 27% 
385 97% 
 
As can be seen from Table 2.17 a number of the TPs were synthesised in very poor (e.g. 382, 
4%) to excellent yields (361, 89%). Yields calculated are for the entire synthesis - whether 
linear or convergent - and include all synthetic transformations performed to reach the final TP. 
Synthesis routes that required >3 steps all suffered from a gradual drop in yield as can be 
expected from linear multi-step synthesis. Convergent synthesis methods employed for (363, 
368) gave higher overall yields (63-74%). Convergent synthesis for the D-prolinium TPs (380, 
382) suffered overall due to the poor yields observed for the N-alkylation of D-proline esters to 
give N-methylated products (343, 43%), (378, 31%) and the moderate to low yields observed 
for the formation of the benzyl ester ILs (379, 47%), (381, 27%). A two step linear synthesis 
such as that employed for (358, 361) gives high final yields (67%, 89% respectively) due to the 
short nature of the synthesis. When compared to a three step linear synthesis such as that 
employed for (359), the additional third step in the synthesis reduces the overall yield 
significantly. 
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Table 2.17. Synthetic routes and final yields for TPs synthesised. 
Transformation Product Route Total Steps Final Step Yield Overall Yield 
 357 A 2 73% 46% 
358 A 2 77% 67% 
359 D 3 37% 32% 
360 D 2 57% 33% 
361 A 2 92% 89% 
362 B 4 75% 64% 
363 C 5 87% 74% 
366 TCI N/A N/A N/A 
367 E 1 51% 51% 
368 C 3 86% 63% 
380 C 6 97% 10% 
382 C 6 95% 4% 
 
The TPs and a number of their intermediates are also ILs, therefore their properties as ILs were 
also of interest. Melting points for the IL TPs are outlined in Table 2.18. 
 
Table 2.18. Melting points for IL TPs and intermediates. 
Final TPs Melting Point °C 
357 207-209 
358 177-179 
359 90-92 
360 85-87 
361 > 250 
362 59-61 
380 162-164 
382 41-43 
IL TP Intermediates  
369 133-135 
370 36-38 
371 227-229 
373 50-52 
376 63-65 
379 159-161 
381 42-44 
385 57-59 
 
As can be seen from Table 2.18 a number of the final TPs melt below 100 °C. TPs (357, 358, 
380) were observed to have a significantly elevated melting point ~100 °C greater than the other 
TPs analysed. DMAP TP (361) had a melting point of > 250 °C. TP (380) was also observed to 
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melt at just 1-2 °C higher than its benzyl ester protected intermediate (379). All of the IL 
intermediates except (369, 371, 379) melted below 100 °C. None of the products synthesised 
were room temperature ILs.  
 
The completion of the synthesis of detected TPs is a significant step in further understanding the 
environmental and toxicological interactions that may occur if ILs enter the terrestrial 
environment. Possessing a stock of synthesised and characterised TPs will allow for their 
further evaluation, whether by further investigations into their biodegradability or (eco)toxicity, 
to give a more complete picture of their lifecycle. The results of antimicrobial screening of the 
TPs are presented in Section 2.5. 
2.4.7 Biodegradation screening conclusions 
From the results of the biodegradation screening it can be shown that one IL (325) was 
determined to be inherently ultimately biodegradable by the Closed Bottle Test (OECD 301D). 
L-phenylalanine ILs (324, 326-335) appeared to be recalcitrant to biodegradation with a number 
of transformation products observed for ILs (325-328, 330-332) screened. The remaining L-
phenylalanine ILs were not examined for their transformation products. At the end of the 28 day 
test the presence of intact parent compound suggests that the ILs ester functionalities are more 
stable to aqueous conditions than expected (20 °C for 28 days). Tertiary amino derivatives 
examined (345-347) were shown to be more biodegradable than their IL counterparts, yet none 
of them passed the CBT. Tertiary amino compound (345) was determined to be inherently 
ultimately biodegradable after CBT test times were exteneded to 42 days. Results collected 
appear to be in agreement with Boethling‟s rules of thumb for designing compounds for 
degradation; tertiary amines are generally more biodegradable than quaternary amines.
3
 The fact 
that one pyridinium IL (325) gave high levels of biodegradability in the CBT, and goes against 
the current trend of poorly biodegradable quaternary amines, shows that rational design of 
biodegradable ILs is challenging but not impossible. As can be seen from the observations made 
in Chapter 1 regarding biodegradability of pyridinium ILs, functionalization at the 3-position to 
give a methoxy pyridinium IL (326) reduces biodegradability. Similarly functionalization at the 
4-position to give DMAP derivative (328) also appears to impede biodegradability. 
Additionally, the presence of an –OH moiety in the L-tyrosine derivatives screened hindered 
biodegradability from 5-13%. 
 
2.5 Antimicrobial screening of transformation products 
With the synthesis and characterisation of the TPs accomplished, the antimicrobial properties of 
the TPs were investigated as part of the same collaboration with Dr. Marcel Špulák, Faculty of 
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Pharmacy, Charles University, Czech Republic. The experimental methods, bacteria and fungi 
are the same as those outlined in Section 2.3. IL TPs (358-363, 380, 382) and tertiary amines 
(366, 368) were examined for their antimicrobial toxicity. Overall the majority of the TPs 
possessed little to no discernible toxic effect towards the bacteria screened against up to the 
concentration limit of 2000 µmol/L. The IL epimer mixture that comprised TP (382) displayed 
an IC95 of 500 µmol/L towards the bacteria S. aureus and S. epidermidis (Table 2.19). The 
toxicity cannot be contributed to any one of the pair of isomers and thus is presented as the 
antimicrobial toxicity of a mixture. 
 
 
Figure 2.33. IL (382). 
Similarly, low levels of antifungal toxicity were observed. Just two ILs (359, 361) showed any 
level of antifungal toxicity (Table 2.20). IL (359) had an IC95 of 2000 µmol/L towards the two 
Candida albicans strains whilst IL (361) displayed an IC95 of 2000 µmol/L towards the fungi 
Candida parapsilosis and Trichophyton mentagrophytes. 
 
Figure 2.34. ILs (359, 361).
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Table 2.19. Antibacterial results obtained for TPS. 
Microorganism Time (h) 
   IL IC95 µmol 
357 358 359 360 361 362 363 366 367 368 380 382 
 
Gram Positive 
 
 
 
           
SA 
24h 
48h 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
>500, 
>500 
>2000, 
>2000 
>1000, 
>1000 
500, 
500 
MRSA 
24h 
48h 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
>500, 
500 
>2000, 
>2000 
>1000, 
>1000 
>1000, 
>1000 
SE 
24h 
48h 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
>500, 
>500 
>2000, 
>2000 
>1000, 
>1000 
500, 
500 
EF 
24h 
48h 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
>500, 
>500 
>2000, 
>2000 
>1000, 
>1000 
>1000, 
>1000 
 
Gram Negative 
 
             
EC 
24h 
48h 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
>500, 
>500 
>2000, 
>2000 
>1000, 
>1000 
>1000, 
>1000 
KP 
24h 
48h 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
>500, 
>500 
>2000, 
>2000 
>1000, 
>1000 
>1000, 
>1000 
KP-E 
24h 
48h 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
>500, 
>500 
>2000, 
>2000 
>1000, 
>1000 
>1000, 
>1000 
PA 
24h 
48h 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
>500, 
>500 
>2000, 
>2000 
>1000, 
>1000 
>1000, 
>1000 
 
 
 
150 
 
Table 2.20. L-Phenylalanine ILs screened for antifungal activity. 
* 
IC50 values were assessed for AF, AC and TM and IC80 for all other strains. 
Microorganism Time 
(h) 
   IL IC80/50 µmol* 
357 358 359 360 361 362 363 366 367 368 380 382 
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24h  
48h 
>2000, 
>2000 
>2000, 
>2000 
2000,  
2000 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
>500, 
>500 
>2000, 
>2000 
>1000, 
>1000 
>1000, 
>1000 
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>2000, 
>2000 
>500, 
>500 
>2000, 
>2000 
>1000, 
>1000 
>1000, 
>1000 
CL 
24h 
48h 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
>500, 
>500 
>2000, 
>2000 
>1000, 
>1000 
>1000, 
>1000 
TA 
24h 
48h 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
>500, 
>500 
>2000, 
>2000 
>1000, 
>1000 
>1000, 
>1000 
AF 
24h 
48h 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
>500, 
>500 
>2000, 
>2000 
>1000, 
>1000 
>1000, 
>1000 
AC 
24h 
48h 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
>500, 
>500 
>2000, 
>2000 
>1000, 
>1000 
>1000, 
>1000 
TM 
72h 
120h 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
2000,  
2000 
>2000, 
>2000 
>2000, 
>2000 
>2000, 
>2000 
>500, 
>500 
>2000, 
>2000 
>1000, 
>1000 
>1000, 
>1000 
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It can be concluded from the antimicrobial screening that the TPs examined displayed negligible 
levels of toxicity at the concentrations screened at. The reduced levels of lipophilicity present in 
each compound may be an important factor in the low levels of toxicity observed.
68, 69
 Low 
levels of toxicity such as those observed for the TPs suggests that IL biodegradation can 
produce relatively benign metabolic products and that the strategies employed within this 
chapter support the 4
th
 principle of green chemistry: “designing safer chemicals”, and the 10th 
principle: “designing for degradation”.  
 
2.6 Conclusions to 1st generation IL synthesis, biodegradation and 
antimicrobial toxicity screening 
 
In conclusion a series of new L-phenylalanine ILs (324-335), tertiary amino analogues (344-
348) and  L-tyrosine ILs (349-353), have been synthesised and characterised by 
1
H-NMR, 
13
C-
NMR, HRMS, IR, optical rotation and melting point. The target IL compounds were all 
produced in moderate to high yield yields with favourable green chemistry metrics established. 
ILs and tertiary amino analogues were produced in sufficient quantity and purity to facilitate an 
antimicrobial screening and biodegradation study. Of the ILs screened, both L-phenylalanine 
and L-tyrosine, possessed a low antimicrobial and low antifungal toxicity with only one IL (331) 
exhibiting an IC95 of 500 µmol/L towards S. aureus and S. epidermidis. No other IL was 
observed with a lower IC95. All of the tertiary amino compounds examined (344-348) displayed 
higher levels of antimicrobial activity, especially towards S. aureus with IC95 ranging from 125-
1000 µmol/L with the tertiary amino proline derivatives (347, 348) displaying an IC95 of 125 
µmol/L towards S. aureus. The absence of a quaternary nitrogen atom in the tertiary amino 
compounds greatly increases the toxicity. From the results observed for the biodegradation 
screening, pyridinium IL (325) was observed to undergo 63% biodegradation within a 28 
daytest period and 76% within a 42 day period and can be considered inherently ultimately 
biodegradble, but not readily biodegradable. Reduced levels of biodegradability (ranging from 
17-51%) were observed for the rest of the ILs examined. None of the tertiary amino compounds 
(344-347) were considered readily biodegradable however a number of the tertiary amino 
derivatives (345, 347) underwent levels of biodegradation 20-22% higher than their IL 
counterparts (330, 332/333). Tertiary amino compounds (344, 345) also showed high levels of 
biodegradability (59% and 78% respectively) after test time extensions and (345) can be 
considered inherently ultimately biodegradable. This observation is in accordance with 
Boethling‟s rules of thumb which suggests that generally tertiary amines undergo higher levels 
of biodegradation than quaternary amines.
3
 A metabolite study on a number of ILs (325-328, 
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330-332) was carried out and persistent TPs were identified and subsequently synthesised; ILs 
(357-363, 380, 382) and tertiary amines (366  ¸367, 387). Overall, the TP‟s displayed little to no 
discernible antimicrobial toxicity and suggest that the IL metabolic products could be benign 
towards certain bacteria and fungi at the concentrations screened at. The TPs have since been 
submitted for investigation into their biodegradability to assess potential bioaccumulation. This 
work will be conducted by the research group of Prof. Klaus Kummerer, Faculty for 
Sustainability, University of Lüneburg, Germany. 
 
It can be concluded that IL derivative (325) was the most "green” candidate of all the ILs 
examined. It can be rapidly synthesised in a short high yielding synthesis with favourable green 
chemistry metrics and did not require silica gel chromatography for purification at any stage. IL 
(325) also displayed very low levels of toxicity to bacteria screened against, displaying an MIC 
of 2000 µmol/L to S. aureus and >2000 µmol/L towards all other bacteria and fungi. IL (325) 
also can be categorised as inherently ultimately biodegradable and did not present any 
detectable transformation products. Overall the design and synthesis of low toxicity 
biodegradable ILs according to the 12 Principles of Green Chemistry and Boethling‟s Rules of 
Thumb has been a success in producing IL (325). For all of the ILs and tertiary amines, the 
antimicrobial toxicity and biodegradation data will prove invaluable in designing future 
generations of ILs. The data alone will be used in the future as data training sets for 
computational studies on the biodegradability and antimicrobial toxicity of ILs. 
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Chapter 3 
Synthesis of 2nd Generation Amino Acid ILs 
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3.1 Aim 
The aim of this chapter of work was to design and synthesise a series of 2
nd
 generation amino 
acid ILs, derived from those presented in Chapter 2, with potential surface active properties (i.e. 
surfactants). Synthesis was carried out with respect to the 12 principles of green chemistry and 
Boethling‟s rules of thumb for designing molecules for their biodegradability and from the 
results presented in Chapter 2 regarding toxicity and biodegradability of ILs. The series of ILs 
presented within this chapter will be referred to as the “2nd generation” of amino acid ILs. 
Biodegradability and antimicrobial toxicity of this 2
nd
 generation was a key point for 
investigation. An introduction to surfactants is given in this chapter, however the study of the 
surfactant properties of the 2nd generation ILs synthesised are presented separately in Chapter 
4. 
3.2 Introduction 
The overlap between surfactant, or surface-active agents, and IL chemistry is one that has been 
observed from the very beginning of the current upsurge in IL research and development. Many 
of the structural features of ILs correspond with the functionalities present in surfactants.
1
 
(Most) ILs and surfactants are amphoteric classes of molecules i.e. they possess a polar, 
hydrophilic head(s) and a lipophilic, hydrophobic tail(s). A number of linear alkyl IL structures 
are analogous to those found in cationic surfactants and the research and design strategies of 
both fields, to promote biodegradation and control toxicity (based on application), are 
comparable. The structure of the 3-methyl-1-octyl imidazolium halide IL series, or [omim][X], 
is one of the many ILs that shares structural features with cationic surfactants (Figure 3.1). 
 
 
Figure 3.1. Structural similarities between ILs and surfactants. 
Since the implementation of the EU regulation on detergents in 2004 (Regulation (EC) No 
648/2004), investigation into the ultimate biodegradability of surfactants has been a 
requirement. This legal requirement has driven a new wave of investigation into the preparation 
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of biodegradable surfactants that coincided with the advent of the first readily biodegradable 
ILs.
2-4
 Strategies that have been employed to promote biodegradation are well documented, 
with the inclusion of hydrolysable ester bonds and cleavable amide links and are discussed in 
Chapter 1, Section 1.3.3 and Section 1.7. 
 
Under the EU regulation on detergents legislation, if a surfactant does not ultimately biodegrade 
then derogation may be applied for depending on the end use application and the calculated risk 
to the environment and health by the expected use of such a surfactant. Hence, antimicrobial 
toxicity data is vital.
5
 
 
Surfactants are of interest due to their ability to adsorb onto surfaces or interfaces at relatively 
low concentrations. This property alters the interfacial energy of the surface or interface. 
Interface is the term used to define a boundary between two immiscible phases such as oil and 
water. Surface can also used as a term when referring to an interface between one phase and a 
gas, e.g. air and water.
6
 
 
Surfactants find a wide range of applications due to their phase boundary behaviour such as in 
detergents, emulsifiers, foaming agents, cleaning agents and phase transfer catalysis.
6,7
 The 
ability to trap a significant proportion of the total mass of a system at a phase boundary, such as 
is present in an emulsion (a dispersion of minute droplets of oil in the aqueous phase), makes 
surfactants particularly useful, e.g. in cleaning an oil spill in an aquatic environment. When a 
surfactant‟s interfacial behaviour is so strong (when compared to the rest of the bulk phase of a 
system) then the entire system‟s behaviour can be dominated by what is occurring at the 
interface, an example of which is phase transfer catalysis. 
 
The amphiphilic nature of surfactants means that if a surfactant is dissolved in an aqueous 
medium, the hydrophobic portion of the molecule can disrupt hydrogen bonding between water 
molecules. Thus the contact area between the hydrophobic portion of the surfactant and water is 
minimised. Repulsive behaviour can orientate the surfactant molecules as a mono-layer at the 
air-water surface boundary with the hydrophobic portion pointing almost entirely towards the 
air. Similar behaviour can be imagined for an oil-water interface where the hydrophobic portion 
is orientated towards the oil and the hydrophilic portion is orientated towards the water. As both 
the oil and the hydrophobic portion of the surfactant are non-polar species, the surfactant 
essentially allows “bridging” of the two phases as one portion of the surfactant exists in each 
phase. A reduction in the energy barrier is observed and the two phases are repelled to a lesser 
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degree, hence a reduction in the surface tension is observable (Figure 3.2). The overall reduction 
of surface tension can eventually lead to an emulsified state. 
 
 
Figure 3.2. Surfactant orientation at an oil-water interface. 
Once an interface reaches saturation point there remains nowhere for additional molecules (i.e. 
higher concentrations) of surfactant to dissolve except for in one of the two phases. In an air-
water system the excess concentration of surfactant begins to aggregate in the aqueous phase as 
colloidal sized particles (particles with diameters between 1 and 1000 nm) i.e micelles. Co-
operative aggregation to hemi-micelles can also occur before surface saturation occurs. Bi-
layers and multilayer organisation is also possible as are rod shapes and hexagonal rods to name 
just a few (Figure 3.3). Solvents capable of hydrogen bonding from two or more centres are the 
only types reported capable of forming micelles due to the extended hydrogen bond network 
required to hold the aggregates together.
6
 Micellisation is of importance for detergency 
(cleaning) applications as micelles allow for the dissolution and solubilisation of otherwise 
immiscible components (Figure 3.4). Micellisation is also of significance in drug delivery 
applications as drug molecules can be encapsulated within a micellar membrane allowing for 
greater control of delivery method and overall solubility. Drug molecules which are not water 
soluble can be enveloped within a micelle, which can in turn dissolve in an aqueous system.
8
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The concentration of surfactant required for the spontaneous formation of micelles is known as 
the critical micelle concentration (CMC). Many factors affect the micellisation process 
including temperature, the presence of electrolytes, and the presence of other organic molecules. 
Temperature increase can at first decrease the CMC, as the increase in tmeperature causes a 
reduction in hydration around the hydrophobic portion of a surfactant thus promoting 
micellisation. However if the temperature continues to increase then the water structure and 
hydrogen bonding that helps to maintain the micelle structure becomes disrupted and 
micellisation becomes unfavourable. The addition of electrolytes such as NaCl etc. can help to 
decrease the CMC as the addition of electrolytes aids in decreasing the ionic repulsion between 
charged headgroups in micelles, thus promoting micellisation. This effect is greater for cationic 
and anionic classes of surfactants followed by zwitter-ionic then non-ionic, see Section 3.2 for 
information on these classes of surfactants.  
 
 
Figure 3.3. Micelles and some of the different forms that they can take.  
Adapted from “Surfactants: the ubiquitous amphiphiles” 
http://www.rsc.org/chemistryworld/Issues/2003/July/amphiphiles.asp.
9
 
 
 
 
 
Figure 3.4. Detergent application of a surfactant.  
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Adapted from “Surfactants: the ubiquitous amphiphiles” 
http://www.rsc.org/chemistryworld/Issues/2003/July/amphiphiles.asp.
9
 
 
 
3.3 Classes of surfactants 
There exists four major classes of surfactants which can be categorised into two main groups: 
three ionic and one non-ionic The three ionic classes are zwitter-ionic, anionic and cationic, 
each of which have considerably different properties, pros and cons.
6
 Global consumption of 
surfactants by class is depicted in Figure 3.5 As can be seen, the anionic and non-ionic classes 
of surfactants combined dominate the global consumption of surfactants, followed by cationic 
and then zwitter-ionic surfactants. The breakdown of surfactant use and consumption by area 
can be seen in Figure 3.6. 
 
Figure 3.5. Consumption of surfactants by class.
10
 
Adapted from I. L. Matthew, in Handbook of Detergents, Part F, CRC Press, 2008, DOI: 
doi:10.1201/9781420014655.ch1 
 
13 million metric tons of surfactants were produced in 2006 and it has been projected that 
upwards of  22 million tons will be produced annually by 2019 making surfactant production a 
lucrative market worth in the excess of €40 billion.11 
 
Non-ionics 
43% 
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Anionic 
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Surfactant Consumption by Class 
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Figure 3.6. Uses of surfactants by sector/ application.
10
 
Adapted from I. L. Matthew, in Handbook of Detergents, Part F, CRC Press, 2008, DOI: 
doi:10.1201/9781420014655.ch1 
 
3.3.1 Non-Ionic 
Non-ionic surfactants do not bear a charge at all on the surface active moiety and are not 
comprised of an anion-cation pair but instead a single uncharged chemical unit. The hydrophilic 
head of the unit is most often comprised of multiple heteroatoms such as a sugar unit or primary 
alcohols, whereas the hydrophobic tail can be comprised of a fatty acid/alcohol derivative 
(Figure 3.5). Due to the absence of a charge carrier the non-ionic surfactants have reduced 
electrostatic effect and do not strongly adsorb onto charged surfaces. Non-ionic surfactants are 
used as detergents and in the personal care and food products industry. Examples of non-ionic 
surfactants included polyethylene glycols (PEG), polysorbates, cocamide ethanolamines (390) 
(Figure 3.7) and nonylphenols.
6, 12 
 
Figure 3.7. Cocamide monoethanolamine (390). 
3.3.2 Zwitter-Ionic 
Zwitter-Ionic surfactants bear both a positively and negatively charged portion on the same 
molecule and can be considered ampholytic. They also do not require a counterion to maintain 
charge balance. Some zwitter-ionic surfactant‟s ionisation states can be pH dependant, thus 
Detergents 
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35% 
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allowing for altering of physico-chemical properties by changing the acidity or basicity of the 
surfactant environment. This leads to the sub classification of amphoteric surfactants i.e. being 
able to act as both a base or an acid. At high pH zwitter-ionics can exhibit the surfactant 
properties of anionic surfactants and at low pH can exhibit cationic surfactant properties. As 
most surfaces in nature are negatively charged, zwitter-ionic surfactants can adsorb onto the 
surface without significantly altering the overall charge state of the surface. Zwitter-ionic 
surfactants find uses as dispersing aids, bactericides and corrosion inhibitors. Examples of 
zwitter-ionic surfactant classes include amidopropyl betaines (391) (Figure 3.8), amphoacetates 
and the sulphobetaines.
6
 
 
 
Figure 3.8. Cocamidopropyl betaine (391). 
3.3.3 Anionic 
Anionic surfactants bear a negative charge on the surface active portion of the molecule and a 
positively charged counterion. Due to their negatively charged surface active portion the anionic 
surfactant family will be repelled by any negatively charged surfaces. Anionic surfactants can 
easily be prepared by neutralising fatty acids with a base to give the classic family of soaps. 
Other popular classes include sulphonic acid or phosphoric acid salts. Some anionic surfactants 
such as the fatty acid soaps can readily be insolubilised by electrolyte solutions (such as brine) 
and can be unstable under acidic conditions. Anionic surfactants play a large role in detergency 
and cleaning applications and are generally cheap to produce. Examples of anionic surfactants 
are the linear alkyl benzene sulphonates (LAS), alkyl sulphonates such as sodium dodecyl 
sulfate (392) (Figure 3.9), alkyl phosphates and metal carboxylates of fatty acids.
6
 
 
Figure 3.9. Sodium dodecyl sulphate (392). 
3.3.4 Cationic 
The cationic class of surfactants carry a positive charge on the surface active portion of the 
molecule and possess a negatively charged counterion. Cationic surfactants can readily adsorb 
onto negatively charged surfaces with the tail orientated away from the surface and thus create a 
water repellent barrier. In general cationic surfactants are more expensive than anionic and 
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display poorer detergent properties.
6
 Cationic surfactants are also generally not compatible with 
anionic surfactants. Quaternary cationic charge carriers retain their water solubility regardless of 
pH. Cationic surfactants see a wide range of applications from herbicides and antimicrobials to 
fabric softeners and water repelling agents.
6, 13
 As they readily adsorb onto surfaces they can 
impart their properties onto the surface. Examples of cationic surfactants include quaternary 
ammonium compounds (QAC‟s), such as distearyldimethylammonium chloride (393) (Figure 
3.10), quaternary phosphonium, alkyl pyridinium surfactants and imidazolium based surfactants 
(Figures 3.11, 3.12).
6
 A number of IL surfactants are also presented in Chapter 1, Section 1.7 
 
 
Figure 3.10. Distearyldimethylammonium chloride 
 
Figure 3.11. Alkyl pyridinium surfactants (n = 10-16, 18) reported by Rosen et al.
14
 and 
Skerjanc et al.
15
 
 
Figure 3.12. Alkyl ester and amide surfactants reported by Pérez et al.
16, 17
 Imidazolium ILs 
(412-414) originally reported by Gathergood and Morrissey.
3, 18
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3.4 Subclasses of surfactants 
Within the classes of surfactant lie three main sub-classes. These sub-classes could be 
considered the overall structure or architecture of a surfactant molecule and are irrespective of 
whether the surfactant is charged or how it derives its charge. Structural composition of a 
surfactant and how its alkyl chain(s) are positioned give rise to the following classes of 
surfactants and are outline in Figure 3.13(cationic headgroups are depicted for illustrative 
purposes but they could also be anionic). 
 
 
Figure 3.13. Subclasses of surfactants. 
The surfactant properties and applications of polymers have also been widely reported but are 
not discussed in depth within the scope of this body of work. Polymeric surfactants derive their 
properties in much the same way as monomeric surfactants would; they are comprised of 
hydrophilic and hydrophobic regions that allow the polymer to interact at the interface of a two 
phase system. A polymeric surfactant structure is depicted in Figure 3.14. Block co-polymers of 
polyethylene and polypropylene glycols with molecular weights ranging from 1000-30,000 
gmol
-1
 have been reported as possessing surface active properties including wetting, gel 
forming, and drug delivery agents.
19, 20
 
165 
 
 
 
Figure 3.14. General structure of a polymeric surfactant.
21
 
Adapted from Jones et al. Eur. J. Pharm. Biopharm., 1999, 48, 101-111.
21
 
3.4.1 Linear alkyl 
 
The most commonly employed surfactant structures are the linear alkyl derivatives. Linear alkyl 
derivatives contain a charged/polar head and a non-polar tail. As previously discussed in 
Section 3.3 the polar head, can be ionised or neutral. A linear alkyl surfactant‟s tail can be 
comprised of many different moieties (Figure 3.15). 
 
 Branched alkyl chains e.g. nonylphenol (422).22 
 Linear alkyl chains e.g. cetylpyridinium bromide (400).22 
 Unsaturated alkyl chains e.g. sodium oleate (423).23 
 Polyoxygenated tails e.g. polyethylene glycol (424).6 
 Perfluorinated tails e.g. perfluorooactanesulphonic acid (425).6 
 Polysiloxanated tails e.g. "Q2-5211” (426).24 
The size of the hydrophobic region (which can often be simplified to the length of the alkyl 
chain) is a key determining factor in the CMC and surface activity. The surface activity triples 
for each additional CH2 unit according to Traube‟s rule which states that:” in a homologous 
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series the interfacial activity increases with increasing size of the hydrophobic group and that 
the surfactant concentration at which a specific interfacial activity is achieved decreases with 
increasing size of the hydrophobic group”.13 Simplified to a rule of thumb, the concentration 
required to produce equal lowering of surface tension decreases x3 for each additional CH2 
group in the surfactant‟s alkyl chain. Increased alkyl chain lengths can also be responsible for 
elevated melting points, closer packing at interfaces, reduced aqueous solubility and depending 
on length, differing levels of toxicity and biodegradability. A rule of thumb is that for every 
additional CH2 unit added to the alkyl chain the CMC is reduced by half.
27
 This trend is 
illustrated by the data in Table 3.1 for pyridinium surfactants of the formula depicted in Figure 
3.16 
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Figure 3.15. Different classes of alkyl chains. 
 
 
 
Figure 3.16. Linear alkyl pyridinium surfactants of general structure and formula (n= 10-16).
15
 
Table 3.1. CMC values for a homologous series of pyridinium bromide linear alkyl 
surfactants.
15
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Surfactant 
Chain Length 
Number of Carbons in Sidechain CMC (mM) 
C10H21 10 44  
C11H23 11 21 
C12H25 12 11.4 
C13H26 13 5.3 
C14H29 14 2.7 
C15H31 15 1.3 
C16H33 16 0.64 
 
Branching of alkyl chains reduces the melting point and packing. Cis double bonds also reduce 
the packing, however chains containing a trans double bond can pack almost as tightly as 
saturated alkyl chains.  Branching of alkyl chains can also lead to a decrease in 
biodegradability.
28-30
 Extending an alkyl chain up to a point will indeed decrease the CMC, 
however with extended chain lengths an increase in antimicrobial toxicity is observed. The trend 
of increasing toxicity will continue up to a point followed by a rapid decline in toxicity as 
aqueous solubility and thus bioavailability decreases.
31, 32
 The trend is highlighted in Figure 3.17 
published by Gilmore et al.
32
 
 
Figure 3.17. MIC of alkylquinolinium ILs (Figure 3.18) screened by Gilmore et al.
32
 
 
Figure 3.18. General structure of alkylquinolium ILs screened by Gilmore et al.
32
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Polyoxypropylene units can increase the hydrophobic nature of a surfactant but the 
polyoxyethylene derivatives will actually decrease the hydrophobic nature. It has also been 
shown that addition of polyoxygenated units can reduce the overall antimicrobial toxicity of 
alkyl chains yet maintain levels of biodegradability.
18
 The addition of fluorinated or siloxanated 
groups to the alkyl chain can lower the CMC below that which is attainable for hydrocarbon 
chains. Perfluorinated chains see widespread use in fire fighting applications and are known to 
be persistent pollutants exhibiting very poor biodegradability.
26
 
3.4.2 Bolaform 
The bolaform, or bolaamphiphile, class of surfactants are a family of surfactants comprised of 
two charged groups located on opposite ends of the molecule (Figure 3.19). Charged regions of 
the molecules are tethered together with a chain of desired length and composition. Bolaform 
surfactants can behave at the air water interface in a number of ways. If the chain between the 
two heads is too short then no surface active properties are observed at all. As the chain length 
extends, the bolaform molecules can adopt a horizontal conformation lying flat on the surface. If 
the chain is extended even further then the bolaform surfactant can be pushed out of the water 
and into the air adopting a “wicket” conformation (Figure 3.20).6, 33 Bolaform surfactants are 
often far poorer surfactants than linear alkyl surfactants with much less of an effective surface 
tension reducing range. The bolaform surfactants double charge confers much greater 
hydrophilicity than more traditional linear alkyl surfactants and CMC values for bolaform 
surfactants are often much higher than that of linear alkyl surfactants. Overall, bolaform 
compounds are less useful for surfactant applications (such as detergency) than linear alkyl 
surfactant molecules. A rule of thumb for the bolaform surfactants is that a bolaform surfactant 
will require almost 2x the number of carbon atoms as that of a comparable linear alkyl 
surfactant to achieve a similar CMC. Another way of stating this relationship is that when 
comparing a linear alkyl surfactant to a bolaform surfactant with the same number of carbon 
atoms in their alkyl chain/linker then the linear alkyl surfactant will have a CMC that is half of 
that observed for the bolaform (Figure 3.19).
34
  
 
Figure 3.19. Comparison for bolaform surfactant C12Me6 (427) and a C12 linear alkyl 
ammonium surfactant (428).
34
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Figure 3.20. Potential bolaform conformations.
33
 
3.4.3 Gemini 
The family of gemini surfactants are a class of surfactant where two linear alkyl derivatives are 
connected at, or very near to, the polar heads by a linker to form a dimeric type surfactant 
(Figure 3.21).
6, 35, 36
 Linker types can include flexible alkyl or polyether chains or more rigid 
aromatic types.
34
 Gemini surfactants appear to be far more effective at lowering the surface 
tension at interfaces than their corresponding monomeric linear alkyl surfactants. The reported 
CMC values are also lower, up to 2-3 orders of magnitude, than the monomeric linear alkyl 
derived surfactants of similar chain length (Figure 3.22).
34, 37
  If a long flexible alkyl chain is 
used as a linker then the gemini surfactant can adopt a wicket conformation similar to that of the 
bolaform in Figure 3.20.
36
 However if a rigid linker such as an aromatic moiety is used then the 
surfactant can lie horizontal on the surface. Apart from forming micelles, gemini surfactants can 
also form lipid like membranes.
34
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Figure 3.21. Gemini surfactant C6H4-1,4-bis-[CH2N
+
(CH3)2C12H25].2Br
-
 
 
Figure 3.22. Comparison of CMC for linear alkyl surfactant (430) to gemini surfactant (431).
37
 
3.5 Synthesis, antimicrobial toxicity and biodegradation studies of 2nd 
generation amino acid ILs 
 
The aim of this section is to present the synthesis, antimicrobial toxicity and biodegradability of 
the 2
nd
 generation of amino acid ILs. Research conducted in IL biodegradability and 
antimicrobial toxicity previously discussed in Chapters 1 and 2 has allowed for the rational 
design of a 2
nd
 generation of amino acid derived ILs which can be synthesised from a number of 
renewable resources (e.g. L-phenylalanine,
38
 and long chain alcohols such as octanol
39
). The 
design strategy chosen further embraces the framework outlined in the twelve principles of 
green chemistry and Boethling‟s rules of thumb and it is reported for the first time the chemical 
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synthesis, surfactant properties, antimicrobial activity and biodegradability of L-phenylalanine 
derived amino acid ionic liquid surfactants. Furthermore, investigations into how the aromatic 
sidechain of the L-phenylalanine moiety and the amino acid heteroatoms would affect the 
surfactant properties was of importance. Antimicrobial activity and biodegradability of this 2
nd
 
generation of amino acid ILs are discussed in detail in Section 3.6 and 3.7. Surfactant properties 
will be presented in Chapter 4. 
 
Two classes of ILs were synthesised. The first class reported is a series of linear alkyl amino 
acid ILs comprised of ester chain lengths C8H17, C10H21 and C12H25, whilst the second class are a 
bolaform class and are comprised of two amino acids linked together at the C-terminus by an 
ester chain linker. Linkers consisted of C8H16, C10H20 and C12H24. Target ILs (432-452) are 
outlined in Figure 3.23. 2
nd
 generation amino acid ILs were synthesised based on the synthesis, 
toxicity and biodegradability results of Chapter 2. Desired ester chain lengths of the ILs were 
determined from the beginning of the design process leading to a small series of targets. Choice 
of alkyl chains was due to the possibility that the amino acid‟s heteroatom content would lead to 
a lack of definition or distinction between the hydrophobic and hydrophilic regions of the 
surfactant candidate molecules, thus a long alkyl chain would increase the chances of promoting 
surfactant behaviour. If the C8-C12 alkyl chain ILs proved to be poor surfactants then synthesis 
of shorter chains such as C4 and C6 would be fruitless. α-Bromoamide alkylating reagents (456-
458, 462-464) developed within this chapter can be considered the key to the series of ILs, 
allowing for any number of nucleophilic substitutions to take place on the bromide atom leading 
to nearly limitless potential headgroups as final targets. 
 
The most promising candidates from Chapter 2 for further investigation were the imidazolium 
(324), pyridinium (325), cholinium (330) ILs due to their favourable green chemistry metrics, 
antimicrobial toxicity and biodegradability. Though IL (330) was shown to only undergo ester 
cleavage in Chapter 2 Section 2.4.1 its rapid and green synthesis and non-aromatic linear 
headgroup made this derivative of interest for further study. Derivatives of ethyl nicotinium 
(327) were also planned based on the proviso that the green metrics for the first derivative 
synthesised were more promising than those calculated for (327) in Chapter 2 (poor E-factor, 
solvent intensity, mass intensity and reaction mass efficiency due to silica gel chromatography 
purification and moderate yields). 
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Figure 3.23. Surfactant targets (432-452). 
 
3.5.1 Synthesis of 2nd generation L-phenylalanine linear alkyl ILs 
Linear alkyl L-phenylalanine derived ILs were synthesised in three stages using a similar 
method to that outlined in Chapter 2, Section 2.2.2.2. Step 1 involved acid catalysed 
esterification of L-phenylalanine with a long chain alcohol in toluene using p-toluene sulfonic 
acid (PTSA) as an acid catalyst to give esters (453-455). Use of SOCl2 was unsuccessful as the 
resulting reaction mixture would not solubilise under the reaction conditions. Reaction workup 
required the neutralisation of the PTSA salt of the esters which resulted in the formation of an 
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emulsion that required several additions of brine and multiple extractions to retrieve the desired 
esters in an appreciable amount. This step is the lowest yielding step of the synthesis giving 
only moderate (e.g., 453, 58%) to poor yields (e.g. 455, 37%), (Table 3.2, Scheme 3.1). 
Inefficient removal of water, even though a Dean-Stark apparatus was employed, may also play 
a role in the poor yields. The quantities of crude PTSA ester salts recovered before 
neutralisation (Table 3.2) suggests that when the neutralisation step was carried out ~30% mass 
was lost in the resulting emulsions. Purification of the esters (453-455) produced was by 
precipitation from the reaction mixture with diethyl ether followed by vacuum filtration and 
washing with hexane. See Chapter 5 for experimental method. 
 
 
Scheme 3.1. General synthetic route employed for step 1, synthesis of esters (453-455) and step 
2, synthesis of alkylating reagents (456-458). 
Table 3.2: Percentage yields for L-phenylalanine esterification reactions. 
Product Acid Employed Crude Salt Product 
Mass Recovery 
Free Base Yield 
453 HCl (SOCl2) 0% 0% 
453 PTSA 94% 58% 
454 PTSA 65% 38% 
455 PTSA 63% 37% 
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Step 2 involved acylation of the esters with bromoacetyl bromide to form alkylating reagents 
(456-458) in moderate (e.g. 457, 51%) to high yields (e.g. 458, 88 %), (Table 3.3, Scheme 3.1). 
Purification of the α-bromoamide alkylating reagents (456-458) was by aqueous workup and 
filtration through a short plug of silica to ensure complete removal of any lipophilic impurities.  
 
Table 3.3. Percentage yields for alkylating reagents (456-458). 
 
Step 3 involved alkylation of pyridine, dimethylamino ethanol or 1-methylimidazole to furnish 
the respective ILs (432-440) in high yields (Scheme 3.2). Solvent of choice for the IL forming 
reaction step is usually diethyl ether, however, precipitation of the IL products only occurred 
with the cholinium ILs (438-440). Instead, ethyl acetate and reflux conditions were employed 
for the pyridinium (432-434) and 1-methylimidazolium ILs (435-437). Final stage products 
(432-440) were purified by trituration. At no stage was silica gel chromatography a requirement 
for purification. 
 
One additional C8 IL (441), an ethyl nicotinate derivative, was synthesised. Neither diethyl 
ether, nor reflux conditions in ethyl acetate, produced the desired product (by TLC) after 48 
hours. The reaction solvent was replaced with DMF and after 48 hours reflux a crude product 
was detected by TLC. Purification of the crude product by silica gel chromatography gave IL 
(441) in poor yield (36%) (Table 3.4, Scheme 3.3). At this stage of the synthesis it was decided 
to postpone further investigations into the ethyl nicotinium IL series due to the poor yield and 
unfavourable green metrics, see Table 3.5, therefore ILs (442, 443) were not synthesised. With 
the exception of ethyl nicotinium (441), no silica gel chromatographt was required for product 
purification thus leading to a simple, streamlined, synthetic approach and a considerable 
prevention of solvent waste. 
 
Compound Yield % 
456 72 
457 51 
458 88 
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Scheme 3.2. General scheme for step 3, the synthesis of linear alkyl ILs from alkylating 
reagents. 
Table 3.4. Percentage yields and melting points for ILs (432-441). 
 
 
Compound Yield % Melting Point °C 
432 98 93-95 
433 99 101-103 
434 98 107-109 
435 97 64-66 
436 92 80-82 
437 73 94-96 
438 94 80-82 
439 61 57-59 
440 89 63-65 
441 36 43-45  
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Scheme 3.3. Synthesis of ethyl nicotinium IL (441). 
 
 
 
Figure 3.24. 
1
H-NMR of imidazolium IL (435) in CDCl3. 
From the 
1
H-NMR of (435) (Figure 3.24) it can be seen that the single C2 proton 2 on the 
imidazolium ring  appears as a singlet downfield at 9.71 ppm. Amide proton 6 is present as a 
doublet at 8.97 ppm with a coupling constant J = 7.7 Hz, coupling to the proton on the 
stereogenic position 7. The aromatic region of 7.41-7.16 ppm contains 7 protons, two methine 
protons from the imidazolium ring are present 3, 4  and the protons on the phenyl ring of the L-
phenylalanine sidechain 9-13. CH2 protons, α to the carbonyl group of the amide linker, 5’, 5” 
are present at 5.39 ppm and 5.34 ppm as two sets of doublets due to their diastereotopicity, with  
J = 15.5 Hz. It is proposed that the presence of the doublets could also be due to hydrogen 
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bonding of the protons 5’, 5”  to the bromide counterion introducing an inequivalency and 
hence geminal coupling of the protons. This mode of binding has been previously discussed in 
Chapter 2, Section 2.2.2.2. Stereogenic proton 7 is present at 4.73-4.63 ppm as a multiplet. 
Protons 14, α to the ester oxygen, appear at 4.01 ppm as a multiplet due to their 
diastereotopicity. Methyl group protons 1 on the imidazolium ring appear at 3.98 ppm as a 
singlet. Amino acid sidechain protons at the benzyllic position 8’, 8” are present as two sets of 
doublet of doublets at 3.21 and 3.18 ppm with J = 11.5, 4.0 Hz.  as they are diastereotopic, each 
coupling viscinally to the proton 7 at the stereogenic position and then geminally. Alkyl ester 
chain protons 15 are present as a multiplet at 1.60-1.46 ppm followed by the protons 16-20 as a 
multiplet between 1.34-1.14 ppm. Lastly the terminal CH3 protons 20 on the alkyl chain are 
present as a triplet at 0.87 ppm with J = 6.8 Hz.  
3.5.1.1 Linear alkyl ILs green chemistry metrics 
Green chemistry metrics are an important benchmark with which to analyse a synthetic route to 
a target. A number of green chemistry metrics have previously been calculated for the 1
st
 
generation of ILs outlined in Section 2.2.2.7. Following on from the information provided in 
Section 2.2.2.7, the following metrics were calculated for all of the linear alkyl compounds 
synthesised within, the results of which are outlined in Table 3.5. 
 
The synthesis of the L-phenylalanine esters (453-455) resulted in low-moderate yields of the 
esters (37-58%) due to the difficulties presented with the workup phase of the reactions. 
Emulsion formation resulted in a difficult extraction, even when the emulsion was filtered over 
celite. Atom economy for the ester formation reactions is moderate due to the use of p-toluene 
sulphonic acid (PTSA) as an acid catalyst in stoichiometric quantities, none of which is 
incorporated into the final product.  Atom economy is 57% for the octyl ester and increases as 
the ester chain length is increased to decyl (60%) and dodecyl (62%). Although caution must be 
excised when comparing these numbers as one can argue that the dodecyl synthesis is no 
greener than the octyl, just because the atom economy is slightly higher. E-factor, solvent and 
mass intensities were moderate (34-61) due to the quantities of solvent used to extract the 
product from the emulsions and the removal of expended PTSA salts as waste. GSK RME is 
moderate (0.21-0.30) and the Andraos RME is poor. Stoichiometric factor is high, >90% for all 
three esters (453-455) and the material recovery parameter is the highest of all three reaction 
steps. 
 
Alkylating reagents (456-458) were synthesised in moderate to high yields (51-88%) with an 
improved atom economy of ~70% for all three compounds, compared to the ester forming 
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reactions. Atom economy still remains at a moderate level (68-71) due to the formation of 
stoichiometric quantities of HBr and subsequently bromoacetic acid from the workup stage of 
the reaction. E-factor, mass intensity and solvent intensity were in general higher than those 
calculated for the ester synthesis due to the stoichiometric quantities of auxiliary base employed 
in this stage of the reaction and the quantities of solvent and workup reagents used. GSK RME 
is moderate (~0.31-0.56) and the Andraos RME and material recovery parameters are both poor. 
Again the stoichiometric factor is high, at 0.89 for all three acylation reactions. 
 
It can be seen from the generated metrics that the synthesis of ILs (432-441) proceeded with 
excellent yields, with >88% yields for all the ILs bar three examples (437, 439, 441). Atom 
economy for these nucleophilic substitution reactions is 100% as all reactants used in this step 
are incorporated into the final product. E-factor, mass intensity and solvent mass intensity are 
poorer when compared to the esterification and acylation reactions, however this can be 
attributed to the quantities of solvent required to wash the ILs in the final stage purification step. 
Environmental factors can be improved hugely if the solvent used in the washing step is 
recycled in the future. GSK RME is the highest of all three stages in the reactions ~90% for the 
majority of ILs (432-436, 438) formed but there is no improvement in the Andraos RME due to 
the quantities of solvent employed. Stoichiometric factors were all excellent due to only a slight 
excess of alkylating reagent required in each of these reactions. Material recovery parameters 
are poor due to the quantities of solvents employed in the purification of the ILs. The least green 
parameters observed were for the ethyl nicotinum IL (441) due to the large volume of solvent 
required to purify the product by silica gel chromatography (300 mL of 7:93 MeOH:DCM). 
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Table 3.5. Green Chemistry metrics calculated for linear alkyl amino acid ILs and precursors. 
Compound 
Atom 
Economy 
Sheldon 
E-factor 
GSK 
RME 
Andraos 
RME 
Mass 
Intensity 
Solvent 
Intensity 
1/ Stoichiometric 
factor 
Material 
Recovery 
Parameter 
Yield 
% 
Amino Acid Esters 
453 57 % 61.0 0.301 0.022 44.8 39.7 0.908 0.074 58 
454 60 % 41.6 0.216 0.023 42.6 36.3 0.965 0.109 38 
455 62 % 37.8 0.219 0.026 38.8 34.2 0.966 0.117 37 
Alkylating Reagents 
456 68 % 56.0 0.438 0.018 57.0 53.0 0.891 0.040 72 
457 70 % 81.1 0.315 0.012 82.1 76.4 0.894 0.039 51 
458 71 % 41.7 0.560 0.023 42.7 39.6 0.899 0.042 88 
L-Phenylalanine ILs 
432 100 % 58.2 0.962 0.017 59.2 58.1 0.976 0.018 99 
433 100 % 76.3 0.976 0.013 77.3 76.3 0.978 0.013 99 
434 100 % 73.8 0.965 0.013 74.8 73.7 0.987 0.014 98 
435 100 % 99.3 0.973 0.010 100.3 99.3 0.991 0.010 97 
436 100 % 86.9 0.909 0.011 87.9 86.8 0.987 0.013 92 
437 100 % 101.6 0.719 0.010 102.6 101.2 0.991 0.014 72 
438 100 % 70.7  0.923 0.014 71.7 70.6 0.971 0.015 94 
439 100 % 117.0 0.599 0.008 118.0 116.3 0.983 0.014 61 
440 100 % 56.6 0.886 0.017 57.6 56.5 0.998 0.020 89 
441 100 % 1091.0 0.353 0.001 1092.0 1089.2 0.984 0.003 36 
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The overall picture that the metrics produce is that the esterification yields could be improved in 
the future, with potential longer reaction times and larger excesses of the alcohol to try and 
drive the equilibrium of the ester forming reaction. However, this approach should be mindful 
of the requirement to recover/recycle the excess of alcohol used. Alkylating reagent forming 
reactions (step 2) have varying yields and the overall yields may be improved by further 
extraction steps. Excessive use of extraction solvent can be balanced by implementing a solvent 
recycling process. Finally the IL forming reactions and the final step of the reactions suffer from 
large solvent use in the washing steps. This can be addressed as above, with recycling of the 
diethyl ether trituration solvent. If 90% of the diethyl ether is recycled then the IL E-Factor can 
be reduced to less than 15. 
3.5.2 Synthesis of 2nd generation L-phenylalanine bolaform (dicationic) ILs 
L-Phenylalanine derived dicationic ILs were synthesised in three steps using the method 
previously reported in Section 3.5.1. Desired ester chain lengths of the ILs were determined 
based on the linear alky ILs synthesised in Section 3.5.1. Linear alkyl ILs with C8H17 ester 
chains were henceforth considered analogues of the dicationic ILs with a C8H16 carbon spacer 
etc. Step 1 of the reaction involved acid catalysed esterification of two equivalents of L-
phenylalanine with one equivalent of diol in toluene using PTSA as an acid catalyst to give 
esters (459-461) (Scheme 3.4). SOCl2 was not employed as the acid source as it was 
unsuccessfully applied in Section 3.5.1. Initially the reactions were carried out according to the 
literature procedure of Becker et al. which involved purification of the ester by recrystallization 
from hot water.
40
 This procedure was found to be ineffective at the smaller scale reactions 
carried out in this section, thus the esters were purified by precipitation from the toluene 
reaction solvent using diethyl ether to give off-white crystalline solids which were then further 
purified by vacuum filtration and washed with hexane (Table 3.6). Hexane and ether used in this 
stage were recycled at 90-95% recovery using a rotary evaporator to redistill. Finally, to achieve 
the free amine products the bis-phenylalanine ester salts were added to sodium bicarbonate 
solution, stirred vigorously until neutralised then extracted using ethyl acetate. Comparable to 
the linear alkyl esters synthesised in Section 3.5.1, formation of an emulsion also occurred. 
Multiple additions of brine and several solvent extractions were performed to retrieve the 
desired esters in poor (e.g. 460, 36%) to moderate (e.g. 461, 61%) yields.  From the percentage 
mass recovery difference between isolated PTSA salt before neutralisation and the free base 
mass recovery it can be said that ~15-20% of the product mass may have been lost during the 
aqueous neutralisation step (Table 3.6). Unfortunately due to incompatibility with the acylation 
conducted in step 2, the amino acid esters must be in the free base form and not in their PTSA 
salt form. 
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Table 3.6. Percentage yields for L-phenylalanine diol esterification reactions, step 1. 
Product Purification Method 
PTSA Salt Product 
Crude Mass 
Recovery 
Free Base Yield 
459 Recrystallization from Water 7% 0% 
460 Recrystallization from Water 5% 0% 
461 Recrystallization from Water Not Carried Out Not Carried Out 
    
459 Precipitation from reaction  78% 55% 
460 Precipitation from reaction 56% 36% 
461 Precipitation from reaction 85% 61% 
 
The second reaction stage was acylation of the bis-amino acids on both terminal nitrogen 
positions using  bromoacetyl bromide to form alkylating reagents (462-464) in low (e.g. 462, 
26%) to moderate yields (464, 40%). All three acylated amino acids required purification by 
silica gel chromatography before further use (Scheme 3.4). 
 
 
Scheme 3.4. General synthetic route employed for step 1, the synthesis of bis-amino acid esters 
(459-461) and step 2, the synthesis of alkylating reagents (462-464). 
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As can be seen from Table 3.7, the percentage yields for the alkylating reagents is much poorer 
when compared to the linear alkyl derivatives described in Section 3.5.1. One possible reason is 
that twice as much auxiliary base was required for this reaction to neutralise the HBr produced 
when the amino acid reacts with bromoacetyl bromide. Extra heterogeneous base required made 
stirring inconsistent and difficult. For the final alkylating reagent of the series (464), three 
equivalents of bromoacetyl bromide were used and this appears to have increased the yields by 
~15%. Future optimisation of the di-acylation of the bis-amino acids will have to be carried out 
before any further investigations are carried out on this class of ILs. Replacement of the 
auxiliary base with a homogeneous amine base (other than TEA as it was shown in Section 
2.2.2.2 to react poorly and cause coloured impurities), and/or the use of continuous effective 
stirring, such as that provided by an overhead stirrer, may elevate the yields of these products.  
 
Table 3.7. Percentage yields for bis alkylating reagents (435-437). 
 
Step 3 involved alkylation of pyridine, dimethylaminoethanol or 1-methylimidazole to furnish 
the respective dicationic ILs (444-452) in excellent yields (Scheme 3.5, Table 3.8). The 
synthesis of the final stage products was carried out under reflux conditions in ethyl acetate to 
facilitate the reaction. Once the dicationic product had formed it was observed to 
serendipitously precipitate. Conveniently, mono-cationic IL was not observed (TLC and 
1
H-
NMR of the crude reaction mixture) precipitating. Therefore isolation and purification of the 
end product was facile, a simple diethyl ether wash was sufficient for the purification of all ILs. 
As per Section 3.5.1, no silica gel chromatography was required for purification of the final 
products leading to a simple streamlined synthetic approach and a considerable prevention of 
solvent waste. Based on the recommendations provided by the metrics collected in Section 
3.5.1.1 the trituration solvent used in the final wash step of the target ILs was also recycled (90-
95% recovery) and re-distilled using a rotary evaporator for further use. 
 
The synthesis outlined in Schemes 3.4 and 3.5 lead to a series of nine dicationic ILs (444-452). 
Once more it can be said that the α-bromoamide alkylating reagents can lead to a nearly 
limitless numbers of potential headgroups as final targets.     
 
Compound Yield % 
462 26 
463 24 
464 40 
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Scheme 3.5. General scheme for the synthesis of dicationic ILs (444-452). 
 
Table 3.8. Percentage yields and melting points for dicationic ILs synthesised. 
 
 
 
 
Compound Yield % Melting Point °C 
444 98 124-126 
445 94 137-139 
446 91 138-140 
447 93 70-72 
448 96 41-43 
449 93 84-86 
450 94 112-114 
451 99 66-68 
452 89 89-91 
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From the 
1
H-NMR of (447) (Figure 3.25) it can be seen that the C-H protons on both the 
imidazolium rings C2 position 2 appear as a singlet downfield at 8.60 ppm. Amide N-H protons 
are not visible due to exchange with deuterium. The aromatic region of 7.39-7.18 ppm contains 
14 protons, four methine protons from the imidazolium ring are present 3, 4 and the protons on 
the phenyl rings of the L-phenylalanine sidechains 9-13 (Figure 3.26). CH2 protons α to the 
carbonyl group of the amide linker 5’, 5” are present at 4.96 ppm and 4.90 ppm as two sets of 
doublets with J = 16.7 Hz. Single protons at each of the stereogenic positions 7 are present at 
4.67 ppm as a multiplet. CH2 protons alpha to the ester oxygen 22 are present as a multiplet at 
4.08 ppm. Each methyl groups CH3 protons 1 on the methylimidazolium ring are present as a 
singlet integrating as 6 at 3.83 ppm. Phenylalanine sidechain protons at the benzyllic position 
8’, 8” are present as two sets of doublets of doublets with J = 13.8, 6.3 Hz. CH2 protons beta to 
the ester oxygen 15 are present as a multiplet upfield at 1.53 ppm. Lastly the remaining protons 
on the alkyl spacer 16, 17 are present as a multiplet at 1.20 ppm integrating as 8. 
 
 
Figure 3.25. 
1
H-NMR of imidazolium IL (447) in D2O. 
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Figure 3.26. Aromatic region. 
3.5.2.1 Dicationic ILs green chemistry metrics 
As per the linear alkyl ILs synthesised in Section 3.5.1, the green chemistry metrics for the 
dicationic class of ILs synthesised were also calculated. From the results presented in Table 3.9 
it can be seen that the metrics for the bis-phenylalanine esters (459-461) are similar to the linear 
alkyl esters synthesised in Section 3.5.1. However due to lessons learned from applying green 
chemistry metrics to previous ILs in this thesis such as the  implementation of solvent recycling 
in the purification and recrystallization stage, there is a huge improvement of one order of 
magnitude (~35 reduced to ~3.5) in solvent intensity and an increase in material recovery. 
However when E-factors of the alkylating reagents (462-464) (ranging from 136-265) are 
compared to the linear alkyl alkylating reagents (456-458) (ranging from 41-81) a large increase 
in E-factor is observed. This is due to the requirement of silica gel chromatography in the 
purification of the bis-alkylating reagents. Chromatography solvent was not recycled and as 
such is reflected in Table 3.9. When comparing the metrics for the dicationic ILs (444-452) to 
the linear alkyl ILs (432-441) it can be seen once more that the atom economy is 100%. The E-
Factors for the dicationic ILs are also considerably lower than that observed for the linear alkyl 
ILs due to full recycling of the trituration solvents used to purify the dicationic ILs. Synthesis of 
the dicationic ILs is also less mass intensive. GSK RME is also very high due to the high 
yielding synthesis and much lower net waste, thus leading to a high material recovery 
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parameter. Percentage yields for all the dicationic ILs were excellent and the Andraos RME is 
2-3 times greater than that calculated for the linear alkyl derivatives.  
 
The overall picture portrayed by the green chemistry metrics is that the synthesis of the 
dicationic ILs from start to finish employed much better green chemistry techniques and utilised 
the lessons learned while synthesising the previous class of linear alky ILs described in Section 
3.5.1. Solvent recycling can be taken even further with recycling of the reaction solvents and 
chromatography solvents, thus lowering the volumes of solvent required. Yields for the bis-
alkylating reagents require optimisation in the future to ensure that further investigations into 
these types of compounds cam be carried out in an efficient manner. The possible optimisations 
have already been outlined in Section 3.5.2, vide supra. 
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Table 3.9. Green Chemistry metrics calculated for dicationic (bolaform) amino acid ILs (417-425) and precursors (432-437). 
Compound 
Atom 
Economy 
Sheldon E-
factor 
GSK 
RME 
Andraos 
RME 
Mass 
Intensity 
Solvent 
Intensity 
1/ Stoichiometric 
factor 
Material Recovery 
Parameter 
Yield 
% 
Amino Acid Esters 
459 51% 31.9 0.189 0.030 32.9 2.6 0.999 0.161 36 
460 53% 31.2 0.279 0.031 32.2 2.7 0.959 0.111 55 
461 61% 25.8 0.319 0.037 26.8 2.3 0.960 0.117 61 
Alkylating Reagents 
462 65% 185.9 0.158 0.005 186.9 171.7 0.927 0.034 26 
463 66% 265.9 0.147 0.004 266.9 247.4 0.938 0.026 24 
464 52% 136.8 0.206 0.007 137.8 126.5 0.985 0.035 40 
L-Phenylalanine ILs 
444 100% 31.1 0.982 0.031 32.1 31.1 1.000 0.032 98 
445 100% 57.3 0.940 0.017 58.3 57.2 1.000 0.018 94 
446 100% 42.0 0.910 0.023 43.0 41.9 1.000 0.026 91 
447 100% 50.9 0.928 0.019 51.9 50.8 1.000 0.021 93 
448 100% 81.1 0.958 0.012 82.1 81.0 1.000 0.013 96 
449 100% 43.5 0.935 0.022 44.5 43.4 1.000 0.024 93 
450 100% 31.2 0.944 0.031 32.2 31.1 1.000 0.033 94 
451 100% 50.8 0.994 0.019 51.8 50.8 1.000 0.019 99 
452 100% 42.4 0.891 0.023 43.4 42.3 1.000 0.026 89 
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3.6 Antimicrobial screening and biodegradation studies of 2nd generation 
amino acid ILs 
 
 
The aim of this series of antimicrobial toxicity investigations was to determine the toxicity of 
the 2
nd
 generation amino acid ILs described in this chapter. As discussed in Chapter 2, the 
toxicity of a number of ILs has previously been reported.
41, 42
 More importantly, the structural 
similarities of the 2
nd
 generation linear alkyl ILs synthesised in this chapter have a comparable 
structure to those of cationic surfactants, a number of which are broad spectrum antimicrobial 
agents themselves.
43, 44
 Antimicrobial toxicity of dicationic/bolaform ILs has also been recently 
reported with the general trend observed that many are less toxic than monocationic ILs.
45-47
  
As previously discussed in Chapter 2, toxicity is a parameter that must be investigated when 
determining the environmental compatibility and “greenness” of ILs. Thus investigations within 
the field of IL research have been conducted to determine the toxicity of ILs towards bacteria
48
, 
fungi 
49
, invertebrates 
50
, aquatic species 
51
, plants 
52
 and algae 
53
. 
 
Within the following section, the antimicrobial activity of a number of 2
nd
 generation amino 
acid ILs are presented. ILs were screened against eight strains of bacteria, four gram positive 
and four gram negative, and twelve strains of fungi. Antimicrobial screening was carried out in 
collaboration with the Department of Biological and Medical Sciences, Faculty of Pharmacy, 
Charles University, Hradec Králové, Czech Republic. Antimicrobial testing carried out is 
according to the same procedure used in Chapter 2, Section 2.3. See Chapter 5, Section 5.8. 
 
3.6.1 Antibacterial screening of the 2nd generation linear alkyl amino acid ILs 
 
To investigate the in vitro antibacterial effect of the linear alkyl ILs (432-441), the following 
eight strains of bacteria from the collection available at Charles University, Czech Republic, 
were screened against: 
 
Gram Positive:  
 S. aureus (ATCC 65382) (SA) 
 Methicillin-res.S.a (HK5996/08) (MRSA) 
 S. epidermidis (HK6966/084 ) (SE) 
 Enterococcus sp. (HK14365/085) (EF) 
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Gram Negative: 
 E. coli (ATCC 87396) (EC) 
 K. pneumoniae (HK11750/087) (KP) 
 K. pneumoniae (HK14368/08) (KP-E) 
 P. aeruginosa (ATCC 9027) (PA) 
The bacteria screened against were the same strains discussed in Chapter 2. 
3.6.1.1 Experimental Method 
The experimental method is as described in Chapter 5, Section 5.8.1. 
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3.6.1.2 Antibacterial Results – Linear Alkyl Surfactant ILs  
Table 3.10. Antibacterial results obtained for L-phenylalanine ILs. 
Microorganism 
 
Chain length 
Time (h) 
IL MIC95 µmol 
432 
C8 
435 
C8 
438 
C8 
441 
C8 
433 
C10 
436 
C10 
439 
C10 
434 
C12 
437 
C12 
440 
C12 
Gram Positive 
SA 
24h 
48h 
3.9, 
7.81 
7.81, 
7.81 
3.9, 
3.9 
15.62, 
15.62 
1.95, 
1.95 
1.95, 
1.95 
1.95, 
1.95 
1.95, 
1.95 
1.95, 
1.95 
1.95, 
1.95 
MRSA 
24h 
48h 
15.62, 
15.62 
31.25, 
31.25 
31.25, 
31.25 
31.25, 
62.5 
1.95, 
1.95 
3.9, 
3.9 
1.95, 
1.95 
3.9, 
3.9 
3.9, 
3.9 
1.95, 
1.95 
SE 
24h 
48h 
7.81, 
7.81 
15.62,  
31.25 
7.81, 
7.81 
7.81, 
7.81 
1.95, 
1.95 
3.9, 
3.9 
1.95, 
1.95 
1.95, 
1.95 
1.95, 
1.95 
1.95, 
1.95 
EF 
24h 
48h 
31.25, 
31.25 
31.25, 
31.25 
31.25, 
31.25 
62.5, 
62.5 
1.95, 
1.95 
3.9, 
3.9 
1.95, 
1.95 
3.9, 
3.9 
1.95, 
1.95 
1.95, 
1.95 
Gram Negative 
EC 
24h 
48h 
62.5, 
62.5 
62.5, 
62.5 
62.5, 
62.5 
125, 
125 
3.9, 
3.9 
31.25, 
31.25 
15.62, 
15.62 
62.5, 
62.5 
31.25, 
31.25 
7.81, 
7.81 
KP 
24h 
48h 
62.5, 
62.5 
62.5, 
62.5 
62.5, 
62.5 
62.5, 
62.5 
3.9, 
3.9 
31.25, 
31.25 
7.81, 
7.81 
62.5, 
62.5 
62.5, 
62.5 
7.81, 
7.81 
KP-E 
24h 
48h 
125, 
125 
125, 
250 
250, 
250 
125, 
125 
3.9, 
3.9 
31.25, 
31.25 
15.62, 
15.62 
62.5, 
62.5 
62.5, 
62.5 
15.62, 
15.62 
PA 
24h 
48h 
125, 
125 
125, 
125 
125, 
125 
250, 
250 
15.62, 
15.62 
31.25, 
31.25 
31.25, 
31.25 
62.5, 
62.5 
125, 
125 
62.5, 
62.5 
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From the results obtained in Table 3.10 for the linear alkyl L-phenylalanine ILs screened (432-
441) (Figure 3.23) it can be seen that in general a broad spectrum antibacterial toxicity can be 
observed for the majority of the compounds screened. A trend of increasing toxicity with 
increased alkyl chain length is also observed for the ILs screened against the gram positive 
bacteria. However, when the ILs were screened against the gram negative bacteria, it was 
observed that the all of the C10 examples were more toxic than the C8 and C12 examples. One 
potential explanation for this behaviour is due to the bioavailability and solubility of the C10 
examples. C8 examples (432, 435, 438, 441) are less toxic due to their reduced lipophilicity and 
the C12 examples (434, 437, 440) are less toxic due to their reduced solubility (even though they 
are more lipophilic the toxicity is reduced due to reduced bioavailability) vide infra Section 4.2. 
C10 examples (433, 436, 439)  appear to be in an optimum region where lipophilicity, solubility 
and thus bioavailability are at a maximum hence the highest levels of toxicity observed.
31
 An 
alternative possibility is that the high toxicity is compound specific. Ethyl nicotinum C8 
derivative (441) was shown to be the least toxic example, see Table 3.10. It is believed that 
linear alkyl quaternary ammonium molecules, such as the ILs presented here, possess their 
antibacterial activity due to their effect on bacterial plasma membranes and as such belong to a 
class of antimicrobials defined as membrane-active agents.
54
 The following sequence of events 
has been proposed in the literature to explain the antimicrobial activity of linear alkyl cationic 
species: 
55, 56
 
 
1. Adsorption of the antimicrobial agent to the cell wall followed by penetration into the 
cell wall 
2. Reaction with the cytoplasmic membrane followed by membrane disorganisation 
3. Leakage of intracellular material through the disrupted membrane 
4. Degradation of proteins and nucleic acids within the cell 
5. Cell wall lysis and cell death 
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3.6.2 Antifungal screening of the 2nd generation linear alkyl amino acid ILs 
 
In tandem with the antibacterial screening, the linear alkyl ILs (432-441) were screened for their 
antifungal activity as per Chapter 2. 
 
To investigate the in vitro anti fungal activity of the aforementioned compounds the following 
strains of fungi, available from the repository at Charles University, Czech Republic, were 
screened against: 
 
9 Yeasts 
 Candida albicans (ATCC 448597) (CA1) 
 Candida albicans (ATCC 900288) (CA2) 
 Candida parapsilosis (ATCC 220199 ) (CP) 
 Candida krusei (ATCC 62581) (CK1) 
 Candida krusei (E2811) (CK2) 
 Candida tropicalis (156) (CT) 
 Candida glabrata (20/I2) (CG) 
 Candida lusitaniae (2446/I3 ) (CL) 
 Trichosporon asahii (11884) (TA) 
3 Filamentous fungi: 
 Aspergillus fumigatus (2315) (AF) 
 Absidia corymbifera (2726) (AC) 
 Trichophyton mentagrophytes (445) (TM) 
The fungi screened against were the same strains discussed in Chapter 2. 
3.6.2.1 Experimental Method 
The experimental method is as described in Chapter 5, Section 5.8.2.  
3.6.2.2 Antifungal Results – Linear Alkyl Surfactant ILs 
 
From the results obtained for the antifungal screening of linear alkyl ILs (432-441) (Table 3.11), 
it can be seen that as alkyl chain length increases so does the antifungal activity. Antifungal 
activity for the C8 examples (432, 435, 438, 441) is generally moderate 250-1000 µmol/L for 
imidazolium, cholinium and ethyl nicotinium derivatives (435, 438, 441).
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Table 3.11. Antifungal results obtained for the linear alkyl ILs (432-441). 
Microorganism Time (h) IL MIC µmol* 
432 
C8 
435 
C8 
438 
C8 
441 
C8 
433 
C10 
436 
C10 
439 
C10 
434 
C12 
437 
C12 
440 
C12 
CA1 
24h 
48h 
250,  
250 
500, 
500 
500, 
500 
500, 
500 
15.62, 
15.62 
31.25, 
31.25 
15.62, 
31.25 
3.9, 
3.9 
7.81, 
7.81 
1.95, 
3.9 
CA2 
24h 
48h 
250,  
250 
500, 
1000 
500, 
500 
500, 
1000 
15.62, 
31.25 
31.25, 
62.5 
15.62, 
31.25 
3.9, 
3.9 
7.81, 
7.81 
3.9, 
3.9 
CP 
24h 
48h 
125, 
250 
250, 
500 
500, 
500 
250, 
500 
15.62, 
31.25 
31.25, 
31.25 
31.25, 
31.25 
7.81, 
7.81 
7.81, 
7.81 
7.81, 
7.81 
CK1 
24h 
48h 
125, 
125 
250, 
500 
125, 
125 
125, 
500 
7.81, 
31.25 
31.25, 
31.25 
15.62, 
15.62 
7.81, 
7.81 
7.81, 
7.81 
3.9, 
3.9 
CK2 
24h 
48h 
125, 
125 
250, 
500 
62.5, 
125 
125, 
250 
7.81, 
31.25 
15.62, 
31.25 
15.62, 
15.62 
7.81, 
7.81 
7.81, 
7.81 
3.9, 
3.9 
CT 
24h 
48h 
250,  
250 
250, 
250 
250, 
250 
250, 
250 
7.81, 
31.25 
62.5, 
62.5 
31.25, 
31.25 
15.62, 
15.62 
7.81, 
15.62 
7.81, 
7.81 
CG 
24h 
48h 
500, 
500 
500, 
500 
1000, 
1000 
500, 
500 
62.5, 
62.5 
62.5, 
62.5 
62.5, 
62.5 
7.81, 
7.81 
7.81, 
15.62 
3.9, 
3.9 
CL 
24h 
48h 
250, 
500 
250, 
250 
250, 
500 
250, 
500 
62.5, 
62.5 
62.5, 
62.5 
125, 
125 
7.81, 
7.81 
31.25, 
31.25 
3.9,  
3.9 
TA 
24h 
48h 
1000, 
1000 
1000, 
1000 
500, 
500 
500, 
1000 
125, 
125 
250, 
250 
250, 
250 
62.5, 
 62.5 
125, 
125 
125, 
125 
AF 
24h 
48h 
250,  
250 
500, 
1000 
250, 
500 
125, 
250 
3.9 
7.81 
15.62, 
15.62 
31.25, 
31.25 
7.81, 
7.81 
7.81, 
7.81 
3.9, 
3.9 
AC 
24h 
48h 
500, 
500 
500, 
500 
500 
500 
125, 
250 
31.25, 
31.25 
62.5, 
62.5 
31.25, 
31.25 
15.62,  
15.62 
15.62, 
15.62 
7.81, 
7.81 
TM 
72h 
120h 
1000, 
1000 
1000, 
1000 
500, 
500 
250, 
250 
62.5, 
62.5 
62.5, 
62.5 
31.25, 
31.25 
15.62, 
15.62 
7.81, 
7.81 
15.62, 
15.62 
* 
IC50 values were assessed for AF, AC and TM and IC80 for all other strains. 
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C8 pyridinium derivative (432) was more toxic with MIC values ranging from 125-1000 µmol/L. 
When the alkyl chain lengths were extended from C8 to C10 an order of magnitude increase in the 
toxicity is observed for all three C10 compounds (433, 436, 439). MIC values for the C10 ILs 
generally ranged from 15.62-250 µmol/L. Pyridinium C10 compound (433) was more toxic than its 
imidazolium (409) and cholinium (439) counterparts with MIC values reaching as low as 3.9 µmol/L 
for the AF fungus. Finally, as the alkyl chain is further extended to C12, a broad spectrum antifungal 
activity is observed for all three C12 compounds (434, 437, 440) with MIC values in the region of 
3.9 – 125 µmol/L. Overall the TA strain of fungus appeared to be the most resistant to the linear 
alkyl ILs screened. 
 
The mechanism of antifungal activity for linear alkyl quaternary ammonium compounds has been 
investigated in the literature. It has been shown that the cationic surfactant cetylpyridinum chloride 
can induce potassium ion leakage from yeasts such as S. cerevisiae. Linear alkyl cationic 
compounds mode of action on fungi is similar to that discussed for bacteria. QACs can insert 
into the plasma membrane of a fungus and cause disruption of the membrane and eventually 
lysis. QAC‟s have also been report as spore growth inhibitors.56 
3.6.3 Antibacterial screening of the 2nd generation bolaform amino acid ILs 
 
To investigate the in vitro antibacterial effect of the bolaform ILs (444-452) the following eight 
strains of bacteria from the collection available at Charles University, Czech Republic, were 
screened against: 
 
Gram Positive:  
 S. aureus (ATCC 65382) (SA) 
 Methicillin-res.S.a (HK5996/08) (MRSA) 
 S. epidermidis (HK6966/084 ) (SE) 
 Enterococcus sp. (HK14365/085) (EF) 
Gram Negative: 
 E. coli (ATCC 87396) (EC) 
 K. pneumoniae (HK11750/087) (KP) 
 K. pneumoniae (HK14368/08) (KP-E) 
 P. aeruginosa (ATCC 9027) (PA) 
The bacteria screened against were the same strains discussed in Chapter 2. 
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3.6.3.1 Experimental Method 
The experimental method is as described in Chapter 5, Section 5.8.1. 
3.6.3.2 Antibacterial Results – Bolaform Surfactant ILs  
As can be seen from the antibacterial result in Table 3.12 all of the bolaform ILs (444-452) 
possessed high levels of antimicrobial toxicity towards the gram positive bacteria (e.g. IL 444 
3.9 µmol IC95 towards SE) and to a lesser extent towards the gram negative. It was also 
observed that an increase in toxicity occurred as the bolaform spacer was increased from C8 to 
C10 (e.g. IL 444 31.25 µmol IC95 towards EF decreasing to 15.62 µmol for IL 445) and again 
from C10 to C12 (e.g. IL 445 15.62 µmol IC95 towards EF decreasing to 3.9 µmol for IL 446). The 
results observed are consistent with the linear alkyl surfactants analaysed in Section 3.6.1 in that 
high levels of antimicrobial toxicity are observed, most likely due to a high level of lipophilicity 
associated with these classes of molecules.                       
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Table 3.12. Antibacterial results obtained for bolaform L-phenylalanine ILs. 
Microorganism 
 
Chain length 
Time (h) 
IL MIC95 µmol 
444 
C8 
447 
C8 
450 
C8 
445 
C10 
448 
C10 
451 
C10 
446 
C12 
449 
C12 
452 
C12 
Gram Positive 
SA 
24h 
48h 
7.81, 
7.81 
7.81, 
7.81 
15.62, 
15.62 
1.95, 
1.95 
1.95, 
1.95 
1.95, 
1.95 
1.95, 
1.95 
1.95, 
1.95 
7.81, 
7.81 
MRSA 
24h 
48h 
7.81, 
7.81 
15.62, 
15.62 
62.5, 
62.5 
1.95, 
1.95 
1.95, 
1.95 
1.95, 
1.95 
1.95, 
1.95 
1.95, 
1.95 
7.81, 
7.81 
SE 
24h 
48h 
3.9, 
3.9 
3.9, 
3.9 
3.9, 
3.9 
1.95, 
1.95 
1.95, 
1.95 
1.95, 
1.95 
1.95, 
1.95 
1.95, 
1.95 
1.95, 
1.95 
EF 
24h 
48h 
31.25, 
31.25 
125, 
125 
125, 
125 
15.62, 
15.62 
15.62, 
15.62 
7.81, 
7.81 
3.9, 
3.9 
3.9, 
3.9 
3.9, 
3.9 
Gram Negative 
EC 
24h 
48h 
15.62, 
15.62 
15.62, 
15.62 
31.25, 
31.25 
7.81, 
7.81 
7.81, 
7.81 
7.81, 
7.81 
1.95, 
1.95 
1.95, 
1.95 
3.9, 
3.9 
KP 
24h 
48h 
125, 
125 
500, 
500 
500, 
500 
62.5, 
62.5 
125, 
125 
62.5, 
62.5 
7.81, 
7.81 
7.81, 
7.81 
15.62, 
15.62 
KP-E 
24h 
48h 
250, 
250 
500, 
500 
500, 
500 
125, 
125 
125, 
125 
62.5, 
62.5 
7.81, 
7.81 
15.62, 
15.62 
15.62, 
15.62 
PA 
24h 
48h 
250, 
250 
500, 
500 
500, 
500 
125, 
125 
250, 
250 
125, 
125 
15.62, 
15.62 
31.25, 
31.25 
15.62, 
15.62 
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3.6.4 Antifungal screening of the 2nd generation bolaform amino acid ILs 
 
To investigate the in vitro anti fungal activity of the bolaform ILs (444-452) the following 
strains of fungi, available from the repository at Charles University, Czech Republic, were 
screened against: 
 
9 Yeasts 
 Candida albicans (ATCC 448597) (CA1) 
 Candida albicans (ATCC 900288) (CA2) 
 Candida parapsilosis (ATCC 220199 ) (CP) 
 Candida krusei (ATCC 62581) (CK1) 
 Candida krusei (E2811) (CK2) 
 Candida tropicalis (156) (CT) 
 Candida glabrata (20/I2) (CG) 
 Candida lusitaniae (2446/I3 ) (CL) 
 Trichosporon asahii (11884) (TA) 
3 Filamentous fungi: 
 Aspergillus fumigatus (2315) (AF) 
 Absidia corymbifera (2726) (AC) 
 Trichophyton mentagrophytes (445) (TM) 
The fungi screened against were the same strains discussed in Chapter 2. 
3.6.4.1 Experimental Method 
The experimental method is as described in Chapter 5, Section 5.8.2. Antifungal Results – 
Bolaform Surfactant ILs. 
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Table 3.13. Antifungal results obtained for bolaform L-phenylalanine ILs. (444-452). 
Microorganism Time 
(h) 
IL MIC µmol* 
444 
C8 
447 
C8 
450 
C8 
445 
C10 
448 
C10 
451 
C10 
446 
C12 
449 
C12 
452 
C12 
CA1 
24h 
48h 
500, 
500 
1000, 
1000 
>500, 
>500 
62.5, 
62.5 
62.5, 
62.5 
62.5, 
62.5 
31.25, 
31.25 
15.62, 
15.62 
31.25, 
31.25 
CA2 
24h 
48h 
500, 
500 
1000, 
1000 
>500, 
>500 
62.5, 
62.5 
62.5, 
62.5 
125, 
125 
15.62, 
15.62 
31.25, 
31.25 
15.62, 
15.62 
CP 
24h 
48h 
250,  
250 
1000, 
1000 
250,  
250 
7.81, 
7.81 
31.25, 
31.25 
31.25, 
31.25 
7.81, 
7.81 
3.9, 
3.9 
7.81, 
7.81 
CK1 
24h 
48h 
1000, 
1000 
1000, 
1000 
500, 
500 
31.25, 
31.25 
62.5, 
62.5 
62.5, 
62.5 
7.81, 
7.81 
7.81, 
7.81 
15.62, 
15.62 
CK2 
24h 
48h 
500, 
500 
1000, 
1000 
500, 
500 
31.25, 
31.25 
62.5, 
62.5 
62.5, 
62.5 
7.81, 
7.81 
15.62, 
15.62 
15.62, 
15.62 
CT 
24h 
48h 
125, 
125 
250,  
250 
500, 
500 
15.62, 
15.62 
31.25, 
31.25 
15.62, 
15.62 
3.9, 
3.9 
15.62, 
15.62 
7.81, 
7.81 
CG 
24h 
48h 
500, 
500 
1000, 
1000 
>500, 
>500 
125, 
125 
125, 
125 
250,  
250 
31.25, 
31.25 
62.5, 
62.5 
31.25, 
31.25 
CL 
24h 
48h 
125, 
125 
500, 
500 
250,  
250 
31.25, 
31.25 
31.25, 
31.25 
15.62, 
15.62 
3.9, 
3.9 
15.62, 
15.62 
7.81, 
7.81 
TA 
24h 
48h 
125, 
125 
250,  
250 
500, 
500 
31.25, 
31.25 
62.5, 
62.5 
62.5, 
62.5 
31.25, 
31.25 
62.5, 
62.5 
31.25, 
31.25 
AF 
24h 
48h 
>1000, 
>1000 
>1000, 
>1000 
>500, 
>500 
250,  
250 
500, 
500 
500, 
500 
62.5, 
62.5 
62.5, 
62.5 
125, 
125 
AC 
24h 
48h 
>1000, 
>1000 
>1000, 
>1000 
>500, 
>500 
250,  
250 
500, 
500 
125, 
125 
31.25, 
31.25 
31.25, 
31.25 
62.5, 
62.5 
TM 
72h 
120h 
62.5, 
62.5 
62.5, 
62.5 
500, 
500 
500, 
500 
500, 
500 
62.5, 
62.5 
15.62, 
15.62 
31.25, 
31.25 
125, 
125 
* 
IC50 values were assessed for AF, AC and TM and IC80 for all other strains. 
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3.6.4.2 Antifungal Results – Bolaform Surfactant ILs  
In general, a trend of increasing antifungal toxicity with increasing alkyl chain length was 
observed for the bolaform ILs (Table 3.13). C8 ILs (444, 447, 450) displayed a wide range of 
IC50 and IC80 values (62.5-1000). With an increase in alkyl chain linker to C10 ILs (445, 448, 
451) the levels of antifungal toxicity increased with the exceptions of the TM fungus which 
showed the opposite behaviour for ILs (445, 448) where the IC50 values increased from 62.5 
to 500 µmol. This behaviour was not observed for IL (451). Finally, for the C12 linked ILs 
(446, 449, 452) the highest levels of toxicity were observed, ranging from 3.9-125 µmol. 
The levels of toxicity observed for the bolaform ILs is of a comparable level to that of the 
linear alkyl ILs examined in section 3.6.2, the presence of a cationic charge on either end of 
the bolaform ILs having no apparent reduction in the levels of antifungal toxicity observed. 
 
3.6.5 Antimicrobial Screening Conclusions 
From the combined antibacterial and antifungal data collected for the linear alky ILs (432-
441) it can be seen that in general a broad spectrum antibacterial activity was observed for 
the ILs screened. It was observed that as chain length increased so did toxicity towards the 
gram positive bacteria. A different trend was observed when compared against the gram 
negative bacteria with the highest levels of toxicity observed at the C10 ester chain length, 
ILs (433, 436, 439). Ethyl nicotinium C8 IL (441) was shown to be the least toxic derivative 
of the linear alkyl ILs but still within the same order of magnitude of toxicity as the other C8 
ILs.  
 
From the antifungal screening conducted for the linear alkyl ILs, a general trend of 
increasing toxicity with increasing chain length can be observed. Ethyl nicotinium IL (441) 
is also observed to be just as toxic as its C8 counterparts. As chain length is increased from 
C8 to C10 an order of magnitude increase in toxicity is observed for all three C10 ILs (433, 
436, 439). The C12 ILs showed the highest level of antifungal toxicity with MIC values in the 
region of 3.9 – 125 µmol/L.  
 
The bolaform ILs examined for their antimicrobial toxicity (444-452) displayed comparable 
levels of toxicity to their linear alkyl counterparts and showed increasing levels of toxicity 
with increasing alkyl chain length. Likewise, the antifungal results showed high levels of 
toxicity, comparable again to the linear alkyl ILs examined. The presence of two polar 
headgroups on the molecule did not appear to influence the levels of toxicity. The levels of 
toxicity for the bolaform ILs were also observed to be higher than those reported by Gindri 
et al.
47
 most likely due to the increased lipophilicity of the bolaform ILs reported here.
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3.7 Biodegradation Studies of 2nd Generation ILs 
The aim of the work within this section was to investigate the biodegradability of the 2
nd
 
generation of L-phenylalanine ILs. The importance of investigating the biodegradability of 
the ILs synthesised has been previously discussed in Chapters 1-2. Furthermore the ILs 
undergoing examination are the 2
nd
 generation derivatives of the ILs investigated in Chapter 
2 and have been synthesised as potential surfactant performance chemicals. As discussed in 
Chapter 1, Section 1.7 and Chapter 3, Section 3.2, the need to produce readily biodegradable 
surfactants has been an on-going challenge for the past 50+ years and has recently been 
reinforced by the European Detergents Regulation 2005 which requires all surfactants to be 
ultimately biodegradable. Based on the biodegradation results obtained in Chapter 2 it was 
proposed that the ILs synthesised in this chapter could potentially breakdown into 
biodegradable fragments analogous to those detected in Chapter 2.  
3.7.1 Biodegradation Studies of Linear Alkyl ILs 
The following linear alkyl ILs were examined for their biodegradability (Figure 3.27). 
 
 
 
Figure 3.27. Linear Alkyl ILs (432-440) screened for their biodegradability. 
From the structure activity biodegradation relationships examined in the metabolite 
examination, Chapter 2, Section 2.4.5, it was proposed that the linear alkyl ILs (432-440)  
(Figure 3.27), could potentially breakdown according to three likely pathways: amide 
hydrolysis, ester hydrolysis, and alkyl chain oxidation. An illustration of the potential 
breakdown sites are proposed for pyridinium IL (432) (Figure 3.28) and the pathways are 
outlined in Schemes 3.6, 3.7, 3.8. 
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Figure 3.28. Potential breakdown sites on pyridinium IL (432). 
 
 
Scheme 3.6. Proposed breakdown pathways of linear alkyl pyridinum IL (432) by ester oxidation. 
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Scheme 3.7. Proposed breakdown pathways of linear alkyl pyridinum IL (432) by ester oxidation.
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Scheme 3.8. Proposed breakdown pathways of linear alkyl pyridinum IL (432) by amide hydrolysis. 
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3.7.1.1 Closed Bottle Test Method 
The CBT was carried out as per Chapter 5, Section 5.9.1 
3.7.1.2 Linear alkyl IL biodegradation results 
Table 3.14. Biodegradability and carbon distribution of examined L-phenylalanine ILs (432-
440), colour coded according to the traffic light classification.
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IL 
Biodegradation 
% 
Amino Acid Ester Carbon 
% 
Ester Carbon 
% 
L-Phenylalanine ILs    
432 53 71 33 
433 36 73 38 
434 4 75 43 
435 48 74 35 
436 44 76 40 
437 15 78 44 
438 36 74 35 
439 27 76 40 
440 20 78 44 
 
As can be seen from Table 3.14 of the ILs screened, none of the ILs examined passed the CBT. 
C8 pyridinium (432) and imidazolium (435) derivatives underwent 53% and 48% 
biodegradation respectively. Cholinium C8 derivative (438) underwent a lower level of 
biodegradation at 36%. When the C8 biodegradation results are compared to the percentage 
carbon distribution of the molecules a number of insights can be made. Levels of biodegradation 
observed for the pyridinium IL (432), 53%, is above that which can be contributed to ester 
mineralisation alone (33%) and less than total amino acid degradation (71%). The identity of the 
biodegradation pathway is currently unknown and a metabolite analysis to determine the 
transformation products as per Chapter 2, Section 2.4.5, would provide invaluable information 
into the transformations taking place.  
 
Figure 3.29. Comparison of biodegradability for pyridinium ILs (325, 432-434). 
There are three possible reasons for the reduction in biodegradability observed for the octyl 
pyridinium IL (432) and decyl pyridinium IL (433) when compared to the short chain C2 
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pyridinium IL (325) screened in Chapter 2 (Figure 3.29). The examples proposed below employ 
the C8 pyridinium IL (432), however the same rationale can be applied to C10 IL (433).  
C8 IL (432) could be undergoing slow rates of hydrolysis to the L-phenylalanine carboxylic acid 
transformation product (465) and this carboxylic acid may be an unsuitable substrate for amide 
cleavage (Scheme 3.9).  
 
 
Scheme 3.9. Unsuitable amide cleavage after ester cleavage. 
 
A second reason could be that octyl chain length parent IL (432) makes for an unsuitable 
substrate for amide cleavage in the first place (Scheme 3.9). This proposal is in agreement with 
the observation made in Chapter 2, Section 2.4.1 where pyridinium ethyl ester (325) (Figure 
3.29), undergoes 62% biodegradation within the 28 day period, equating to almost the exact 
theoretical percentage degradation expected from amino acid and ester.  
 
 
 
Scheme 3.10. Unsuitable amide cleavage before ester cleavage. 
 
A final variation and extension upon Scheme 3.10 is that the octyl ester of L-phenylalanine may 
itself by an unsuitable substrate for ester cleavage and may be undergoing slow rates of ester 
hydrolysis or β-oxidation as shown in Scheme 3.11. 
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Scheme 3.11. Slow rates of biodegradation for amino acid octyl ester. 
A middle ground between total ester degradation and total amino acid ester degradation 
suggests that the rate of biodegradation may be too slow to pass within the 28 day time limit and 
that rates of biodegradation for compounds cleaved at the ester or amide position could be 
different. If the tests were extended then ultimate biodegradability may be achieved for the C8 
compounds. C8 cholinium IL (438) underwent 36% biodegradation which is almost exactly the 
carbon contribution from total ester degradation. Reduced biodegradability could be attributed 
to the cholinium IL undergoing a different biodegradation pathway to that observed for the 
pyridinium IL. In Chapter 2, a C2 ester cholinium IL (330) was seen to undergo ester cleavage 
only, with an amino acid carboxylate IL remaining, it may be that the C8 cholinium IL (438) is 
undergoing the same breakdown pathway as its C2 counterpart (Scheme 3.12) however only a 
metabolite study on these ILs an confirm the breakdown pathways.  
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Scheme 3.12. Cholinium C8 biodegradation compared to Cholinium C2 biodegradation. 
 
Upon extension of the alkyl chains to C10, a reduced biodegradability was observed for all three 
ILs (433, 436, 439). 36% Biodegradation was observed for pyridinium C10 IL (433), 2% less 
than that which can be attributed to total ester mineralisation, 38%. 44% Biodegradation was 
observed for imidazolium C10 IL (436), 4% above the theoretical degradation according to total 
ester degradation. Cholinium C10 (439) displayed degradation levels 13% less than total ester 
degradation. See Table 3.14. From these values it cannot be inferred whether the amide bond of 
the C10 ILs is undergoing hydrolysis. Reduced levels of biodegradability may be attributed to 
the broad spectrum antimicrobial activity of this series of ILs, previously determined in Section 
3.6. 
 
Further extension of the alkyl chains to C12 to give ILs (434, 437, 440) saw a dramatic reduction 
in biodegradability. 4% biodegradation was observed for the pyridinium C12 IL (434). All three 
C12 ILs failed the toxicity control test carried out during the biodegradation screening and 
inhibited the WWTP organisms. Failure of the toxicity control helps to explain the sudden 
reduction in levels of biodegradability and is supported by the results obtained for the 
antimicrobial screening of the linear alkyl ILs, Section 3.6. According to Boethling‟s rules of 
thumb an extension in alkyl chain length should increase biodegradability.
28
 However as the 
toxicity levels have increased with alkyl chain length, the potential increase in biodegradability 
is offset by the bacteria inability to degrade the IL. Indeed Boethling states that in many cases 
structural changes made to reduce the toxicity of small molecules can reduce biodegradability.
28
 
Though the C10 and C12 ILs undergo reduced levels of biodegradation, conclusions about their 
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biodegradation pathways and ultimate biodegradability cannot be drawn without a full 
metabolite analysis and test time extensions. 
3.7.2 Biodegradation Studies of Bolaform ILs 
The following bolaform ILs were examined for their biodegradability (Figure 3.30). The 
biodegradability of bolaform and dicationic ILs has been reported in the literature and in general 
very poor results have been observed (< 5% biodegradation, see Chapter 1 Section 1.3.6).
45,58,59
 
Therefore the design features of the bolaform ILs such as the ester and amide linkages and the 
tentative QSABR observed in Chapter 2, Section 2.4.5 should allow for elevated levels of 
biodegradability. It is proposed that the bolaform ILs (444-452) (Figure 3.30) could potentially 
breakdown according to two likely pathways: amide hydrolysis and ester hydrolysis in a similar 
manner to that proposed for the linear alkyl ILs (Schemes 3.6, 3.7, 3.8). An illustration of the 
proposed breakdown sites for pyridinium IL (444) are depicted in Figure 3.31. 
 
 
Figure 3.30. Linear Alkyl ILs (444-452) screened for their biodegradability 
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Figure 3.31. Potential biodegradation initiation points for IL (444). 
3.7.2.1 Closed Bottle Test Method 
The CBT was carried out as per Chapter 5, Section 5.2.1 
3.7.2.2 Linear alkyl IL biodegradation results 
Table 3.15. Biodegradability and carbon distribution of examined L-phenylalanine ILs (444-
452), colour coded according to the traffic light classification.
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IL 
Biodegradation 
% 
Amino Acid Ester Carbon 
% 
Linker Carbon 
% 
L-Phenylalanine 
ILs 
 
  
444 47 65 20 
445 40 67 24 
446 18 68 27 
447 53 68 21 
448 44 70 25 
449 40 71 29 
450 28 68 21 
451 24 70 25 
452 19 71 29 
 
As can be seen from Table 3.15 of the ILs screened, none of the ILs examined passed the CBT. 
However the results presented are to the author‟s knowledge the highest levels of 
biodegradation observed for dicationic ILs reported in the literature by nearly +50%. The 
highest levels of biodegradation attained were for imidazolium C8 linked IL (447), which 
displayed a tenfold increase over dicationic examples in the literature. It can be observed for 
each series of ILs that as spacer length is increased from C8 to C10 a decrease in biodegradability 
is observed, the same is also observed as the linker is increased from C10 to C12. Cholinium C8 
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bolaform (450) displayed just 28% biodegradation and the cholinium class represents the lowest 
levels of bolaform biodegradability. Overall the highest levels of biodegradation within each 
headgroup class are observed for the C8 linked ILs (444, 447, 450) (Table 3.15). It was also 
observed that all of the ILs with the exceptions of (446, 452) had reached a plateau in their 
biodegradation after 28 days and were not expected to undergo further levels of biodegradation. 
The plateau phase obtained further poses the question of what exactly is breaking down within 
the test and why is it that the C8 bolaforms observed higher levels than the C10 and C12 
analogues. Levels of biodegradation obtained combined with the presence of the plateau phase 
suggest the ILs are breaking down into recalcitrant metabolites. 
 
 
Scheme 3.13. Potential amide cleavage pathway for IL (444). 
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The example of IL (444), which displayed 47% biodegradation and had reached a plateau by the 
28 day period could be accounted for by the pathway depicted in Scheme 3.13 where amide 
hydrolysis initially occurs followed by mineralisation of a portion of the linker chain and amino 
acids. Possible recalcitrant metabolites include (357) and (465) further reinforcing the need to 
examine (357) and (465) amongst other potential metabolites, for their biodegradability. The 
higher levels of biodegradability of the C8 and C10 pyridinium (444, 445) and C8 and C10 
imidazolium (447, 448) analogues compared to the cholinium ILs (450-452), may be due to 
enzymatic considerations where the cholinium IL cannot fit into a specific region or binding site 
of a particular enzyme, whereas the imidazolium and pyridinium can.  
 
The rapid reduction in biodegradability observed when the linker lengths are increased to C12 
may be due to a toxic effect or an incompatibility with esterase or amidase enzymes. However, 
this remains speculation as no toxicity controls were failed by any of the bolaform ILs. 
Antimicrobial toxicity results observed for the bolaform ILs screened  in Chapter 3, Section 3.6 
suggests that although the toxicity control did not fail in this CBT, a certain level of microbial 
inhibition is possible. 
3.8 Conclusions to 2nd generation IL synthesis, biodegradation and 
antimicrobial toxicity screening 
 
In conclusion a series of new L-phenylalanine linear alkyl and bolaform ILs (432-441, 444-452), 
and alkylating reagents (456-458, 462-464)  have been synthesised and characterised by 
1
H-
NMR, 
13
C-NMR, HRMS, IR, optical rotation and melting point. Target IL compounds were 
produced in moderate to high yield yields with favourable green chemistry metrics established 
with the exception of ethyl nicotinium IL (441). Based on the poor synthesis and metrics for IL 
(441) it was decided to postpone synthesis of the ethyl nicotinium ILs (442, 443). 
Implementation of solvent recycling for the bolaform ILs (444-452) has shown to vastly 
improve the green chemistry metrics of the ILs synthesised. Linear alkyl and bolaform ILs were 
produced in sufficient quantity and purity to facilitate an antimicrobial screening and 
biodegradation study. 
 
The linear alkyl ILs screened for their antimicrobial toxicity (432-441), possessed a broad 
spectrum antimicrobial activity towards the four gram positive bacteria screened against. A 
trend of increasing toxicity with increasing chain length was also observed. For the gram 
negative bacteria, the C10 ILs (433, 436, 439) were shown to be more toxic towards the four 
bacteria than the C8 or C12 ILs. The reason for this higher level of toxicity for the C10 examples 
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has been postulated as being a combination of solubility, lipophilicity and bioavailability. 
Linear alkyl ILs also showed a broad spectrum antifungal activity with increased activity 
observed as chain length was increased. The least toxic derivative screened was the ethyl 
nicotinium derivative (441), however it is important to note that the derivatives still possessed 
an activity in the region of 15.62-62.5 µmol/L MIC95 towards the gram positive bacteria and 
125-250 µmol/L MIC95 towards the gram negative bacteria. Ethyl nicotinum IL (441) possessed 
moderate antifungal activity comparable to the other C8 analogues, 125-1000 µmol/L IC80. 
 
Bolaform ILs (444-452) also displayed high levels of antimicrobial and antifungal toxicity. 
Similar trends were observed for the bolaform ILs, with increasing toxicity linked to increasing 
alkyl spacer length. 
 
From the results observed for the biodegradation screening, none of the linear alkyl ILs 
screened (432-440) could be classified as readily biodegradable. However a number of insights 
were drawn from the percentage biodegradation values observed. Biodegradation values 
calculated for the C8 derivatives (432, 435, 438) were above the percentage attributable to total 
ester degradation yet less than total ester + amino acid degradation (and only 7% below what is 
required to be considered readily biodegradable for C8 pyridinium IL (432)) . The significance 
of such a result is that it can be proposed that the C8 ILs are undergoing a rate of biodegradation 
that is too slow for the 28 day test yet may continue on towards ultimate biodegradability. 
Biodegradation data for the bolaform ILs (444-452) was also obtained. Once again none of the 
ILs could be considered readily biodegradable however the results obtained are the highest 
levels of biodegradation reported for dicationic ILs in the literature. All of the bolaform ILs, 
with the exception of ILs (446, 452), had reached a plateau in their biodegradability by the end 
of the 28 day test suggesting the presence of recalcitrant metabolite products such as those 
depicted in Figure 3.32. To determine whether potential metabolites such as an amino acid IL 
with an unprotected carboxylic acid group can undergo further biodegradation the following ILs 
(362, 465, 466) are proposed for further investigation into their biodegradability (Figure 3.32). 
Note IL (362) has been previously synthesised from Chapter 2, Section 2.4.5. 
 
 
Figure 3.32. Proposed carboxylic acid ILs. 
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Furthermore, to investigate the suitability of ester chain lengths towards amidase, esterase and 
enzymes involved in β-oxidation, the following series of C4-C6 alkyl chain length ILs (101, 467-
471) are proposed (Figure 3.33). Note IL (101) has already been reported in Chapter 1, Section 
1.3.4.1 and underwent 61% biodegradation in the CO2 headspace test ISO 14593.  
 
 
Figure 3.33. Proposed intermediate length ILs (101, 467-471). 
It is suggested that the test times of 28 days are extended for all of the linear alkyl ILs (432-440) 
and the two bolaform ILs that hadn‟t reached a plateau (446, 452), so as to determine the 
ultimate biodegradability. C10 ILs examined (433, 436, 439) underwent reduced levels of 
biodegradability possibly attributable to increased levels of toxicity, however the toxicity 
control blank was not failed for the C10 compounds. For C12 ILs (434, 437, 440) the toxicity 
blank failed and this elevated level of toxicity, which is in agreement with the antimicrobial 
screening results, is the most likely cause for the dramatic reduction in levels of 
biodegradability observed for the C12 ILs. In 10 years of screening IL and other organic 
compounds from the Gathergood group, these are the first to „shut down‟ biodegradation 
processes due to high toxicity to the activated sludge used in the CBT. 
 
In conclusion, the aims of this chapter have been met. A new series of surfactant candidate ILs 
has been synthesised in accordance to the 12 principles of green chemistry and have been 
designed for degradation. A number of green chemistry metrics have been calculated and the 
data gathered has allowed for an ongoing improvement in the synthetic techniques employed in 
the synthesis of this 2
nd
 generation of amino acid ILs. Antimicrobial toxicity and 
biodegradability of the ILs has also been carried out with broad spectrum antimicrobial activity 
observed. Future investigation into the cytotoxicity of the 2
nd
 generation ILs will provide an 
insight into how the ILs may interact with mammalian tissues. QAC‟s are amongst the most 
widely used antiseptics and the ILs synthesised within this chapter may be of value as ultimately 
biodegradable antiseptic surfactants, however QAC‟s are also know to possess a strong toxicity 
towards mammalian cells and further investigation is necessary.
60
 It is proposed that the 
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biodegradation screening tests are extended beyond the 28 period so as to assess the ultimate 
biodegradability of the ILs undergoing examination. 
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Chapter 4 
Self-assembly and Surface Active Properties of 
2nd Generation L-Phenylalanine Ionic Liquids 
 
 
 
 
 
 
 
 
 
 
 
 
 
218 
 
 
4.1 Aim 
The aim of this chapter was to investigate the surface activity and surfactant properties of the 2
nd
 
generation ILs described in Chapter 3. The premise for this investigation is described in the 
introduction to Chapter 3. A number of properties were investigated such as the critical micelle 
concentration (CMC), surface tension properties, liquid crystal behaviour at different 
temperatures, pH stability and susceptibility to hydrolysis. 
4.2 Introduction  
Determination of the CMC gives an indication as to how well a surfactant may perform in 
certain applications where the formation of micelles is beneficial e.g. cleaning, oil dispersion, 
foaming etc. Other information that can be obtained once the CMC is determined is the degree 
of ionisation (α) surrounding a micelle i.e. the degree of counterion dissociation. Degree of 
ionisation is a factor of how many counterions are associated around a micelle and how many 
are free in solution.
1
 Dissociation of counterions means that the micelle can exist as a charged 
structure and the α parameter can give insight into the stability of the micelles formed.2 CMC 
was determined by two methods. The first was by conductivity and the second was by 
tensiometry. Both methods are discussed in full in Section 4.3, vide infra.  
 
The second property investigated was the ILs ability to lower surface tension. Ability to lower 
surface tension at the interface of two phases is significant. Reduction in the repulsion forces 
between two otherwise immiscible phases can allow for dispersions of oil in water, emulsions, 
phase transfer catalysis etc.
3-5
 A surfactant‟s effectiveness and efficiency at reducing surface 
tension can both be determined. Effectiveness is the maximum reduction in surface tension 
(effective range) achievable before surface saturation occurs and no more surfactant molecules 
can align at the surface and therefore the surface tension can be lowered no further.
6
 At this 
point the excess concentration that can‟t access the saturated surface is forced to remain in the 
bulk solution and can begin to form aggregates such as micelles. Efficiency of a surfactant is the 
concentration of surfactant required to reduce surface tension by 20 mN/m.
7
 Some surfactants 
may be efficient at lowering the surface tension by 20 mN/m but their effective range may be 
lacking. Such specific properties are application dependant i.e. whether efficiency, effectiveness 
or both are required and to what extent. A surfactant may have a high effective range but in 
achieving the lowest possible surface tension may require large concentrations. Thus the two 
components of efficiency and effectiveness must be considered. Furthermore the toxicity and 
biodegradability of the surfactants chosen for applications must be considered. Is it better to 
have a less efficient/effective surfactant if the overall toxicity is low and the biodegradability 
high? 
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To study the physicochemical properties of the surfactants a qualitative investigation into the 
liquid crystal forming behaviour was conducted using a polarised light microscope with heat 
controlled stage. A digital camera mounted on the stereo head of the microscope allowed for 
photography of the liquid crystal behaviour. 
 
Lastly a preliminary investigation into the aqueous stability and  hydrolysis in acidic and basic 
media was conducted for a number of surfactants. 
4.3 Self-Aggregation and physicochemical properties of linear alkyl L-
phenylalanine ILs. 
 
The aggregation properties of the linear alkyl L-phenylalanine IL surfactants (432-440) (Figure 
4.1) were determined by conductivity and tensiometry experiments. The results of these 
experiments are summarised in Table 4.1 and 4.5 respectively.  
 
 
Figure 4.1. Linear alkyl ILs examined (432-440). 
4.3.1 Conductivity measurements 
The change in specific conductivity with respect to concentration for aqueous solutions of the 
surfactants was measured. See Chapter 5, Section 5.10 for experimental details. The slope 
before the CMC has been reached is much steeper due to the concentration of free ions in 
solution. Once the CMC is achieved an abrupt change and reduction in the rate of increase in 
slope is observed due to the reduced ability of micelles to act as charge carriers as the free ions 
in solution are now involved in the aggregation process.
8
 Surfactant counterions are bound to a 
certain degree to the micelle and this counterion binding parameter (β) can be estimated by 
comparing the ratio of the two slopes to each other. Degree of ionisation (α) can also be 
determined by the following equation: α = 1-β. A typical conductivity plot is summarised in 
Figure 4.2. There are two distinct slopes observable for specific conductivity (Figure 4.2) and 
the CMC can be determined from the intersection of these two slopes. In total a conductivity vs. 
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concentration plot was constructed for each of the surfactant ILs undergoing investigation and 
are presented in Appendix II.  
 
Figure 4.2. Plot of conductivity vs. concentration for imidazolium C10 IL surfactant (436). 
Table 4.1. Results obtained by conductimetry. 
IL Headgroup Chain Length CMC (mM) α β ΔG
o
mic (kJ/mol) 
432 Pyridinium 8 4.00 0.697 0.303 -30.81 
433 Pyridinium 10 1.30 0.47 0.53 -40.45 
434 Pyridinium 12 0.20 0.407 0.593 -49.49 
435 Imidazolium 8 3.70 0.497 0.503 -35.83 
436 Imidazolium 10 1.70 0.377 0.623 -41.81 
437 Imidazolium 12 0.22 0.455 0.545 -47.63 
438 Cholinium 8 4.00 0.455 0.545 -36.52 
439 Cholinium 10 1.50 0.427 0.573 -41.11 
440 Cholinium 12 0.36 0.537 0.463 -43.32 
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As can be seen from Table 4.1, a progressive decrease in CMC was observed as ester chain 
length increased; a well-documented characteristic present in various surfactant classes with the 
progressive addition of each C2H4 unit decreasing the CMC by a factor of ~4 (the actual 
relationship is a progressive decrease of the CMC by half for every additional CH2 unit).
3
 Very 
little difference was observed between the CMCs of the various headgroups. It can also be 
observed that as alkyl chain length increased so did the degree of counter-ion binding β.  
The spontaneity of the phenomenon of micellisation and aggregation of these surfactants in 
aqueous solution means that the Gibbs free energy (ΔG°mic) of micellisation can be determined 
as a negative value. ΔG°mic was determined using the following equation: 
 
                     
 
β is the previously discussed counter-ion binding parameter (degree of association) and      is 
the critical micelle concentration expressed as a mole fraction of the solution measured. Results 
of the investigation into the        show that as the alkyl chain length is increased, the energy 
required to form a micelle is decreased. This is due to the increase in hydrophobic repulsion 
interactions present with longer alkyl chains.  
 
The CMC of the new IL surfactants (432-435) were compared to CMC values of linear alkyl 
surfactants reported in the literature, the observations of which are outlined in Table 4.2. 
Surfactants used for comparision include linear alkyl pyridinium surfactants depicted in Figure 
4.3 (reported by Rosen et al.
9
 and Skerjanc et al.
10
), and ester and amide functionalised 
imidazolium and pyridinium surfactants depicted in Figure 4.4 (investigated by Pérez et al).
8, 11
 
 
When compared to the ester functionalised pyridinium ILs examined by Pérez et al. the new 
amino acid surfactants reported here are comparable to ester surfactants with 3-4 more carbons. 
One reasonable explanation for this is that the phenylalanine sidechain residue is contributing to 
the overall lipophilicity of the surfactant therefore reducing the concentration required to form 
micelles. According to Rosen, a phenyl group as part of a hydrophobic group is equivalent to 
~3.5 carbon atoms.
3
 This would help account for some of the decrease in CMC, the rest may be 
attributed to the remaining lipophilicity of the amino acid group; the amino acid heteroatoms 
themselves not contributing significant hydrophilicity to increase the CMC. The contribution of 
the phenyl sidechain is further exemplified when the predicted CMC values were determined 
and compared to the experimentally observed values. 
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Figure 4.3. Alkyl pyridinium surfactants (R = CnH2n+1, n = 10-16, 18) reported by Rosen et al.
9
 
and Skerjanc et al. 
10
 
 
Figure 4.4. Alkyl ester and amide surfactants reported by Pérez et al.
8, 11
 Imidazolium IL (412-
414) originally reported by Gathergood and Morrissey.
12, 13
 
CMC can be tentatively predicted using the Stauff-Klevens rule 
14
: 
 
            
 
A is a constant for the headgroup employed in the surfactant and B is an empirical constant 
constant for surfactant classes (originally approximated as log2 (0.301) in Klevens original 1953 
publication), n is the number of carbon atoms in the hydrophobic chain.
14
 The value A for 
alkylpyridinium  bromide surfactants (394-401) was determined to be 1.72 while B was 
determined to be 0.31 (at 30 °C).
15,
 
16
 The accuracy of the predictions for ILs (394-401) 
compared to literature values are illustrated in Figure 4.5. 
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Table 4.2. Comparison of pyridinium surfactants reported by Rosen et al. (394-401), 
pyridinium ester (402-406) and amide (407-411) reported by Pérez et al.
8,
 
11
 with new amino 
acid pyridinium IL surfactants (432-434). All surfactants were measured at 25 °C. 
IL 
Chain 
Length 
Counterion 
No. Carbons 
in Sidechain 
CMC (mM) Reference 
Linear Alkyl Pyridinium 
394 C10H21 [Br] 10 44 
10
 
395 C11H23 [Br] 11 21 
10
 
396 C12H25 [Br] 12 11.4 
9
 
397 C13H26 [Br] 13 5.3 
10
 
398 C14H29 [Br] 14 2.7 
10
 
399 C15H31 [Br] 15 1.3 
10
 
400 C16H33 [Br] 16 0.64 
10
 
401 C18H37 [Cl] 18 0.24 
17
 
Alkyl Ester Pyridinium 
402 C6H13 [Br] 6 200  
403 C8H17 [Br] 8 73 
8
 
404 C10H21 [Br] 10 17 
8
 
405 C12H25 [Br] 12 4.1 
8
 
406 C14H29 [Br] 14 0.91 
8
 
Alkyl Amide Pyridinium 
407 C6H13 [Br] 6 262 
11
 
408 C8H17 [Br] 8 73 
11
 
409 C10H21 [Br] 10 18 
11
 
410 C12H25 [Br] 12 4.6 
11
 
411 C14H29 [Br] 14 1.2 
11
 
New Pyridinium Amino Acid ILs 
432 C8H17 [Br] 8 4.00 n/a 
433 C10H21 [Br] 10 1.30 n/a 
434 C12H25 [Br] 12 0.20 n/a 
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Figure 4.5. Comparison of literature CMC values to predicted CMC values for linear 
alkyl pyridinium surfactants previously reported in the literature (394-401). 
Table 4.3. Predicted CMC vs actual CMC for alkylpyridinium surfactants (394-400) and the 
new amino acid pyridinium ILs (432-434) reported in this chapter. 
IL Chain Length 
No.  
Carbon atoms 
Predicted CMC 
(mM) 
Actual CMC 
(mM) 
Linear Alkyl Pyridinium 
394 C10H21 10 41.69 44 
395 C11H23 11 20.42 21 
396 C12H25 12 10.00 11.4 
397 C13H26 13 4.89 5.3 
398 C14H29 14 2.39 2.7 
399 C15H31 15 1.17 1.3 
400 C16H33 16 0.58 0.64 
Amino Acid ILs 
432 C8H17 8 173.78 4.0 
433 C10H21 10 41.69 1.3 
434 C12H25 12 10 0.2 
Amino Acid ILs - No. Carbon atoms including + 5 (Phenyl ring) 
432 C8H17 13 4.89 4.0 
433 C10H21 15 1.17 1.3 
434 C12H25 17 0.28 0.2 
y = -1.493ln(x) + 15.549 
y = -1.401ln(x) + 15.226 
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When applying the Stauff-Klevens equation to the amino acid pyridinium ILs in Table 4.3 it can 
be seen that the equation can give estimates for the alkyl pyridinium surfactants examples taken 
from the literature. However, if the carbon count used in the new ILs (432-434) only takes into 
consideration the amino acids ester carbon quantity, then the prediction does not hold true. Only 
when the approximate additional lipophilicity from the amino acid sidechain phenyl group is 
included ~+5 does the prediction give meaningful results. 
 
As can be seen from Table 4.4, the degree of binding for the surfactants increases as the alkyl 
chain length increases. This trend can also be compared to the CMC; the degree of binding 
increases as the hydrophobicity of the alkyl chain increases. When the amino acid ILs are 
compared to the alkyl pyridinium surfactants it can be seen that the degree of binding is lower. 
This may be due to the amino acid increasing the area per cationic headgroup in the micelle thus 
decreasing the number of counterions that can physically bind to the micelle before repulsion 
forces the remainder (α) into solution as free ions. 
 
Table 4.4. Comparison of degree of binding, β, in linear alky pyridinium surfactants from the 
literature (394-400) and the new amino acid pyridinium ILs (432-434) reported in this chapter.  
IL Chain Length Counterion β Reference 
Linear Alkyl Pyridinium 
394 C10H21 [Br] 0.62 
10
 
395 C11H23 [Br] 0.64 
10
 
396 C12H25 [Br] 0.66 
10
 
397 C13H26 [Br] 0.66 
10
 
398 C14H29 [Br] 0.69 
10
 
399 C15H31 [Br] 0.69 
10
 
400 C16H33 [Br] 0.69 
10
 
Amino Acid ILs 
432 C8H17 [Br] 0.303 n/a 
433 C10H21 [Br] 0.530 n/a 
434 C12H25 [Br] 0.593 n/a 
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4.3.2 Tensiometry measurements 
 
The surface tension properties were determined according to the experimental method outlined 
in Chapter 5, Section 5.10. For each of the surfactant ILs examined, a plot of surface tension (γ) 
vs. log concentration of the surfactant in aqueous solution was constructed. From the 
tensiometry plots a number of characteristics of the surfactants were determined. See Figure 4.6 
for a typical plot determined for the surfactants analysed.  CMC values were determined from 
the tensiometry plot from the intercept of the two distinct slopes present. The presence of two 
slopes can be attributed to the decrease in surface tension as surfactant concentration increases 
up to a minima where the surface becomes saturated by surfactant molecules. After this 
saturation has been reached the surfactant in solution begins forming micelles and the surface 
tension can be lowered no further.
8
 For each of the linear alkyl ILs examined (432-440) a 
surface tension plot such as that presented in Figure 4.6 was constructed, see Appendix II for 
relevant graphs. 
 
The surfactant efficiency (pC20) - the ability of a surfactant to reduce surface tension by 20 
mN/m - was determined by the following equation: 
 
                
 
Where     is the concentration (in moles) required to reduce the surface tension by 20 mN/m
11
 
The larger the pC20 value, the more efficient the surfactant is. 
 
The effectiveness of the surfactants (πCMC), was determined by the following equation: 
 
               
 
Where γ0 is the surface tension of pure water and γcmc is the surface tension observed at the 
CMC.
11
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Figure 4.6. Plot of Surface Tension vs. Log10 Concentration for C8 pyridinium IL surfactant 
(432). 
The average area per molecule occupied by each surfactant molecule was also determined; 
using the Gibb‟s equation: 
 
     
 
         
    
  
     
   
 
Where Γ is the surface excess concentration,   
  
     
   is the slope of the surface tension γ vs. 
log surfactant concentration dependence. R = 8.32 J/K mol and T =  298.15 K. n is the number 
of ionic species in solution and a value of two is used for the cation surfactants.  
 
The surface excess concentration Γ is related to the area per surfactant molecule A using the 
following equation: 
   
 
       
 
 
Where NA  is Avogadro‟s constant. 
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Table 4.5. Surfactant properties for ILs (432-440) determined by tensiometry. 
IL Headgroup 
Chain 
Length 
CMC 
(mM) 
γCMC 
(mN/m) 
C20 
(mM) 
pC20 
Area per 
molecule 
Å
2 
/ nm
2
 
432 Pyridinium 8 3.00 40.84 0.26 3.59 
108.60 /  
1.09 
433 Pyridinium 10 0.70 36.65 0.03 4.49 
105.26 /  
1.05 
434 Pyridinium 12 0.15 35.84 0.01 5.28 
154.82 /  
1.55 
435 Imidazolium 8 2.50 38.24 0.19 3.71 
108.13 /  
1.08 
436 Imidazolium 10 1.50 35.46 0.05 4.28 
151.61 / 
 1.52 
437 Imidazolium 12 0.25 36.77 0.01 4.99 
154.58 /  
1.55 
438 Cholinium 8 2.00 37.03 0.11 3.96 
126.52 /  
1.27 
439 Cholinium 10 1.70 35.04 0.04 4.36 
126.52 /  
1.27 
440 Cholinium 12 0.20 35.85 0.02 4.82 
112.58 /  
1.13 
 
From the results determined in Table 4.5, the CMC was determined for each of the IL 
surfactants and displayed a general decrease in CMC as alkyl chain length increased and was in 
agreement with the results obtained by conductivity, see Table 4.7 for method comparison. 
Overall effectiveness γCMC was shown to be in the region of ~35-40 mN/m and varied very 
little across the surfactants when headgroup was changed. C8 surface active ILs (432, 435, 438) 
appeared to have the largest γCMC with a reduction in effectiveness observed as alkyl chain 
length is increased. The effective range for the surface active ILs examined was determined to 
be typical for long chain cationic surfactants and displayed a larger effective range than 
traditional linear alkyl pyridinium surfactants. γCMC was comparable to the C6-C10 ester 
functionalised pyridinium ILs synthesised and characterised by Pérez et al. Table 4.6.
8
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Table 4.6. Comparison of surface tension properties of new pyridinium surfactants to those 
reported in the literature. 
IL Surfactant 
γCMC 
(mN/m) 
pC20 
Area Per 
Molecule 
nm
2
 
Reference 
Linear Alkyl Pyridinium 
394 C10H21 32 1.9 - 
3, 9
 
396 C12H25 35 2.3 0.5 
3, 9
 
398 C14H29 31 2.9 0.6 
3, 9
 
Alkyl Ester Pyridinium 
402 C6H13 38 1.6 0.9 
8
 
403 C8H17 39 2.1 0.7 
8
 
404 C10H21 41 2.7 0.7 
8
 
405 C12H25 43 3.5 0.6 
8
 
406 C14H29 48 4.0 0.4 
8
 
Alkyl Amide Pyridinium 
407 C6H13 - - -  
408 C8H17 42 1.8 - 
11
 
409 C10H21 45 2.8 - 
11
 
410 C12H25 37 3.6 - 
11
 
411 C14H29 36 4.1 - 
11
 
New Pyridinium Amino Acid ILs 
432 C8H17 41 3.6 1.1 n/a 
433 C10H21 37 4.5 1.1 n/a 
434 C12H25 36 5.3 1.6 n/a 
 
The pC20, or efficiency parameter, was observed to increase as alkyl chain length increased as 
less surfactant was required to reduce the surface tension by 20 mN/m. This may be due to the 
increase in negative free energy of adsorption at the air/water interface for the additional 
methylene groups present as the chain length increases.
8
 The amino acid surfactant ILs reported 
here had a greater efficiency than any of the reported linear alkyl or ester functionalised 
pyridinium examples (Table 4.6). Unfortunately no γCMC or pC20 data was available in the 
literature for C6H13 or C16H33 alkyl pyridinium bromide surfactants. Area per molecule for the 
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surfactants was determined and is presented in nm
2
. Area per molecule was determined to be >1 
nm
2
 for each surfactant analysed, a larger area than that observed for the linear alkyl/amide 
examples from the literature, Table 4.6. This larger area can be attributed to the bulky amino 
acid that links the headgroup to the alkyl chain.  
 
Table 4.7. Comparison of CMC by conductivity and by tensiometry. 
IL Headgroup Chain Length 
CMC 
Tensiometry 
(mM) 
CMC 
Conductivity 
(mM) 
432 Pyridinium 8 3.00 4.00 
433 Pyridinium 10 0.70 1.30 
434 Pyridinium 12 0.15 0.20 
435 Imidazolium 8 2.50 3.70 
436 Imidazolium 10 1.50 1.70 
437 Imidazolium 12 0.25 0.22 
438 Cholinium 8 2.00 4.00 
439 Cholinium 10 1.70 1.50 
440 Cholinium 12 0.20 0.36 
 
As can be seen from Table 4.7, the CMC was also determined by tensiometry and confirms the 
validity of the results observed by conductivity. There are many more methods that could be 
used to determine the CMC, some of the most popular include fluorescence spectroscopy
11
, 
1
H 
and 
23
Na NMR experiments
18
 and dynamic light scattering (DLS).
18
 
4.3.3 HPLC Models 
The purity of all of the surfactants was determined by HPLC/UV to ensure >98% purity by the 
method outlined in Chapter 5, Section 5.10.5. 
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Figure 4.7. HPLC/UV trace for IL C10 Pyridinium IL (433). 
Retention Time 
Minutes 
Area mAU Area % Height Height % 
4.79 358179 0,14 40979 0,61 
10.44 251752507 99,86 6700948 99,39 
Table 4.8. HPLC/UV retention time results. 
Analysis of the surfactant by HPLC/UV showed that all of the linear alkyl ILs synthesised had a 
purity of greater than >98%.  
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From the HPLC/UV analysis it was also possible to construct a model based on retention time 
and CMC. With an increase in lipophilicity there is also a subsequent increase in retention time 
as a C18 column was employed as the stationary phase. An increase in lipophilicity results in a 
decrease in CMC until solubility limits are reached. Therefore the retention time can be 
described as proportional to the CMC and a linear relationship was observed when retention 
time was plotted against CMC (Figure 4.8). Retention time, in the literature,  has also be used to 
estimate the log octanol-water partition coefficients (logP) for surfactants in conjunction with 
the traditional shake-flask method (the shake-flask method itself is unsuitable due to the 
amphiphilic nature of surfactants).
19
 Furthermore the interconnected relationships between logP 
and toxicity have also been reported.
20
  
 
 
Figure 4.8. Retention time vs CMC for linear alkyl surfactants (432-440) examined by 
conductivity. 
Figure 4.8 represents the HPLC retention time model developed for approximating the CMC of 
the surfactants examined. If further surfactants were developed with different alkyl chain 
lengths in this series then the HPLC retention time values could be used to extrapolate an 
approximate CMC value.  
 
Figure 4.9 is a further development of the idea behind the HPLC model and represents another 
method in determining the approximate CMC of any further surfactants that could be developed 
from the linear alkyl series so far examined. The benefit of these models is that CMC can be 
“tailored” with a specific target CMC in mind. Both relationships presented will give an 
estimated figure in conjunction with the Stauff-Klevensequation             described 
in Section 4.3.1. 
C8 
C10 
C12 
 y = -0.7622x + 11.727, Pyridinium 
y = -0.5594x + 11.468, Cholinium 
   y = -0.9437x + 12.695, Imidazolium 
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Figure 4.9. No of Carbon atoms in the linear alkyl chain vs CMC (conductivity). 
If a further series of C4 and C6 surfactants (Figure 4.10) were synthesised then the CMC values 
may be predicted using the Stauff-Klevens equation. 
 
 
Figure 4.10. Potential C4 and C6 surfactants (101, 467-471). 
For pyridinium ILs, literature values of A = 1.72 and B = 0.31 were used.
16
  
For imidazolium ILs, literature values of A = 1.78 and B = 0.32 were used.
15
 
For cholinium ILs, literature values of A = 1.96 and B = 0.30 were used.
15
 
 
Using the Stauff-Klevens rule, the predicted values for future C4 and C6 linear alkyl surfactants 
were calculated.When the predicted values were compared to the CMC values calculated from 
the equations of the line in Figure 4.9, a general disagreement between the values was observed, 
see Table 4.9. This discrepancy suggests that the literature values for A and B employed in the 
Stauff-Klevens equation used to predict the C4 and C6 surfactant‟s CMCs are not appropriate. 
While the A and B values previously used for longer chain pyridinium ILs in Section 4.3.1 may 
have given good correlations, any error associated with these values has been amplified by the 
larger CMC values predicted. New A and B values are therefore proposed for all three series of 
C8 
C10 C12 
y = -1.308ln(x) + 10.017, Pyridnium 
y = -1.647ln(x) + 10.408, Cholinium 
   y = -1.328ln(x) + 10.144, Imidazolium 
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amino acid ILs based on linear regressions plotted in Figure 4.9. It should be stated that the 
column in Table 4.9 entitled “Predicted CMC Carbon Count From Figure 4.9” is a derivation of 
the Stauff-Klevens rule and can be rewritten as follows to provide new A and B values 
according to Figure 4.9. 
 
Table 4.9. Predicted CMC values for C4 and C6 surfactants. 
IL Headgroup Chain Length 
Predicted CMC (mM) 
              
Predicted CMC 
From Figure 4.9 
467 Pyridinium 4 85.11 99.49 
468 Pyridinium 6 20.41 21.56 
101 Imidazolium 4 79.43 102.16 
469 Imidazolium 6 18.19 22.65 
470 Cholinium 4 181.97 48.94 
471 Cholinium 6 45.71 14.53 
 
Pyridinium: y = -1.308ln(x) + 10.017 → Log(CMC) = 3.326 - 0.332(y). A = 3.326, B = 0.332 
Imidazolium: y = -1.328ln(x) + 10.144 → Log(CMC) = 3.368 - 0.332(y). A = 3.368, B = 0.332 
Cholinium: y = -1.647ln(x) + 10.408 → Log(CMC) = 2.744 - 0.264(y). A = 2.744, B = 0.264 
 
Substituting the newly calculated A and B values, the following predicted CMC values are 
presented, Table 4.10. 
 
With the newly calculated A and B values, there is a much better correlation between predicted 
values and observed CMC values, Table 4.10. Imidazolium C8 and C10 ILs (435, 436) are the 
least accurately described of the series of ILs using this equation. 
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Table 4.10. Comparison of actual CMC and predicted CMC values using linear regression from 
Figure 4.9. 
IL Headgroup Chain Length Predicted CMC (mM)* 
Actual CMC 
(mM)(conductimetry) 
434 Pyridinium 12 0.22 0.20 
433 Pyridinium 10 1.01 1.30 
432 Pyridinium 8 4.67 4.00 
468 Pyridinium 6 21.57 - 
467 Pyridinium 4 99.54 - 
437 Imidazolium 12 0.24 0.22 
436 Imidazolium 10 1.12 1.70 
435 Imidazolium 8 5.15 3.70 
469 Imidazolium 6 18.19 - 
101 Imidazolium 4 79.43 - 
440 Cholinium 12 0.38 0.36 
439 Cholinium 10 1.27 1.50 
438 Cholinium 8 4.29 4.00 
471 Cholinium 6 45.71 - 
470 Cholinium 4 181.97 - 
* Calculated using log(CMC) = A - Bn. 
4.3.4 Optical Microscopy 
The IL surfactants (432-434, 437, 440) were analysed by polarised light optical microscopy to 
study their phase behaviour. It is possible to study the qualitative phase behaviour of binary 
water/surfactants mixtures as a function of temperature by optical microscopy according to the 
“flooding” (penetration) method of Lawrence described in Chapter 5, Section 5.10.4. In this 
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experiment, a drop of water was added onto anhydrous surfactant between a glass slide and a 
cover slip. Gradually different compositions of liquid crystals are produced and different 
separated mesophases develop.
21
 These mesophases are lyotropic i.e. they are determined by 
interactions with other surfactant molecules in a bulk solvent phase. Mesophases are also 
anisotropic, i.e. they are structures in which one or more dimensions are highly extended. The 
use of a heated stage microscope also allowed for qualitative observations of how heat affected 
the formation and composition of mesophases as thermotropic properties can affect the phase 
formations. The various properties and mesophases obtainable are depicted in Figure 4.11 as a 
phase diagram. A number of different liquid crystal phases are depicted in Figure 4.12. The 
mesophasic liquid crystal behaviour is of particular interest for drug delivery applications as 
drug molecules can be “loaded” inside a particular mesophase and then delivered to a target.22 
Mesophases are also of interest for biological applications due to some of their similarities to 
biological membranes.
22
 
 
 
Figure 4.11. Typical phase diagram for a non-ionic poly-ethoxylated surfactant. 
Adapted from P. Sciences, in Particle Sciences - Technical Brief, 2012, vol. 6.
22
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Figure 4.12. A selection of phases and mesophases that surfactants can form.  
Adapted from P. Sciences, in Particle Sciences - Technical Brief, 2012, vol. 6,
22
 
and P. Sciences, in Particle Sciences - Technical Brief, 2010, vol. 1.
23
 
 
Hexagonal and lamellar phase liquid crystals are anisotropic, i.e. are not uniform structures in 
all directions and therefore will scatter polarised light and appear as white areas when viewed. 
24
 
Isotropic structures such as cubic phase crystals appear as black areas when exposed to 
polarized light but can be identified by exposing them to non-polarised light and comparing the 
before and after images.  
 
In the following section a number of optical microscopy images captured using the 
aforementioned flooding/penetration method are presented. The experiments were also carried 
out over a range of temperatures ranging from 25 °C and 100 °C. A number of linear alkyl 
surfactants were analysed for their liquid crystal behaviour. The pyridinium C8, C10 and C12 
(432-434) were analysed to determine whether chain length greatly affected the liquid crystal 
behaviour. Imidazolium C12 (437) and cholinium C12 (440) were also examined to determine 
whether headgroup affected the compositions observed. 
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Figure 4.13. C8 Pyr IL (432). 25 °C, x10 magnification 
The image shown in Figure 4.13 is the solid hydrated surfactant and is referred to as a mosaic. 
The black area is the water added slowly diffusing into the surfactant. 
 
 
Figure 4.14. C8 Pyr IL (432) “Maltese Crosses” visibly forming. 35°C, x10 magnification 
The formation of “Maltese crosses” is apparent (Figure 4.14). These crosses are representative 
of lamellar crystals.
24
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Figure 4.15. C8 Pyr IL (432), Lamellar phase crystals. 35°C, x10 magnification 
Oily streaks or tendrils are visible (Figure 4.15). These streaks represent lamellar phase liquid 
crystals. 
 
 
Figure 4.16. C8 Pyr IL (432) Hexagonal phase liquid crystals. 55°C, x10 magnification 
The formation of lyotropic hexagonal phase liquid crystals can be observed in the centre of the 
image (Figure 4.16). The hexagonal phase crystals appear as fans or sheet like structures. 
Heating from 25 °C to 35 °C to 55 °C shows a change as the phase thermotropically shifts from 
one mesomorph to another, as depicted by the sample phase diagram in Figure 4.4. After 65 °C 
solubilisation of (432) occurred rapidly. 
 
The images captured for C10 Pyridinium were very similar to those observed for C8. 
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Figure 4.17. C10 Pyr IL (433), an abundance of lamellar phase liquid crystals are visible. 30 °C, 
x10 magnification. 
 
 
Figure 4.18. C10 Pyr IL (433), an abundance of lamellar phase liquid crystals are visible. 30 °C, 
x10 magnification. 
At 30 °C IL (433) was observed to be predominately in the lamellar phase as can be seen in 
Figures 4.17 and 4.18. No hexagonal phase liquid crystals were observed however for (433). 
 
Upon extension of the alkyl chain length to C12, the surfactant (434) was observed under the 
same experimental conditions, Figure 4.19. 
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Figure 4.19. C12 Pyr IL (434), lamellar phase crystals visible as streaks and Maltese crosses. 45 
°C, x10 magnification. 
 
 
Figure 4.20. C12 Pyr IL (434) Hexagonal phase liquid crystals. 70 °C, x10 magnification. 
When the temperature was increased to 70 °C the formation of hexagonal phase liquid crystals 
occurred as can be seen from the image captured (Figure 4.20). 
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Figure 4.21. C12 Pyr IL (434). Cubic liquid crystals observed under a polarised  light source 
 
Figure 4.22. The same frame as Figure 4.21, cubic phase observed under non-polarised light 
Both images are observed at 90 °C, x10 magnification. 
 
The dark area in the centre of the image (Figure 4.21)  represents cubic liquid crystals. 
Confirmation that they are indeed isotropic comes when the light shone through the microscope 
is switched to a non-polarised source (Figure 4.22). The dark area appears as white along with 
the rest of the hexagonal phase crystals present. 
 
When the headgroup was altered from a pyridinium to an imidazolium or cholinium similar 
structures were observed to form readily. Alkyl chains were maintained at C12. 
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Figure 4.23. Lamellar phase liquid crystals observed for imidazolium C12 IL (437). 40 °C, x10 
magnification. 
 
 
Figure 4.24. Hexagonal phase liquid crystals observed for IL (437). 60 °C, x10 magnification. 
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Figure 4.25. A forest of Maltese crosses observed for C12 imidazolium IL (437).70 °C, x10 
magnification. 
 
 
Figure 4.26. Needles growing upon cooling back to room temperature. 
 
When imidazolium C12 IL (437) was cooled back to room temperature, thin needles of crystals 
were observed to rapidly form (Figure 4.26).  
 
When the headgroup was switched to cholinium the following set of images were captured. 
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Figure 4.27. Cholinium C12 (440), mosaic and hexagonal phase 20 °C, x10 magnification. 
A rough textured and colourful mosaic can be observed (Figure 4.27). This mosaic is hydrated 
solid surfactant. On the lower half of the image grey hexagonal phase crystals can be seen 
expanding and encroaching on the bulk of the hydrated solid. 
 
 
Figure 4.28. Lamellar phase liquid crystals observed for C12 cholinium IL (440). 60 °C, x10 
magnification. 
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Figure 4.29. Lamellar phase liquid crystals observed for C12 cholinium IL (440). 60 °C, x10 
magnification. 
It was noted that the formation of lamellar phase liquid crystals did not occur at lower 
temperatures for C12 cholinium IL (440) and only became apparent >50 °C. Overall it can be 
noted that to fully identify and determine the nature of the liquid crystals, and the surfactants 
tendency to form lyotropic or thermotropic liquid crystals, additional investigations would be 
required. Differential scanning calorimetry (DSC) would enable the identification of the phase 
transitions. Investigations solely into the thermotropic properties could also be conducted using 
dry surfactant and not adding water so as to observe the liquid crystal properties solely 
attributable to temperature change.
25, 26
 
4.3.5 Aqueous stability measurements 
Qualitative aqueous hydrolysis of a number of surfactant IL samples (433, 436, 439) were 
measured over a one week period at 50 °C and repeated at pH 2 and pH 10, both at 25 °C. The 
aim of this study was to determine the onset of degradation and is a preliminary study into the 
overall stability of the ILs examined. HPLC/UV traces for each measurement are available in 
Appendix II. 
4.3.5.1 Hydrolysis study, pH 7, 50 °C 
The results of the stability study show that hydrolysis was observed at 24 hours for each 
compound examined with the presence of a new product peak eluting at 3-4 minutes. 
An example trace collected for the HPLC/UV analysis is displayed in Figure 4.30 and 4.31. The 
traces show pyridinium C10 (433) at t = 0 h and t = 168 h and the appearance of degradation 
peaks due to hydrolysis. A UV visible hydrolysis product elutes much more rapidly than the 
parent product suggesting that the hydrolysis product is more polar than the parent compound. If 
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the ester functionality of the molecule is hydrolysed then the resultant amino acid carboxylic 
acid ionic liquid would indeed be far more polar than the parent compound. Amide hydrolysis 
would also produce a highly polar IL product. To confirm the hydrolysis pathway would require 
an MS study or isolation of the hydrolysed product and was not within the scope of this 
investigation. Similar HPLC/UV traces were prepared for C10 imdazolium (436) (Figures 4.32-
4.34) and C10 cholinium (439) (Figures 4.35-4.36). Imidazole C10 is observed undergoing 
hydrolysis at t  = 24 h with a peak observed eluting at 3-4 minutes (Figure 4.33). The rapid 
onset for imidazolium degradation may be due to the inherent Brønsted acidity associated with 
imidazolium ILs.
27-29
 For the cholinium IL (439), a shoulder to the main peak can be observed 
occurring at 168 hours after the hydrolysis experiment began (Figure 4.36). 
 
 
 
Figure 4.30. Pyridinium C10 (433) concentration = 2.5 mM, pH = 7, 50°C, at t = 0 h. 
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Figure 4.31. Pyridinium C10 (433), pH = 7, 50°C, t = 168 h. 
 
 
 
Figure 4.32. Imidazole C10 (436), concentration = 2.5 mM, pH = 7, 50°C, t = 0 h. Parent peak 
eluting at 9.5 minutes 
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Figure 4.33. Imidazole C10 (436), pH = 7, 50°C, t = 24 h. Parent peak eluting at 9.5 minutes. 
Hydrolysis product eluting at 3.5 minutes. 
 
 
 
Figure 4.34. Imidazole C10 (436),pH = 7, 50°C, t = 168 h. 
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Figure 4.35. HPLC/UV trace of cholinium C10 (439), concentration 2.5 mM, 50°C pH = 7, t = 0 
h. 
 
 
Figure 4.36. HPLC/UV trace of cholinium C10 (439), 50°C pH = 7, t =168 h displaying 
shoulder to main peak and rapidly eluting hydrolysis product at 3-5 minutes. 
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4.3.5.2 Acid hydrolysis study, pH 2, 25 °C 
The stability study was repeated at 25 °C and the pH was altered to 2. The aim was to assess the 
acidic stability stability of the surfactant molecules in aqueous media. Overall from the HPLC 
traces provided (Figures 4.37-4.39), there appears to be acid hydrolysis occurring for all 3 ILs 
examined, however the  peak eluting at 3-5 minutes is much smaller than that observed for the 
pH 7, 50 °C conditions previously described. Tentatively, it may appear that the ILs have a 
characteristic resistance to acid hydrolysis as the presence of sharp peaks eluting at 3-5 minutes 
were not detected until 168 hours and even then the peaks detected were far smaller than those 
present at pH7, 50 °C . A quantitative examination of the degradation is proposed for future 
work. 
 
 
 
 
Figure 4.37. Pyridinium C10 (433) at pH 2, concentration 2.5 mM, 25°C, t = 168 h. 
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Figure 4.38. Imidazolium C10 (436) at pH2, initial concentration 2.5 mM, 25°C, t = 168 h. 
 
 
Figure 4.39. Cholinium C10 (439) at pH2, initial concentration 2.5 mM, 25°C, t = 168 h. 
4.3.5.3 Base hydrolysis study, pH 10, 25 °C 
For the samples run at pH 10, higher levels of hydrolysis were observed after the 7 day period. 
The onset for alkaline hydrolysis was observed at t = 24 hours. Overall the ILs appear to be 
more susceptible to alkaline hydrolysis as can be seen from Figures 4.40-4.42. The 
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susceptibility of the amide and ester to hydrolysis also appears to occur more rapidly than that 
observed for acidic conditions. 
 
 
 
 
Figure 4.40. Pyridinium C10 (433) at pH 10, initial concentration 2.5 mM, 25°C, t = 24 h. 
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Figure 4.41. Imidazolium C10 (436) at pH 10, initial concentration 2.5 mM, 25°C, t = 24 h. 
 
 
Figure 4.42. Cholinium C10 (439) at pH10, initial concentration 2.5 mM, 25°C, t = 24 h. 
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4.4 Self-Aggregation and physico-chemical properties of bolaform L-
phenylalanine ILs (444-452). 
 
The aggregation properties of the bolaform L-phenylalanine IL surfactants (444-452) (Figure 
4.43), were determined by conductivity and tensiometry experiments. Results of these 
experiments are summarised in Tables 4.11 and 4.12 respectively.  
 
 
Figure 4.43. Bolaform ILs (444- 452) examined for their surfactant properties. 
4.4.1 Conductivity measurements 
As per section 4.3.1 the change in specific conductivity of the bolaform ILs in aqueous media 
with respect to concentration was measured. 
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Table 4.11. Results obtained by conductimetry for bolaform ILs (444-452). 
IL Headgroup 
Spacer 
Length 
CMC 
mM 
α β 
ΔGomic 
(kJ/mol) 
444 Pyridinium 8 2.00 0.68 0.32 -33.34 
445 Pyridinium  10 0.70 0.71 0.29 -15.62 
446 Pyridinium  12 0.20 0.31 0.69 -24.01 
447 Imidazolium 8 2.00 0.72 0.28 -32.35 
448 Imidazolium 10 0.75 0.77 0.23 -13.62 
449 Imidazolium 12 0.27 0.52 0.48 -20.00 
450 Cholinium 8 2.50 0.71 0.29 -31.89 
451 Cholinium  10 0.60 0.81 0.19 -14.67 
452 Cholinium  12 0.27 0.74 0.26 -17.06 
 
 
From the results shown in Table 4.11 it can be seen that the CMC values for the bolaform 
compounds decrease as the spacer length that joins each headgroup is increased in length. CMC 
values overall are approximately twice as low as their linear alkyl surfactant counterparts 
previously described in 4.3.1. This lower CMC was not expected and goes against the trends 
observed in the literature that suggest that a bolaform surfactant will have a CMC twice as large 
as that observed for a linear alkyl surfactant of the same carbon count (in the hydrophobic 
region). 
 
Counterion binding β is in general much lower than the values observed for the linear alkyl 
surfactants and there is a proportional increase in the degree of ionisation α. ΔGomic calculated 
was also generally lower ~20-30 kJ/mol than the linear alkyl surfactants and this represents a 
much less energetically favourable micellisation process occurring, most likely due to the 
repulsion forces present between the two cationic headgroups and other surfactant molecules in 
solution. The lowest ΔGomic observed were for the 8 carbon spacer bolaform surfactants. 
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Figure 4.44.  CMC as determined by conductimetry for C12 linked pyridinium bolaform (446). 
 
The C8 bolaform ILs (444, 447, 450) have a CMC ~half as large as their linear alkyl 
counterparts (432, 435, 438). For the C10 bolaform ILs (445, 448, 450) the trend continues. 
However when the C12 bolaform surfactants (446, 449, 452) are compared to their linear alkyl 
counterparts (434, 437, 440) a similar CMC is observed (0.20 mM-0.36 mM), Table 4.12. When 
compared to linear alkyl examples previously reported in the literature (and presented in Section 
4.3.1) the bolaform surfactants here with a C8 spacer have the equivalent CMC values as a C14-
C15 linear alkyl pyridinium surfactant.
10
 C10 spacer bolaform ILs are equivalent to ~C16 linear 
alkyl surfactants 
10
 and the C12 are equivalent to ~C18.
17
 As per the new linear alkyl amino acid 
surfactants reported in Section 4.3.1 the carbon count and lipophilicity of the phenylalanine 
sidechain must be accounted for. If the relationship presented by Rosen (previously discussed in 
section 4.3.1.)
3
 is applied then a C8 bolaform with two phenyl groups ((8 + (2 x 3.5)) would 
count as a ~15 carbon surfactant and indeed this is the relationship observed and can justify the 
CMC values that are lower than expected. 
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Table 4.12. Comparison of CMC for bolaform and linear alkyl ILs. 
Headgroup 
Linear 
Alkyl 
IL 
Chain 
Length 
CMC 
(mM) 
Bolaform 
IL 
Spacer 
Length 
CMC 
(mM) 
Pyridinium 432 8 4.00 444 8 2.00 
Pyridinium 433 10 1.30 445 10 0.70 
Pyridinium 434 12 0.20 446 12 0.20 
Imidazolium 435 8 3.70 447 8 2.00 
Imidazolium 436 10 1.70 448 10 0.75 
Imidazolium 437 12 0.22 449 12 0.27 
Cholinium 438 8 4.00 450 8 2.50 
Cholinium 439 10 1.50 451 10 0.60 
Cholinium 440 12 0.36 452 12 0.27 
 
4.4.2 Tensiometry measurements 
As per section 4.3.2 the surface tension properties were examined by tensiometry for the 
bolaform ILs synthesised. It was unknown before the surface tension was examined as to 
whether the carbon spacers chosen would be long enough to give a reasonable reduction in 
surface tension and whether the bolaform ILs would adopt a flat conformation at the air water 
interface, a wicket conformation, or would they just dissolve in the aqueous phase. Investigation 
into the surface activity of the bolaform ILs (444-452) provided typical surface tension plots 
such as that depicted in Figure 4.44. All of the surface tension plots are available in Appendix 
II. 
 
 
 
 
 
 
 
 
259 
 
 
 
 
 
 
Table 4.13. Tensiometry results obtained for bolaform ILs.  
IL Headgroup 
Spacer 
Length 
CMC 
(mM) 
γCMC 
(mN/m) 
C20 (mM) PC20 
Area per 
molecule 
 Å
2
 / nm
2
 
444 Pyridinium 8 2.00 29.08 8.50E-04 3.07 
81.50/ 
0.81 
445 Pyridinium  10 0.70 23.91 1.20E-04 3.92 
297.26/ 
2.97 
446 Pyridinium  12 0.60 25.34 7.20E-05 4.14 
286.80 / 
2.87 
447 Imidazolium 8 1.50 29.42 4.60E-04 3.34 
81.10/ 
0.81 
448 Imidazolium 10 0.75 23.90 1.10E-04 3.96 
216.90/ 
2.17 
449 Imidazolium 12 0.60 24.12 2.80E-04 3.55 
150.40/ 
1.50 
450 Cholinium 8 - - - - - 
451 Cholinium  10 2.75 33.98 4.97E-04 3.30 
118.95/ 
1.19 
452 Cholinium  12 0.40 23.79 2.60E-04 3.59 
166.83/ 
1.67 
 
From the results presented in Table 4.13, it can be seen that again a decrease in CMC is 
observed as the alkyl chain length increases, as expected. When it comes to the effectiveness, 
the γCMC is far worse than the linear alkyl derivatives. Where the pyridinium C8 linear alkyl 
derivative (432) was able to reduce the surface tension by ~41 mN/m, the bolaform C8 
pyridinium (444) was only able to reduce the surface tension by 29 mN/m. As the spacer length 
was increased from C8 to C10-C12 a large drop off in the effectiveness was also observed going 
generally from 30 to ~24-25 mN/m. Bolaform C8 cholinium derivative (450) did not display 
appreciable surface active properties and the tensiometry plot is depicted in Figure 4.46. 
Efficiency or PC20 for the bolaform surfactants was lower than the linear alkyl derivatives; C8 
bolaform ILs all had calculated PC20 of ~3-3.30 whereas a linear alkyl C8 had 3.59-3.96. As the 
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bolaform spacer was increased the efficiency was seen to increase to ~4. On comparison, the C12 
linear alkyl amino acid surfactants all reached an efficiency rating of ~5. 
 
The area per molecule for the bolaform surfactants generally exceeds that observed for the 
linear alkyl examples. This is due to the orientation of the bolaform surfactant at the air water 
interface. For the C10 bolaform compoudns, large values suggest that the surfactant is lying flat 
across the surface, but when the spacer length is increased to 12, the chain is pushed into the air 
to a certain degree, lowering the surface area that the surfactant occupies. Much smaller values 
are observed for the C8 linked bolaform surfactants. Values of 0.81 nm
2
 are observed and 
suggest a completely different orientation of the C8 surfactants (similar to that of the linear alkyl 
derivatives) than that observed for the C10 and C12 examples.   
 
Figure 4.45. Tensiometry curve for C8 pyridinium bolaform (444). 
Figure 4.45 depicts a typical tensiometry curve for the bolaform surfactant (444). Of note is the 
much lower effectiveness in reducing the surface tension. At the far left of the plot, at 
concentrations in the 0.1 mM range, the tensiometry plot shows a plateau. This plateau 
represents the area where the concentration is too low to reduce the surface tension. The surface 
tension of pure water has a literature value of 71.99 mN/m at 25 °C 
30
, however the plateau area 
of the tensiometry curve begins below 71.99 mN/m at ~60 mN/m. There are a number of 
possible reasons for this. The first is that the water used was not pure. This can be ruled out due 
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to the water being tested for surface tension properties before samples were made. The second is 
that minute amounts of lipophilic impurities present in the surfactant sample are known to 
reduce the initial surface tension of the water.
31
 This reason is more likely, even though the 
surfactants were triturated multiple times during their synthesis and HPLC/UV analysis showed 
≥98% purity, 1-2% trace impurities can be enough to lower the initial surface tension, even in 
micro-molar concentrations.
31
  
 
Figure 4.46. Surface tension plot of C8 cholinium bolaform (450). 
As previously discussed in Chapter 3, Section 3.4.2, bolaform surfactants can adopt a number of 
different conformations at an air-water interface. From the plot of C8 cholinium bolaform (450) 
it can be seen that very little reduction in surface tension was observed, even at higher 
concentrations (1-10 mM). It can be inferred from this result that the C8 cholinium bolaform 
surfactant does not behave in the same way as their imidazolium and pyridinium counterparts. 
The reason for this may be attributed to the increased polarity of the cholinium headgroup due 
to the presence of a quaternary nitrogen and a primary alcohol. As the spacer length is increased 
for the cholinium bolaform series it can be observed that the C10 (451) and C12 (452) begin to 
show surface activity. The C10 cholinium derivatives CMC is still higher than the C8 pyridinium 
(444) and C8 imidazolium (447)  bolaform surfactants. If further investigations were to be 
conducted into this surfactant class the first modification attempted should be increasing the 
spacer lengths considerably to observe the effect on CMC.  
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Table 4.14. Comparison of CMC results by tensiometry and conductimetry. 
IL Headgroup CMC Conductivity (mM) CMC Tensiometry (mM) 
444 Pyridinium 2.00 2.00 
445 Pyridinium  0.70 0.70 
446 Pyridinium  0.20 0.60 
447 Imidazolium 2.00 1.50 
448 Imidazolium 0.75 0.75 
449 Imidazolium 0.27 0.60 
450 Cholinium 2.50 - 
451 Cholinium  0.60 2.75 
452 Cholinium  0.27 0.40 
 
The comparison of CMC by conductimetry and tensiometry (Table 4.14) helps to confirm the 
accuracy of the CMC determination. Very little difference is observed between the experimental 
values for conductimetry and tensiometry. 
4.4.3 HPLC Models 
The purity of all of the surfactants, as per section 4.3.3, was determined by HPLC/UV to ensure 
>98% purity of all surfactants. 
 
An example HPLC/UV trace (Figure 4.47 and Table 4.15), showed that bolaform IL (444) 
synthesised had a greater than >98% purity. HPLC/UV analysis was carried out for all bolaform 
ILs. As per section 4.3.3 it was also possible to construct a model based on retention time and 
CMC 
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Figure 4.47. HPLC/UV trace for IL C8 pyridinium bolaform (444). 
 
Retention Time 
Minutes 
Area Area % Height Height % 
9.12 336365765 99,30 5164733 97,81 
13.17 2368078 0,70 115793 2,19 
Table 4.15. HPLC/UV retention time results. 
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Figure 4.48. Retention time vs CMC for bolaform surfactants (444-452) examined by 
conductivity. 
There is a good correlation between retention time and CMC with just one of the cholinium 
points lying below the line by >1 minute of retention time (Figure 4.48). If bolaform surfactants 
with longer spacers were synthesised then HPLC/UV retention time could provide an estimate 
of their CMC. 
 
 
Figure 4.49. No of Carbon atoms in the linear alkyl chain vs CMC (conductivity). 
Figure 4.49 shows a good correlation between carbon spacer length and CMC as expected. 
From these models an estimate, in conjunction with the equation             previously 
described in section 4.3.1, can give a reasonable indication of CMC. As per section 4.3.3, new A 
and B values can be determined from the equations of the lines (Figure 4.49). 
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Pyridinium bolaform: y = -1.733ln(x) + 9.2648 → log(x) = 2.322 - 0.251(y). A = 2.322, B = -
0.251 
Imidazolium bolaform: y = -1.997ln(x) + 9.3983 → log(x) = 2.044 – 0.217 (y). A = 2.044, B = 
0.217 
Cholinium bolaform: y = -1.751ln(x) + 9.4725 → log(x) = 2.337 – 0.248 (y). A = 2.337, B = 
0.248 
 
From the calculated A and B values, a reasonable model of further bolaform surfactants of these 
classes may be constructed. However, caution must be exercised as the structural conformation 
that the bolaform surfactants assume is uncertain and can lead to varying values and properties. 
The predicted values are outlined in Table 4.16. As can be seen, a good agreement between 
predicted values and actual CMC is observed. Predicted CMC values for C6, C14 and C16 spaced 
bolaform surfactants (472-480) have also been included (Figure 4.50). 
 
 
 
Figure 4.50. Bolaform ILs with C6, C14 and C16 spacers. 
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Table 4.16. Calculated CMC and actual CMC values for bolaform surfactant ILs. 
IL Headgroup Spacer Length 
Predicted CMC 
(mM)* 
CMC (mM) 
(conductimetry) 
472 Pyridinium 6 6.55 - 
444 Pyridinium 8 2.06 2.00 
445 Pyridinium 10 0.65 0.70 
446 Pyridinium 12 0.20 0.20 
473 Pyridinium 14 0.06 - 
474 Pyridinium 16 0.02 - 
475 Imidazolium 6 5.52 - 
447 Imidazolium 8 2.03 2.00 
448 Imidazolium 10 0.75 0.75 
449 Imidazolium 12 0.28 0.27 
476 Imidazolium 14 0.10 - 
477 Imidazolium 16 0.04 - 
478 Cholinium 6 7.06 - 
450 Cholinium 8 2.25 2.50 
451 Cholinium 10 0.72 0.60 
452 Cholinium 12 0.23 0.27 
479 Cholinium 14 0.07 - 
480 Cholinium 16 0.02 - 
*Calculated using log(CMC) = A - Bn 
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4.5 Conclusion 
In conclusion two series of novel amino acid ionic liquid surfactants have been synthesised and 
a number of their surfactant properties have been characterised including CMC by conductivity 
and tensiometry, surface active properties by tensiometry including efficiency and effectiveness, 
aqueous stability in neutral, alkaline and basic media, and liquid crystal behaviour by optical 
microscopy. Addition of an amino acid linker containing a lipophilic side chain has 
demonstrated that the linker (L-phenylalanine) can contribute to the self-assembling properties, 
contributing lipophilicity to the micelle. In effect, the C8 linear alkyl IL surfactants have an 
equivalent CMC to that of a surfactant 3-4 carbon atoms longer, as do C10 and C12. 
 
The effectiveness (in the ability to reduce surface tension) of the linear alkyl surfactants 
reported in this chapter is greater than that observed for linear alky surfactants found in the 
literature (even linear alkyl surfactants with ≥4 more carbon atoms). Effectiveness appears to be 
greatest for the C8 linear alkyl amino acid surfactants and decreases for the C10-12. Efficiency of 
the linear alkyl surfactants reported are around twice that of similar linear alkyl surfactants. 
Area per molecule calculations for the linear alkyl surfactants showed a range of surface areas 
(1.05-1.55 nm
2
). A surface area of this size, when compared to analogous examples in the 
literature (~0.5 nm
2
) can be attributed to the bulk of the amino acid sidechain.  Construction of 
HPLC retention time models will allow for rapid prediction of CMC of future generations of 
surfactants based upon the classes reported within this chapter. Adjusted A and B values for use 
in the Stauff-Klevens equation will allow for predicting CMC values of potential future 
surfactants with a reasonable degree of accuracy. It is proposed, in conjunction with the 
antimicrobial and biodegradation results in Chapter 3, that the following range of intermediate 
chain length ILs are synthesised to investigate just how short the chain length can be lowered 
before micellisation and surface activity ceases to occur (Figure 4.51). 
 
 
Figure 4.51. Intermediate length C4 and C6 linear alkyl ILs. 
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Optical microscopy studies showed a wide range of liquid crystal behaviour for the surfactant 
ILs examined. A multitude of structures were observed over a wide range of temperatures (20-
100 °C). Amongst the liquid crystals observed were hexagonal phase, lamellar phase and cubic 
phase. The study was qualitative in nature and could be further developed in the future by way 
of a quantitative study to produce phase diagrams for the surfactants of interest. 
 
Aqueous, acid and alkaline hydrolysis experiments conducted on a number of surfactants gave 
an insight into the stability of the linear alkyl ILs examined. It can be observed from the 
preliminary study that the cholinium and imidazolium ILs (436, 439) undergo hydrolysis at pH 
7, 50 °C but the pyridinium IL (433) could potentially be more stable.  Rapid onset of 
degradation was not observed for any of the three ILs at pH 2, 25 °C. Rapid base mediated 
hydrolysis is observed for the three ILs examined (433, 436, 439). A quantitative examination 
of the ILs stability will be of future importance for application considerations. 
 
The bolaform ILs assessed showed CMC values that were generally lower than their linear alkyl 
counterparts. This observation was unexpected due to the general trend presented by Rosen et 
al. which suggests that bolaform surfactants must have 2x the number of carbon atoms to reach 
a similar CMC as that of linear alkyl surfactants.
3
 One possible reason for this may be due to the 
reduced surface activity of the bolaform surfactants; there are more free molecules in solution 
forcing the formation of micelles at lower concentrations as the surface is not as saturated as 
that which is present in linear alkyl surfactants – even though the ΔGomic is lower. Another 
possible explanation is the presence of an additional amino acid in the bolaform ILs. A C8 
bolaform IL with two L-phenylalanine moieties present has ~+3.5 extra theoretical carbon atoms 
for each phenyl sidechain in the hydrophobic region, than that of a C8 linear alky surfactant. 
 
When the surface activity was examined for the bolaform surfactants  a lower efficiency and 
lower effective range - than that which was observed for the linear alkyl surfactants - was 
observed. As per the linear alkyl surfactants, A and B values were calculated for the bolaform 
surfactants to provide insight into estimating the CMC of potential future bolaform surfactants 
of this type. The bolaform class of surfactants represents a niche class of surface active agents 
and may be of interest for biological and medicinal applications due to their similarities to 
biological membranes.
32
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Chapter 5 
Experimental 
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5.1 Experimental 
5.1.1 Chemicals 
All chemicals used in Chapters 2-3 were purchased from Sigma Aldrich or TCI Europe. 
Methanol and ethanol were distilled over magnesium turnings activated by iodine before use. 
DCM and ethyl acetate were pre-dried over magnesium sulphate and then distilled over CaH2 
before use. THF and diethyl ether were dried over sodium wire and benzophenone and distilled 
before use. DMF used was purchased from Sigma Aldrich as an anhydrous sureseal preparation. 
Sigma Aldrich (Riedel de Haën) 220-440 mesh, 60 Å pore size, 35-75 µm particle size, silica 
gel was used for flash and thin layer chromatography. 
5.1.2 NMR 
The majority of NMR analysis was performed on a Bruker AC 400 MHz spectrometer operating 
at 400 MHz for 
1
H-NMR and 100 MHz for 
13
C-NMR. Samples were run in deuterated 
chloroform (CDCl3), deuterated water (D2O), deuterated methanol (MeOD), or deuterated 
dimethyl sulfoxide (DMSO) where appropriate. A 600 MHz Bruker spectrometer, operating at 
600 MHz for 
1
H-NMR and 150 MHz for 
13
C-NMR was also used for analysis of some 
examples. All chemical shifts are reported in parts per million (ppm) are relative to the internal 
standard TMS and coupling constants (J) are measured in Hertz (Hz). Multiplicity is stated as 
follows: s-singlet, d-doublet, t-triplet, q-quartet, dd-doublet of doublets, dt doublet of triplets, 
dq-doublet of quartets, tt-triplet of triplets, tq-triplet of quartets, ddd-doublet of doublet of 
doublets, m-multiplet, bs-broad singlet. 
5.1.3 IR analysis 
All IR analysis was carried out on a Perkin Elmer 100 FT-IR spectrometer with ATR. The 
strength of reported peaks are described as weak (w), medium (m), broad (b), strong (s) and 
very strong (vs). 
5.1.4 Melting point 
Melting points were determined using a Lennox automated melting point apparatus and the 
values are expressed in degrees Celsius (°C). The parameters for the melting point analysis were 
set at 5 °C per minute ramp and melting point was determined manually. Melting points are 
uncorrected. 
5.1.5 Optical Rotation 
Optical rotations were measured using a Perkin Elmer 343 Polarimeter in chloroform, methanol 
or ethanol at 20 °C and values are expressed in degrees 
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5.1.6 ESI-MS 
High resolution mass spectrometry (HRMS) with accurate mass measurement to four decimal 
places was obtained for new ILs, new tertiary amines and new alkylating regents described in 
Chapters 2-3. The analysis was conducted in the ABCRF Mass Spectrometry Lab, Cavanagh 
Building, in University College Cork. Accurate mass measurement was obtained using a Waters 
Micromass LCT Premier run in ESI+ mode. An external reference standard of leucine 
encephalin was used in order to confirm mass accuracy and a sulfadimethoxine concentration 
test was performed to ensure the accuracy of peaks in the ion count range of 1x10
3
 – 1x106. 
5.2 Experimental preparation of Chapter 2 L-phenylalanine ILs 
5.2.1 Preparation of L-phenylalanine ethyl ester (336) - general procedure “A” 
 
To a stirred suspension of ethanol (86 ml, 1.5 mol) and L-phenylalanine (25.00 
g, 151.3 mmol) at 0 °C was added dropwise SOCl2 (26.3 ml, 303 mmol). The 
solution was allowed to warm to room temperature then heated under reflux 
conditions for 12 hours. Solubilisation of the reaction mixture was observed 
after 30 minutes reflux. After 12 hours the reaction mixture was allowed to cool to room 
temperature and a stream of nitrogen was bubbled through it for 30 minutes. After 30 minutes, 
ethanol was removed in vacuo to furnish the product as a hydrochloride salt in 99% yield. The 
salt product could then be retained for long term storage or neutralised as follows for immediate 
use. The salt product was dissolved in deionised water (50 ml) in a 1 litre separating funnel and 
a saturated aqueous bicarbonate solution was added slowly (50 ml). Neutralisation of the 
solution was accomplished and the free base amino acid ester was extracted using ethyl acetate 
(5 x 50 ml). The organic layer was washed with brine (3 x 50 ml) and dried over anhydrous 
magnesium sulphate followed by gravity filtration. Ethyl acetate was removed in vacuo to yield 
the title compound (336) as a pale yellow oil in 99% yield, (28.89 g, 149.5 mmol). 
 
Molecular formula: C11H15NO2; Molecular weight: 193.246 gmol
-1
. 
 
1
H-NMR (400 MHz, CDCl3) δ (ppm): 7.35 (m, 5H), 4.19 (q, J = 7.1 Hz, 2H), 3.74 (dd, J = 7.9, 
5.3 Hz, 1H), 3.10 (dd, J = 13.5, 5.3 Hz, 1H), 2.89 (dd, J = 13.5, 7.9 Hz, 1H), 1.27 (t, J = 7.1 Hz, 
3H). 
13
C-NMR (100 MHz, CDCl3) δ (ppm): 175.07, 137.31, 129.34, 128.55, 126.82, 60.95, 
55.88, 41.16, 14.22 
 
1
H-NMR and 
13
C-NMR were in agreement with the literature.
1
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5.2.2 Preparation of L-phenylalanine ethyl ester α-bromoamide alkylating reagent (337) 
- general procedure “B” 
 
To a stirred solution of L-phenylalanine ethyl ester (336) (6.23 g, 32.2 
mmol) in DCM (50 ml) was added solid Na2CO3 (5.13 g, 48.4 mmol) 
and dropwise, bromoacetyl bromide (3.4 ml, 39 mmol). The reaction 
mixture was allowed to cool to room temperature and stirred for 5 hours. 
After 5 hours the Na2CO3 was removed by gravity filtration. The DCM layer was washed with 
saturated sodium bicarbonate solution (3 x 50 ml), dried over anhydrous magnesium sulphate 
and gravity filtered. The DCM was removed in vacuo to afford the title compound as a white 
solid in 89% yield, (0.998 g, 28.6 mmol). 
 
Molecular formula: C13H16BrNO3; Molecular weight: 314.179 gmol
-1
. 
 
1
H-NMR (400 MHz, CDCl3) δ (ppm): 7.32 – 7.27 (m, 3H), 7.14-7.12 (m, 2H), 6.86 (d, J = 6.8 
Hz, 1H), 4.70 (dt, J = 7.8, 5.8Hz, 1H), 4.25 (q, J = 7.1 Hz, 2H), 3.86 (d, J = 13.7 Hz, 1H), 3.83 
(d, J = 13.6 Hz, 1H), 3.17 (dd, J = 14.0, 5.8 Hz, 1H), 3.13 (dd, J = 14.0, 5.8 Hz, 1H), 1.25 (t, J = 
7.1 Hz, 3H) 
13
C-NMR (100 MHz, CDCl3) δ (ppm): 170.87, 165.15, 135.42, 129.37, 128.64, 
127.30, 61.78, 53.76, 37.76, 28.71, 14.13 
1
H-NMR and 
13
C-NMR were in agreement with the literature.
2
 
5.2.3 Preparation of IL (324) - general procedure “C” 
3-({[(2S)-1-Ethoxy-1-oxo-3-phenylpropan-2-yl]carbamoyl}methyl)-1-methyl-1H-imidazol-3-
ium bromide (324). 
To a stirred solution of L-phenylalanine ethyl ester α-bromoamide 
(337) (0.607 g, 1.93 mmol) in diethyl ether (10 ml) was added 1-
methylimidazole (140 µl, 1.76 mmol). The reaction was stirred at 
room temperature under an N2 atmosphere for 24 hours. After 24 
hours a waxy precipitate had formed. The supernatant was 
decanted and the waxy crude product was washed with diethyl ether (3 x 25 ml) to afford the 
title compound (324) as a white solid in 89% yield, (0.622 g, 1.57 mmol). 
 
Molecular formula: C17H22BrN3O3; Molecular weight: 396.285 gmol
-1
;
 
Mp: 77-79° C. 
 
[α]D
20 
= +7.49 (0.4 c, CHCl3); 
1
H-NMR (400 MHz, CDCl3) δ (ppm): 9.80 (s, 1H), 8.89 (d, J = 
7.6 Hz, 1H), 7.42 (t, J = 1.6, 1H), 7.34 (t, J = 1.6, 1H), 7.32 – 7.11 (m, 5H), 5.37 (d, J = 15.2, 
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1H), 5.31 (d, J = 14.8, 1H), 4.67 (ddd, J = 8.6, 7.8, 6.0 Hz, 1H), 4.11 (q, J = 7.2 Hz, 2H), 3.98 
(s, 3H), 3.23 (dd, J = 14.0, 6.0 Hz, 1H), 3.17 (dd, J = 14.0, 8.8 Hz, 1H) 1.18 (t, J = 7.2 Hz, 3H).
 
13
C-NMR (100 MHz, CDCl3) δ (ppm): 171.16, 164.77, 137.75, 136.69, 129.53, 128.40, 126.78, 
123.65, 122.48, 61.47, 54.83, 51.58, 37.41, 36.77, 14.05. IR (neat) (cm
-1
): 3202 (w), 3027 (w), 
1732 (s), 1676 (vs), 1527 (m), 1373 (m), 1261 (m), 1218 (vs), 1178 (vs), 1107 (s), 767 (m), 749 
(m). ESI-MS (+ve) m/z: Found [M–Br–]+ 316.1657, C17H22N3O3
+
 requires 316.1656. 
1
H-NMR and 
13
C-NMR were in agreement with the literature.
2
 
5.2.4 Preparation of IL (325) 
(S)-1-(2-((1-Ethoxy-1-oxo-3-phenylpropan-2-yl)amino)-2-oxoethyl)pyridin-1-ium bromide 
(325). 
According to the general procedure “C”, using L-phenylalanine ethyl 
ester α-bromoamide (337) (0.581 g, 1.85 mmol) and pyridine (135 
µl, 1.68 mmol), the title compound (325) was isolated as a white 
solid in 98% yield, (0.643 g, 1.64 mmol). 
 
Molecular formula: C18H21BrN2O3; Molecular weight: 393.281 gmol
-1
; Mp: 98-100°C. 
 
[α]D
20 
= +2.26 (0.4 c, CHCl3);
 1
H-NMR (400 MHz, CDCl3) δ (ppm): 9.36 (d, J = 7.6 Hz, 1H), 
9.22 (d, J = 4.8 Hz, 2H), 8.41 (t, J = 8.0 Hz, 1H), 7.96 (t, J = 7.6 Hz, 2H), 7.37-7.25 (m, 2H), 
7.24-7.14 (m, 3H), 6.04 (d, J = 14.4 Hz, 1H), 5.98 (d, J = 14.8 Hz, 1H), 4.70-4.65 (m, 1H), 
4.12-4.06 (m, 2H), 3.25 (dd, J = 14.0, 8.2 Hz, 1H), 3.18 (dd, J = 14.0, 8.0 Hz 1H), 1.17 (t, J = 
7.2 Hz, 3H).
 13
C-NMR (100 MHz, CDCl3): δ 170.95, 163.97, 146.06, 145.31, 136.61, 129.61, 
128.43, 127.63, 126.80, 62.12, 61.55, 54.95, 37.53, 14.07. IR (neat) (cm
-1
): 3184 (w), 3042 (w), 
1736 (vs), 1686 (vs), 1632 (m), 1560 (s), 1484 (s), 1368 (s), 1264 (s), 1188 (vs). ESI-MS (+ve) 
m/z: Found [M–Br–]+ 313.1543, C18H21N2O3
+
 requires 313.1547. 
5.2.5 Preparation of IL (326) 
 (S)-1-(2-((1-Ethoxy-1-oxo-3-phenylpropan-2-yl)amino)-2-oxoethyl)-3-methoxypyridin-1-ium 
bromide (326). 
 According to the general procedure “C”, using L-phenylalanine 
ethyl ester α-bromoamide (337) (1.046 g, 3.329 mmol) and 3-
methoxypyridine (320 µl, 3.18 mmol), the title compound (326) 
was isolated as a white, hygroscopic solid in 96% yield, (1.295 
g, 3.059 mmol). 
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Molecular formula: C19H23BrN2O4; Molecular weight: 423.307 gmol
-1
; Mp: 72-74°C. 
[α]D
20 
= -7.2 (2.0 c, CHCl3); 
1
H-NMR (400 MHz, CDCl3) δ (ppm): 9.39 (d, J = 7.8 Hz, 1H), 
9.32 (d, J = 1.1 Hz, 1H), 8.54 (d, J = 5.8 Hz, 1H), 7.87-7.85 (ddd, 9.0, 2.4, 0.8 Hz, 1H), 7.77 
(dd, J = 8.8, 5.8 Hz, 1H), 7.35-7.33 (m, 2H), 7.23-7.12 (m, 3H), 5.94 (d, J = 14.1 Hz, 1H) 5.88 
(d, J = 14.1 Hz, 1H), 4.66 (ddd, J = 8.9 ,8.1, 5.9 Hz, 1H), 4.10 (s, 3H), 4.09-4.03 (m, 2H), 3.24 
(dd, J = 13.9, 5.8 Hz, 1H), 3.17 (dd, J = 13.8, 8.0 Hz, 1H), 1.16 (t, J = 7.2, 3H). 
13
C-NMR (100 
MHz, CDCl3) δ (ppm): 170.83, 163.93, 158.38, 138.15, 136.66, 132.40, 131.99, 129.56, 128.36, 
127.58, 126.75, 62.23, 61.51, 58.29, 54.91, 37.40, 14.07. IR (neat) (cm
-1
): 3187 (w), 3028 (w), 
1736 (s), 1683 (vs), 1507 (vs), 1294 (vs), 1198 (b). ESI-MS (+ve) m/z: Found [M–Br–]+ 
343.1649, C19H23N2O4
+
 requires 343.1652 
5.2.6 Preparation of IL (327) 
(S)-1-(2-((1-Ethoxy-1-oxo-3-phenylpropan-2-yl)amino)-2-oxoethyl)-3-(ethoxycarbonyl)pyridin-
1-ium bromide (327). 
To a stirred solution of L-phenylalanine ethyl ester α-
bromoamide (337) (0.507 g, 1.61 mmol) in THF (25 ml) 
was added ethyl nicotinate (200 µl, 1.46 mmol). The 
reaction was stirred under reflux conditions for 24 hours. 
After 24 hours the THF was removed in vacuo to afford a brown crude product. The crude 
product was purified by silica gel chromatography (gradient elution of 5:95 MeOH:DCM to 
10:90 MeOH:DCM) to afford the title compound (327) as an orange solid in 56% yield, (0.381 
g, 0.819 mmol). 
 
Molecular formula: C21H25BrN2O5; Molecular weight: 465.344 gmol
-1
; Mp: 60-62°C. 
 
[α]D
20 
= + 1.4 (2.0 c, CHCl3); 
1
H-NMR (400 MHz, CDCl3) δ (ppm): 9.71 (d, J = 6.0Hz, 1H), 
9.37 (m, 2H), 8.93-8.90 (m, 1H), 8.10 (dd, J = 8.0, 6.4 Hz, 1H), 7.37-7.35 (m, 2H), 7.25-7.22 
(m, 2H), 7.17-7.13 (m, 1H), 6.26 (d, J = 15.2 Hz, 1H), 6.19 (d, J = 15.2 Hz, 1H), 4.72-4.67 (m, 
1H), 4.48 (q, J = 7.2 Hz, 2H), 4.11-4.05 (m, 2H), 3.25-3.14 (m, 2H), 1.44 (t, J = 7.2 Hz, 3H), 
1.15 (t, J = 7.1 Hz, 3H). 
13
C-NMR (100 MHz, CDCl3) δ (ppm): 171.00, 163.80, 160.96, 149.75, 
146.96, 145.36, 136.74, 130.41, 129.72, 128.49, 127.73, 126.87, 63.63, 62.88, 61.59, 55.14, 
37.73, 14.28, 14.14. IR (neat) (cm
-1
): 3180 (w), 3027 (w), 1730 (vs), 1683 (vs), 1296 (vs), 1188 
(b), 1110 (m), 1014 (s). ESI-MS (+ve) m/z: Found [M–Br–]+ 385.1755, C20H26N3O3
+
 requires 
385.1758 
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5.2.7 Preparation of IL (328) 
(S)-4-(Dimethylamino)-1-(2-((1-ethoxy-1-oxo-3-phenylpropan-2-yl)amino)-2-oxoethyl)pyridin-
1-ium bromide (328). 
According to the general procedure “C”, using L-phenylalanine 
ethyl ester α-bromoamide (337) (0.446 g, 1.42 mmol) and 
dimethylaminopyridine (0.158 g, 1.29 mmol), the title 
compound (328) was isolated as a white solid in 88% yield, 
(0.498 g, 1.14 mmol). 
 
Molecular formula: C20H26BrN3O3; Molecular weight: 436.350 gmol
-1
; Mp: 135-137°C. 
 
[α]D
20 
= -13.2 (2.0 c, CHCl3). 
1
H-NMR (400 MHz, CDCl3) δ (ppm): 9.26 (d, J = 7.2 Hz, 1H), 
8.36 (d, J = 7.8 Hz, 2H), 7.35-7.33 (m, 2H), 7.21-7.19 (m, 2H), 7.15-7.11 (m, 1H), 6.73 (d, J = 
7.8, 2H), 5.38 (d, J = 14.6, 1H), 5.31 (d, J = 14.6 Hz, 1H), 4.58 (dd, J = 14.9, 7.4 Hz, 1H), 4.06 
(q, J = 6.8 Hz, 2H), 3.22 (s, 6H), 3.21-3.19 (m, 2H), 1.13 (t, J = 7.1 Hz, 3H). 
13
C-NMR (100 
MHz, CDCl3) δ (ppm): 170.70, 165.33, 156.37, 143.17, 136.86, 129.62, 128.35, 126.62, 107.43, 
61.33, 58.62, 55.12, 40.43, 37.30, 14.09. IR (neat) (cm
-1
): 3165 (w), 3012 (w), 1743 (s), 1678 
(vs), 1651 (vs), 1574 (m), 1404 (w), 1181 (b), 1024 (w), 818 (s). ESI-MS (+ve) m/z: Found [M–
Br
–
]
+ 
356.1969, C20H26N3O3
+
 requires 356.1969. 
5.2.8 Preparation of IL (329) 
(S)-4-(2-((1-Ethoxy-1-oxo-3-phenylpropan-2-yl)amino)-2-oxoethyl)-4-methylmorpholin-4-ium 
bromide (329). 
According to the general procedure “C”, using L-phenylalanine ethyl 
ester α-bromoamide (337) (1.165 g, 3.708 mmol) and N-
methylmorpholine (370 µL, 3.37 mmol), the title compound (329) 
was isolated as a white solid in 34% yield, (0.482 g, 1.16 mmol). 
 
Molecular formula: C18H27BrN2O4; Molecular weight: 415.328 gmol
-1
 Mp: 162-164°C. 
[α]D
20 
= -22.71 (0.5 c, CHCl3). 
1
H-NMR (400 MHz, CDCl3) δ (ppm): 9.40 (d, J = 8.0 Hz, 1H), 
7.43-7.41 (m, 2H), 7.29-7.26 (m, 2H), 7.20-7.17 (m, 1H), 5.06 (d, J = 13.8 Hz, 1H), 4.79 (d, J = 
14.1 Hz, 1H), 4.76-4.72 (m, 1H), 4.15 (q, J = 7.2 Hz, 2H), 4.08-4.03 (m, 2H), 3.91 (d, J = 10.2 
Hz, 2H), 3.85-3.75 (m, 1H), 3.57 – 3.49 (m, 1H), 3.47 (s, 3H), 3.36-3.33 (m, 1H), 3.33 (dd, J = 
14.0, 4.6 Hz, 1H), 3.11 (dd, J = 14.1, 10.8 Hz, 1H), 1.24 (t, J = 7.2 Hz, 3H). 
13
C-NMR (100 
MHz, CDCl3) δ (ppm): 170.80, 162.78, 136.73, 129.62, 128.44, 126.82, 61.67, 61.30, 60.57, 
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60.50, 54.43, 51.40, 37.03, 14.12. IR (neat) (cm
-1
): 3186 (w), 3019 (w), 1735 (s), 1674 (vs), 
1534 (s), 1456 (w), 1247 (b), 1120 (m), 1029 (m), 897 (m). ESI-MS (+ve) m/z: Found [M–Br–]+ 
335.1963, C18H27N2O4
+
 requires 335.1965. 
5.2.9  Preparation of IL (330) 
(S)-2-((1-Ethoxy-1-oxo-3-phenylpropan-2-yl)amino)-N-(2-hydroxyethyl)-N,N-dimethyl-2-
oxoethan-1-aminium bromide (330). 
 
According to the general procedure “C”,  using L-phenylalanine 
ethyl ester α-bromoamide (337) (0.594 g, 1.89 mmol) and 
dimethylaminoethanol (175 µl, 1.70 mmol), the title compound 
(330) was isolated as a white solid in 99% yield, (0.682 g, 1.69 
mmol). 
 
Molecular formula: C17H27BrN2O4; Molecular weight: 403.317 gmol
-1
; Mp: 97-99 °C. 
 
[α]D
20 
= -45.24 (0.4 c, CHCl3). 
1
H-NMR (400 MHz, CDCl3) δ (ppm): 9.01 (d, J = 7.6 Hz, 1H), 
7.40-7.38 (m, 2H), 7.30-7.20 (m, 3H), 4.80 (d, J = 14 Hz, 1H), 4.74 (ddd, J = 10.3, 7.9, 4.8 Hz, 
1H), 4.67 (t, J = 5.2 Hz, 1H), 4.43 (d, J = 14 Hz, 1H), 4.16 (q, J = 7.2 Hz, 2H), 4.12-4.08 (m, 
2H), 3.65 (ddd, J = 13.5, 6.2, 2.5 Hz, 1H), 3.56 (ddd, J = 13.7, 6.8, 2.8 Hz, 1H), 3.36 (s, 3H), 
3.29 (s, 3H), 3.29 (dd, J = 13.6 Hz, 5.1 Hz, 1H), 3.11 (dd, J = 14.0, 10.3 Hz, 1H), 1.24 (t, J = 
7.2 Hz, 3H). 
13
C-NMR (100 MHz, CDCl3) δ (ppm): 171.01, 163.08, 136.47, 129.52, 128.55, 
127.01, 67.47, 63.29, 61.73, 55.86, 54.42, 53.40, 37.21, 14.11. IR (neat) (cm
-1
): 3345 (m), 3207 
(m), 3056 (w), 1741 (s), 1686 (vs), 1547 (s), 1281 (s), 1210 (s) 1177 (s), 1079 (m). ESI-MS 
(+ve) m/z: Found [M–Br–]+ 323.1959, C17H27N2O4
+
 requires 323.1965. 
 
5.2.10 Preparation of IL (331) 
1,3-Bis(2-(((S)-1-ethoxy-1-oxo-3-phenylpropan-2-yl)amino)-2-oxoethyl)-1H-imidazol-3-ium 
bromide (331). 
To a stirred solution of L-phenylalanine ethyl ester α-
bromoamide (337) (3.260 g, 10.38 mmol) in diethyl 
ether (25 ml) was added TMS-imidazole (0.715 g, 
5.10 mmol). The reaction was stirred at room 
temperature under an N2 atmosphere for 24 hours. 
After 24 hours a white precipitate of TMS-imidazolium ionic liquid had formed. The diethyl 
278 
 
 
ether was removed in vacuo and the white precipitate was rapidly dissolved in ethyl acetate (25 
ml). The reaction mixture was then heated under reflux for 24 hours. After 24 hours the reaction 
was cooled to room temperature and the solvent removed in vacuo. The resulting white solid 
was washed with diethyl ether (3 x 50 ml). Further drying under high vacuum afforded the title 
compound (331) as a white solid in 91% yield, (2.857 g, 4.641 mmol). 
 
Molecular formula: C29H35BrN4O6; Molecular weight: 615.525 gmol
-1
; Mp: 102-104°C. 
 
[α]D
20 
= +8.20 (1.0 c, CHCl3). 
1
H-NMR (400 MHz, CDCl3) δ (ppm): 9.36 (s, 1H), 8.65 (d, J = 
7.72 Hz, 2H), 7.30-7.17 (m, 12H), 5.28 (d, J = 15.6 Hz, 2H), 5.05 (d, J = 15.6, 2H), 4.71-4.66 
(m, 2H), 4.06 (q, J = 7.2 Hz, 4H), 3.20 (dd, J = 13.8, 6.0 Hz, 2H), 3.14 (dd, J = 13.9, 8.6 Hz, 
2H), 1.16 (t, J = 7.2 Hz, 6H). 
13
C-NMR (100 MHz, CDCl3) δ (ppm): 171.31, 164.50, 137.63, 
129.46, 128.46, 126.91, 122.79, 61.61, 54.72, 51.51, 37.43, 14.01. IR (neat) (cm
-1
): 3336 (w), 
3092 (w), 3047 (w), 2988 (w), 2951 (w), 2899 (w), 1732 (vs), 1663 (vs), 1537 (m), 1198 (s), 
747 (m), 701 (m). ESI-MS (+ve) m/z: Found [M–Br–]+ 535.2555, C29H35N4O6
+
 requires 
535.2551. 
5.2.11 Preparation of L-prolinium ILs (332-333) and their intermediates (340, 341) 
5.2.11.1 Preparation of N-methyl-L-proline (340) – General Procedure “D” 
 
 To a stirred solution of L-proline (2.086 g, 18.12 mmol) in methanol (20 ml) was 
added 40% v/v formaldehyde solution (aq.) 2.2 ml, 22 mmol). The solution was 
stirred for 30 minutes before 10% Pd/C was added (0.316 g, 2.80 mol%). The 
reaction was stirred vigorously under a H2 atmosphere for 48 hours. After 48 hours 
determination of reaction completion was accomplished by 
1
H-NMR in D2O. The hydrogen 
atmosphere was removed and the reaction flask was degassed with a stream of N2. The reaction 
mixture was then filtered over a pad of celite to remove the Pd/C. Solvent was removed in 
vacuo and the crude product was further dried under high vacuum for 48 hours to afford the title 
compound (340) as a white waxy solid in 98% yield (1.390 g, 10.77 mmol). 
 
Molecular formula: C6H11NO2; Molecular weight: 129.159 gmol
-1
. 
 
1
H-NMR (400 MHz, D2O) δ (ppm): 4.10 (dd, J = 9.4, 7.1 Hz, 1H), 3.72– 3.66 (m, 1H), 3.17– 
3.10 (m, 1H), 2.90 (s, 3H), 2.55 – 2.45 (m, 1H), 2.17 – 2.00 (m, 2H), 1.99 – 1.89 (m, 1H). 13C-
NMR (100 MHz, D2O) δ (ppm): 173.16, 70.05, 56.23, 40.55, 28.55, 22.60 
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1
H-NMR and 
13
C-NMR was in agreement with the literature.
3 
5.2.11.2 Preparation of N-methyl-L-proline ethyl ester (341) 
 
According to the general procedure “A” using N-methyl-L-proline (340) (1.512 
g, 11.71 mmol), ethanol (30 ml) and SOCl2 (1.70 ml, 23.4 mmol) the target 
compound was isolated as a HCl salt. The salt product was stirred in DCM (25 
ml) and Na2CO3 (1.272 g, 12.00 mmol) for 1 hour to neutralise. After 1 hour the reaction 
mixture was gravity filtered and solvent was removed in vacuo to afford the title compound 
(341) as a red oil in 83% yield, (1.283 g, 8.17 mmol).  
 
Molecular formula: C8H15NO2; Molecular weight: 157.213 gmol
-1
. 
 
1
H-NMR (400 MHz, D2O) δ (ppm): 4.27 (q, J = 7.2 Hz, 2H), 4.25-4.20 (m, 1H), 3.76-3.66 (m, 
1H), 3.24-3.11 (m, 1H), 3.21 (s, 3H), 2.56-2.51 (m, 1H), 2.19-2.12 (m, 2H), 2.03-1.96 (m, 1H), 
1.25 (t, J = 7.2 Hz, 3H). 
13
C-NMR (100 MHz, CDCl3) δ (ppm): 173.78, 67.68, 60.68, 56.41, 
40.93, 29.68, 23.10, 14.31. 
5.2.11.3 Preparation of IL (332) 
(1S,2S)-1-({[(2S)-1-Ethoxy-1-oxo-3-phenylpropan-2-yl]carbamoyl}methyl)-2-
(ethoxycarbonyl)-1-methylpyrrolidin-1-ium bromide (332). 
 
 To a stirred solution of L-phenylalanine ethyl ester α-
bromoamide (337) (0.564 g, 1.79 mmol) in DMF (5 ml) was 
added N-methyl-L-proline-ethyl ester (341) (0.250 g, 1.61 
mmol). The reaction was stirred under reflux conditions for 48 
hours. After 48 hours the reaction mixture was allowed to cool 
to room temperature and the DMF was removed in vacuo. Analysis by TLC (1:10 MeOH:DCM) 
showed the presence of two spots separated by 0.05 Rf and were presumed to be diastereomers 
of the target compound. The crude product was purified by silica gel chromatography (gradient 
elution of 5:95 MeOH:DCM to 10:90 MeOH:DCM) to afford the title compound (332) as a pale 
yellow oil in 37% yield (0.281 g, 0.596 mmol). 
 
Molecular formula: C21H31BrN2O5; Molecular weight: 471.392 gmol
-1
. 
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[α]D
20 
= -52.9 (2.5 c, EtOH). 
1
H-NMR (600 MHz, CDCl3) δ (ppm): 9.05 (d, J = 8.2 Hz, 1H), 
7.38 – 7.37 (m, 2H), 7.23-7.20 (m, 2H), 7.13 – 7.11 (m, 1H), 5.14 (t, J = 9.5 Hz, 1H), 5.04 (d, J 
= 13.2 Hz, 1H), 4.73 (ddd, J = 10.6, 8.1, 4.7 Hz, 1H), 4.61 (d, J = 13.2 Hz, 1H), 4.21 (qd, J = 
7.2, 2.1 Hz, 2H), 4.14-4.09 (m, 3H), 3.26 (dd, J = 14.1, 4.8 Hz, 1H), 3.17-3.14 (m, 1H), 3.15 (s, 
3H), 3.06 (dd, J = 14.1, 10.7 Hz, 1H), 2.61-2.59 (m, 1H), 2.21 – 2.10 (m, 2H), 1.98-1.90 (m, 
1H), 1.24 (t, J = 7.2 Hz, 3H), 1.18 (t, J = 7.2 Hz, 3H). 
13
C-NMR (150 MHz, CDCl3) δ (ppm): 
170.34, 165.63, 163.13, 136.73, 129.86, 128.46, 126.78, 73.00, 64.26, 63.37, 62.48, 61.73, 
54.58, 45.71, 37.12, 24.16, 18.94, 14.15, 14.00. IR (neat) (cm
-1
): 3715 (w), 2981 (b), 1735 (vs), 
1678 (vs), 1548 (m), 1454 (m), 1371 (m), 1202 (b), 1020 (m), 700 (s). ESI-MS (+ve) m/z: 
Found [M–Br–]+ 391.2230, C21H31N2O5
+
 requires 391.2227.
 
5.2.11.4 Preparation of IL (333) 
(1R,2S)-1-(2-(((S)-1-Ethoxy-1-oxo-3-phenylpropan-2-yl)amino)-2-oxoethyl)-2-
(ethoxycarbonyl)-1-methylpyrrolidin-1-ium bromide (333). 
 
The title compound was isolated during purification of (332), as 
a pale yellow oil in 13% yield (0.099 g, 0.21 mmol). 
 
Molecular formula: C21H31BrN2O5; Molecular weight: 471.392 
gmol
-1
. 
 
[α]D
20 
= -46.7 (3.0c, EtOH). 
1
H-NMR (400 MHz, CDCl3) δ (ppm): 9.49 (d, J = 7.4 Hz, 1H), 7.36 
– 7.32 (m, 2H), 7.24 – 7.20 (m, 2H), 7.17 – 7.08 (m, 1H), 5.16 (d, J = 13.6 Hz, 1H), 4.58 – 4.52 
(m, 1H), 4.53 – 4.45 (m, 1H), 4.33 (d, J = 13.5 Hz, 1H), 4.23 – 4.14 (m, 2H), 4.12 – 4.03 (m, 
2H), 4.03 – 3.95 (m, 1H), 3.88 – 3.80 (m, 1H), 3.51 (s, 3H), 3.19 (dd, J = 13.9, 4.7 Hz, 1H), 
3.11 (dd, J = 14.0, 10.2 Hz, 1H), 2.65 – 2.55 (m, 1H), 2.45 – 2.34 (m, 2H), 2.33 – 2.21 (m, 1H), 
1.22 (t, J = 7.1 Hz, 3H), 1.15 (t, J = 7.1 Hz, 3H). 
13
C-NMR (100 MHz, CDCl3) δ (ppm): 170.80. 
166.97, 163.70, 136.78, 129.48, 128.51, 126.88, 73.60, 64.96, 63.20, 61.62, 58.75, 55.40, 51.01, 
37.28, 26.11, 19.42, 14.13, 13.91. IR (neat) (cm
-1
): 3183 (w), 2981 (b), 1737 (vs), 1682 (s), 
1552 (m), 1455 (m), 1372 (w), 1211 (b), 1027 (m), 702 (m). ESI-MS (+ve) m/z: Found [M–Br–
]
+ 
391.2227, C21H31N2O5
+
 requires 391.2227. 
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5.2.12 Preparation of D-prolinium ILs (334-335) and their intermediates (342, 343) 
5.2.12.1 Preparation of N-methyl-D-proline (342) 
 
According to the general procedure “C” using D-proline (3.079 g, 26.74 mmol), the 
title compound (342) was isolated as a white crystalline solid in 36% yield, 
(1.235g, 9.562 mmol). 
 
Molecular formula: C6H11NO2; Molecular weight: 129.159 gmol
-1
. 
 
1
H-NMR (400 MHz, D2O) δ (ppm): 3.84 (dd, J =10.2, 6.9 Hz, 1H), 3.67– 3.61 (m, 1H), 3.10– 
3.03 (m, 1H), 2.84 (s, 3H), 2.44 – 2.39 (m, 1H), 2.08– 1.88 (m, 3H). 13C-NMR (100 MHz, D2O) 
δ (ppm): 173.16, 70.05, 56.23, 40.55, 28.55, 22.60. 
5.2.12.2 Preparation of N-methyl-D-proline ethyl ester (343) 
 
According to the general procedure “A” using N-methyl-D-proline (342) (1.235 g, 
9.562 mmol), ethanol (20 ml), SOCl2 (0.69 ml, 9.6 mmol) (the title compound 
(343) was isolated as a pale yellow oil in 43% yield, (0.649 g, 4.13 mmol).  
 
Molecular formula: C8H15NO2; Molecular weight: 157.213 gmol
-1
. 
 
1
H-NMR (400 MHz, CDCl3) δ (ppm): 4.21 (q, J = 7.2 Hz, 2H), 3.18-3.14 (m, 1H), 2.99-2.96 
(m, 1H), 2.42 (s, 3H), 2.34 (dd, J = 9.8, 8.8 Hz, 1H), 2.20-2.10 (m, 1H), 2.00-1.88 (m, 2H), 
1.84-1.75 (m, 1H), 1.28 (t, J = 7.2 Hz, 3H). 
13
C-NMR (100 MHz, CDCl3) δ (ppm): 173.57, 
67.70, 60.87, 56.45, 40.93, 29.72, 23.16, 14.40. 
5.2.12.3 Preparation of IL (334) 
(1S,2R)-1-(2-(((S)-1-Ethoxy-1-oxo-3-phenylpropan-2-yl)amino)-2-oxoethyl)-2-
(ethoxycarbonyl)-1-methylpyrrolidin-1-ium bromide (334). 
 
To a stirred solution of L-phenylalanine ethyl ester α-
bromoamide (337) (0.951 g, 3.02 mmol) in ethyl acetate (25 ml) 
was added N-methyl-D-proline-ethyl ester (343) (0.475 g, 3.02 
mmol). The reaction was stirred under reflux conditions for 48 
hours. After 48 hours the reaction was allowed to cool to room 
temperature and the solvent was removed in vacuo to afford a crude product. Analysis by TLC 
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(1:10 MeOH:DCM) showed the presence of two spots separated by 0.05 Rf and were presumed 
to be diastereomers. The crude product was purified by silica gel chromatography (gradient 
elution of 5:95 MeOH:DCM to 10:90 MeOH:DCM)  to afford the title compound (334) as a 
pale yellow oil in 25% yield (0.358 g, 0.759 mmol). 
 
Molecular formula: C21H31BrN2O5; Molecular weight: 471.392 gmol
-1
. 
 
[α]D
20 
= +1.92 (0.1 c, EtOH). 
1
H-NMR (400 MHz, CDCl3) δ (ppm): 9.26 (d, J = 8.6 Hz, 1H), 
7.38 – 7.36 (m, 2H), 7.24 – 7.12 (m, 3H), 4.87 – 4.78 (m, 3H), 4.42 (d, J = 14.2 Hz, 1H), 4.20 
(qd, J = 7.1, 1.7 Hz, 2H), 4.12 (q, J = 7.2 Hz, 2H), 3.87 – 3.81 (m, 1H), 3.46 – 3.39 (m, 1H), 
3.34 (s, 3H), 3.26 (dd, J = 13.8, 4.6 Hz, 1H), 3.04 (dd, J = 13.9, 10.9 Hz, 1H), 2.61-2.53 (m, 
1H), 2.48 – 2.39 (m, 1H), 2.33 – 2.18 (m, 1H), 2.28 – 2.22 (m, 1H), 1.26 (t, J = 7.2 Hz, 3H), 
1.21 (t, J = 7.3 Hz, 3H). 
13
C-NMR (100 MHz, CDCl3) δ (ppm): 170.62, 166.69, 163.14, 139.84, 
129.72, 128.46, 126.91, 74.30, 64.48, 63.07, 61.66, 58.17, 54.12, 50.51, 37.39, 25.56, 19.40, 
14.18, 13.94. IR (neat) (cm
-1
): 3183 (w), 2981 (b), 1737 (vs), 1682 (vs), 1552 (m), 1455 (m), 
1372 (w), 1211 (b), 1027 (m), 702 (w). ESI-MS (+ve) m/z: Found [M–Br–]+ 391.2223, 
C21H31N2O5
+
 requires 391.2227.  
5.2.12.4 Preparation of IL (335) 
(1R,2R)-1-(2-(((S)-1-Ethoxy-1-oxo-3-phenylpropan-2-yl)amino)-2-oxoethyl)-2-
(ethoxycarbonyl)-1-methylpyrrolidin-1-ium bromide (335). 
 
The title compound (335), was isolated during purification of 
(334), as a pale yellow oil in 34% yield (0.486 g, 1.03 mmol). 
 
 
 
Molecular formula: C21H31BrN2O5; Molecular weight: 471.392 gmol
-1
. 
 
[α]D
20 
= +1.86 (1.0 c, EtOH). 
1
H-NMR (400 MHz, CDCl3) δ (ppm): 9.28 (d, J = 7.3 Hz, 1H), 
7.43 – 7.41 (m, 2H), 7.30 – 7.27 (m, 2H), 7.22-7.21 (m, 1H), 5.32 (d, J = 13.1 Hz, 1H), 5.11 (t, 
J = 9.5 Hz, 1H), 4.62 (ddd, J = 10.4, 7.4, 4.8 Hz, 1H), 4.48-4.43 (m, 1H), 4.42 (d, J = 13.0 Hz, 
1H), 4.27 (qd, J = 7.2, 1.3 Hz, 2H), 4.16 (qd, J = 7.2, 2.7 Hz, 2H), 3.86-3.79 (m, 1H), 3.31 – 
3.28 (m, 1H), 3.26 (s, 3H), 3.13 (dd, J = 14.0, 10.4 Hz, 1H), 2.72-2.63 (m, 1H), 2.39 – 2.31 (m, 
1H), 2.28-2.21 (m, 1H), 2.13-2.02 (m, 1H), 1.30 (t, J = 7.1 Hz, 3H), 1.23 (t, J = 7.1 Hz, 3H). 
13
C-NMR (100 MHz, CDCl3) δ (ppm): 170.57, 165.61, 163.38, 136.61, 129.62, 128.56, 126.92, 
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73.41, 64.84, 63.39, 62.64, 61.66, 55.23, 45.47, 36.82, 24.24, 18.97, 14.16, 14.01. IR (neat) (cm
-
1
): 3175 (w), 2981 (b), 1737 (vs), 1678 (vs), 1548 (m), 1545 (m), 1371 (w), 1202 (b), 1020 (s), 
700 (w). ESI-MS (+ve) m/z: Found [M–Br–]+ 391.2215, C21H31N2O5
+
 requires 391.2227. 
5.3 Experimental preparation of Chapter 2 L-phenylalanine tertiary amino 
compounds 
5.3.1 Preparation of tertiary amine (344) 
 Ethyl (2-(1H-imidazol-1-yl)acetyl)-L-phenylalaninate (344). 
 
To a stirred solution of L-phenylalanine ethyl ester α-bromoamide 
(337) (1.010 g, 3.215 mmol) in diethyl ether (20 ml) was added 
TMS-imidazole (0.321 g, 2.29 mmol). The reaction was stirred at 
room temperature under an N2 atmosphere for 24 hours. After 24 
hours a white precipitate of TMS-imidazolium ionic liquid had formed. Diethyl ether was 
removed in vacuo and the white precipitate was dissolved in 5 ml of water and stirred for 30 
minutes to facilitate the removal of the TMS group. Water was removed in vacuo and the 
resulting crude product was purified by silica gel chromatography (eluent 10:90 MeOH:DCM) 
to afford the title compound (344) as a pale yellow oil in 55% yield, (0.383g, 1.27 mmol). 
 
Molecular formula: C16H19N3O3; Molecular weight: 301.346gmol
-1
. 
 
[α]D
20 
= +19.6 (2.0 c, CHCl3). 
1
H-NMR (400 MHz, CDCl3) δ (ppm): 7.42 (s, 1H), 7.29 – 7.26 
(m, 3H), 7.11 (s, 1H), 6.98 – 6.95 (m, 2H), 6.81 (s, 1H), 5.84 (d, J = 7.9 Hz, 1H), 4.82-4.77 (m, 
1H), 4.61 (d, J = 17.2 Hz, 1H), 4.56 (d, J = 17.7 Hz, 1H), 4.16 (q, J = 7.1 Hz, 2H), 3.12 (dd, J = 
13.9, 5.7 Hz, 1H), 3.00 (dd, J = 14.0, 6.5 Hz, 1H), 1.24 (t, J = 7.1 Hz, 3H). 
13
C-NMR (100 
MHz, CDCl3) δ (ppm): 170.81, 166.40, 137.50, 135.31, 130.94, 129.14, 128.86, 127.47, 119.58, 
61.92, 53.11, 50.00, 37.56, 14.18. IR (neat) (cm
-1
): 3202 (w), 2982 (b), 1735 (s), 1673 (s), 1548 
(m), 1509 (m), 1454 (w), 1372 (w), 1199 (b), 1107 (s), 1079 (s), 1030 (s), 744 (s), 701 (s). ESI-
MS (+ve) m/z: Found [M+H]
+ 
302.1493, C16H20N3O3
+
 requires 302.1499. 
5.3.2 Preparation of tertiary amine (345) 
Ethyl N-(2-hydroxyethyl)-N-methylglycyl-L-phenylalaninate (345). 
 
To a stirred solution of L-phenylalanine ethyl ester α-
bromoamide (337) (0.505 g, 1.60 mmol) in diethyl ether (25 ml) 
284 
 
 
was added 2-(methylamino)ethanol (115 µl, 1.43 mmol). The reaction was stirred at room 
temperature under an N2 atmosphere for 24 hours. After 24 hours a waxy precipitate had 
formed. The supernatant was decanted and the waxy crude product was purified by silica gel 
chromatography (gradient elution of 1:99 MeOH:DCM to 5:95 MeOH:DCM) to afford the title 
compound (345) as a pale yellow oil in 34% yield, (0.148 g, 0.48 mmol). 
 
Molecular formula: C16H24N2O4; Molecular weight: 308.378 gmol
-1
. 
 
[α]D
20 
= +29.1 (0.9 c, CHCl3).
1
H-NMR (400 MHz, CDCl3) δ (ppm): 7.74 (d, J = 8.8 Hz, 1H) 
7.29-7.22 (m, 3H), 7.14-7.12 (m, 2H), 4.86 (ddd, J = 8.7, 7.0, 6.1 Hz, 1H), 4.15 (q, J = 7.2 Hz, 
2H), 3.63 – 3.49 (m, 2H), 3.15 (dd, J = 13.9, 5.9 Hz, 1H), 3.07 (dd, J = 14.0, 6.8 Hz, 1H), 3.05 
(d, J = 16.7 Hz, 1H), 2.99 (d, J = 16.9 Hz, 1H), 2.56-2.46 (m, 2H), 2.35 (bs, 1H), 2.28 (s, 3H), 
1.22 (t, J = 7.2 Hz, 3H). 
13
C-NMR (100 MHz, CDCl3) δ (ppm): 172.46, 170.78, 136.06, 129.22, 
128.57, 127.15, 61.73, 61.24, 60.07, 59.61, 52.54, 43.50, 37.90, 14.09. IR (neat) (cm
-1
): 3298 
(b), 2939 (w), 1737 (s), 1656 (vs), 1517 (s), 1455 (m), 1373 (w), 1199 (b), 1129 (w), 1079 (w), 
1040 (m), 746 (m), 702 (s). ESI-MS (+ve) m/z: Found [M+H]
+ 
309.1809, C16H25N2O4
+
 requires 
309.1809 
5.3.3 Preparation of tertiary amine (346) 
Ethyl (2-morpholinoacetyl)-L-phenylalaninate (346). 
 
To a stirred solution of L-phenylalanine ethyl ester α-bromoamide 
(337) (1.073 g, 3.415 mmol) in THF (50 ml) was added morpholine 
(280 µl, 3.25 mmol). The reaction was stirred under reflux conditions 
for 24 hours. After 24 hours the reactions was allowed to cool to room 
temperature and solid Na2CO3 (0.371 g, 3.50 mmol) was added to the reaction and stirred 
vigorously for 1 hour. After one hour the Na2CO3 was removed by gravity filtration and the 
solvent was removed in vacuo. The crude product was purified by silica gel chromatography 
(eluent 50:50 ethyl acetate:hexane) to afford the title compound (346) as a brown oil in 56% 
yield, (0.587 g, 1.83 mmol). 
 
Molecular formula: C17H24N2O4; Molecular weight: 320.389 gmol
-1 
[α]D
20 
= +15.4 (1.0 c, CHCl3). 
1
H-NMR (400 MHz, CDCl3) δ (ppm): 7.56 (bs, 1H), 7.30-7.21 
(m, 3H), 7.14-7.13 (m, 2H), 4.85 (ddd, J = 8.4, 6.9, 5.7 Hz, 1H), 4.17 (q, J = 7.2 Hz, 2H), 3.58 
(m, 3.61-3.54, 4H), 3.19 (dd, J = 14.0, 5.7 Hz, 1H), 3.10 (dd, J = 14.0, 7.0 Hz, 1H), 3.02-2.92 
(m, 2H), 2.46 (s, 2H), 2.34 (s, 2H), 1.25 (t, J = 7.2 Hz, 3H). 
13
C-NMR (100 MHz, CDCl3) δ 
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(ppm): 171.68, 136.09, 129.29, 128.74, 127.29, 66.90, 61.66, 53.61, 52.46, 37.77, 14.26. IR 
(neat) (cm
-1
): 3344 (w), 2962 (w), 2856 (w), 2822 (w), 1737 (s), 1676 (s), 1507 (s), 1454 (m), 
1373 (w), 1190 (b), 1114 (vs), 1032 (m), 865 (m), 747 (vs), 700 (m). ESI-MS (+ve) m/z: Found 
[M+H]
+ 
321.1809, C17H25N2O4
+
 requires 321.1809. 
5.3.4 Preparation of tertiary amine (347) 
5.3.4.1 Preparation of L-proline ethyl ester hydrochloride (338) 
L-proline ethyl ester hydrochloride (338). 
 
According to the general procedure “A”, using L-proline (5.011g, 43.52 
mmol), the title compound (338) was isolated as a pale yellow oil in 99% 
yield, (7.751 g, 43.15 mmol). 
 
 
Molecular formula: C7H14ClNO2; Molecular weight: 179.644 gmol
-1
. 
 
1
H-NMR (400 MHz, D2O) δ (ppm):  4.43 (dd, J = 8.7, 7.2 Hz, 1H), 4.26 (q, J = 7.2 Hz, 2H), 
3.44-3.32 (m, 2H), 2.44-2.35 (m, 1H), 2.20 – 2.08 (m, 1H), 2.06-1.98 (m, 2H), 1.25 (t, J = 7.2 
Hz, 3H).
 13
C-NMR (100 MHz, D2O) δ (ppm): 168.59, 62.38, 58.15, 44.86, 26.91, 22.00, 14.10. 
1
H-NMR and 
13
C-NMR were in agreement with the literature.
4
 
5.3.4.2 Preparation of tertiary amine (347) 
Ethyl (2-(((S)-1-Ethoxy-1-oxo-3-phenylpropan-2-yl)amino)-2-oxoethyl)-L-prolinate (347). 
 
To a stirred solution of L-phenylalanine ethyl ester α-
bromoamide (337) (0.581 g, 1.85 mmol) in THF (10 ml) was 
added L-proline ethyl ester hydrochloride (338) (0.302 g, 1.68 
mmol) and solid Na2CO3 (0.356g, 3.36 mmol). The reaction 
mixture was stirred at room temperature for 24 hours. After 24 
hours the Na2CO3 was removed by gravity filtration and the solvent was removed in vacuo. The 
crude product was purified by silica gel chromatography (eluent 50:50 ethyl acetate:hexane) to 
afford the title compound (347) as a yellow oil in 53% yield, (0.334 g, 0.887 mmol). 
 
Molecular formula: C20H28N2O5; Molecular weight: 376.453 gmol
-1
. 
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[α]D
20 
= -6.2 (2.0 c, CHCl3). 
1
H-NMR (400 MHz, CDCl3) δ (ppm): 7.87 (d, J = 8.4 Hz, 1H), 7.31 
– 7.27 (m, 1H), 7.26 – 7.15 (m, 4H), 4.88-4.82 (m, 1H), 4.14 (q, J = 7.2 Hz, 4H), 3.43-3.39 (m, 
2H), 3.15-3.09 (m, 4H), 2.41 (dd, J = 8.0, 7.6 Hz, 1H), 2.41 (dd, J = 16.6, 7.9 Hz, 1H), 1.97-
1.92 (m, 1H), 1.84-1.79 (m, 2H), 1.24 (t, J = 7.2 Hz, 3H), 1.21 (t, J = 7.2 Hz, 3H). 
13
C-NMR 
(100 MHz, CDCl3) δ (ppm): 173.79, 171.62, 170.76, 136.21, 129.35, 128.45, 126.96, 65.40, 
61.28, 60.76, 57.67, 54.07, 52.68, 38.07, 29.59, 23.92, 14.29, 14.10. IR (neat) (cm
-1
): 3340 (w), 
2980 (w), 1733 (s), 1679 (s), 1509 (m), 1454 (w), 1372 (w), 1187 (b), 1027 (m), 746 (w), 701 
(m). ESI-MS (+ve) m/z: Found [M+H]
+ 
377.2067, C20H29N2O5
+
 requires 377.2071. 
5.3.5 Preparation of tertiary amine (348) 
5.3.5.1 Preparation of D-proline ethyl ester hydrochloride (339) 
D-proline ethyl ester hydrochloride (339). 
 
According to the general procedure “A” using D-proline (1.897 g, 16.48 
mmol), the title compound (339) was isolated as a pale yellow oil in 99% 
yield, (2.194 g, 16.31 mmol). 
 
 
Molecular formula: C7H14ClNO2; Molecular weight: 179.644 gmol
-1
. 
 
1
H-NMR (400 MHz, CDCl3) δ (ppm): 10.26 (bs, 1H), 8.91 (bs, 1H), 4.48-4.42 (m, 1H), 4.23 (q, 
J = 7.1 Hz, 2H), 3.59-3.45 (m, 2H), 2.43-2.34 (m, 1H), 2.16-1.98 (m, 3H), 1.27 (t, J = 7.2 Hz, 
3H). 
5.3.5.2 Preparation of tertiary amine (348) 
Ethyl (2-(((S)-1-Ethoxy-1-oxo-3-phenylpropan-2-yl)amino)-2-oxoethyl)-D-prolinate (348). 
 
To a stirred solution of L-phenylalanine ethyl ester α-
bromoamide (337) (0.803 g, 2.55 mmol) in THF (25 ml) was 
added D-proline ethyl ester hydrochloride of (339) (0.454 g, 2.53 
mmol) and triethylamine (0.78 ml, 5.6 mmol) dropwise. The 
reaction mixture was stirred under reflux conditions for 48 hours. 
After 48 hours the reaction mixture was cooled to room temperature and the triethylamine 
hydrobromide salts that had precipitated were removed by gravity filtration. Solvent was 
removed in vacuo and the crude product was purified by silica gel chromatography (eluent 
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50:50 ethyl acetate:hexane) to afford the title compound (348) as a yellow oil in 58% yield, 
(0.556 g, 1.48 mmol). 
 
Molecular formula: C20H28N2O5; Molecular weight: 376.453 gmol
-1
. 
 
[α]D
20 
= +22.6 (1.0 c, CHCl3). 
1
H-NMR (400 MHz, CDCl3) δ (ppm): 7.83 (d, J = 8.2 Hz, 1H), 
7.28-7.16 (m, 5H), 4.80 (td, J = 7.8, 5.7 Hz, 1H), 4.17 (q, J = 7.2 Hz, 2H), 4.14 (q, J = 7.1 Hz, 
2H), 3.39 (d, J = 16.7 Hz, 1H), 3.37 (dd, J = 9.0, 5.1 Hz, 1H), 3.21 (dd, J = 13.9, 5.7 Hz, 1H), 
3.11 (d, J = 16.8 Hz, 1H), 3.06 (dd, J = 13.8, 7.6 Hz, 1H), 2.79 (ddd, J = 8.9, 6.3, 5.0 Hz, 1H), 
2.42 (dd, J = 16.6, 7.8 Hz, 1H), 2.15 – 2.08 (m, 1H), 1.97– 1.89 (m, 1H), 1.80 – 1.73 (m, 2H), 
1.23 (t, J = 7.1 Hz, 3H), 1.22 (t, J = 7.2 Hz, 3H). 
13
C-NMR (100 MHz, CDCl3) δ (ppm): 174.08, 
171.55, 171.06, 136.48, 129.36, 128.56, 127.06, 65.70, 61.40, 60.96, 57.94, 54.24, 52.98, 37.98, 
29.78, 24.18, 14.31, 14.22. IR (neat) (cm
-1
): 3342 (w), 2980 (w), 1732 (s), 1675 (s), 1511 (m), 
1454 (w), 1373 (w), 1182 (b), 1026 (m), 748 (s), 700 (m). ESI-MS (+ve) m/z: Found [M+H]
+ 
377.2066, C20H29N2O5
+
 requires 377.2071. 
5.4 Experimental preparation of Chapter 2 L-tyrosine ILs 
5.4.1 Preparation of Chapter 2 L-tyrosine ethyl ester (354) and alkylating reagents (355-
356) 
5.4.1.1 Preparation of L-Tyrosine ethyl ester hydrochloride (354). 
 
According to the general procedure “A”, using L-tyrosine (9.882 g, 54.54 
mmol), the title compound (354) was isolated as a white solid in 87% 
yield, (11.71 g, 47.67 mmol). 
 
 
Molecular formula: C11H16ClNO3; Molecular weight: 245.703 gmol
-1
. 
 
1
H-NMR (400 MHz, DMSO) δ (ppm): 9.46 (s, 1H), 8.52 (s, 3H), 7.02 (d, J = 8.5 Hz, 2H), 6.72 
(d, J = 8.5 Hz, 2H), 4.16 – 4.09 (m, 3H), 3.07 (dd, J = 14.1, 5.8 Hz, 1H), 2.96 (dd, J = 14.1, 7.3 
Hz, 1H), 1.13 (t, J = 7.1 Hz, 3H).  
 
1
H-NMR was in agreement with the literature.
5
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5.4.1.2 Preparation of alkylating reagent (355). 
Ethyl (S)-2-(2-bromoacetamido)-3-(4-(2-bromoacetoxy)phenyl)propanoate (355). 
 
The title compound (355) was isolated from an over acylated 
preparation of (356), by silica gel chromatography (eluent 
50:50 ethyl acetate:hexane) to afford compound (355) as a 
white solid in 5% yield (0.056 g, 0.12 mmol). 
 
Molecular formula: C15H17Br2NO5; Molecular weight: 451.111 gmol
-1
; Mp: 101-103 °C. 
 
[α]D
20 
= +33.1 (1.0 c, CHCl3). 
1
H-NMR (400 MHz, CDCl3) δ (ppm): 7.17 (d, J = 8.6 Hz, 2H), 
7.07 (d, J = 8.5 Hz, 2H), 6.87 (d, J = 7.8 Hz, 1H), 4.82 (dt, J = 7.8, 5.9 Hz, 1H), 4.19 (q, J = 7.2 
Hz, 2H), 4.05 (s, 2H), 3.87 (d, J = 13.6 Hz, 1H), 3.83 (d, J = 13.6 Hz, 1H), 3.18 (dd, J = 13.8, 
5.9 Hz, 1H), 3.13 (dd, J = 13.9, 5.7 Hz, 1H), 1.25 (t, J = 7.2 Hz, 3H). 
13
C-NMR (100 MHz, 
CDCl3) δ (ppm): 170.79, 165.87, 165.27, 149.72, 133.83, 130.62, 133.83, 130.62, 121.39, 
62.06, 53.79, 37.30, 28.80, 25.67, 14.24. IR (neat) (cm
-1
): 3426(m), 3303(m), 1721(s), 1672 (s), 
1519 (m), 1227 (vs), 1199 (vs), 1101 (m), 822 (w). ESI-MS (+ve) m/z: Found [M+H]
+
 
449.9550, C15H18Br2NO5
+
 requires 449.9546. 
 
5.4.1.3 Preparation of ethyl (2-bromoacetyl)-L-tyrosinate (356). 
 
To a stirred solution of L-tyrosine ethyl ester hydrochloride (354), 
(3.648 g, 14.85 mmol), in DCM (50 ml) was added solid Na2CO3 
(3.462 g, 32.66 mmol). The reaction mixture was stirred vigorously for 
one hour to neutralise the L-tyrosine hydrochloride salt. The reaction 
mixture was then cooled to 0 °C and bromoacetyl bromide was added dropwise (2.6 ml, 30 
mmol). The reaction mixture was allowed to warm to room temperature and stirred for 12 hours. 
After 12 hours the Na2CO3 and other salts were removed by gravity filtration. The DCM layer 
was washed with saturated sodium bicarbonate solution (3 x 50 ml), dried over anhydrous 
magnesium sulphate and gravity filtered. TLC at this point (50:50 ethyl acetate: hexane) showed 
that over-acylation had occurred as expected on the O-position of the phenol side chain. The 
DCM was removed in vacuo and the solid crude product was dissolved in ethanol (10 ml) and 
acidified to pH 1 using conc. HCl. The solution was stirred for 24 hours until TLC showed the 
complete hydrolysis of the phenolic ester and the ethyl ester remaining intact. Precipitation of 
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the product by dropwise addition of hexane afforded the title compound (356) as a white solid 
in 54% yield (4.337 g, 13.14 mmol). 
 
Molecular formula: C13H16BrNO4; Molecular weight: 330.178 gmol
-1
; Mp: 111-113° C. 
 
[α]D
20 
= +20.9 (1.0 c, CHCl3).
1
H-NMR (400 MHz, CDCl3) δ (ppm): 6.99 (d, J = 8.5 Hz, 2H), 
6.88 (d, J = 8.0 Hz, 1H), 6.74 (d, J = 8.5 Hz, 2H), 5.35 (s, 1H), 4.79 (dt, J = 8.0, 5.8 Hz, 1H), 
4.20 (q, J = 7.1 Hz, 2H), 3.87 (d, J = 13.7 Hz, 1H), 3.83 (d, J = 13.7 Hz, 1H), 3.10 (dd, J = 14.1, 
5.7 Hz, 1H), 3.04 (dd, J = 14.0, 5.9 Hz, 1H), 1.28 (t, J = 7.1 Hz, 3H). 
13
C-NMR (100 MHz, 
CDCl3) δ (ppm): 171.26, 165.51, 155.24, 130.76, 127.40, 115.78, 62.11, 54.11, 37.23, 28.95, 
14.40. IR (neat) (cm
-1
): 3300(b), 1734(s), 1646 (s), 1547 (m), 1268 (m), 1194 (vs), 1101 (s), 
1019 (m), 932 (w), 851 (w). ESI-MS (+ve) m/z: Found [M+H]
+
 330.0334, C13H17BrNO4
+
 
requires 330.0335. 
5.4.2 Preparation of IL (349) – General Procedure “E” 
(S)-3-(2-((1-Ethoxy-3-(4-hydroxyphenyl)-1-oxopropan-2-yl)amino)-2-oxoethyl)-1-methyl-1H-
imidazol-3-ium bromide (349). 
 
To a stirred solution of L-tyrosine ethyl ester α-bromoamide 
(356) (0.504 g, 1.53 mmol) in ethyl acetate (50 ml) was added 1-
methylimidazole (0.12 ml, 1.5 mmol). The reaction was stirred 
under reflux conditions for 24 hours. After 24 hours the reaction 
was allowed to cool to room temperature and the solvent was 
removed in vacuo to afford a crude product. The crude product was washed with diethyl ether (3 
x 50 ml) to afford the title compound (349) as a white solid in 83% yield, (0.514 g, 1.25 mmol). 
 
Molecular formula: C17H22BrN3O4; Molecular weight: 412.284 gmol
-1
; Mp: 38-40° C. 
 
[α]D
20 
= +9.8 (0.6 c, EtOH). 
1
H-NMR (400 MHz, DMSO) δ (ppm): 9.30 (s, 1H), 9.08 (s, 1H), 
8.98 (d, J = 7.5 Hz, 1H), 7.69 (t, J = 1.8 Hz, 1H), 7.63 (t, J = 1.8 Hz, 1H), 6.99 (d, J = 8.4 Hz, 
2H), 6.68 (d, J = 8.4 Hz, 2H), 5.05 (d, J = 16.6 Hz, 1H), 5.00 (d, J = 16.8 Hz, 1H), 4.43 – 4.38 
(m, 1H), 4.07 – 4.01 (m, 2H), 3.88 (s, 3H), 2.91 (dd, J = 13.8, 6.2 Hz, 1H), 2.83 (dd, J = 13.8, 
8.2 Hz, 1H), 1.10 (t, J = 7.1 Hz, 3H). 
13
C-NMR (100 MHz, DMSO) δ (ppm): 171.07, 165.04, 
156.16, 137.71, 130.10, 126.57, 123.67, 123.00, 115.12, 60.68, 54.42, 50.29, 36.17, 35.82, 
13.97.  
290 
 
 
5.4.3 Preparation of IL (350) 
(S)-1-(2-((1-Ethoxy-3-(4-hydroxyphenyl)-1-oxopropan-2-yl)amino)-2-oxoethyl)pyridin-1-ium 
bromide (350). 
According to the general procedure “E”, using pyridine (250 µl, 
3.16 mmol), alkylating reagent (356) (1.065 g, 3.226 mmol) and 
ethyl acetate (50 mL), the title compound (350) was isolated as a 
white solid in 99% yield, (1.290 g, 3.152 mmol). 
 
Molecular formula: C18H21BrN2O4; Molecular weight: 409.280 gmol
-1
; Mp: 30-32° C. 
 
[α]D
20 
= +15.4 (1.0 c, CHCl3). 
1
H-NMR (400 MHz, DMSO) δ (ppm): 9.30 (s, 1H), 9.19 (d, J = 
7.5 Hz, 1H), 8.92 (d, J = 5.3 Hz, 2H), 8.66 (t, J = 7.8 Hz, 1H), 8.17 (d, J = 7.1 Hz, 1H), 7.01 (d, 
J = 8.5 Hz, 2H), 6.68 (d, J = 8.4 Hz, 2H), 5.52 (d, J = 16.0 Hz, 2H), 5.48 (d, J = 16.1 Hz, 1H), 
4.45 – 4.40 (m, 1H), 4.07 – 3.99 (m, 2H), 2.91 (dd, J = 13.9, 6.5 Hz, 1H), 2.86 (dd, J = 13.8, 7.8 
Hz, 1H), 1.09 (t, J = 7.1 Hz, 3H). 
13
C-NMR (100 MHz, DMSO) δ (ppm): 171.86, 165.44, 
156.19, 146.22, 146.19, 130.15, 127.54, 126.43, 115.14, 61.32, 60.72, 54.53, 36.31, 13.95. IR 
(neat) (cm
-1
): 3197 (b), 3052 (b), 1732 (m), 1683 (s), 1514 (s), 1201 (bs), 1112 (m), 1021 (m), 
853 (m). ESI-MS (+ve) m/z: Found [M–Br–]+ 329.1501, C18H21N2O4
+
 requires 329.1496.  
5.4.4 Preparation of IL (351) 
(S)-1-(2-((1-Ethoxy-3-(4-hydroxyphenyl)-1-oxopropan-2-yl)amino)-2-oxoethyl)-3-
methoxypyridin-1-ium bromide (351). 
 
According to the general procedure “E”, using 3-methoxy 
pyridine (280 µl, 2.88 mmol), alkylating reagent (356) (0.973 g, 
2.95 mmol) and ethyl acetate (50 mL), the title compound (351) 
was isolated as a white solid in 99% yield, (1.251 g, 2.848 
mmol). 
 
Molecular formula: C19H23BrN2O5; Molecular weight: 439.306 gmol
-1
;
 
Mp: 117-119 °C. 
 
[α]D
20 
= +12.7 (1.0 c, CHCl3). 
1
H-NMR (400 MHz, MeOD) δ (ppm): 8.67 (dd, J = 2.7, 1.3 Hz, 
1H), 8.44 (d, J = 6.0 Hz, 1H), 8.25 (ddd, J = 8.8, 2.6, 0.9 Hz, 1H), 8.03 (dd, J = 8.9, 5.9 Hz, 
1H), 7.09 (d, J = 8.5 Hz, 2H), 6.74 (d, J = 8.5 Hz, 2H), 5.48 (d, J = 16.3 Hz, 1H), 5.43 (d, J = 
15.8 Hz, 1H), 4.68 (dd, J = 8.7, 5.8 Hz, 1H), 4.18 (q, J = 7.1 Hz, 2H), 4.08 (s, 3H), 3.13 (dd, J = 
14.0, 5.8 Hz, 1H), 2.95 (dd, J = 14.0, 8.7 Hz, 1H), 1.25 (t, J = 7.2 Hz, 3H). 
13
C-NMR (100 
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MHz, DMSO) δ (ppm): 172.66, 165.71, 159.97, 157.53, 139.52, 134.89, 132.38, 131.33, 
129.21, 128.24, 116.26, 63.01, 62.57, 58.08, 56.03, 37.77, 14.36. IR (neat) (cm
-1
): 3196 (b), 
3038 (b), 1731 (m), 1682 (m), 1509 (s), 1201 (bs), 1112 (m), 1012 (m), 826 (w). ESI-MS (+ve) 
m/z: Found [M–Br–]+ 359.1607, C19H23N2O5
+
 requires 359.1601. 
5.4.5 Preparation of IL (352) 
(S)-1-(2-((1-Ethoxy-3-(4-hydroxyphenyl)-1-oxopropan-2-yl)amino)-2-oxoethyl)-3-
(ethoxycarbonyl)pyridin-1-ium bromide (352). 
 
The target compound was synthesised according to the 
general procedure “E”, using ethyl nicotinate (0.40 ml, 
2.98 mmol), alkylating reagent (356) (1.004 g, 3.041 
mmol) and ethyl acetate (50 mL) to give a crude product 
as a brown solid. The crude product was purified by silica 
gel chromatography (eluent 5:95 MeOH:DCM) to afford the title compound (352) as an orange 
solid in 71% yield, (1.016 g, 2.111 mmol). 
 
Molecular formula: C21H25BrN2O6; Molecular weight: 481.343 gmol
-1
; Mp: 53-55° C. 
 
[α]D
20 
= +9.0 (1.0 c, CHCl3). 
1
H-NMR (400 MHz, CDCl3) δ (ppm): 9.34 (s, 1H), 9.21 (d, J = 6.1 
Hz, 1H), 8.86 (d, J = 8.2 Hz, 1H), 8.82 (d, J = 8.3 Hz, 1H), 8.20 (dd, J = 8.1, 6.1 Hz, 1H), 7.05 
(d, J = 8.2 Hz, 2H), 6.67 (d, J = 8.4 Hz, 2H), 6.14 (d, J = 15.5 Hz, 1H), 5.89 (d, J = 15.4 Hz, 
1H), 4.72 (td, J = 8.6, 4.3 Hz, 1H), 4.47 – 4.35 (m, 2H), 4.13 (q, J = 6.9 Hz, 2H), 3.12 (dd, J = 
14.1, 4.3 Hz, 1H), 2.97 (dd, J = 14.1, 9.1 Hz, 1H), 1.39 (t, J = 7.1 Hz, 3H), 1.25 (t, J = 7.1 Hz, 
3H). 
13
C-NMR (100 MHz, CDCl3) δ (ppm): 171.11, 164.01, 161.25, 155.64, 149.02, 146.89, 
145.75, 130.78, 130.16, 128.45, 127.27, 115.65, 63.55, 62.73, 61.85, 54.80, 36.58, 14.27, 14.23. 
IR (neat) (cm
-1
): 3191 (b), 3047 (b), 1729 (vs), 1685 (vs), 1514 (s), 1297 (s), 1191 (bs), 1111 
(m), 1014 (m), 855 (m), 736 (m). ESI-MS (+ve) m/z: Found [M–Br–]+ 401.1713, C21H25N2O6
+
 
requires 401.1707. 
5.4.6 Preparation of IL (353) 
To a stirred solution of L-tyrosine ethyl ester α-bromoamide 
(356) (1.027 g, 3.110 mmol) in diethyl ether (25 mL) was 
added dimethylaminoethanol (0.30 mL, 3.1 mmol). The 
reaction was stirred at room temperature under an N2 
atmosphere for 24 hours. After 24 hours a white precipitate had formed. The supernatant was 
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decanted and the white precipitate was washed with diethyl ether (3 x 50 mL) to afford the title 
product as a white solid in 79% yield, (1.004 g, 2.394 mmol) 
 
Molecular formula: C17H27BrN2O5; Molecular weight: 419.316 gmol
-1
; Mp: 141-143° C. 
 
 [α]D
20 
= -3.0 (1.0 c, CHCl3).
1
H-NMR (400 MHz, DMSO) δ (ppm): 9.27 (s, 1H), 9.00 (d, J = 7.4 
Hz, 1H), 7.01 (d, J = 8.1 Hz, 2H), 6.67 (d, J = 8.2 Hz, 2H), 5.33 (s, 1H), 4.47 (d, J = 5.6 Hz, 
1H), 4.21 – 4.11 (m, 2H), 4.08 (q, J = 6.7 Hz, 2H), 3.80 (s, 2H), 3.52 (s, 2H), 3.17 (s, 3H), 3.16 
(s, 3H), 2.95 (dd, J = 14.3, 5.3 Hz, 1H), 2.81 (dd, J = 13.7, 9.0 Hz, 1H), 1.14 (t, J = 7.1 Hz, 3H). 
13
C-NMR (100 MHz, DMSO) δ (ppm): 170.81, 163.39, 156.16, 130.17, 126.57, 115.11, 66.02, 
62.50, 60.86, 54.97, 53.98, 52.07, 52.03, 35.78, 13.99. IR (neat) (cm
-1
): 3357 (b), 3188 (b), 3056 
(m), 1737 (vs), 1665 (vs), 1556 (m), 1514 (m), 1369 (m), 1342 (m), 1287 (s), 1218 (vs), 1179 
(vs), 1103 (m), 1071 (m), 1015 (m), 804 (m), 732 (m). ES-MS (+ve) m/z: Found [M–Br–]+ 
339.1920,  C19H23N2O5
+
 requires 339.1914 
 
5.5 Experimental preparation of Chapter 2 IL and tertiary amino 
metabolites 
5.5.1 Preparation of IL (357) – Acid hydrolysis route 
5.5.1.1 Preparation of IL (369) 
1-(2-Ethoxy-2-oxoethyl)pyridin-1-ium bromide (369). 
 
To a stirred solution of pyridine (320 µl, 3.97 mmol) in ethyl acetate (25 ml) 
was added dropwise ethyl bromoacetate (0.50 ml, 4.4 mmol). The reaction 
was stirred under reflux conditions for 12 hours. After 12 hours a yellow 
precipitate had formed. The supernatant was decanted and the solid yellow 
crude product was isolated by vacuum filtration and washed with ethyl acetate (3 x 25 ml) to 
afford the title compound (369) as a yellow solid in 63% yield, (0.615 g, 2.50 mmol). 
 
Molecular formula: C9H12BrNO2; Molecular weight: 246.104 gmol
-1
; Mp: 133-135° C. 
 
1
H-NMR (400 MHz, CDCl3) δ (ppm): 9.50 (dd, J = 6.7, 1.2 Hz, 2H), 8.55 (tt, J = 7.9, 1.3 Hz, 
1H), 8.13 – 8.05 (m, 2H), 6.34 (s, 2H), 4.27 (q, J = 7.1 Hz, 2H), 1.29 (t, J = 7.2 Hz, 3H). 13C-
NMR (100 MHz, CDCl3) δ (ppm): 165.86, 146.77, 146.08, 127.70, 63.45, 61.04, 14.12. 
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1
H-NMR and 
13
C-NMR were in agreement with the literature.
6
 
5.5.1.2 Preparation of IL (357) - general procedure “F” 
1-(carboxymethyl)pyridin-1-ium bromide (357). 
 
Pyridinium IL (369) (0.345 g, 1.40 mmol) was stirred in a 25% (v/v) conc. 
HBr/H2O solution (10 ml) under reflux conditions for 2 hours. After two hours 
the solution was cooled to room temperature and dried in vacuo. The solid red 
crude product was washed with acetone (3 x 10 ml) to afford the title 
compound (357) as a white solid in 73% yield (0.224 g, 1.03 mmol).  
 
Molecular formula: C7H8BrNO2; Molecular weight: 218.050 gmol
-1
; Mp: 207-209° C. 
 
1
H-NMR (400 MHz, CDCl3) δ (ppm): 8.80 – 8.73 (m, 2H), 8.57 (tt, J = 7.9, 1.3 Hz, 1H), 8.04 
(s, 2H), 5.38 (s, 2H). 
13
C-NMR (100 MHz, D2O) δ (ppm): 172.03, 148.80, 148.01, 130.45, 
64.19. 
 
5.5.2 Preparation of IL (358) – Acid hydrolysis route 
5.5.2.1 Preparation of IL (370). 
 
3-Methoxy-1-(2-methoxy-2-oxoethyl)pyridin-1-ium bromide (370). 
 
To a stirred solution of methoxy pyridine (460 µl, 4.57 mmol) in diethyl 
ether (10 ml) was added dropwise methyl bromoacetate (430 µl, 4.57 
mmol). The reaction was stirred at room temperature under an N2 
atmosphere for 24 hours. After 24 hours a white precipitate had formed. The supernatant was 
decanted and the white solid crude product was washed with diethyl ether (3 x 25 ml) to afford 
the title compound (370) as a white hygroscopic solid in 87% yield, (1.042 g, 3.976 mmol). 
 
Molecular formula: C9H12BrNO3; Molecular weight: 262.103 gmol
-1
; Mp: 36-38° C. 
 
1
H-NMR (400 MHz, CDCl3) δ (ppm): 9.53 – 9.47 (m, 1H), 9.08 (d, J = 5.8 Hz, 1H), 8.03 – 7.87 
(m, 2H), 6.39 (s, 2H), 4.12 (s, 3H), 3.80 (s, 3H). 
13
C-NMR (100 MHz, CDCl3) δ (ppm): 160.49, 
152.41, 133.47, 126.96, 126.87, 121.79, 54.90, 52.55, 47.85. IR (neat) (cm
-1
): 3033 (b), 2952 
(b), 1748 (vs), 1625 (m), 1581 (vs), 1441 (s), 1296 (vs), 766 (s), 713 (s). 
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5.5.2.2 Preparation of IL (358) 
1-(carboxymethyl)-3-methoxypyridin-1-ium bromide (358). 
 
According to general procedure “F”, using IL (370) (0.709 g, 2.70 mmol), 
the title compound (358) was isolated as a white solid in 77% yield (0.516 
g, 2.08 mmol).  
 
Molecular formula: C8H10BrNO3; Molecular weight: 248.076 gmol
-1
; Mp: 177-179° C. 
 
1
H-NMR (400 MHz, D2O) δ (ppm): 8.44 (dd, J = 2.6, 1.3 Hz, 1H), 8.30 (dt, J = 5.9, 1.2 Hz, 
1H), 8.06 (ddd, J = 8.9, 2.6, 1.0 Hz, 1H), 7.88 (dd, J = 8.9, 5.9 Hz, 1H), 5.29 (s, 2H), 3.90 (s, 
3H). 
13
C-NMR (100 MHz, D2O) δ (ppm): 169.26, 158.51, 137.98, 132.98, 131.44, 128.22, 
61.67, 57.09. IR (neat) (cm
-1
): 2827 (b), 1737 (vs), 1583 (vs), 1508 (vs), 1291 (vs), 1192 (vs), 
1057 (vs), 806 (vs), 776 (s), 693 (vs). ESI-MS (+ve) m/z: Found [M-Br
-
]
+
 168.0661,
 
C8H10NO3
+
 
requires 168.0655. 
5.5.3 Alternative preparation of IL (359) 
(S)-3-Carboxy-1-(2-((1-ethoxy-1-oxo-3-phenylpropan-2-yl)amino)-2-oxoethyl)pyridin-1-ium 
bromide (359). 
To a stirred solution of sodium nicotinate (0.480 g, 3.31 
mmol) in DMF (25 ml) was added alkylating reagent (337) 
(3.210 g, 10.22 mmol). The reaction mixture was heated under 
reflux conditions for 72 hours and was observed to change 
from colourless to yellow. After 72 hours the reaction mixture was allowed to cool to room 
temperature. DMF was removed in vacuo and the crude orange product was purified by silica 
gel chromatography (eluent 5:95 MeOH:DCM) to afford the title compound (359) as an orange 
solid in 37% yield (0.532 g, 1.22 mmol). 
 
Molecular formula: C19H21BrN2O5; Molecular weight: 437.290 gmol
-1
; Mp: 90-92° C. 
 
[α]D
20 
= -8.0 (0.1 c, EtOH). 
1
H-NMR (400 MHz, D2O) δ (ppm): 8.92 (s, 1H), 8.86 (dt, J = 8.1, 
1.4 Hz, 1H), 8.61 (dt, J = 6.2, 1.3 Hz, 1H), 8.04 (dd, J = 8.0, 6.2 Hz, 1H), 7.32 – 7.16 (m, 5H), 
5.42 (d, J = 16.0 Hz, 1H), 5.34 (d, J = 16.0 Hz, 1H), 4.77 – 4.72 (m, 1H), 4.14 (q, J = 7.2 Hz, 
2H), 3.24 (dd, J = 13.9, 5.5 Hz, 1H), 2.93 (dd, J = 13.8, 9.7 Hz, 1H), 1.16 (t, J = 7.2 Hz, 3H). 
13
C-NMR (100 MHz, D2O) δ (ppm): 175.04, 169.21, 167.77, 149.14, 148.79, 138.76, 131.75, 
131.23, 130.30, 129.76, 65.40, 64.15, 57.07, 37.00, 15.71. IR (neat) (cm
-1
): 2969 (b), 2779 (s), 
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2437 (m), 1733 (m), 1686 (s), 1641 (s), 1372 (s), 1211 (s), 1022 (vs), 705 (s), 668 (s). ESI-MS 
(+ve) m/z: Found [M-Br
-
]
+
 357.1451,
 
C19H21N2O5
+
 requires 357.1445. 
 
5.5.4 Alternative preparation of IL (360) 
5.5.4.1 Preparation of alkylating reagent (389) 
(2-bromoacetyl)-L-phenylalanine (389). 
 
To a stirred suspension of L-phenylalanine (0.865 g, 5.23 mmol) in 
deionised water (10 ml) at 0 °C was added a 1M NaOH solution (0.2 ml). 
The solution was stirred for 30 minutes until dissolution of the L-
phenylalanine was achieved. After complete dissolution was observed, a 
solution of bromoacetyl bromide (0.50 ml, 5.7 mmol) in toluene (10 ml) was added to the stirred 
aqueous reaction mixture dropwise. Reaction pH was maintained at pH 9 by the concomitant 
addition of supplementary 1M NaOH if pH was determined to be decreasing by universal 
indicator paper checks every 5 minutes. After 30 minutes the reaction mixture was acidified to 
pH 1 and the target product was observed to precipitate as a white solid. Isolation of the target 
product was achieved by vacuum filtration of the reaction mixture followed by washing with ice 
cold deionised water (3 x 5 ml). Excess water was removed in vacuo to afford the title 
compound (389) as a white solid in 58% yield (0.861 g, 3.01 mmol). 
 
Molecular formula: C11H12BrNO3; Molecular weight: 286.125 gmol
-1
. 
 
1
H-NMR (400 MHz, CDCl3) δ (ppm): 7.38 – 7.26 (m, 3H), 7.21 – 7.13 (m, 2H), 6.83 (d, J = 7.7 
Hz, 1H), 4.93 – 4.83 (m, 1H), 3.89 (d, J = 13.9 Hz, 1H), 3.84 (d, J = 13.9 Hz, 1H), 3.25 (dd, J = 
14.0, 5.5 Hz, 1H), 3.17 (dd, J = 14.0, 6.1 Hz, 1H). 
13
C-NMR (100 MHz, CDCl3) δ (ppm): 
172.42, 165.88, 137.29, 129.10, 128.19, 126.50, 53.78, 36.47, 28.97. 
No 
1
H or 
13
C-NMR spectra were reported in the literature procedure.
10
 
 
5.5.4.2 Final preparation of IL (360) 
(S)-1-(2-((1-carboxy-2-phenylethyl)amino)-2-oxoethyl)-3-(ethoxycarbonyl)pyridin-1-ium 
bromide (360). 
 To a stirred solution of ethyl nicotinate (0.66 ml, 4.8 mmol) in 
DMF (25 ml) was added alkylating reagent (389) (0.703 g, 
2.41 mmol). The reaction was heated under reflux conditions 
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for 72 hours and was observed to change from colourless to yellow. After 72 hours the reaction 
mixture was allowed to cool to room temperature. DMF was removed in vacuo and the crude 
orange product was purified by silica gel chromatography (eluent 5:95 MeOH:DCM) to afford 
the title compound (360) as an orange solid in 57% yield (0.604 g, 1.38 mmol).  
 
Molecular formula: C19H21BrN2O5; Molecular weight: 437.290 gmol
-1
; Mp: 85-87° C. 
 
[α]D
20 
=+-9.0 (0.1 c, EtOH). 
1
H-NMR (400 MHz, D2O) δ (ppm): 9.18 (s, 1H), 9.02 (d, J = 8.2 
Hz, 1H), 8.74 (d, J = 6.1 Hz, 1H), 8.17 – 8.09 (m, 1H), 7.32 – 7.19 (m, 5H), 5.45 (d, J = 16.1 
Hz, 1H), 5.35 (d, J = 16.0 Hz, 1H), 4.70 (dd, J = 9.9, 5.1 Hz, 1H), 4.43 (q, J = 7.1 Hz, 2H), 3.26 
(dd, J = 13.9, 4.9 Hz, 1H), 2.92 (dd, J = 13.7, 10.0 Hz, 1H), 1.34 (t, J = 7.1 Hz, 3H). 
13
C-NMR 
(100 MHz, D2O) δ (ppm): 177.13, 167.39, 164.99, 150.98, 149.32, 149.14, 139.14, 133.31, 
131.75, 131.20, 130.66, 129.66, 66.45, 64.26, 57.20, 39.50, 15.71. IR (neat) (cm
-1
): 3201 (b), 
3029 (m), 2928 (m), 1729 (vs), 1682 (vs), 1540 (s), 1298 (vs), 1207 (vs), 1188 (vs), 741 (s), 643 
(s). ESI-MS (+ve) m/z: Found [M-Br
-
]
+
 357.1451,
 
C19H21N2O5
+
 requires 357.1445. 
5.5.5 Preparation of IL (361) – Acid hydrolysis route 
5.5.5.1 Preparation of IL (371) 
4-(dimethylamino)-1-(2-methoxy-2-oxoethyl)pyridin-1-ium bromide (371). 
 
To a stirred solution of dimethylaminopyridine (0.500 g, 4.09 mmol) in 
diethyl ether (10 ml) was added dropwise methyl bromoacetate (0.50 ml, 
5.3 mmol). The reaction was stirred at room temperature under an N2 
atmosphere for 24 hours. After 24 hours a white precipitate had formed. 
The supernatant was decanted and the white solid crude product was washed with diethyl ether 
(3 x 25 ml) to afford the title compound (371) as a white solid in 97% yield, (1.089 g, 3.957 
mmol). 
 
Molecular formula: C10H15BrN2O2; Molecular weight: 275.146 gmol
-1
; Mp: 227-229 ° C 
 
1
H-NMR (400 MHz, CDCl3) δ (ppm): 8.20 – 8.10 (m, 2H), 7.08 – 6.97 (m, 2H), 5.13 (s, 2H), 
3.68 (s, 3H), 3.16 (s, 6H). 
13
C-NMR (100 MHz, CDCl3) δ (ppm): 168.17, 156.07, 143.08, 
107.43, 56.53, 52.82, 39.92. IR (neat) (cm
-1
): 3064 (m), 2940 (m), 1751 (vs), 1650 (vs), 1569 
(vs), 1435 (s), 1207 (vs), 1178 (vs), 828 (s), 743 (s), 693 (s). 
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5.5.5.2 Preparation of IL (361) 
1-(carboxymethyl)-4-(dimethylamino)pyridin-1-ium bromide (361). 
 
According to general procedure “F”, using IL (371) (0.596 g, 2.17 mmol), 
the title compound (361) was isolated as a white solid in 92% yield (0.519 
g, 1.99 mmol). 
 
Molecular formula: C9H13BrN2O2; Molecular weight: 261.119 gmol
-1
; Mp: >250°C. 
 
1
H-NMR (400 MHz, D2O) δ (ppm): 7.86 – 7.77 (m, 2H), 6.82 – 6.74 (m, 2H), 4.86 (s, 2H), 3.09 
(s, 6H). 
13
C-NMR (100 MHz, D2O) δ (ppm): 171.09, 156.43, 142.20, 107.33, 57.27, 39.47. IR 
(neat) (cm
-1
): 2807 (b), 1735 (s), 1650 (s), 1573 (s), 1178 (s), 824 (vs), 643 (vs). ESI-MS (+ve) 
m/z: Found [M-Br
-
]
+
 181.0977,
 
C9H13N2O2
+
 requires 181.0972. 
5.5.6 Preparation of IL (362) – Base hydrolysis route 
(S)-2-((1-carboxy-2-phenylethyl)amino)-N-(2-hydroxyethyl)-N,N-dimethyl-2-oxoethan-1-
aminium bromide (362). 
To a stirred solution of IL (330) (0.244 g, 0.65 mmol) in a 50% 
(v/v) THF/H2O solution (10 ml) was added LiOH (0.250 g, 5.96 
mmol). The solution was allowed to stand in the fridge for 12 
hours. After 12 hours the basic solution was acidified to pH 6 by 
dropwise addition of HBr. Evaporation of the solvent in vacuo yielded a waxy crude white 
product. The crude product was washed with acetonitrile (3 x 10 ml) to extract the title 
compound leaving the inorganic salt behind. Solvent was removed in vacuo to afford the title 
compound (362) as a white solid in 85% yield (0.211 g, 0.55 mmol). 
 
Molecular formula: C15H23BrN2O4; Molecular weight: 375.258 gmol
-1
; Mp: 59-61° C. 
 
[α]D
20 
= +5.0 (0.1 c, EtOH). 
1
H-NMR (400 MHz, DMSO) δ (ppm): 8.37 (d, J = 8.5 Hz, 1H), 
7.30 – 7.14 (m, 5H), 7.14 – 7.02 (m, 1H), 5.36 (s, 1H), 4.21 (td, J = 9.7, 3.9 Hz, 2H), 4.13 (d, J 
= 14.2 Hz, 1H), 4.06 (d, J = 14.2 Hz, 1H), 3.48 – 3.38 (m, 2H), 3.22 – 3.10 (m, 2H), 3.09 (s, 
3H), 3.06 (s, 3H), 2.70 (dd, J = 13.7, 10.0 Hz, 1H). 
13
C-NMR (100 MHz, D2O) δ (ppm): 174.74, 
162.46, 139.32, 129.53, 128.32, 126.31, 66.12, 63.72, 56.47, 55.17, 52.30, 52.16, 38.01. IR 
(neat) (cm
-1
): 3406 (s), 3236 (m), 1636 (s), 1614 (vs), 1395 (m), 1085 (m), 699 (m). ESI-MS 
(+ve) m/z: Found [M-Br
-
]
+
 295.1660,
 
C15H23N2O45
+
 requires 295.1652. 
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5.5.7 Preparation of IL (363) – Hydrogenolysis route 
5.5.7.1 Preparation of intermediate (384) 
Benzyl 2-(1H-imidazol-1-yl)acetate (384). 
 
To a stirred solution of TMS-imidazole (1.400 g, 9.981 mmol) in 
diethyl ether (25 ml) was added dropwise benzyl bromoacetate (0.88 
ml, 10 mmol). The reaction was stirred at room temperature under an 
N2 atmosphere for 2 hours at which point a white precipitate of TMS-imidazolium ionic liquid 
had formed. The diethyl ether was removed in vacuo and the white precipitate was dissolved in 
water (10 ml) and stirred for 1 hour. After 1 hour the water was removed in vacuo resulting in a 
crude white solid product. Purification of the crude product was accomplished by silica gel 
chromatography (eluent 5:95 MeOH:DCM) to afford the title compound (384) as a white solid 
in 44% yield (0.946 g, 4.37 mmol). 
 
Molecular formula: C12H12N2O2; Molecular weight: 216.240 gmol
-1 
 
1
H-NMR (400 MHz, CDCl3) δ (ppm): 7.61 (s, 1H), 7.40-7.35 (m, 5H), 7.34 (s, 1H), 6.97 (s, 
1H), 5.21 (s, 2H), 4.76 (s, 2H). 
13
C-NMR (100 MHz, CDCl3) δ (ppm): 167.33, 137.98, 134.70, 
129.85, 128.84, 128.79, 128.58, 120.01, 67.78, 48.05. 
 
1
H-NMR and 13C-NMR were in agreement with the literature.
11
  
5.5.7.2 Preparation of IL (385) 
(S)-1-(2-(Benzyloxy)-2-oxoethyl)-3-(2-((1-ethoxy-1-oxo-3-phenylpropan-2-yl)amino)-2-
oxoethyl)-1H-imidazol-3-ium bromide (385). 
 
To a stirred solution of ethyl alkylating reagent 
(337) (0.667 g, 2.13 mmol) in diethyl ether (25 ml) 
and ethyl acetate (5 ml) was added imidazole 
intermediate (384) (0.383 g, 1.77 mmol). An off-
white precipitate was observed forming after 30 
minutes. The reaction was stirred at room temperature for 72 hours. After 72 hours the solvent 
was decanted and the resulting white crude product was washed with diethyl ether (3 x 25 ml) to 
afford the title compound (385) as an off white solid in 97% yield (0.913 g, 1.72 mmol). 
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Molecular formula: C25H28BrN3O5; Molecular weight: 527.415 gmol
-1
; Mp: 57-59° C. 
 
 [α]D
20 
= +9.5 (1.95 c, CHCl3). 
1
H-NMR (400 MHz, CDCl3) δ (ppm): 9.58 (s, 1H), 8.95 (d, J = 
7.7 Hz, 1H), 7.46 – 7.28 (m, 9H), 7.25 – 7.07 (m, 3H), 5.36 – 5.28 (m, 3H), 5.27 – 5.18 (m, 1H), 
5.17 (s, 2H), 4.69 – 4.59 (m, 1H), 4.08 – 3.96 (m, 2H), 3.17 (d, J = 2.0 Hz, 1H), 3.14 (dd, J = 
12.0, 3.9 Hz, 1H), 1.12 (t, J = 7.1 Hz, 3H). 
13
C-NMR (100 MHz, CDCl3) δ (ppm): 171.47, 
165.96, 164.78, 138.39, 136.76, 134.45, 129.66, 129.06, 128.93, 128.89, 128.62, 127.01, 
123.41, 123.04, 68.73, 61.71, 54.98, 51.75, 50.56, 37.52, 14.18. IR (neat) (cm
-1
): 3033 (b), 1736 
(vs), 1684 (vs), 1551 (s), 1178 (vs), 1024 (s), 743 (s), 697 (vs). ESI-MS (+ve) m/z: Found [M-
Br
-
]
+ 
450.2027,
 
C25H28N3O5
+
 requires 450.2023. 
5.5.7.3 Preparation of IL (363) 
(S)-1-(Carboxymethyl)-3-(2-((1-ethoxy-1-oxo-3-phenylpropan-2-yl)amino)-2-oxoethyl)-1H-
imidazol-3-ium bromide (363). 
To a stirred solution of IL (385) (0.450 g, 0.853 mmol) in 
DCM (25 ml) was added 10% Pd/C (0.045 g). The reaction 
mixture was stirred vigorously under 1 atmosphere of H2 for 
12 hours. After 12 hours the reaction mixture was degassed 
with a stream of N2 and filtered over a pad of celite. The 
ceilite filter pad was washed with DCM (3 x 25 ml).The combined filtrate was collected and 
organic solvent was removed in vacuo. The resulting crude product was washed with 
chloroform (3 x 25 ml) to afford the title compound (363) as an off white solid in 87% yield 
(0.325 g, 0.738 mmol). 
 
Molecular formula: C18H22BrN3O5; Molecular weight: 440.294 gmol
-1
; Mp: 162-164° C. 
 
[α]D
20 
= +4.0 (0.1 c, EtOH). 
1
H-NMR (400 MHz, D2O) δ (ppm): 8.71 (t, J = 1.6 Hz, 1H), 7.45 (t, 
J = 1.9 Hz, 1H), 7.36 – 7.16 (m, 6H), 5.05 – 4.88 (m, 4H), 4.74 – 4.68 (m, 1H), 4.14 (qd, J = 
7.2, 1.3 Hz, 2H), 3.23 (dd, J = 13.9, 5.7 Hz, 1H), 2.96 (dd, J = 13.9, 9.4 Hz, 1H), 1.16 (t, J = 7.2 
Hz, 3H). 
13
C-NMR (100 MHz, D2O) δ (ppm): 172.61, 170.12, 166.42, 137.85, 136.20, 129.11, 
128.65, 127.14, 123.48, 123.07, 62.76, 54.41, 50.54, 50.48, 36.62, 13.09. IR (neat) (cm
-1
): 3311 
(b), 3108 (m), 2981 (m), 1726 (vs), 1664 (vs), 1555 (s), 1537 (s), 1215 (s), 1195 (s), 1178 (s), 
691 (s). ESI-MS (+ve) m/z: Found [M-Br
-
]
+
 360.1561,
 
C18H22N3O5
+
 requires 360.1554. 
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5.5.8 Preparation of tertiary amine (367) 
N-(2-hydroxyethyl)-N-methylglycine (367). 
 
To a stirred solution of 40 wt.% glyoxal/H2O (3.75 ml, 33.0 mmol) was 
added 2-(methylamino)ethanol (2.40 ml, 30.0 mmol). The reaction mixture 
was stirred under reflux conditions for 12 hours. After 12 hours the reaction mixture was cooled 
to room temperature and the water was removed in vacuo. The resultaing brown crude product 
was recrystallised from ethanol/acetone to afford the title compound (367) as a white crystalline 
solid in 51% yield (2.048 g, 15.38 mmol). 
 
Molecular formula: C5H11NO3; Molecular weight: 133.147 gmol
-1
. 
 
1
H-NMR (400 MHz, D2O) δ (ppm): 3.86 (t, J = 5.4Hz, 2H), 3.73 (bs, 2H), 3.30 (bs, 2H), 2.90 
(s, 3H). 
13
C-NMR (100 MHz, D2O) δ (ppm): 170.20, 58.40, 57.59, 55.37, 41.34. ESI-MS (+ve) 
m/z: Found [M+H]
+
 134.0815 C5H12NO
 +
 requires 134.0812. 
1
H-NMR and 
13
C-NMR were in agreement with the literature.
12
 
5.5.9 Preparation of IL (373) – Failed hydrogenolysis route 
5.5.9.1 Preparation of ester (372) 
Benzyl nicotinate (372). 
 
To a round bottom flask was added benzyl alcohol (0.76 ml, 7.8 mmol), 
tosylimidazole (2.083 g, 9.372 mmol), triethylamine (1.75 ml, 12.5 
mmol), sodium nicotinate (2.265 g, 15.61 mmol), tetrabutylammonium 
iodide (0.430g, 1.16 mmol) and DMF (20 ml). The reaction was stirred under reflux conditions 
for 6 hours and was observed darkening to a brown colour. After 6 hours the reaction mixture 
was cooled to room temperature and diluted with water (20 ml). The crude product was 
extracted using DCM (3 x 20 ml). Purification was achieved by silica gel chromatography 
(gradient elution of ethyl acetate:hexane 30:70 to 50:50 ethyl acetate:hexane). The title 
compound (372) was isolated as a pale yellow oil in 97% yield (1.610 g, 7.550 mmol). 
 
Molecular formula: C13H11NO2; Molecular weight: 213.236 gmol
-1
. 
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1
H-NMR (400 MHz, CDCl3) δ (ppm): 9.27 (s, 1H), 8.78 (d, J = 4.8 Hz, 1H), 8.32 (dt, J = 8.0, 
1.9 Hz, 1H), 7.46 – 7.34 (m, 6H), 5.40 (s, 2H). 13C-NMR (100 MHz, CDCl3) δ (ppm): 165.14, 
153.52, 151.00, 137.23, 135.49, 128.73, 128.56, 128.38, 126.06, 123.37, 67.17. 
1
H-NMR and 
13
C-NMR
 
were in agreement with the literature. 
7
 
5.5.9.2 Preparation of IL (373) 
(S)-3-((Benzyloxy)carbonyl)-1-(2-((1-ethoxy-1-oxo-3-phenylpropan-2-yl)amino)-2-
oxoethyl)pyridin-1-ium bromide (373). 
According to a modified general procedure “E,” using 
benzyl nicotinate (0.998 g, 4.68 mmol), ethyl 
alkylating reagent (337), (2.061 g, 6.559 mmol) and 
THF (25 ml) under reflux conditions, the title 
compound was isolated as a crude solid orange product. Purification of the crude product was 
achieved by silica gel chromatography (gradient elution of 1:99 MeOH:DCM to 5:95 
MeOH:DCM) to afford the title compound (373) as a hygroscopic orange solid in 59% yield 
(1.449 g, 2.747 mmol). 
 
Molecular formula: C26H27BrN2O5; Molecular weight: 527.415 gmol
-1
; Mp: 50-52° C. 
 
[α]D
20 
= +1.5 (1.3 c, CHCl3). 
1
H-NMR (400 MHz, CDCl3) δ (ppm): 9.72 (dt, J = 6.1, 1.4 Hz, 
1H), 9.40 – 9.33 (m, 2H), 8.92 (dt, J = 8.2, 1.5 Hz, 1H), 8.10 (dd, J = 8.1, 6.1 Hz, 1H), 7.53 – 
7.32 (m, 7H), 7.28 – 7.19 (m, 2H), 7.18 – 7.09 (m, 1H), 6.19 (d, J = 15.1 Hz, 1H), 6.14 (d, J = 
15.1 Hz, 1H), 5.47 (s, 2H), 4.70 (ddd, J = 9.1, 7.9, 5.9 Hz, 1H), 4.12 – 4.03 (m, 2H), 3.25 (dd, J 
= 13.8, 5.9 Hz, 1H), 3.18 (dd, J = 13.8, 9.0 Hz, 1H), 1.17 (t, J = 7.1 Hz, 3H). 
13
C-NMR (100 
MHz, CDCl3) δ (ppm): 171.01, 163.73, 160.87, 149.89, 146.97, 145.43, 136.67, 134.12, 130.11, 
129.69, 129.26, 129.15, 128.99, 128.47, 127.74, 126.86, 69.15, 62.83, 61.62, 55.09, 37.70, 
14.14. IR (neat) (cm
-1
): 3194 (b), 3032 (b), 1731 (vs), 1684 (vs), 1547 (m), 1377 (m), 1292 (vs), 
1185 (vs), 1112 (s), 735 (s), 698 (vs). ESI-MS (+ve) m/z: Found [M-Br
-
]
+ 
447.1927,
 
C26H27N2O5
+
 requires 447.1914. 
5.5.10 Preparation of IL (376) – Failed hydrogenolysis route 
5.5.10.1 Preparation of ester (374) 
L-Phenylalanine benzyl ester (374). 
 
To a stirred suspension of L-phenylalanine (5.046 g, 30.55 mmol) in 
toluene (25 ml) was added benzyl alcohol (6.5 ml, 62 mmol) and PTSA 
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(11.62 g, 61.09 mmol). The reaction was stirred under reflux conditions using a Dean-Stark 
apparatus for 24 hours. After 24 hours the reaction mixture was cooled to room temperature and 
the PTSA salt of the crude product was precipitated by portionwise addition of diethyl ether (3 x 
50 ml). The solid precipitate was isolated by vacuum filtration and washed with toluene (3 x 50 
ml). The PTSA salt of the title compound (374) (8.721 g) was dissolved in a saturated sodium 
bicarbonate solution (50 ml) in a 250 ml beaker and stirred for 10 minutes until neutralisation 
had occurred. The solution was transferred to a separating funnel and the free base title 
compound (374) was extracted using DCM (3 x 50 ml). Removal of solvent in vacuo afforded 
the title compound (374) as a brown oil in 48% yield (3.722 g, 14.58 mmol). 
 
Molecular formula: C16H17NO2; Molecular weight: 255.317 gmol
-1
. 
 
1
H-NMR (400 MHz, CDCl3) δ (ppm): 7.43 – 7.21 (m, 10H), 7.21 – 7.10 (m, 2H), 5.15 (d, J = 
12.2 Hz, 1H), 5.12 (d, J = 12.4 Hz, 1H), 3.80 (dd, J = 7.6, 5.5 Hz, 1H), 3.10 (dd, J = 13.6, 5.5 
Hz, 1H), 2.91 (dd, J = 13.5, 7.6 Hz, 1H). 
1
H-NMR was in agreement with the literature.
8
  
 
5.5.10.2 Preparation of alkylating reagent (375) 
Benzyl (2-bromoacetyl)-L-phenylalaninate (375). 
 
To a stirred solution of L-phenylalanine benzyl ester (374) (0.781 g, 
3.06 mmol) in DCM (25 ml) was added solid Na2CO3 (0.486 g, 
4.59 mmol). To this reaction mixture was added bromoacetyl 
bromide dropwise (290 µl, 3.34 mmol). The reaction was stirred for 
12 hours. After 12 hours the Na2CO3 was removed by gravity filtration. The DCM layer was 
washed with saturated sodium bicarbonate solution (3 x 25 ml), dried over anhydrous 
magnesium sulphate and gravity filtered. The DCM was removed in vacuo to afford the title 
compound (375) as a white solid in 69% yield, (0.788 g, 2.10 mmol). 
 
Molecular formula: C18H18BrNO3; Molecular weight: 376.250 gmol
-1
. 
 
1
H-NMR (400 MHz, CDCl3) δ (ppm): 7.43 – 7.34 (m, 3H), 7.34 – 7.28 (m, 2H), 7.25 – 7.19 (m, 
3H), 7.05 – 6.97 (m, 2H), 6.85 (d, J = 8.0 Hz, 1H), 5.19 (d, J = 12.1 Hz, 1H), 5.13 (d, J = 12.1 
Hz, 1H), 4.94 – 4.84 (m, 1H), 3.86 (d, J = 13.7 Hz, 1H), 3.82 (d, J = 13.6 Hz, 1H), 3.16 (dd, J = 
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12.0, 5.8 Hz, 1H), 3.12 (dd, J = 12.4, 5.7 Hz, 1H). 
13
C-NMR (100 MHz, CDCl3) δ (ppm): 
170.76, 165.17, 135.20, 134.95, 129.42, 128.76, 127.38, 67.57, 53.77, 37.72, 28.77. 
1
H-NMR and 
13
C-NMR were in agreement with the literature.
9
 
5.5.10.3 Preparation of IL (376) 
(S)-1-(2-((1-(benzyloxy)-1-oxo-3-phenylpropan-2-yl)amino)-2-oxoethyl)-3-
(ethoxycarbonyl)pyridin-1-ium bromide (376). 
To a stirred solution of ethyl nicotinate (250 µl, 1.81 
mmol) in ethyl acetate (25 ml) was added benzyl 
alkylating reagent (375) (0.751 g, 2.00 mmol). The 
reaction mixture was stirred under reflux conditions 
for 48 hours and was observed to change to an orange colour. After 48 hours the reaction 
mixture was cooled to room temperature and the solvent was removed in vacuo. The resulting 
solid orange crude product was purified by silica gel chromatography (eluent 5:95 
MeOH:DCM) to afford the title product (376) as an orange solid in 89% yield (0.850 g, 1.61 
mmol). 
 
Molecular formula: C26H27BrN2O5; Molecular weight: 527.415 gmol
-1
; Mp: 63-65° C. 
 
 
[α]D
20 
= +5.5 (1.75 c, CHCl3). 
1
H-NMR (400 MHz, CDCl3) δ (ppm): 9.64 (dt, J = 6.1, 1.4 Hz, 
1H), 9.48 (d, J = 7.9 Hz, 1H), 9.35 (s, 1H), 8.85 (dt, J = 8.2, 1.5 Hz, 1H), 8.06 – 7.97 (m, 1H), 
7.36 – 7.27 (m, 5H), 7.24 – 7.18 (m, 4H), 7.17 – 7.11 (m, 1H), 6.26 (d, J = 15.1 Hz, 1H), 6.10 
(d, J = 15.1 Hz, 1H), 5.08 (d, J = 12.3 Hz, 1H), 4.99 (d, J = 12.3 Hz, 1H), 4.82 – 4.71 (m, 1H), 
4.48 (q, J = 7.1 Hz, 2H), 3.30 – 3.15 (m, 2H), 1.44 (t, J = 7.1 Hz, 3H). 13C-NMR (100 MHz, 
CDCl3) δ (ppm): 170.93, 163.82, 160.90, 149.55, 146.90, 145.37, 136.49, 135.29, 130.43, 
129.71, 128.67, 239.59, 128.45, 138.36, 127.72, 126.95, 67.31, 63.71, 62.78, 55.16, 37.57, 
14.29. IR (neat) (cm
-1
): 3031 (b), 1729 (vs), 1684 (vs), 1543 (m), 1497 (m), 1455 (m), 1369 (m), 
1296 (vs), 1190 (vs), 1110 (m), 1012 (m), 736 (s), 698 (vs). ESI-MS (+ve) m/z: Found [M-Br
-
]
+ 
447.1928,
 
C26H27N2O5
+
 requires 447.1914. 
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5.5.11 Preparation of IL (380) – Hydrogenolysis route 
5.5.11.1 Preparation of ester (377) 
D-Proline benzyl ester hydrochloride (377). 
 
To a stirred suspension of D-proline (5.75 g, 49.9 mmol) and benzyl alcohol 
(24 ml, 2.5 mol) was added SOCl2 (7.25 ml, 99.9 mmol). The reaction 
mixture was stirred at room temperature for 12 hours. The title compound 
(377) was precipitated by portionwise addition of diethyl ether (3 x 50 ml). 
The title compound (377) was dried under high vacuum for 48 hours to give a brown solid in 
72% yield (8.707g, 36.02 mmol). 
 
Molecular formula: C12H16ClNO2; Molecular weight: 241.715 gmol
-1
. 
 
1
H-NMR (400 MHz, D2O) δ (ppm): 7.45 – 7.30 (m, 5H), 5.28 (d, J = 12.0 Hz, 1H), 5.23 (d, J = 
12.0 Hz, 1H), 4.46 (dd, J = 8.8, 7.1 Hz, 1H), 3.45 – 3.26 (m, 2H), 2.45 – 2.30 (m, 1H), 2.17 – 
2.04 (m, 1H), 2.04 – 1.95 (m, 2H). 13C-NMR (100 MHz, D2O) δ (ppm): 169.62, 134.51, 128.93, 
128.81, 128.50, 68.62, 59.41, 46.14, 28.01, 23.11. 
 
1
H-NMR and 
13
C-NMR
 
were in agreement with the literature.
13
 
5.5.11.2 Preparation of N-methyl-D-proline benzyl ester (378) 
N-Methyl-D-proline benzyl ester (378). 
 
To a stirred solution of D-proline benzyl ester hydrochloride (377) (4.862 g, 
23.69 mmol) in methanol (25 ml) was added NaHCO3 (1.990 g, 23.69 mmol). 
The solution as stirred for 5 minutes followed by the addition of formaldehyde 
solution 40% v/v (4.1 ml, 47 mmol).The reaction mixture was stirred for 2 
hours followed by the portionwise addition of NaBH4 (1.135 g, 29.96 mmol). 
After a further 30 minutes the aqueous reaction mixture was added to a separating funnel and 
the product was extracted with DCM (3 x 20 ml). DCM was removed in vacuo to afford a crude 
product as a colourless oil. The crude product was purified by silica gel chromatography (eluent 
50:50 ethyl acetate:hexane) to afford the title compound (378) as a colourless oil in 31% yield 
(1.614 g, 7.360 mmol). 
 
Molecular formula: C13H17NO2; Molecular weight: 219.284 gmol
-1
. 
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1
H-NMR (400 MHz, CDCl3) δ (ppm): 7.32 – 7.15 (m, 5H), 5.11 (d, J = 12.3 Hz, 1H), 5.07 (d, J 
= 12.4 Hz, 1H), 3.09 – 2.99 (m, 1H), 2.91 (dd, J = 8.8, 6.9 Hz, 1H), 2.31 (s, 3H), 2.27 – 2.16 (m, 
1H), 2.13 – 1.99 (m, 1H), 1.94 – 1.78 (m, 2H), 1.75 – 1.62 (m, 1H). 13C-NMR (100 MHz, 
CDCl3) δ (ppm): 173.76, 136.08, 128.67, 128.35, 127.72, 67.50, 66.40, 56.41, 40.99, 29.71, 
23.23. 
 
1
H-NMR and 
13
C-NMR were in agreement with the literature.
14
  
5.5.11.3 Preparation of IL (379) 
(2R)-2-((Benzyloxy)carbonyl)-1-(2-(((S)-1-ethoxy-1-oxo-3-phenylpropan-2-yl)amino)-2-
oxoethyl)-1-methylpyrrolidin-1-ium bromide (379). 
 
To a stirred solution of N-methyl-D-proline benzyl ester 
(378) (1.029 g, 4.693 mmol) in THF (25 ml) was added 
ethyl alkylating reagent (337) (1.769 g, 5.631 mmol). The 
reaction was heated under reflux conditions for 72 hours. 
After 72 hours the reaction was allowed to cool to room 
temperature and the solvent was removed in vacuo. The resulting crude product was purified by 
silica gel chromatography (gradient elution of 1:99 MeOH:DCM to 5:95 MeOH:DCM) to 
afford the title compound (379) as a white solid, mixture of epimers (1:3.3 ratio), in 47% yield 
(1.180 g, 2.212 mmol). 
 
Molecular formula: C26H33BrN2O5; Molecular weight: 533.463 gmol
-1
; Mp: 159-161° C. 
 
[α]D
20 
= -8.0 (0.1 c, EtOH). 
1
H-NMR (400 MHz, CDCl3) δ (ppm): 9.27 – 8.98 (m, 1H), 7.39 – 
6.96 (m, 10H), 5.28 – 4.99 (m, 2H), 4.99 – 4.67 (m, 2H), 4.58 – 4.33 (m, 1H), 4.07 (q, J = 7.1 
Hz, 2H), 4.00 – 3.72 (m, 2H), 3.75 (s, 1H), 3.50 – 3.33 (m, 1H), 3.28 (s, 2H), 3.24 – 3.08 (m, 
2H), 3.08 – 2.94 (m, 1H), 2.54 – 2.25 (m, 1H), 2.29 – 1.86 (m, 2H), 1.18 – 1.12 (m, 3H). 13C-
NMR (100 MHz, CDCl3) δ (ppm): 171.46, 170.62, 170.50, 136.75, 135.89, 133.81, 129.83, 
129.39, 129.19, 128.88, 126.85, 73.23, 68.70, 65.20, 62.58, 61.50, 54.89, 45.83, 37.01, 24.31, 
19.15, 14.14. IR (neat) (cm
-1
): 3029 (m), 2981 (m), 1736 (vs), 1680 (vs), 1550 (s), 1453 (s), 
1443 (s), 1213 (vs), 1024 (s), 739 (s), 699 (vs). ESI-MS (+ve) m/z: Found [M-Br
-
]
+ 
453.2396,
 
C26H33N2O5
+
 requires 453.2384. 
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5.5.11.4 Preparation of IL (380) – General procedure “G” 
(2R)-2-Carboxy-1-(2-(((S)-1-ethoxy-1-oxo-3-phenylpropan-2-yl)amino)-2-oxoethyl)-1-
methylpyrrolidin-1-ium bromide (380). 
 
To a stirred solution of IL (379) (0.136 g, 0.255 mmol) in DCM 
was added 10% Pd/C (0.025 g). The reaction mixture was stirred 
at room temperature under 1 atmosphere of H2 for 72 hours. After 
72 hours the reaction mixture was degassed with a stream of 
nitrogen and filtered over a pad of celite. Solvent was removed from the filtrate to afford the 
title compound (380) as a mixture of epimers (1:3.3 ratio) as a pale yellow solid in 97% yield 
(0.108 g, 0.244 mmol). 
 
Molecular formula: C19H27BrN2O5; Molecular weight: 443.338 gmol
-1
; Mp: 39-41° C. 
 
[α]D
20 
= -32.0 (0.1 c, EtOH). 
1
H-NMR (400 MHz, D2O) δ (ppm): 7.27 – 7.07 (m, 5H), 4.60 – 
4.52 (m, 1H), 4.48 – 4.32 (m, 1H), 4.32 – 4.22 (m, 1H), 4.07 (q, J = 7.1 Hz, 2H), 4.01 – 3.82 
(m, 1H), 3.71 – 3.60 (m, 1H), 3.51 – 3.32 (m, 1H), 3.25 – 3.14 (m, 1H), 2.95 (s, 0.7H), 2.82 (dd, 
J = 14.0, 10.2 Hz, 1H), 2.72 (s, 2.3H), 2.40 – 2.25 (m, 1H), 2.23 – 2.05 (m, 1H), 2.04 – 1.87 (m, 
2H), 1.09 (t, J = 7.1 Hz, 3H). 
13
C-NMR (100 MHz, D2O) δ (ppm): 172.35, 168.74, 163.95, 
136.28, 129.14, 128.72, 127.19, 74.56, 66.21, 63.09, 62.81, 53.98, 44.35, 36.55, 23.27, 18.40, 
13.15. IR (neat) (cm
-1
): 3197 (b), 3035 (w), 2985 (w), 1734 (s), 1680 (vs), 1546 (m), 1209 (b), 
1022 (s), 730 (m), 699 (vs). ESI-MS (+ve) m/z: Found [M-Br
-
]
+ 
363.1922,
 
C26H33N2O5
+
 requires 
363.1914. 
5.5.12 Preparation of IL (382) – Hydrogenolysis route 
5.5.12.1 Preparation of IL (381) 
(2R)-1-(2-(((S)-1-(Benzyloxy)-1-oxo-3-phenylpropan-2-yl)amino)-2-oxoethyl)-2-
(ethoxycarbonyl)-1-methylpyrrolidin-1-ium bromide (381). 
 
To a stirred solution of N-methyl-D-proline ethyl ester 
hydrochloride (343) (0.196 g, 1.09 mmol) in THF (25 ml) 
was added triethylamine (0.15 ml, 4.3 mmol) and benzyl 
alkylating reagent (375) (0.490 g, 1.31 mmol). The reaction 
was heated under reflux conditions for 48 hours. After 48 hours the reaction was allowed to cool 
to room temperature and the solvent was removed in vacuo. The resulting crude product was 
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purified by silica gel chromatography (gradient elution of 1:99 MeOH:DCM to 5:95 
MeOH:DCM) to afford the title compound (381) as a white solid, mixture of epimers (1:4 ratio), 
in 27% yield (0.158 g, 0.296 mmol). 
 
Molecular formula: C26H33BrN2O5; Molecular weight: 533.463 gmol
-1
; Mp: 42-44° C. 
 
[α]D
20 
= -12.0 (0.1 c, EtOH). 
1
H-NMR (400 MHz, CDCl3) δ (ppm): 9.33 (d, J = 7.4 Hz, 1H), 
7.44 – 7.27 (m, 7H), 7.24 – 7.00 (m, 3H), 5.20 (dd, J = 12.8, 7.2 Hz, 2H), 5.03 (dd, J = 21.0, 
11.0 Hz, 2H), 4.72 – 4.62 (m, 1H), 4.36 (d, J = 13.3 Hz, 1H), 4.29 – 4.18 (m, 3H), 3.55 (ddd, J 
= 11.7, 8.6, 2.7 Hz, 1H), 3.39 – 3.25 (m, 1H), 3.16 (d, J = 3.9 Hz, 3H), 3.14 – 3.04 (m, 1H), 
2.68 – 2.51 (m, 1H), 2.20 – 1.81 (m, 3H), 1.28 (t, J = 7.1 Hz, 3H). 13C-NMR (100 MHz, CDCl3) 
δ (ppm): 170.47, 165.56, 163.43, 136.48, 135.27, 129.67, 129.58, 128.64, 128.55, 128.48, 
128.38, 126.96, 73.56, 67.36, 64.75, 63.40, 62.64, 55.39, 45.33, 36.76, 24.19, 18.85, 14.02. IR 
(neat) (cm
-1
): 3031 (m), 2981 (m), 1737 (vs), 1679 (vs), 1549 (s), 1455 (s), 1208 (vs), 1028 (s), 
739 (s), 698 (vs). ESI-MS (+ve) m/z: Found [M-Br
-
]
+ 
453.2396 ,
 
C26H33N2O5
+
 requires 
453.2384. 
5.5.12.2 Preparation of IL (382) 
(2R)-1-(2-(((S)-1-carboxy-2-phenylethyl)amino)-2-oxoethyl)-2-(ethoxycarbonyl)-1-
methylpyrrolidin-1-ium (382). 
 
According to general procedure “G”, using IL (381) (0.101 g, 
0.189 mmol, the title compound was  isolated as a pale yellow 
solid, mixture of epimers (1:4 ratio), in 95% yield (0.081 g, 0.18 
mmol). 
 
Molecular formula: C19H27BrN2O5; Molecular weight: 443.338 gmol
-1
; Mp: 41-43° C. 
 
[α]D
20 
= -13.0 (0.1 c, EtOH). 
1
H-NMR (400 MHz, D2O) δ (ppm): 7.28 – 7.10 (m, 5H), 4.75 – 
4.71 (m, 1H), 4.47 – 4.36 (m, 1H), 4.29 (d, J = 14.8 Hz, 1H), 4.16 (q, J = 7.1 Hz, 2H), 4.03 (d, J 
= 14.8 Hz, 1H), 3.74 – 3.63 (m, 1H), 3.50 – 3.35 (m, 1H), 3.30 – 3.20 (m, 1H), 2.98 (s, 0.6H), 
2.88 – 2.77 (m, 1H), 2.73 (s, 2.4H), 2.49 – 2.30 (m, 1H), 2.29 – 2.13 (m, 1H), 2.11 – 1.89 (m, 
2H), 1.15 (t, J = 7.2 Hz, 3H). 
13
C-NMR (100 MHz, D2O) δ (ppm): 174.37, 166.30, 163.57, 
136.59, 129.15, 128.70, 127.14, 73.42, 66.78, 63.74, 63.21, 53.94, 44.92, 36.68, 23.20, 18.58, 
13.01. IR (neat) (cm
-1
): 3192 (b), 2920 (m), 2918 (m), 1734 (s), 1679 (vs), 1548 (m), 1205 (b), 
1025 (s), 731 (s), 701(vs).  
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5.5.13 Preparation of tertiary amine (387) 
5.5.13.1 Preparation of ester (386) 
Ethyl (2-(benzyloxy)-2-oxoethyl)-D-prolinate (386). 
 
To a stirred solution of D-proline ethyl ester hydrochloride (339) (0.250 g, 
1.39 mmol) in acetonitrile (15 ml) at room temperature was added dropwise 
triethylamine (0.43 ml, 3.1 mmol). The reaction mixture was stirred for 30 
minutes followed by the dropwise addition of benzyl bromoacetate (0.24 ml, 
1.5 mmol). The reaction mixture was stirred for 6 hours. After 6 hours 
volatile organics were removed in vacuo and the resulting crude product was 
purified by silica gel chromatography (eluent 10:90 ethyl acetate:hexane) to afford the title 
compound (386) as a pale yellow oil in 74% yield (0.299 g, 1.03 mmol). 
 
Molecular formula: C16H21NO4; Molecular weight: 291.347 gmol
-1
. 
 
[α]D
20 
= +88.6 (1.8 c, CHCl3). 
1
H-NMR (400 MHz, CDCl3) δ (ppm): 7.40 – 7.30 (m, 5H), 5.15 
(s, 2H), 4.24 – 4.07 (m, 2H), 3.68 (d, J = 17.4 Hz, 1H), 3.65 – 3.62 (m, 1H), 3.59 (d, J = 17.3 
Hz, 1H), 3.22 – 3.12 (m, 1H), 2.87 – 2.76 (m, 1H), 2.26 – 2.11 (m, 1H), 2.05 – 1.78 (m, 3H), 
1.25 (t, J = 7.1 Hz, 3H). 
13
C-NMR (100 MHz, CDCl3) δ (ppm): 173.90, 170.74, 135.78, 128.68, 
128.44, 66.38, 63.73, 60.77, 53.40, 52.96, 29.80, 23.87, 14.34. IR (neat) (cm
-1
): 2980 (b), 1733 
(vs), 1175 (vs), 1155(vs), 1094 (s), 736 (s), 697 (vs). ESI-MS (+ve) m/z: Found [M+H]
+ 
292.1538,
 
C16H22NO4
+
 requires 292.1543.  
 
5.5.13.2 Preparation of tertiary amine (387) 
(R)-2-(2-(Ethoxycarbonyl)pyrrolidin-1-yl)acetic acid (387). 
 
To a stirred solution of (386) (0.127 g, 0.44 mmol) in 50:50 ethanol:ethyl 
acetate was added 10% Pd/C (0.011 g). The reaction mixture was stirred 
vigorously under 1 atmosphere of H2 for 12 hours. After 12 hours the reaction 
mixture was degassed with a stream of N2 and filtered over a pad of celite. The 
ceilite filter pad was washed with 50:50 ethanol:ethyl acetate (3 x 25 ml).The combined filtrate 
was collected and organic solvent was removed in vacuo to afford the title compound (387) as a 
pale yellow oil in 86% yield (0.076 g, 0.38 mmol).  
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Molecular formula: C9H15NO4; Molecular weight: 201.222 gmol
-1
. 
 
 [α]D
20 
= -46.15 (0.1 c, EtOH). 
1
H-NMR (400 MHz, D2O) δ (ppm): 4.42 (dd, J = 9.3, 6.1 Hz, 
1H), 4.30 (q, J = 7.1 Hz, 2H), 4.01 (d, J = 16.2 Hz, 1H), 3.91 – 3.76 (m, 2H), 3.27 (ddd, J = 
11.6, 8.4, 7.1 Hz, 1H), 2.59 – 2.43 (m, 1H), 2.27 – 2.08 (m, 2H), 2.12 – 1.97 (m, 1H), 1.28 (t, J 
= 7.1 Hz, 3H). 
13
C-NMR (100 MHz, D2O) δ (ppm): 170.28, 169.74, 67.32, 63.68, 57.47, 56.07, 
28.15, 22.63, 13.01. IR (neat) (cm
-1
): 2981 (b), 1733 (vs), 1619 (vs), 1372 (s), 1186 (b), 1022 
(s). ESI-MS (+ve) m/z: Found [M+H]
+
 202.1077 C9H16NO4
 +
 requires 202.1074 
5.6 Experimental preparation of Chapter 3 linear alkyl amino acid 
surfactant ILs 
5.6.1 Preparation of Chapter 3 linear alkyl amino acid esters (453-455) 
5.6.1.1 Preparation of ester (453) – general procedure “H” 
Octyl L-phenylalaninate (453). 
 
To a stirred suspension of L-phenylalanine (8.094 g, 48.99 
mmol), in toluene (50 ml) was added PTSA (10.251 g, 59.53 
mmol), and 1-octanol (9.5 ml, 60 mmol). The suspension was 
heated under reflux conditions for 12 hours using a Dean-Stark 
apparatus. After 2 hours, a homogenous solution was obtained. After 12 hours the solution was 
allowed to cool to room temperature. Addition of diethyl ether (50 ml) caused precipitation of 
the product as a crude PTSA salt. The crude PTSA salt product was isolated by vacuum 
filtration and washed with hexane (3 x 50 ml). The crude product PTSA salt was then 
neutralised by stirring in an aqueous sodium bicarbonate solution (150 ml) and then transferred 
to a separating funnel. The title compound (453) was extracted with ethyl acetate (3 x 50 ml), 
breaking the emulsion formed with brine (3 x 50 ml). The organic phase was dried over 
magnesium sulphate, filtered and volatiles removed in vacuo to afford the title compound (453) 
as a pale yellow oil in 58% yield (7.900 g, 28.48 mmol). 
 
Molecular formula: C17H27NO2; Molecular weight: 277.408 gmol
-1
. 
 
1
H-NMR (400 MHz, CDCl3) δ (ppm): 7.32 – 7.19 (m, 5H), 4.09 (t, J = 6.8 Hz, 2H), 3.76 (dd, J 
= 7.6, 5.6 Hz, 1H), 3.10 (dd, J = 13.6, 5.2 Hz, 1H), 2.90 (dd, J = 13.6, 7.6 Hz, 1H), 1.60-1.57 
(m, 2H), 1.30 -1.24 (m, 10 H), 0.88 (t, J = 6.4 Hz, 3H). 
13
C-NMR (100 MHz, CDCl3) δ (ppm): 
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174.81, 137.12, 129.42, 128.68, 126.98, 65.39, 55.84, 40.93, 31.89, 29.27, 28.63, 25.97, 22.75, 
14.22. 
1
H-NMR and 
13
C-NMR were in agreement with the literature.
15
 
5.6.1.2 Preparation of ester (454) 
Decyl L-phenylalaninate (454). 
 
According the general procedure “H”, using L-
phenylalanine (12.361 g, 74.828 mmol), PTSA (15.657 g, 
82.31) and decanol (15 ml, 78 mmol), the title compound 
(454) was isolated as a pale yellow oil in 38% yield (8.602 
g, 26.26 mmol). 
 
Molecular formula: C19H31NO2; Molecular weight: 305.462 gmol
-1
. 
 
1
H-NMR (400 MHz, CDCl3) δ (ppm): 7.32 – 7.19 (m, 5H), 4.09 (t, J = 6.8 Hz, 2H), 3.75 (dd, J 
= 7.6, 5.6 Hz, 1H), 3.11 (dd, J = 13.6, 5.2 Hz, 1H), 2.90 (dd, J = 13.6, 7.6 Hz, 1H), 1.61-1.56 
(m, 2H), 1.32 -1.22 (m, 14 H), 0.88 (t, J = 6.4 Hz, 3H). 
1
H-NMR was in agreement with the literature.
16
  
 
5.6.1.3 Preparation of ester (455) 
Dodecyl L-phenylalaninate (455) 
According the general procedure “H”,  using L-
phenylalanine (12.255 g, 74.188 mmol), PTSA 
(15.524 g, 81.612 mmol) and dodecanol (13.823 g, 
74.182 mmol) the title compound was isolated as a 
pale yellow oil in 37% yield (9.130 g, 27.38 mmol). 
 
Molecular formula: C21H35NO2; Molecular weight: 333.516 gmol
-1
. 
 
1
H-NMR (400 MHz, CDCl3) δ (ppm): 7.30 – 7.19 (m, 5H), 4.09 (t, J = 6.8 Hz, 2H), 3.74 (dd, J 
= 7.6, 5.6 Hz, 1H), 3.10 (dd, J = 13.6, 5.2 Hz, 1H), 2.89 (dd, J = 13.6, 7.6 Hz, 1H), 1.61-1.58 
(m, 2H), 1.31-1.19 (m, 18 H), 0.88 (t, J = 6.4 Hz, 3H). 
1
H-NMR was in agreement with the literature.
16
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5.6.2 Preparation of Chapter 3 linear alkyl alkylating reagens (456-458) 
5.6.2.1 Preparation of alkylating reagent (456) 
Octyl (2-bromoacetyl)-L-phenylalaninate (456). 
 
According to general procedure “B”, using L-
phenylalanine octyl ester (453) (7.900 g, 28.48 mmol), 
Na2CO3 (3.924 g, 37.02 mmol), bromoacetyl bromide 
(2.95 ml, 33.9 mmol) and DCM (100 ml) the crude 
product was isolated as an off white solid. Purification was achieved by passing the crude 
product through a short plug of silica gel using 150 ml of 10% ethyl acetate: hexane. Solvent 
was removed in vacuo and the product was further dried under high vacuum for 24 hours to 
afford the title compound (456) as a white solid in 72% yield (8.184 g, 20.55 mmol). 
 
Molecular formula: C19H28BrNO3; Molecular weight: 398.341 gmol
-1
; Mp: 39-40 °C. 
 
[α]D
20 
= +16.8 (1.0 c, CHCl3), +0.9 (1.0 c, EtOH). 
1
H-NMR (400 MHz, CDCl3) δ (ppm): 7.35 – 
7.21 (m, 3H), 7.16 – 7.09 (m, 2H), 6.86 (d, J = 7.9 Hz, 1H), 4.89 – 4.79 (m, 1H), 4.17 – 4.03 
(m, 2H), 3.87 (d, J = 13.7 Hz, 1H), 3.83 (d, J = 13.8 Hz, 1H), 3.17 (dd, J = 12.5, 2.6 Hz, 1H), 
3.13 (dd, J = 12.2, 2.5 Hz, 1H), 1.64 – 1.56 (m, 2H), 1.35 – 1.22 (m, 10H), 0.89 (t, J = 6.8 Hz, 
3H). 
13
C-NMR (100 MHz, CDCl3) δ (ppm): 171.00, 165.16, 135.49, 129.43, 128.74, 127.40, 
66.02, 53.87, 37.92, 31.87, 29.25, 28.81, 28.52, 25.92, 22.75, 14.22. IR (neat) (cm
-1
): 3298 (b), 
2920 (m), 2854 (m), 1737 (s), 1719 (vs), 1649 (vs), 1542 (vs), 1280 (s), 1236 (s) 1208 (s), 1182 
(m), 1139 (m), 699 (s). ESI-MS (+ve) m/z: Found [M+H]
+
 398.1338, C19H29BrNO3
+
 requires 
398.1325. 
5.6.2.2 Preparation of alkylating reagent (457) 
Decyl (2-bromoacetyl)-L-phenylalaninate (457). 
 
According to the general procedure “B”, using L-
phenylalanine decyl ester (454) (8.020 g, 26.26 
mmol), Na2CO3 (3.618 g, 34.14 mmol), bromoacetyl 
bromide (2.75 ml, 31.5 mmol) and DCM (100 ml),  
the title compound was isolated as a white solid in 51% yield (5.675 g, 13.31 mmol). 
 
Molecular formula: C21H32BrNO3; Molecular weight: 426.395 gmol
-1
; Mp: 43-44 °C. 
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[α]D
20 
= +15.4 (1.0 c, CHCl3), +2.4 (1.0 c, EtOH). 
1
H-NMR (400 MHz, CDCl3) δ (ppm): 7.35 – 
7.21 (m, 3H), 7.16 – 7.09 (m, 2H), 6.86 (d, J = 7.9 Hz, 1H), 4.89 – 4.79 (m, 1H), 4.17 – 4.03 
(m, 2H), 3.87 (d, J = 13.7 Hz, 1H), 3.83 (d, J = 13.8 Hz, 1H), 3.17 (dd, J = 12.5, 2.6 Hz, 1H), 
3.13 (dd, J = 12.2, 2.5 Hz, 1H), 1.64 – 1.56 (m, 2H), 1.35 – 1.22 (m, 14H), 0.89 (t, J = 6.8 Hz, 
3H). 
13
C-NMR (100 MHz, CDCl3) δ (ppm): 170.96, 165.11, 135.46, 129.40, 128.70, 127.36, 
65.99, 53.83, 37.89, 31.96, 29.60, 29.56, 29.38, 29.26, 28.78, 28.49, 25.89, 22.76, 14.21. IR 
(neat) (cm
-1
): 3298 (b), 2920 (m), 2854 (m), 1719 (vs), 1649 (vs), 1542 (vs), 1280 (s), 1208 (s), 
1182 (m), 1139 (m), 971 (m), 699 (s). ESI-MS (+ve) m/z: Found [M+Na]
+ 
448.1462, 
NaC21H32BrNO3
+
 requires 448.1458. 
5.6.2.3 Preparation of alkylating reagent (458) 
Dodecyl (2-bromoacetyl)-L-phenylalaninate (458). 
 
According to the general procedure “B”, using L-
phenylalanine dodecyl ester (455) (9.130 g, 27.38 
mmol), Na2CO3 (3.772 g, 35.59 mmol), 
bromoacetyl bromide (2.9 ml, 33 mmol) and 
DCM (100 ml), the title compound was isolated as a white solid in 88% yield (10.940 g, 24.073 
mmol). 
 
Molecular formula: C23H36BrNO3; Molecular weight: 454.449 gmol
-1
; Mp: 55-56 °C. 
 
[α]D
20 
= +14.7 (1.0 c, CHCl3), +1.0 (1.0 c, EtOH). 
1
H-NMR (400 MHz, CDCl3) δ (ppm): 7.35 – 
7.21 (m, 3H), 7.16 – 7.09 (m, 2H), 6.87 (d, J = 7.9 Hz, 1H), 4.89 – 4.79 (m, 1H), 4.16 – 4.05 
(m, 2H), 3.85 (d, J = 13.6 Hz, 1H), 3.84 (d, J = 13.6 Hz, 1H), 3.17 (dd, J = 12.1, 6.0 Hz, 1H), 
3.12 (dd, J = 12.3, 5.7 Hz, 1H), 1.66 – 1.51 (m, 2H), 1.35-1.22 (m, 18H), 0.88 (d, J = 6.9 Hz, 
3H). 
13
C-NMR (100 MHz, CDCl3) δ (ppm): 171.01, 165.15, 135.40, 129.45, 128.76, 127.42, 
66.05, 53.89, 37.95, 32.04, 29.78, 29.76, 29.70, 29.62, 29.48, 29.31, 28.84, 28.55, 25.94, 22.83, 
14.27. IR (neat) (cm
-1
): 3311 (b), 2918 (s), 2850 (m), 1734 (vs), 1647 (vs), 1533 (vs), 1496 (m), 
1199 (vs), 986 (m), 699 (s). ESI-MS (+ve) m/z: Found [M+Na]
+ 
476.1783, NaC23H36BrNO3
+
 
requires 476.1771. 
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5.6.3 Preparation of IL (432) 
(S)-1-(2-((1-(Octyloxy)-1-oxo-3-phenylpropan-2-yl)amino)-2-oxoethyl)pyridin-1-ium bromide 
(432). 
 
According to general procedure “E”, using octyl(2-
bromoacetyl)-L-phenylalaninate (456) (1.926 g, 4.835 
mmol), pyridine (380 µl, 4.72 mmol) and ethyl acetate 
(25 ml) the title compound (432) was isolated as a 
white solid in 98% yield (2.210 g, 4.629 mmol). 
 
Molecular formula: C24H33BrN2O3; Molecular weight: 477.443 gmol
-1
; Mp: 93-95 °C. 
 
[α]D
20 
= +1.5 (1.0 c, EtOH). 
1
H-NMR (400 MHz, CDCl3) δ (ppm): 9.27 (d, J = 7.8 Hz, 1H), 9.19 
– 9.12 (m, 2H), 8.40 (tt, J = 7.8, 1.4 Hz, 1H), 7.96 (dd, J = 7.9, 6.5 Hz, 2H), 7.38 – 7.30 (m, 
2H), 7.30 – 7.12 (m, 3H), 5.99 (s, 2H), 4.69 (ddd, J = 8.9, 7.7, 6.0 Hz, 1H), 4.07 – 3.96 (m, 2H), 
3.23 (dd, J = 13.9, 6.1 Hz, 1H), 3.16 (dd, J = 13.9, 8.9 Hz, 1H), 1.66 – 1.41 (m, 2H), 1.36 – 1.12 
(m, 10H), 0.87 (t, J = 6.8 Hz, 3H). 
13
C-NMR (100 MHz, CDCl3) δ (ppm): 171.08, 163.97, 
146.17, 145.29, 136.39, 129.69, 128.53, 127.69, 126.89, 65.85, 65.26, 55.05, 37.67, 31.89, 
29.28, 29.25, 28.49, 25.87, 22.75, 14.22. IR (neat) (cm
-1
): 3335 (b), 2915 (m), 2815 (m), 1737 
(vs), 1661 (vs), 1629 (s), 1534 (s), 1478 (s), 1349 (m), 1198 (s), 974 (s), 724 (s), 702 (s), 678 
(s). ESI-MS (+ve) m/z: Found [M–Br–]+ 397.2488, C24H33N2O3
+
 requires 397.2486. 
5.6.4 Preparation of IL (433) 
 (S)-1-(2-((1-(Decyloxy)-1-oxo-3-phenylpropan-2-yl)amino)-2-oxoethyl)pyridin-1-ium bromide 
(433). 
According to the general procedure “E”, decyl 
(2-bromoacetyl)-L-phenylalaninate (457) 
(1.461 g, 3.43 mmol), pyridine (270 µl, 3.36 
mmol) and ethyl acetate (25 ml), the title 
compound was isolated as a white solid in 99% 
yield (1.683 g, 3.329 mmol). 
 
Molecular formula: C26H37BrN2O3; Molecular weight: 505.497 gmol
-1
; Mp: 101-103 °C. 
 
[α]D
20 
= +2.0 (1.0 c, EtOH). 
1
H-NMR (400 MHz, CDCl3) δ (ppm): 9.30 (d, J = 7.8 Hz, 1H), 9.21 
– 9.14 (m, 2H), 8.40 (tt, J = 7.8, 1.4 Hz, 1H), 8.01 – 7.92 (m, 2H), 7.39 – 7.31 (m, 2H), 7.28 – 
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7.13 (m, 3H), 6.06 (d, J = 14.8 Hz, 1H), 6.01 (d, J = 14.7 Hz, 1H), 4.69 (ddd, J = 8.8, 7.7, 6.1 
Hz, 1H), 4.10 – 3.87 (m, 2H), 3.23 (dd, J = 13.8, 6.1 Hz, 1H), 3.17 (dd, J = 13.9, 8.8 Hz, 1H), 
1.56 – 1.47 (m, 2H), 1.35 – 1.12 (m, 14H), 0.87 (t, J = 7.0 Hz, 3H). 13C-NMR (100 MHz, CD-
Cl3) δ (ppm): 171.16, 164.06, 146.28, 145.38, 136.82, 129.84, 128.66, 127.80, 127.02, 66.00, 
62.34, 55.20, 37.77, 32.13, 29.79, 29.74, 29.56, 29.47, 28.64, 26.01, 22.93, 14.38. IR (neat) (cm
-
1
): 3335 (b), 2915 (m), 2815 (m), 1737 (s), 1661 (s), 1629 (m), 1534 (m), 1478 (m), 1349 (m), 
1198 (m), 974 (m), 724 (m), 702 (m), 678 (m). ESI-MS (+ve) m/z: Found [M–Br–]+ 425.2803, 
C26H37N2O3
+
 requires 425.2799. 
5.6.5 Preparation of IL (434) 
 (S)-1-(2-((1-(Dodecyloxy)-1-oxo-3-phenylpropan-2-yl)amino)-2-oxoethyl)pyridin-1-ium 
bromide (434). 
According to the general procedure “C”, 
using dodecyl (2-bromoacetyl)- L-
phenylalaninate (458) (1.541 g, 3.391 mmol), 
pyridine (270 µl, 3.32 mmol) and ethyl 
acetate (25 ml), the title compound (434) was isolated as a pale pink solid in 98% yield (1.742 
g, 3.265 mmol). 
 
Molecular formula: C28H41BrN2O3; Molecular weight: 533.551 gmol
-1
; Mp: 107-109 °C. 
 
[α]D
20 
= +2.6 (1.0 c, EtOH). 
1
H-NMR (400 MHz, CDCl3) δ (ppm): 9.28 (d, J = 7.8 Hz, 1H), 9.19 
– 9.11 (m, 2H), 8.40 (tt, J = 7.8, 1.4 Hz, 1H), 7.96 (dd, J = 7.9, 6.5 Hz, 2H), 7.37 – 7.30 (m, 
2H), 7.28 – 7.10 (m, 3H), 6.06 (d, J = 14.9 Hz, 1H), 6.03 (d, J = 14.9 Hz, 1H), 4.74 – 4.64 (m, 
1H), 4.07 – 3.91 (m, 2H), 3.22 (dd, J = 13.6, 6.4 Hz, 1H), 3.16 (dd, J = 13.6, 8.8 Hz, 1H), 1.63 – 
1.43 (m, 2H), 1.33 – 1.08 (m, 18H), 0.86 (t, J = 7.0 Hz, 3H). 13C-NMR (100 MHz, CDCl3) δ 
(ppm): 171.25, 164.13, 146.31, 145.42, 136.82, 129.82, 128.66, 127.80, 127.02, 65.99, 62.36, 
55.17, 37.80, 32.15, 29.90, 29.88, 29.84, 29.74, 29.60, 29.48, 28.63, 26.01, 22.93, 14.38. IR 
(neat) (cm
-1
): 3335 (b), 2915 (vs), 2815 (vs), 1737 (vs), 1661 (vs), 1629 (s), 1534 (s), 1478 (s), 
1349 (s), 1198 (m), 974 (m), 724 (s), 702 (m), 678 (m). ESI-MS (+ve) m/z: Found [M–Br–]+ 
453.3113, C28H41N2O3
+
 requires 453.3112. 
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5.6.6 Preparation of IL (435) 
(S)-1-Methyl-3-(2-((1-(octyloxy)-1-oxo-3-phenylpropan-2-yl)amino)-2-oxoethyl)-1H-imidazol-
3-ium bromide (435). 
According to the general procedure “E”, using octyl 
(2-bromoacetyl)-L-phenylalaninate (456) (1.060 g, 
2.661 mmol), 1-methylimidazole (210 µl, 2.63 
mmol) and ethyl acetate (25 ml), the title compound 
(435) was isolated as a white solid in 97% yield (1.244 g, 2.589 mmol). 
 
Molecular formula: C23H34BrN3O3; Molecular weight: 480.447 gmol
-1
; Mp: 64-66 °C. 
 
[α]D
20 
= +5.4 (1.0 c, EtOH). 
1
H-NMR (400 MHz, CDCl3) δ (ppm): 9.71 (s, 1H), 8.97 (d, J = 7.7 
Hz, 1H), 7.41 (t, J = 1.7 Hz, 1H), 7.38 – 7.29 (m, 2H), 7.29 – 7.26 (m, 1H), 7.26 – 7.23 (m, 1H), 
7.21 – 7.14 (m, 2H), 5.39 (d, J = 15.5 Hz, 1H), 5.34 (d, J = 15.5 Hz, 1H), 4.73 – 4.63 (m, 1H), 
4.01 (m, 2H), 3.98 (s, 3H), 3.26 – 3.19 (m, 1H), 3.17 (dd, J = 11.5, 4.0 Hz, 1H), 1.60 – 1.46 (m, 
2H), 1.34-1.14 (m, 10H), 0.87 (t, J = 6.8 Hz, 3H). 
13
C-NMR (100 MHz, CDCl3) δ (ppm): 
171.36, 164.81, 137.86, 136.73, 129.60, 128.51, 126.88, 123.76, 122.46, 65.79, 54.89, 51.67, 
37.54, 36.87, 31.87, 29.28, 29.24, 28.48, 25.87, 22.74, 14.21. IR (neat) (cm
-1
): 3431 (b), 3340 
(b), 2915 (m), 1736 (vs), 1666 (vs), 1533 (s), 1352 (s), 1201 (vs), 1167 (vs), 974 (s), 752 (s), 
702 (s). ESI-MS (+ve) m/z: Found [M–Br–]+ 400.2603, C23H34N3O3
+
 requires 400.2595. 
5.6.7 Preparation of IL (436) 
(S)-3-(2-((1-(Decyloxy)-1-oxo-3-phenylpropan-2-yl)amino)-2-oxoethyl)-1-methyl-1H-imidazol-
3-ium bromide (436). 
According to the general procedure “E”, using 
decyl (2-bromoacetyl)-L-phenylalaninate (457) 
(1.317 g, 3.089 mmol), 1-methylimidazole (240 
µl, 3.03 mmol) and ethyl acetate (25 ml) the 
title compound (436) was isolated as a white solid in 92% yield (1.424 g, 2.800 mmol). 
 
Molecular formula: C25H38BrN3O3; Molecular weight: 508.501 gmol
-1
; Mp: 80-82 °C. 
 
[α]D
20 
= +5.2 (1.0 c, EtOH). 
1
H-NMR (400 MHz, CDCl3) δ (ppm): 9.80 (s, 1H), 8.94 (d, J = 7.7 
Hz, 1H), 7.42 (t, J = 1.5 Hz, 1H), 7.37 – 7.30 (m, 2H), 7.29 – 7.24 (m, 2H), 7.24 – 7.16 (m, 1H), 
7.13 (t, J = 1.6 Hz, 1H), 5.38 (d, J = 15.4 Hz, 1H), 5.32 (d, J = 15.4 Hz, 1H), 4.73 – 4.63 (m, 
1H), 4.03 (m, 2H), 3.98 (s, 3H), 3.22 (dd, J = 12.9, 5.3 Hz, 1H), 3.17 (dd, J = 12.9, 7.6 Hz, 1H), 
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1.61 – 1.47 (m, 2H), 1.34 – 1.15 (m, 14H), 0.87 (t, J = 6.8 Hz, 3H). 13C-NMR (100 MHz, CD-
Cl3) δ (ppm): 171.49, 164.94, 137.92, 136.80, 129.67, 128.60, 126.97, 123.83, 122.58, 65.89, 
54.96, 51.71, 37.62, 36.93, 32.06, 29.72, 29.67, 29.49, 29.41, 28.56, 25.96, 22.85, 14.30. IR 
(neat) (cm
-1
): 3431 (b), 3340 (b), 2915 (m), 1736 (vs), 1666 (vs), 1533 (s), 1352 (s), 1201 (vs), 
1168 (vs), 974 (s), 752 (vs), 702 (s). ESI-MS (+ve) m/z: Found [M–Br–]+ 428.2913, 
C25H38N3O3
+
 requires 428.2908 
5.6.8 Preparation of IL (437) 
(S)-3-(2-((1-(Dodecyloxy)-1-oxo-3-phenylpropan-2-yl)amino)-2-oxoethyl)-1-methyl-1H-
imidazol-3-ium bromide (437). 
According to the general procedure “E”, 
using dodecyl (2-bromoacetyl)-L-
phenylalaninate (458) (1.438 g, 3.164 
mmol), 1-methylimidazole (250 µl, 3.13 
mmol) and ethyl acetate (25 ml), the title 
compound (437) was isolated as a white solid in 73% yield (1.221 g, 2.276 mmol). 
 
Molecular formula: C27H42BrN3O3; Molecular weight: 536.555 gmol
-1
; Mp: 94-96 °C. 
 
[α]D
20 
= +5.3 (1.0 c, EtOH). 
1
H-NMR (400 MHz, CDCl3) δ (ppm): 9.75 (s, 1H), 8.94 (d, J = 7.7 
Hz, 1H), 7.42 (t, J = 1.5 Hz, 1H), 7.37 – 7.29 (m, 2H), 7.34 – 7.22 (m, 2H), 7.23 – 7.16 (m, 1H), 
7.15 (t, J = 1.5 Hz, 1H), 5.38 (d, J = 15.5 Hz, 1H), 5.33 (d, J = 15.5 Hz, 1H), 4.74 – 4.63 (m, 
1H), 4.02 (m, 2H), 3.98 (s, 3H), 3.22 (dd, J = 12.5, 4.9 Hz, 1H), 3.17 (dd, J = 12.5, 7.0 Hz, 1H), 
1.62 – 1.46 (m, 2H), 1.34 – 1.22 (m, 18H), 0.87 (t, J = 7.2 Hz, 3H). 13C-NMR (100 MHz, CD-
Cl3) δ (ppm): 171.28, 164.72, 137.92, 136.70, 129.63, 128.52, 126.88, 123.83, 122.29, 65.84, 
54.89, 51.74, 37.51, 36.87, 32.02, 29.77, 29.75, 29.71, 29.61, 29.46, 29.35, 28.51, 25.89, 22.80, 
14.24. IR (neat) (cm
-1
): 3432 (b), 3340 (b), 2916 (m), 1735 (vs), 1666 (vs), 1535 (s), 1352 (s), 
1202 (s), 1162 (m), 970 (m), 753 (m), 703 (m). ESI-MS (+ve) m/z: Found [M–Br–]+ 456.3227, 
C27H42N3O3
+
 requires 456.3221.  
5.6.9 Preparation of IL (438) 
(S)-N-(2-Hydroxyethyl)-N,N-dimethyl-2-((1-(octyloxy)-1-oxo-3-phenylpropan-2-yl)amino)-2-
oxoethan-1-aminium bromide (438). 
The title compound was synthesised according to 
general procedure “C”, using octyl (2-
bromoacetyl)-L-phenylalaninate (456) (1.559 g, 
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3.914 mmol), dimethylethanolamine (380 µl, 3.84 mmol) and diethyl ether (25 ml). Product was 
observed precipitating as a white solid after 30 min. The solution was stirred at room 
temperature (48 hours) until no more dimethylethanolamine could be detected by TLC 10% 
MeOH: DCM visualised using ninhydrin stain. The crude product was washed with diethyl 
ether (3 x 50 ml) to afford the title compound (438) as a white solid in 94% yield (1.750 g, 
3.590 mmol). 
 
Molecular formula: C23H39BrN2O4; Molecular weight: 487.479 gmol
-1
; Mp: 80-82 °C. 
 
[α]D
20 
= -18.2 (1.0 c, EtOH). 
1
H-NMR (400 MHz, CDCl3) δ (ppm): 8.95 (d, J = 7.9 Hz, 1H), 
7.40 – 7.32 (m, 2H), 7.31 – 7.15 (m, 3H), 4.80 – 4.72 (m, 1H), 4.70 (d, J = 14.0 Hz, 1H), 4.45 
(d, J = 14.0 Hz, 1H), 4.15 – 4.00 (m, 4H), 3.75 – 3.59 (m, 2H), 3.36 (s, 3H), 3.30 (s, 3H), 3.26 
(dd, J = 14.0, 5.1 Hz, 1H), 3.09 (dd, J = 13.9, 10.0 Hz, 1H), 1.65 – 1.52 (m, 2H), 1.34 – 1.18 (m, 
10H), 0.88 (t, J = 7.5 Hz, 3H). 
13
C-NMR (100 MHz, CDCl3) δ (ppm): 171.11, 163.06, 136.53, 
129.59, 128.62, 127.06, 67.72, 65.99, 63.24, 55.96, 54.54, 53.70, 37.28, 31.86, 29.26, 29.23, 
28.51, 25.88, 22.72, 14.19. IR (neat) (cm
-1
): 3323 (b), 3222 (b), 2921 (b), 1738 (vs), 1689 (vs), 
1547 (s), 1347 (s), 1279 (s), 1215 (m), 1180 (s), 1083 (s), 979 (s), 763 (s), 681 (s).ESI-MS (+ve) 
m/z: Found [M–Br–]+ 407.2905, C23H39N2O4
+
 requires 407.2904. 
5.6.10 Preparation of IL (439) 
(S)-2-((1-(Decyloxy)-1-oxo-3-phenylpropan-2-yl)amino)-N-(2-hydroxyethyl)-N,N-dimethyl-2-
oxoethan-1-aminium bromide (439). 
According to the general procedure “C”, 
using decyl (2-bromoacetyl)-L-
phenylalaninate (457) (1.471 g, 3.450 mmol), 
dimethylethanolamine (340 µl, 3.38 mmol) 
and diethyl ether (25 ml), the title compound 
(439) was isolated as a white solid in 61% yield (1.062 g, 2.060 mmol). 
 
Molecular formula: C25H43BrN2O4; Molecular weight: 505.497 gmol
-1
; Mp: 57-59 °C. 
 
[α]D
20 
= -5.6 (1.0 c, EtOH). 
1
H-NMR (400 MHz, CDCl3) δ (ppm): 8.93 (d, J = 7.9 Hz, 1H), 7.39 
– 7.15 (m, 5H), 4.75 (ddd, J = 10.0, 7.9, 5.1 Hz, 1H), 4.67 (d, J = 14.1 Hz, 1H), 4.45 (d, J = 14.1 
Hz, 1H), 4.15 – 4.00 (m, 4H), 3.75 – 3.61 (m, 2H), 3.36 (s, 3H), 3.30 (s, 3H), 3.25 (dd, J = 14.0, 
5.1 Hz, 1H), 3.08 (dd, J = 14.0, 10.0 Hz, 1H), 1.61 – 1.53 (m, 2H), 1.33 – 1.13 (m, 14H), 0.87 
(t, J = 7.0 Hz, 3H).
13
C-NMR (100 MHz, CDCl3) δ (ppm): 171.16, 163.11, 136.53, 129.59, 
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128.63, 127.08, 67.67, 66.01, 63.30, 55.97, 54.52, 53.62, 37.32, 31.98, 29.64, 29.59, 29.41, 
29.33, 28.53, 25.90, 22.78, 14.23. IR (neat) (cm
-1
): 3323 (b), 3231 (b), 2920 (vs), 1738 (vs), 
1689 (vs), 1547 (s), 1200 (vs), 1083 (s), 681 (s). ESI-MS (+ve) m/z: Found [M–Br–]+ 435.3226, 
C25H43N2O4
+
 requires 435.3217. 
5.6.11 Preparation of IL (440) 
(S)-2-((1-(Dodecyloxy)-1-oxo-3-phenylpropan-2-yl)amino)-N-(2-hydroxyethyl)-N,N-dimethyl-
2-oxoethan-1-aminium bromide (440). 
According to a modified general 
procedure “C”, using dodecyl (2-
bromoacetyl)-L-phenylalaninate (458) 
(1.946 g, 4.282 mmol), 
dimethylethanolamine (430 µl, 4.27 mmol) and diethyl ether (25 ml) were stirred at room 
temperature for 25 hours. The product did not readily precipitate and the crude product was 
isolated after solvent was removed in vacuo. General procedure “C” was modified to employ 
hexane as the trituration solvent (3 x 50 ml) as opposed to diethyl ether due to increased 
solubility of the title compound (440) in diethyl ether. The triturated product was dried under 
high vacuum to give the title product as a white solid in 89% yield (2.062 g 3.793 mmol). 
 
Molecular formula: C27H47BrN2O4; Molecular weight: 543.587 gmol
-1
; Mp: 63-65 °C. 
 
[α]D
20 
= -5.8 (1.0 c, EtOH). 
1
H-NMR (400 MHz, CDCl3) δ (ppm): 8.91 (d, J = 8.0 Hz, 1H), 7.38 
– 7.12 (m, 5H), 4.74 (ddd, J = 9.9, 7.9, 5.2 Hz, 1H), 4.65 (d, J = 14.1 Hz, 1H), 4.45 (d, J = 14.1 
Hz, 1H), 4.14 – 4.00 (m, 4H), 3.74 – 3.64 (m, 2H), 3.35 (s, 3H), 3.30 (s, 3H), 3.24 (dd, J = 13.9, 
5.1 Hz, 1H), 3.08 (dd, J = 14.1, 10.0 Hz, 1H), 1.57 (q, J = 6.9 Hz, 2H), 1.36-1.17(m, 18H), 0.87 
(t, J = 6.6 Hz, 3H). 
13
C-NMR (100 MHz, CDCl3) δ (ppm): 171.23, 163.18, 136.58, 129.63, 
128.68, 127.13, 67.67, 66.06, 63.38, 56.01, 54.55, 53.60, 37.38, 32.06, 29.81, 29.79, 29.74, 
29.66, 29.50, 29.40, 28.58, 25.96, 22.83, 14.28. IR (neat) (cm
-1
): 3320 (b), 3230 (b), 2920 (vs), 
1738 (vs), 1689 (vs), 1546 (vs), 1180 (vs), 1084 (s), 694 (s). ESI-MS (+ve) m/z: Found [M–Br–
]
+
 463.3539, C27H47N2O4
+
 requires 463.3530. 
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5.6.12 Preparation of IL (441) 
(S)-3-(Ethoxycarbonyl)-1-(2-((1-(octyloxy)-1-oxo-3-phenylpropan-2-yl)amino)-2-
oxoethyl)pyridin-1-ium bromide (441). 
The title compound was synthesised 
according to a modified general procedure 
“E”, using using octyl (2-bromoacetyl)-L-
phenylalaninate (456)(0.741 g, 1.86 mmol), 
ethyl nicotinate (240 µl, 1.82 mmol) and 
DMF (5 ml). The reaction was heated at 100 °C for 48 hours. After 48 hours the reaction 
mixture was allowed to cool to room temperature and the DMF was removed in vacuo to afford 
a brown crude product. Purification of the crude product was accomplished by silica gel 
chromatography (eluent 7:93 MeOH:DCM) to afford the title compound (441) as an orange 
solid in 36% yield (0.359 g, 0.653 mmol). 
 
Molecular formula: C27H37BrN2O5; Molecular weight: 549.506 gmol
-1
; Mp: 43-45 °C. 
 
[α]D
20 
= -0.7 (1.0 c, EtOH). 
1
H-NMR (400 MHz, CDCl3) δ (ppm): 9.65 (d, J = 6.0 Hz, 1H), 9.40 
– 9.31 (m, 2H), 8.91 (d, J = 8.1 Hz, 1H), 8.10 (dd, J = 7.9, 6.2 Hz, 1H), 7.38 – 7.31 (m, 2H), 
7.29 – 7.20 (m, 2H), 7.20 – 7.10 (m, 1H), 6.21 (d, J = 15.3 Hz, 1H), 6.15 (d, J = 15.3 Hz, 1H), 
4.78 – 4.64 (m, 1H), 4.50 (q, J = 7.1 Hz, 2H), 4.10 – 3.94 (m, 2H), 3.28 – 3.11 (m, 2H), 1.59 – 
1.47 (m, 1H), 1.45 (t, J = 7.1 Hz, 3H), 1.34 – 1.16 (s, 10H), 0.87 (t, J = 6.9 Hz, 3H). 13C-NMR 
(100 MHz, CDCl3) δ (ppm): 171.18, 163.75, 160.93, 149.69, 147.00, 145.42, 136.67, 130.48, 
129.69, 128.55, 127.76, 126.92, 65.88, 63.69, 62.85, 55.14, 37.78, 31.90, 29.30, 29.27, 28.50, 
25.88, 22.76, 14.31, 14.23. IR (neat) (cm
-1
): 3192 (b), 3031 (m), 2926 (s), 2856 (m), 1733 (vs), 
1687 (vs), 1547 (m), 1467 (m), 1370 (m), 1299 (vs), 1203 (vs), 1113 (m), 1016 (m), 742 (m), 
701 (m). ESI-MS (+ve) m/z: Found [M–Br–]+ 469.2704, C27H37N2O5
+
 requires 469.2697. 
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5.7 Experimental preparation of Chapter 3 bolaform amino acid 
surfactant ILs 
5.7.1 Preparation of Chapter 3 bolaform amino acid esters (459-561) 
5.7.1.1 Preparation of ester (459) 
Octane-1,8-diyl (2S,2'S)-bis(2-amino-3-phenylpropanoate) (459). 
 
 
 
 
 
 
 
According to the general procedure “H”, using L-phenylalanine (15.029 g, 90.981 mmol), 1,8-
octane diol (7.236 g, 49.49 mmol), PTSA (19.037 g, 100.05 mmol) and toluene (100 ml), the 
title compound (459) was isolated as a pale yellow oil in 36% yield (7.810 g, 17.73 mmol) 
 
Molecular formula: C26H36N2O4; Molecular weight: 440.584 gmol
-1
. 
 
1
H-NMR (400 MHz, CDCl3) δ (ppm): 7.33 – 7.17 (m, 10H), 4.08 (t, J = 6.7 Hz, 4H), 3.71 (dd, J 
= 7.7, 5.5 Hz, 2H), 3.07 (dd, J = 13.5, 5.4 Hz, 2H), 2.86 (dd, J = 13.5, 7.8 Hz, 2H), 1.70-1.45 
(m, 4H), 1.35 – 1.26 (m, 8H). 13C-NMR (100 MHz, CDCl3) δ (ppm): 175.14, 137.27, 129.30, 
128.55, 126.82, 65.04, 55.88, 41.21, 29.09, 28.52, 25.81. 
5.7.1.2 Preparation of ester (460) 
Decane-1,10-diyl (2S,2'S)-bis(2-amino-3-phenylpropanoate) (460). 
 
 
 
 
 
 
According to the general procedure “H” using L-phenylalanine (9.629 g, 58.29 mmol), 1,10-
decane diol (5.079 g, 29.14 mmol), PTSA (12.197 g, 64.120 mmol) and toluene (75 ml), the 
title compound (460) was isolated as an orange oil in 55% yield (7.512 g, 16.029 mmol). 
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Molecular formula: C28H40N2O4; Molecular weight: 468.638 gmol
-1
.  
 
1
H-NMR (400 MHz, CDCl3) δ (ppm): 7.43 – 7.10 (m, 10H), 4.19 – 4.03 (m, 2H), 3.66 (t, J = 
6.6 Hz, 2H), 3.12 (dd, J = 13.3, 5.5 Hz, 2H), 2.91 (dd, J = 13.7, 7.7 Hz, 2H), 2.86 (dd, J = 13.5, 
7.8 Hz, 2H), 1.64-1.53 (m, 4H), 1.33 – 1.28 (m, 12H). 13C-NMR (100 MHz, CDCl3) δ (ppm): 
175.12, 137.33, 129.44, 128.70, 126.98, 65.31, 55.94, 41.20, 29.29, 28.67, 25.85. 
5.7.1.3 Preparation of ester (461) 
Dodecane-1,12-diyl (2S,2'S)-bis(2-amino-3-phenylpropanoate) (461). 
 
According to the general procedure “H”, using L-phenylalanine (9.890 g, 59.87 mmol), 1,12-
dodecane diol (6.057 g, 29.93 mmol), PTSA (12.527 g, 65.856 mmol) and toluene (75 ml), the 
title compound (461) was isolated as an orange oil in 61% yield (9.093 g, 18.31 mmol). 
 
Molecular formula: C30H44N2O4; Molecular weight: 496.692 gmol
-1
. 
 
1
H-NMR (400 MHz, CDCl3) δ (ppm): 7.40 – 7.01 (m, 10H), 4.09 (t, J = 6.7 Hz, 2H), 3.80 – 
3.69 (m, 2H), 3.63 (td, J = 6.6, 1.3 Hz, 2H), 3.09 (dd, J = 13.5, 5.3 Hz, 2H), 2.88 (dd, J = 13.5, 
7.8 Hz, 2H), 1.64 – 1.50 (m, 4H), 1.38 – 1.24 (m, 16H). 13C-NMR (100 MHz, CDCl3) δ (ppm): 
175.23, 137.40, 129.44, 128.69, 126.96, 65.31, 56.00, 41.29, 29.33, 28.68, 25.87. 
5.7.2 Preparation of Chapter 3 bolaform alkylating reagens (462-465) 
5.7.2.1 Preparation of alkylating reagent (462) 
Octane-1,8-diyl (2S,2'S)-bis(2-(2-bromoacetamido)-3-phenylpropanoate) (462). 
 
 
 
 
 
 
According to the general procedure “B”, using bis-ester (459) (6.923 g, 15.71 mmol), 
bromoacetyl bromide (3.05 ml, 35.0 mmol), Na2CO3 (3.995 g, 37.70 mmol) and DCM (50 ml) a 
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crude product was isolated as a white solid. The crude product was purified by silica gel 
chromatography (eluent 30:70 ethyl acetate:hexane), to afford the title compound (462) as white 
solid in 26% yield (2.822 g, 4.135 mmol). 
 
Molecular formula: C30H38Br2N2O6; Molecular weight: 682.450 gmol
-1
; Mp: 97-99 °C. 
 
[α]D
20 
= + 30.2 (1.0 c, CHCl3). 
1
H-NMR (400 MHz, CDCl3) δ (ppm): 7.34 – 7.19 (m, 6H), 7.16 
– 7.08 (m, 4H), 6.88 (d, J = 7.9 Hz, 2H), 4.88 – 4.78 (m, 2H), 4.19 – 4.03 (m, 4H), 3.86 (d, J = 
13.6 Hz, 2H), 3.81 (d, J = 13.5 Hz, 2H), 3.17 (dd, J = 12.8, 4.8 Hz, 2H), 3.12 (dd, J = 12.8, 4.9 
Hz, 2H), 1.64 – 1.54 (m, 4H), 1.29 (s, 8H). 13C-NMR (100 MHz, CDCl3) δ (ppm): 171.02, 
165.19, 135.50, 129.44, 128.77, 127.42, 65.90, 53.88, 39.79, 29.14, 28.83, 28.51, 25.84. IR 
(neat) (cm
-1
): 2935 (m), 2847 (w), 1727 (vs), 1650 (vs), 1536 (s), 1202 (vs), 1183 (s), 1138 (m), 
1275 (m), 1232 (s), 1205 (vs), 1174 (s), 698 (vs). ESI-MS (+ve) m/z: Found [M+H]
+ 
681.1174, 
C30H39Br2N2O6
+
 requires 681.1169. 
5.7.2.2 Preparation of alkylating reagent (463) 
Decane-1,10-diyl (2S,2'S)-bis(2-(2-bromoacetamido)-3-phenylpropanoate) (463). 
 
According to the general procedure “B”, using bis-ester (460) (5.403 g, 11.54 mmol), 
bromoacetyl bromide (2.25 ml, 25.8 mmol), Na2CO3 (2.813 g, 26.54 mmol) and DCM (50 ml) 
the crude product was isolated as a white solid. The crude product was purified by silica gel 
chromatography (eluent 30:70 ethyl acetate:hexane), to afford the title compound (463) as white 
solid in 24% yield (1.959 g, 2.757 mmol). 
 
Molecular formula: C32H42Br2N2O6; Molecular weight: 710.504 gmol
-1
; Mp: 88-90 °C. 
 
[α]D
20 
= + 30.5 (1.0 c, CHCl3). 
1
H-NMR (400 MHz, CDCl3) δ (ppm): 7.35 – 7.21 (m, 6H), 7.16 
– 7.08 (m, 4H), 6.87 (d, J = 7.9 Hz, 2H), 4.88 – 4.79 (m, 2H), 4.18 – 4.03 (m, 4H), 3.86 (d, J = 
14.0 Hz, 2H), 3.83 (d, J = 13.9 Hz, 2H), 3.17 (dd, J = 12.9, 5.8 Hz, 2H), 3.12 (dd, J = 12.6, 4.6 
Hz, 2H), 1.66 – 1.54 (m, 4H), 1.33 – 1.19 (m, 12H). 13C-NMR (100 MHz, CDCl3) δ (ppm): 
170.99, 165.14, 135.48, 129.42, 128.74, 127.40, 65.96, 53.86, 37.92, 29.48, 29.24, 28.81, 28.51, 
25.89. IR (neat) (cm
-1
): 2920 (m), 2849 (w), 1727 (vs), 1654 (vs), 1537 (s), 1355 (s), 1222 (s), 
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1192 (vs), 1183 (vs), 693 (vs). ESI-MS (+ve) m/z: Found [M+H]
+ 
709.1495, C32H43Br2N2O6
+
 
requires 709.1482. 
5.7.2.3 Preparation of alkylating reagent (464) 
Dodecane-1,12-diyl (2S,2'S)-bis(2-(2-bromoacetamido)-3-phenylpropanoate) (464). 
 
According to the general procedure “B”, using bis-dodecyl ester (461) (6.396 g, 12.88 mmol), 
bromoacetyl bromide (3.4 ml, 39.0 mmol), Na2CO3 (4.369 g, 41.22 mmol) and DCM (50 ml) 
the crude product was isolated as a white solid. The crude product was purified by silica gel 
chromatography (eluent 30:70 ethyl acetate: hexane) to afford the title compound (464) as white 
solid in 40% yield (3.832 g, 5.188 mmol). 
 
Molecular formula: C34H46Br2N2O6; Molecular weight: 738.558 gmol
-1
; Mp: 64-66 °C. 
 
[α]D
20 
= + 20.1 (1.0 c, CHCl3). 
1
H-NMR (400 MHz, CDCl3) δ (ppm): 7.33 – 7.22 (m, 6H), 7.15 
– 7.10 (m, 4H), 6.86 (d, J = 7.8 Hz, 2H), 4.87 – 4.80 (m, 2H), 4.15 – 4.05 (m, 4H), 3.86 (d, J = 
13.6 Hz, 2H), 3.83 (d, J = 13.7 Hz, 2H), 3.16 (dd, J = 13.5, 5.8 Hz, 2H), 3.12 (dd, J = 13.6, 6.2 
Hz, 2H), 1.63 – 1.58 (m, 4H), 1.31 – 1.24 (m, 16H). 13C-NMR (100 MHz, CDCl3) δ (ppm): 
170.99, 165.15, 135.48, 129.42, 128.73, 127.39, 65.99, 53.85, 37.91, 29.62, 29.56, 29.27, 28.80, 
28.51, 25.90. IR (neat) (cm
-1
): 2924 (b), 2853 (w), 1732 (vs), 1650 (vs), 1529 (s), 1362 (s), 1228 
(s), 1201 (vs), 974 (vs), 699 (vs). ESI-MS (+ve) m/z: Found [M+H]
+
 737.1802, C34H47Br2N2O6
+
 
requires 737.1795. 
5.7.3 Preparation of IL (444) 
1,1'-((4S,17S)-4,17-Dibenzyl-2,5,16,19-tetraoxo-6,15-dioxa-3,18-diazaicosane-1,20-
diyl)bis(pyridin-1-ium) bromide (444). 
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According to the general procedure “E”, using bis-alkylating reagent (462) (0.880 g, 1.29 
mmol), pyridine (210 µl, 2.58 mmol) and ethyl acetate (25 ml), the title compound (444) was 
isolated as a white solid in 98% yield (1.065 g, 1.267 mmol). 
 
Molecular formula: C40H48Br2N4O6; Molecular weight: 840.654 gmol
-1
;Mp: 124-126 °C. 
 
[α]D
20 
= + 3.2 (1.0 c, MeOH).
1
H-NMR (400 MHz, D2O) δ (ppm): 8.62 – 8.51 (m, 6H), 8.06 – 
7.97 (m, 4H), 7.27 – 7.08 (m, 10H), 5.43 (d, J = 16.1 Hz, 2H), 5.37 (d, J = 16.1 Hz, 2H), 4.63 
(dd, J = 8.3, 7.0 Hz, 2H), 4.02 – 3.86 (m, 4H), 3.07 (dd, J = 13.8, 6.9 Hz, 2H), 2.99 (dd, J = 
13.8, 8.3 Hz, 2H), 1.45 – 1.26 (m, 4H), 1.10 – 0.93 (m, 8H). 13C-NMR (100 MHz, D2O) δ 
(ppm): 172.54, 165.29, 146.72, 145.42, 136.01, 129.11, 128.66, 127.98, 127.18, 66.21, 61.48, 
54.64, 36.96, 28.29, 27.66, 25.08. IR (neat) (cm
-1
): 3219 (b), 3039 (b), 2926 (m), 2744 (w), 
1738 (s), 1679 (vs), 1634 (s), 1555 (m), 1488 (s), 1200 (s), 693 (m). ESI-MS (+ve) m/z: Found 
[M-2Br]
+
 340.1790, C40H48N4O6
2+
 requires (680.3563)/2 = 340.1782 
5.7.4 Preparation of IL (445) 
1,1'-((4S,19S)-4,19-Dibenzyl-2,5,18,21-tetraoxo-6,17-dioxa-3,20-diazadocosane-1,22-
diyl)bis(pyridin-1-ium) (445). 
 
According to the general procedure “E”, using bis-alkylating reagent (463) (0.502 g, 0.707 
mmol), pyridine (110 µl, 1.41 mmol) and ethyl acetate (25 ml), the title compound (445) was 
isolated as a white solid in 94% yield (0.579 g, 0.667 mmol). 
 
Molecular formula: C42H52Br2N4O6; Molecular weight: 868.708 gmol
-1
; Mp: 137.139 °C. 
 
[α]D
20 
= + 3.4 (1.0 c, MeOH). 
1
H-NMR (400 MHz, D2O) δ (ppm): 8.65 – 8.52 (m, 6H), 8.11 – 
8.00 (m, 4H), 7.34 – 7.15 (m, 10H), 5.42 (d, J = 15.9 Hz, 2H), 5.35 (d, J = 16.2 Hz, 2H), 4.73 – 
4.65 (m, 2H), 4.15 – 3.93 (m, 4H), 3.16 (dd, J = 13.9, 6.4 Hz, 2H), 3.01 (dd, J = 13.8, 8.8 Hz, 
2H), 1.55 – 1.38 (m, 4H), 1.27 – 1.06 (m, 12H). 13C-NMR (100 MHz, D2O) δ (ppm): 172.35, 
165.20, 146.71, 145.44, 136.05, 129.12, 128.57, 127.98, 127.07, 65.86, 61.53, 54.58, 37.10, 
29.01, 28.84, 27.87, 25.44. IR (neat) (cm
-1
): 3166 (b), 3034 (b), 2911 (m), 2853 (w), 1738 (s), 
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1668 (vs), 1634 (m), 1527 (s), 1487 (s), 1200 (s), 689 (vs). ESI-MS (+ve) m/z: Found [M-2Br]
+ 
345.1936, C42H52N4O6
2+
 requires (708.3876)/2 = 354.1938. 
5.7.5 Preparation of IL (446) 
1,1'-((4S,21S)-4,21-Dibenzyl-2,5,20,23-tetraoxo-6,19-dioxa-3,22-diazatetracosane-1,24-
diyl)bis(pyridin-1-ium) bromide (446). 
 
According to the general procedure “E”, using bis-alkylating reagent (464) (0.716 g, 0.969 
mmol), pyridine (150 µl, 1.92 mmol) and ethyl acetate (25 ml), the title compound (446) was 
isolated as a white solid in 91% yield (0.790 g, 0.881 mmol). 
 
Molecular formula: C44H56Br2N4O6; Molecular weight: 896.762 gmol
-1
; Mp: 138-140 °C. 
 
[α]D
20 
= + 5.1 (1.0 c, MeOH). 
1
H-NMR (400 MHz, CDCl3) δ (ppm): 8.61 – 8.56 (m, 4H), 8.53 
(tt, J = 7.9, 1.4 Hz, 2H), 8.03 – 7.94 (m, 4H), 7.20 – 7.02 (m, 10H), 5.63 – 5.30 (m, 4H), 4.64 – 
4.49 (m, 2H), 3.89 (dt, J = 12.0, 6.3 Hz, 2H), 3.79 (dt, J = 11.2, 6.1 Hz, 2H), 2.99 (d, J = 7.7 Hz, 
4H), 1.34 – 1.18 (m, 4H), 1.16 – 0.87 (m, 16H). 13C-NMR (100 MHz, CDCl3) δ (ppm): 172.23, 
165.15, 146.69, 145.45, 136.09, 129.14, 128.52, 127.97, 127.00, 65.69, 61.56, 54.53, 38.76, 
37.17, 29.46, 29.35, 29.12, 27.98, 25.61. IR (neat) (cm
-1
): 3180 (b), 3030 (b), 2920 (s), 2849 
(m), 1734 (vs), 1672 (vs), 1628 (m), 1531 (s), 1487 (vs), 1200 (vs), 693 (vs). ESI-MS (+ve) 
m/z: Found [M-2Br]
+
 368.2104, C44H56N4O6
2+
 requires (736.4189)/2 = 368.2095. 
5.7.6 Preparation of IL (447) 
3,3'-((4S,17S)-4,17-Dibenzyl-2,5,16,19-tetraoxo-6,15-dioxa-3,18-diazaicosane-1,20-diyl)bis(1-
methyl-1H-imidazol-3-ium) bromide (447). 
 
According to the general procedure “E”, using bis-alkylating reagent (462) (0.567 g, 0.831 
mmol), 1-methylimidazole (130 µl, 1.66 mmol) and ethyl acetate (25 ml), the title compound 
(447) was isolated as a white solid in 93% yield (0.652 g, 0.770 mmol). 
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Molecular formula: C38H50Br2N6O6; Molecular weight: 846.662 gmol
-1
; Mp: 70-72 °C. 
 
[α]D
20 
= +6.3 (1.0 c, MeOH). 
1
H-NMR (400 MHz, D2O) δ (ppm): 8.60 (s, 2H), 7.39 (t, J = 1.8 
Hz, 2H), 7.34 – 7.25 (m, 6H), 7.24 (t, J = 1.8 Hz, 2H), 7.22 – 7.16 (m, 4H), 4.96 (d, J = 16.7 Hz, 
2H), 4.90 (d, J = 16.7 Hz, 2H), 4.68 (dd, J = 8.9, 6.3 Hz, 2H), 4.13 – 4.04 (m, 4H), 3.83 (s, 6H), 
3.18 (dd, J = 13.8, 6.3 Hz, 2H), 2.99 (dd, J = 13.9, 8.9 Hz, 2H), 1.57 – 1.49 (m, 4H), 1.28 – 1.11 
(m, 8H). 
13
C-NMR (100 MHz, D2O) δ (ppm): 172.86, 166.59, 136.06, 129.09, 128.70, 127.23, 
123.45, 123.13, 66.55, 54.33, 50.35, 36.74, 35.79, 28.01, 27.51, 24.89. IR (neat) (cm
-1
): 3309 
(b), 3033 (b), 2920 (m), 1728 (vs), 1660 (vs), 1549 (s), 1205 (vs), 1173 (vs), 698 (s). ESI-MS 
(+ve) m/z: Found [M-2Br]
+
 343.1895, C38H50N6O6
2+
  requires (686.3781)/2 = 343.1891. 
5.7.7 Preparation of IL (448) 
3,3'-((4S,19S)-4,19-Dibenzyl-2,5,18,21-tetraoxo-6,17-dioxa-3,20-diazadocosane-1,22-
diyl)bis(1-methyl-1H-imidazol-3-ium) bromide (448). 
 
According to the general procedure “E”, using bis-alkylating reagent (463) (0.348 g, 0.489 
mmol), 1-methylimidazole (77 µl, 0.96 mmol) and ethyl acetate (25 ml), the title compound 
(448) was isolated as a beige solid in 96% yield (0.409 g, 0.468 mmol). 
 
Molecular formula: C40H54Br2N6O6; Molecular weight: 874.716 gmol
-1
; Mp: 41-43 °C. 
 
[α]D
20 
= + 6.0 (1.0 c, MeOH). 
1
H-NMR (400 MHz, D2O) δ (ppm): 7.38 (d, J = 2.0 Hz, 2H), 7.26 
– 7.13 (m, 10H), 7.09 (d, J = 6.9 Hz, 2H), 4.97 (d, J = 16.7 Hz, 2H), 4.91 (d, J = 11.0 Hz, 2H), 
4.65 – 4.56 (m, 2H), 4.02 – 3.85 (m, 4H), 3.80 (s, 6H), 3.04 (dd, J = 13.8, 6.8 Hz, 2H), 2.96 (dd, 
J = 13.7, 8.4 Hz, 2H), 1.43 – 1.29 (m, 4H), 1.12 – 0.98 (m, 12H). 13C-NMR (100 MHz, D2O) δ 
(ppm): 172.65, 166.46, 136.04, 129.07, 128.62, 127.14, 123.45, 123.15, 66.19, 54.42, 50.40, 
36.93, 35.83, 28.82, 28.61, 27.76, 25.32. IR (neat) (cm
-1
): 3310 (b), 3063 (b), 2922 (m), 2850 
(m), 1729 (vs), 1662 (vs), 1551 (s), 1204 (vs), 1173 (vs), 700 (s). ESI-MS (+ve) m/z: Found [M-
2Br]
+ 
357.2063, C40H54N6O6
2+
 requires (714.4094)/2 = 357.2047. 
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5.7.8 Preparation of IL (449) 
3,3'-((4S,21S)-4,21-Dibenzyl-2,5,20,23-tetraoxo-6,19-dioxa-3,22-diazatetracosane-1,24-
diyl)bis(1-methyl-1H-imidazol-3-ium) bromide (449). 
 
According to the general procedure “E”, using bis-alkylating reagent (464) (0.669 g, 0.906 
mmol), 1-methylimidazole (140 µl, 1.79 mmol) and ethyl acetate (25 ml), the target compound 
(449) was isolated as a beige solid in 93% yield (0.763 g, 0.845 mmol). 
 
Molecular formula: C42H58Br2N6O6; Molecular weight: 902.770 gmol
-1
; Mp: 84-86 °C. 
 
[α]D
20 
= +3.3 (1.0 c, MeOH). 
1
H-NMR (400 MHz, D2O) δ (ppm): 7.38 (d, J = 2.0 Hz, 2H), 7.23 
(d, J = 2.0 Hz, 2H), 7.19 – 7.01 (m, 10H), 5.03 – 4.90 (m, 4H), 4.62 – 4.53 (m, 2H), 3.96 – 3.78 
(m, 4H), 3.79 (s, 6H), 2.96 (d, J = 7.5 Hz, 4H), 1.31 – 1.25 (m, 4H), 1.12 – 1.07 (m, 16H). 13C-
NMR (100 MHz, D2O) δ (ppm): 172.38, 166.30, 136.08, 129.10, 128.52, 127.00, 123.45, 
123.18, 65.79, 54.33, 50.49, 37.11, 35.90, 29.49, 29.39, 29.14, 28.01, 25.65. IR (neat) (cm
-1
): 
3395 (b), 3069 (b), 2921 (s), 2851 (m), 1732 (vs), 1661 (vs), 1544 (s), 1206 (vs), 1172 (vs), 701 
(s). ESI-MS (+ve) m/z: Found [M-2Br]
2+
 371.2228, C42H58N6O6
+
 requires (742.4407)/2 = 
371.2204. 
5.7.9 Preparation of IL (450) 
(4S,17S)-4,17-Dibenzyl-N1,N20-bis(2-hydroxyethyl)-N1,N1,N20,N20-tetramethyl-2,5,16,19-
tetraoxo-6,15-dioxa-3,18-diazaicosane-1,20-diaminium bromide (450). 
 
According to the general procedure “E”, using bis-alkylating reagent (462) (0.895 g, 1.31 
mmol), dimethylaminoethanol (270 µl, 2.62 mmol) and ethyl acetate (25 ml), the title 
compound (450) was isolated as a white solid in 94% yield (1.064 g, 1.236 mmol). 
 
Molecular formula: C38H60Br2N4O8; Molecular weight: 860.726 gmol
-1
; Mp: 112-114 °C. 
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[α]D
20 
= -1.6 (1.0 c, MeOH). 
1
H-NMR (400 MHz, D2O) δ (ppm): 7.37 – 7.18 (m, 10H), 4.73 (dd, 
J = 9.3, 6.1 Hz, 2H), 4.18 – 4.06 (m, 6H), 4.00 (d, J = 15.2 Hz, 2H), 3.93 – 3.85 (m, 4H), 3.55 – 
3.48 (m, 4H), 3.21 (dd, J = 14.0, 6.0 Hz, 2H), 3.13 (s, 6H), 3.12 (s, 6H), 2.96 (dd, J = 13.9, 9.3 
Hz, 2H), 1.60 – 1.50 (m, 4H), 1.23 (s, 8H). 13C-NMR (100 MHz, D2O) δ (ppm): 172.68, 163.88, 
136.09, 129.09, 128.77, 127.30, 66.67, 66.01, 63.11, 55.39, 54.13, 52.89, 52.84, 36.55, 27.97, 
27.52, 24.85. IR (neat) (cm
-1
): 3294 (b), 2920 (m), 2858 (m), 1729 (vs), 1672 (vs), 1540 (s), 
1452 (m), 1196 (s), 738 (s), 689 (s). ESI-MS (+ve) m/z: Found [M-2Br]
+
 350.2203, 
C38H60N4O8
2+
 requires (700.4400)/2 = 350.2200. 
5.7.10 Preparation of IL (451) 
(4S,19S)-4,19-Dibenzyl-N1,N22-bis(2-hydroxyethyl)-N1,N1,N22,N22-tetramethyl-2,5,18,21-
tetraoxo-6,17-dioxa-3,20-diazadocosane-1,22-diaminium bromide (451). 
 
According to the general procedure “E”, using bis-alkylating reagent (463) (0.529 g, 0.745 
mmol), dimethylaminoethanol (150 µl, 1.47 mmol) and ethyl acetate (25 ml), the title 
compound (451) was isolated as a white solid in 99% yield (0.657 g, 0.739 mmol). 
 
Molecular formula: C40H64Br2N4O8; Molecular weight: 888.780 gmol
-1
; Mp: 66-68° C. 
 
[α]D
20 
= -6.7 (1.0 c, MeOH). 
1
H-NMR (400 MHz, D2O) δ (ppm): 7.34 – 7.21 (m, 6H), 7.20 – 
7.14 (m, 4H), 4.73 – 4.68 (m, 2H), 4.17 – 3.96 (m, 8H), 3.96 – 3.83 (m, 4H), 3.57 – 3.50 (m, 
4H), 3.15 (s, 12H), 3.14 – 3.05 (m, 2H), 2.98 (dd, J = 13.9, 9.0 Hz, 2H), 1.56 – 1.40 (m, 4H), 
1.28 – 1.10 (m, 12H). 13C-NMR (100 MHz, D2O) δ (ppm): 172.27, 163.76, 135.99, 129.07, 
128.66, 127.19, 66.12, 63.11, 55.38, 53.99, 52.81, 52.79, 36.79, 28.99, 28.78, 27.88, 25.45. IR 
(neat) (cm
-1
): 3289 (b), 2920 (m), 2852(m), 1731 (vs), 1671 (vs), 1553 (m), 1466 (m), 1200 (s), 
1176 (s), 742 (m), 698 (m). ESI-MS (+ve) m/z: Found [M-2Br]
2+ 
364.2358, C40H64N4O8
+
 
requires (728.4713)/2 = 364.2357. 
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5.7.11 Preparation of IL (452) 
(4S,21S)-4,21-Dibenzyl-N1,N24-bis(2-hydroxyethyl)-N1,N1,N24,N24-tetramethyl-2,5,20,23-
tetraoxo-6,19-dioxa-3,22-diazatetracosane-1,24-diaminium bromide (452). 
 
According to the general procedure “E”, using bis-alkylating reagent (464) (0.707 g, 0.957 
mmol), dimethylaminoethanol (190 µl, 1.91 mmol) and ethyl acetate (25 ml), the title 
compound was isolated as a white solid in 89% yield (0.783 g, 0.854 mmol). 
 
Molecular formula: C42H68Br2N4O8; Molecular weight: 916.834 gmol
-1
; Mp: 89-91 °C. 
 
[α]D
20 
= -2.6 (1.0 c, CHCl3). 
1
H-NMR (400 MHz, D2O) δ (ppm): 7.31 – 7.19 (m, 6H), 7.18 – 
7.10 (m, 4H), 4.71 – 4.65 (m, 2H), 4.12 (d, J = 15.8 Hz, 2H), 4.09 – 3.93 (m, 6H), 3.93 – 3.84 
(m, 4H), 3.61 – 3.47 (m, 4H), 3.14 (s, 12H), 3.09 (dd, J = 14.0, 6.5 Hz, 2H), 2.97 (dd, J = 13.9, 
8.9 Hz, 2H), 1.54 – 1.36 (m, 4H), 1.19 (s, 16H).13C-NMR (100 MHz, D2O) δ (ppm): 172.12, 
163.73, 135.99, 129.08, 128.62, 127.14, 66.11, 65.92, 63.12, 55.38, 53.92, 52.77, 36.87, 29.49, 
29.13, 28.03, 25.68. IR (neat) (cm
-1
): 3285 (b), 2922 (s), 2852 (m), 1732 (vs), 1670 (vs), 1550 
(s), 1468 (m), 1199 (vs), 1177 (vs), 742 (s), 698 (s). ESI-MS (+ve) m/z: Found [M-2Br]
+
 
378.2514, C42H68N4O8
2+
 requires (756.5026)/2 = 378.2513. 
5.8 Antimicrobial Screening 
The antimicrobial screening was carried out in collaboration with Dr. Marcel Špulák, Faculty of 
Pharmacy, Charles University, Czech Republic.  
5.8.1 Antibacterial Screening 
In vitro antibacterial testing was carried out on the following strains of bacteria available from 
the collection maintained at the Department of Biological and Medical Sciences, Faculty of 
Pharmacy, Charles University, Hradec Králové, Czech Republic: 
 
Gram Positive:  
 S. aureus (ATCC 65382) 
 Methicillin-res.S.a (HK5996/08) 
 S. epidermidis (HK6966/084 ) 
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 Enterococcus sp. (HK14365/085) 
Gram Negative: 
 E. coli (ATCC 87396) 
 K. pneumoniae (HK11750/087) 
 K. pneumoniae (HK14368/08) 
 P. aeruginosa (ATCC 9027) 
The ATCC strains served as the quality control strains. All the bacterial isolates were 
maintained on Mueller-Hinton dextrose agar (MH, HiMedia, adersky-Envitek, Czech Republic), 
prior to being tested. Mueller-Hinton agar buffered to pH 7.4 (± 0.2) was employed as the test 
medium. To the wells of the microdilution tray were added 200 µL of the agar medium, 10 µl of 
inoculum suspension and 2-fold serial dilutions of the test compound (2000 to 0.488 µmol l
−1
). 
DMSO served as diluent for all the test compounds with a final concentration of no greater than 
2%. The inoculum was prepared in Mueller-Hinton medium to give a final concentration of 0.5 
McFarland scale (1.5 × 108 cfu ml
−1
).The test trays were incubated at 37 °C and MICs were 
read visually after 24 h and 48 h. The MICs were defined as 95% inhibition of the growth of 
control (MIC95) and were determined twice and in duplicate. The deviations from the usually 
obtained values were no higher than the nearest concentration value up and down the dilution 
scale. 
5.8.2 Antifungal Screening 
In vitro antifungal testing was carried out on the following strains of fungi available from the 
collection maintained at the Department of Biological and Medical Sciences, Faculty of 
Pharmacy, Charles University, Hradec Králové, Czech Republic: 
Yeasts: 
 Candida albicans (ATCC 448597) 
 Candida albicans (ATCC 900288) 
 Candida parapsilosis (ATCC 220199 ) 
 Candida krusei (ATCC 62581) 
 Candida krusei (E2811) 
 Candida tropicalis (156) 
 Candida glabrata (20/I2) 
 Candida lusitaniae (2446/I3 ) 
 Trichosporon asahii (11884) 
Filamentous fungi: 
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 Aspergillus fumigatus (2315) 
 Absidia corymbifera (2726) 
 Trichophyton mentagrophytes (445) 
 
Three ATCC strains (Candida albicans ATCC 90028, Candida parapsilosis ATCC 22019, 
Candida krusei ATCC 6258) served as the quality control strains. All the fungal isolates were 
maintained on Sabouraud dextrose agar prior to being tested. Minimum Inhibitory 
Concentrations were determined by modified CLSI standard of microdilution format of the 
NCCLS M27-A3 and M38-A2 document guidelines.
17, 18
 The deviations from the usually 
obtained values were no higher than the nearest concentration value up and down the dilution 
scale. DMSO (100 %) served as a diluent for all compounds; the final concentration of DMSO 
did not exceed 2 %. RPMI 1640 (Sevapharma, Prague) medium supplemented with L-glutamine 
and buffered with 0.165 M morpholinepropanesulfonic acid (Serva) to pH 7.0 by 10 N NaOH 
was used as the test medium. The wells of the microdilution tray contained 100 μl of the RPMI 
1640 medium with 2-fold serial dilutions of the compounds (2000 or 1000 to 0.48 μmol l-1) and 
100 μl of inoculum suspension. Fungal inoculum in RPMI 1640 was prepared to give a final 
concentration of 5 × 103 ± 0.2 cfu ml
-1
. The trays were incubated at 35°C and MICs were read 
visually for filamentous fungi and photometrically for yeasts as an absorbance at 540 nm after 
24 h and 48 h. The MIC/IC50 values for the dermatophytic strain (T. mentagrophytes) were 
determined after 72 h and 120 h and for A. fumigatus, A. corymbifera after 24 and 48 h. For all 
other strains MIC/IC80 values were evaluated. The MICs were defined as 50% or 80% 
inhibition of the growth of control. MICs were determined twice and in duplicate. The 
deviations from the usually obtained values were no higher than the nearest concentration value 
up and down the dilution scale. 
5.9 Biodegradation Screening 
5.9.1 Closed Bottle Test Method 
The testing was carried out at 20°C in the dark for 28 days in the Institute of Sustainable and 
Environmental Chemistry at Leuphana University according to OECD method 301D.
19-21
 A 
compound can be classifies as readily biodegradable if it undergoes more than 60% 
biodegradation within the 28 day test. The compound must also reach 60% biodegradation 
within a ten day period as soon as 10% biodegradation is observed.
21
 
The testing carried out involves four separate test vessels making up one series. Each series was 
carried out in duplicate. 
 Test blank vessel – mineral medium + inoculum 
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 Quality control vessel - mineral medium + sodium acetate + inoculum 
 Test series vessel – mineral medium + inoculum + test compound 
 Toxicity control – mineral medium + sodium acetate + inoculum + test compound 
The test blank records the overall theoretical oxygen demand (ThOD) of the bacteria and their 
growth with no sources of organic carbon. 
The quality control series employs readily biodegradable sodium acetate to demonstrate that the 
bacteria are performing as expected, degrading the prescribed amount of sodium acetate within 
14 days. 
The test series vessel contains the organic compound under examination as the only source of 
organic carbon. The oxygen demand of this vessel can therefore be directly compared to the 
amount of organic carbon undergoing degradation from the test compound. 
The toxicity control contains a quantity of sodium acetate and the test compound calculated to 
provide ThOD of 5 mg l
-1
. If the difference in ThOD compared to the predicted ThOD is more 
than 25% observed then a potential inhibitory effect due to antimicrobial effects of the test 
compound may be occurring and a compound is labelled as toxic. 
The levels of aerobic biodegradation were measured using a sensor unit within the bottle 
containing an oxygen electrode (Oxi 196 with EO 196-1.5WTW Weilheim, Germany). The 
times of measurement were Day: 0, 0 (3 hours), 1, 7, 14, 21 and 28. 
5.9.2 LCMS Metabolite Study 
5.9.2.1 Materials 
LC-MS grade acetonitrile was purchased from VWR (VWR International, GmbH, Darmstadt, 
Germany). The aqueous buffer solutions were prepared using ultrapure water 18.2 MΩ·cm 
(Ultra Clear UV TM, Barsbüttel, Germany) and formic acid for analysis (Merck KGaA, 
Darmstadt, Germany).  
5.9.2.2 Instrumentation 
The analysis was performed on a Dionex Ultimate 3000 UHLPC, equipped with a solvent rack 
(SRD-3600), a binary pump (HPG-3400-RS), an auto-sampler (WPS-3000-TRS), and column 
oven (TCC-3000) coupled with a LTQ Orbitrap XL (Thermo Scientific, Dreieich, Germany) 
equipped with a HES source. 
5.9.2.3 LC-MS method 
The separations were carried out on a Hypersil Gold CN (100/3mm, 3µm, Thermo Scientific) 
equipped with an HILIC guard column (Macherey-Nagel, Düren, Germany) kept at 30°C with a 
flow rate of 400 µl min
-1
 using a gradient of acetonitrile and 0.05% formic acid in water (V:V). 
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The gradient started with 97% acetonitrile, held for 1minute, decreased to 60% over 11 minutes, 
held for 3 minutes, then increased back to the initial condition of 97% within 3 minutes and 
terminated by 7 minutes re-equilibration time. The mass spectra were acquired in positive 
centroid mode with a resolving power of 30000. The parameters for the heated electrospray 
source for sheath and auxiliary gas flow rates were 15 and 5 arbitrary units, respectively. The 
spray voltage and the vaporizer temperature were set to 4 kV and 200 °C, the capillary voltage 
and the capillary temperature were set to -9 V and 275 °C and the tube lens voltage was kept at 
100 V. 
5.10 Self assembly and physico-chemical surfactant property investigations 
5.10.1 Aqueous sample preparation 
Water from a Milli-Q system was used in all sample preparation. Stock solutions were prepared 
by weight, shaken first by hand for ca. 1 minute and then sonicated for 15 minutes at 25°C in a 
sonicator bath (Ultrasons-H, Selecta S.A.) to ensure complete dissolution of each sample. 
Samples of lower concentration were prepared by dilution from stock solutions. The samples 
were kept at 25°C for at least 2 h for equilibration.  
5.10.2 Conductivity measurements 
Conductivity was measured at 25°C using an Orion Conductivity Cell 011010A with platinized 
platinum electrode in conjunction with a Thermo Orion 550 A instrument with a cell constant of 
0.998 cm
-1
. Temperature for all measurements was maintained at 25°C using a thermostatically 
controlled water bath. Cell constant was calibrated with NaCl solutions of known conductivities 
and was used for calculating the conductivity of the surfactant solution. The conductivity of 
water was subtracted from the measured conductivity of each sample. Measurements were made 
at increasing concentrations to minimise errors from possible contamination of the electrode. 
5.10.3 Surface tension measurements 
Surface tension was measured at 25°C by the Wilhelmy plate technique using a Krüss K-12 
tensiometer. Glass containers and plate were cleaned with chromic acid solution and rinsed 
thoroughly with distilled water. The plate was flame dried before each measurement. Surface 
tension was considered to be at equilibrium when the standard deviation of five consecutive 
measurements did not exceed 0.10 mN m
-1
. 
5.10.4 Optical Microscopy 
The polarised optical microscopy method used to examine the surfactants was the 
flooding/penetration method according to Lawrence. 
22
 In this technique, water is allowed to 
diffuse onto anhydrous surfactants placed between a glass slide and a cover slip. After a short 
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time, gradients in composition are produced and different separated mesomorphic or 
mesophases develop around the crystalline surfactant allowing the determination of the liquid 
crystal structures formed. The microscope used was a Zeiss binocular microscope with heated 
stage and the images were examined at x10 and x40 optical magnification. Images were 
captured using a digital camera attached to the microscope head and pointing through an 
aperture above the turret objective lenses. 
5.10.5 HPLC-UV analysis 
Purity of surfactants synthesised was analysed by HPLC, with a VWR L-2130 model using an 
L-2400 UV-vis detector at 215 nm and a LiChrospher 100 RP-18 (5 µm) LiChroCART 250x4 
mm C18 column at room temperature. A gradient elution profile was employed from the initial 
solvent composition of A/B 50/50 (by volume), changing during 30 minutes to a final 
composition of 100% B where A is 0.1% v/v TFA in H2O and B is 0.085% of TFA in 
H2O/CH3CN 1:4. The flow rate through the column was 1.0 ml min
-1
. 
5.10.6 Aqueous stability measurements 
Aqueous stability of the L-phenylalanine surfactant ILs was determined by maintaining an 
aqueous solution (~10 mg in 5 ml) of the surfactant to be analysed at 50 °C for 1 week. The 
sample vials prepared were glass test tubes with a threaded lid. Parafilm was wrapped around 
the lid to prevent evaporation. The samples were maintained at the desired temperature in a 
thermostatically controlled water bath. 
Degradation was measured by taking a 0.5 ml aliquot at 1 day intervals and analysing parent 
peak area decline by HPLC-UV using the parameters previously outlined in Section 5.10.5. The 
method outlined above was also repeated at pH 2 and pH 10, both at 25 °C over a 1 week 
period. 
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Chapter 6 
Conclusions and Future Work 
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6.1 Conclusions and future work 
A series of amino acid derived ILs (324-335, 349-353) and tertiary amines  (344-348) have been 
synthesised according to the 12 principles of green chemistry and Boethling‟s rules of thumb for 
designing biodegradable molecules and their antimicrobial toxicity and biodegradability have 
been assessed (Chapter 2). Green chemistry metrics were calculated for the synthesis of these 
compounds and favourable characteristics as well as areas that can be improved upon have been 
identified. Antimicrobial toxicity assessments have shown that in general the amino acid 
derived compounds had a low to moderate toxicity with the tertiary amines exhibiting a greater 
toxic effect than the quaternary. Biodegradation studies have shown that one pyridinium IL 
(325) and one tertiary amine (345) could be classified as inherently ultimately biodegradable. In 
conjunction to the biodegradation studies a preliminary examination of the metabolic products 
at the end of the 28 day test was conducted and has given insight into the breakdown pathways 
of the ILs and tertiary amines. No organic metabolic products were detected (apart from 
remaining parent compound) for pyridinium IL (325) suggesting complete mineralisation within 
the 28 day test. Metabolic products themselves have been synthesised and their antimicrobial 
toxicity results showed little to no toxic effect for the metabolites screened. Metabolite 
biodegradability is currently undergoing assessment to give a greater picture of the potential 
environmental fate and impact of the ILs and tertiary amines and their transformation products. 
From the assessments carried out in Chapter 2, pyridinium IL (325) was deemed to be the most 
green candidate synthesised and was proposed as a building block from which to design further 
generations of ILs. 
 
Following on from the work carried out in Chapter 2, Chapter 3 reports a series of L-
phenylalanine ILs subsequently designed from the most green candidates, including pyridinium 
IL (325), with the aim to produce surfactant ILs. These ILs were derivatives of those 
synthesised in Chapter 2 and represent a rational design in producing surface active molecules 
from shorter chain analogues. A series of linear alkyl ILs of chain length C8-C12 (432-434) were 
synthesised. Analogous imidazolium (435-437), cholinium (438-440) and ethyl nicotinium 
(441) ILs were also synthesised due to their Chapter 2 counterparts‟ favourable characteristics 
in synthesis, antimicrobial toxicity, biodegradation or a combination of all three. In total 10 new 
linear alkyl ILs and three new alkylating reagents (456-458) were synthesised. Furthermore 9 
new bolaform pyridinium (444-446), imidazolium (447-449) and cholinium (450-452) ILs and 3 
new alkylating reagents (462-464) were also designed and synthesised using C8-C12 linkers with 
the aim of producing low toxicity surface active molecules. Similar to the assessments carried 
out in Chapter 2, the green chemistry metrics were again determined for the 19 2
nd
 generation 
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amino acid ILs, 6 alkylating reagents and 6 esters synthesised in Chapter 3. Overall the metrics 
produced for the linear alkyl ILs in Chapter 3 were more favourable due to the synthetic 
methodologies employed and the replacement of column chromatography with alternative 
purification methods using reduced quantities of organic solvent. From the unfavourable green 
chemistry metrics calculated for the ethyl nicotinium C8 IL (441) it was decided to postpone the 
further investigation of C10 (442) and C12 (443) ethyl nicotinium ILs. It was decided that to 
improve the overall metrics for the bolaform ILs that solvent recycling would be employed for 
the derivatives. Diethyl ether and hexane trituration solvents were recycled at 95% recovery 
using a rotary evaporator to rapidly distil large quantities of solvent which was subsequently 
reused in further purification of other ILs. Moderate to poor yields were observed for the 
bolaform esters and alkylating reagents and this presents a key area for future optimisation if 
further investigations into this class of ILs is to be conducted.  
 
Antimicrobial toxicity results for the linear alkyl ILs showed in general a broad spectrum 
antibacterial toxicity towards gram positive bacteria. Similarly a broad spectrum activity was 
observed towards gram negative bacteria with C10 ILs displaying the most toxic effects. 
Moderate (e.g. 432, 250-1000 µmol
-1 
IC50) to high levels (e.g. 434, 3.9-62.5 µmol
-1
 IC50) of 
antifungal toxicity was also observed for all of the linear alkyl ILs. The lowest levels of 
antibacterial toxicity (though still considerable 15.62-250 µmol
-1 
MIC95)  were observed for the 
ethyl nicotinium C8 IL (441) which suggests that future investigations into this IL as a surface 
active agent with lower antimicrobial toxicity could be promising. Bolaform ILs (444-452) 
displayed similar levels of antimicrobial activity to their linear alkyl counterparts with broad 
spectrum activity towards both fungi and bacteria observed and an increase in toxicity as alkyl 
chain spacer length was increased. Biodegradation studies of the linear alkyl ILs did not 
produce any readily biodegradable ILs even though their carbon content was significantly 
greater with respect to the ethyl ester ILs examined in Chapter 2. The C8 (432, 435, 438) and C10 
(433, 436, 439) ILs examined may prove to be ultimately biodegradable if their test time is 
extended due to slower rates of biodegradability. The C12 linear alkyl ILs (434, 437, 440) 
examined failed the toxicity control test of the biodegradation screening and are the first to do 
so in the preceding decade of research conducted within the Gathergood group. Bolaform ILs 
examined for their biodegradability (444-452) showed that the C10 examples (447-449) were the 
most biodegradable of the bolaform ILs with moderate levels (e.g. 447, 53%) observed. A rapid 
drop off when spacer length was increased to C12 was observed for the bolaform ILs (449-452). 
This rapid drop-off could be due to enzymatic steric considerations or due to the broad spectrum 
antimicrobial effect of the bolaform ILs (though no toxicity controls were failed). 
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The surface active properties of the linear alkyl (432-440) and bolaform (444-452) ILs were 
assessed during two separate two month placements in the laboratory of Dr. Lourdes Pérez, 
CSIC, IQAC, Barcelona. Surfactant properties examined include critical micelle concentration 
by conductimetry and tensiometry, surface active properties by tensiometry, liquid crystal 
behaviour by optical microscopy and a preliminary investigation into aqueous stability in 
neutral, acidic and basic media. It was shown that the linear alky ILs synthesised all displayed 
excellent surface active properties such as large effective range and high levels of efficiency. 
Micelles were also observed forming at lower than expected concentrations. The amino acid 
sidechain was proposed to be contributing lipophilicity towards the alkyl chain thus reducing 
the concentrations of surfactant required for activity. Bolaform ILs synthesised also displayed 
surface activity at lower concentrations than expected due to a proposed amino acid 
contribution, however a lower effective range was observed for the bolaform ILs. Cholinium C8 
bolaform (450) was an exception to this observation, not displaying considerable surface tension 
reduction at all and was deemed to have poor surface tension reducing properties. Aqueous 
stability in a number of media was also investigated and the preliminary investigations showed 
a general resistance of the ILs to acid hydrolysis and a susceptibility toward base hydrolysis and 
hydrolysis in media at pH 7 with temperature elevated to 50 °C. Optical microscopy 
experiments were able to produce visual examples of the liquid crystal behaviour of a number of 
linear alkyl ILs (432, 433, 434, 436, 439). The images observed over a wide range of 
temperatures (20-100 °C) were able to give insight into the interactions of the ILs in aqueous 
media including hexagonal, lamellar and cubic phase liquid crystals. Crystals were also 
observed growing in real time, most likely due to the greatly increased coordination and 
crystallinity due to a combination of the L-phenylalanine sidechain and long alkyl chain, not 
generally observed for shorter chain ILs. HPLC models were constructed for the linear alkyl and 
bolaform ILs to aid in predicting the possible CMC values for future generations of L-
phenylalanine derived ILs. Values for the Stauff-Klevens equation for the three series of ILs 
(pyridinium, imidazolium and cholinium) were also calculated to assist with such predictions.  
 
6.2 Future Work 
The future work of this project lies immediately with the ongoing metabolite biodegradation 
studies. Additional investigations into the cytotoxicity of the surfactant ILs is also of the utmost 
importance if real world applications of these surfactants are to be considered. Further 
investigation into shorter chain linear alkyl ILs of C4-C6 (101, 467-471) ester lengths should 
also be considered to investigate whether surface activity with reduced antimicrobial toxicity 
and potentially greater biodegradability of intermediate length alkyl chains can be achieved.  
The following ILs (Figure 6.1) have been proposed in Chapters 3 and 4 for future synthesis: 
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Figure 6.1: Future intermediate ester chain ILs. 
Biodegradation studies of amino acid carboxylic acid ILs (362, 465-466) (Figure 6.2) should 
also be investigated to determine whether an amino acid IL with an unprotected carboxylic acid 
can undergo biodegradation through the amino acid or by amide bond cleavage followed by 
mineralisation. 
 
 
Figure 6.2. Amino acid carboxylic acid ILs. 
Biodegradation studies on L-DOPA derived ILs (Figure 6.3). would also be of interest as l-
phenylalanine and L-tyrosine can both be converted into L-DOPA in biological systems.
1
 
 
Figure 6.3. L-DOPA derived IL 
Bolaform ILs with longer spacer units should also be considered as a C8 chain length did not 
seem to be adequate for surface activity for the cholinium derivative (450). A series of surface 
active ILs could also potentially synthesised from L-phenylalanine glycerol esters or L-tyrosine 
esters. This selection includes linear alkyl derivatives, dialkyl derivatives and gemini 
derivatives, using the already defined synthetic methodologies described within Chapters 2-3 of 
this body of work. A number of potential structures are outlined below, Figure 6.3. 
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Figure 6.4. Potential future generation L-phenylalanine and L-tyrosine derived surfactants. 
 
To combat the high levels of toxicity associated with cationic surfactants a number of poly 
propylene or poly ethylene glycol esters of the ILs could be synthesised. As previously 
discussed in Chapters 3-4 polypropylene can effectively reduce the CMC and polyethylene can 
increase the CMC. It has also been shown in the literature that polyethylene containing IL esters 
can help in reducing toxicity.
2
 Two such structures are proposed below in Figure 6.4. 
 
Figure 6.5. PEG and PPG L-phenylalanine derived surfactant ILs. 
Potential applications of the surface active ILs include their use as broad spectrum antimicrobial 
and biodegradable cleaning agents. Determination of ultimate biodegradability and cytotoxicity 
will be required before further consideration of these applications. The imidazolium and 
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pyridinium surface active ILs may also present themselves as dual functioning Brønsted-acidic 
phase transfer catalysts due to their dual nature as surface active agents and the known acidity 
and liberation of acidic species associated with imidazolium ILs reported by Gathergood and 
Connon.
3-7
  
 
Lastly the C2 symmetrical IL reported in Chapter 2 could also be considered as an N-
heterocyclic carbene ligand as depicted in Figure 6.5. The presence of sterically 
hindering/directing L-phenylalanine sidechain groups or indeed functionalised/unfunctionalised 
tyrosine sidechain may contribute towards the discovery of future generations of 
enantioselective catalyst ligands, though the acidity of the amide protons may complicate this 
avenue of investigation. 
 
Figure 6.6. NHC ligand derived from IL (331). 
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Appendix I 
IL biodegradation under aerobic biodegradation conditions 
The information within this appendix is the ESI for the ILs discussed in Chapter 1 
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IL Head Group Side Chain R Anion 
Biodegrad-
ation  
% 
Classification Test Method Inoculum 
IL 
Conc. 
Test 
Duration 
Measured 
Parameter 
Ref 
Imidazolium 
68 
  
C2H5 
 
10 
Not readily 
biodegradable 
Respirometric 
BOD  
(OxiDirect® by 
Lovibond) 
Waste-
water 
organisms 
100 
mg/L 
10 d BOD 
1
 
8 
 
“ C2H5  0 
Not primarily 
biodegradable 
Primary 
Biodegradation 
by HPLC from 
modified OECD 
301 
Activated 
Sludge 
200 
µM 
28 d  
2
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8 
  
C2H5  n.d. 
Not readily 
biodegradable 
Manometric 
Respirometry 
(OECD 301F) 
Activated 
Sludge 
120-
150 
mg/L 
28 d BOD 
2
 
9 
 
“ C4H9  03 
Not readily 
biodegradable 
Respirometric 
BOD  
(OxiDirect® by 
Lovibond) 
Waste-
water 
organisms 
100 
mg/L 
10 d BOD 
 
1
 
4 
 
“ C4H9 
 
0 
Not readily 
biodegradable 
BOD5 
Activated 
sludge 
10 
g/L 
30 d BOD 
3
 
29 
 
“ C4H9 
 
0 
Not readily 
biodegradable 
BOD5 
Activated 
sludge 
10 
g/L 
30 d BOD 
3
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12 
 
“ C6H13  02 
Not readily 
biodegradable 
Respirometric 
BOD  
(OxiDirect® by 
Lovibond) 
Waste-
water 
organisms 
100 
mg/L 
10 d BOD  
69 
 
C3H7  0 
Not primarily 
biodegradable 
Primary 
Biodegradation 
by HPLC from 
modified OECD 
301 
Activated 
Sludge 
200 
µM 
28 d  
2
 
69 “ “ “ n.d. 
Not readily 
biodegradable 
Manometric 
Respirometry 
(OECD 301F) 
Activated 
Sludge 
120-
150 
mg/L 
28 d BOD 
2
 
70 
 
C4H9  0 
Not primarily 
biodegradable 
Primary 
Biodegradation 
by HPLC from 
modified OECD 
301 
Activated 
Sludge 
200 
µM 
28 d  
2
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70 “ “ “ 0 
Not readily 
biodegradable 
Manometric 
Respirometry 
(OECD 301F) 
Activated 
Sludge 
120-
150 
mg/L 
28 d BOD 
2
 
71 
 
C4H9  0 
Not primarily 
biodegradable 
Primary 
Biodegradation 
by HPLC from 
modified OECD 
301 
Activated 
Sludge 
200 
µM 
28 d  
2
 
71 
 
C4H9  n.d. 
Not readily 
biodegradable 
Manometric 
Respirometry 
(OECD 301F) 
Activated 
Sludge 
120-
150 
mg/L 
28 d BOD 
2
 
72 
 
C5H11  0 
Not primarily 
biodegradable 
Primary 
Biodegradation 
by HPLC from 
modified OECD 
301 
Activated 
Sludge 
200 
µM 
28 d  
2
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72 “ “ “ n.d. 
Not readily 
biodegradable 
Manometric 
Respirometry 
(OECD 301F) 
Activated 
Sludge 
120-
150 
mg/L 
28 d BOD 
2
 
73 
 
C4H9  0 
Not primarily 
biodegradable 
Primary 
Biodegradation 
by HPLC from 
modified OECD 
301 
Activated 
Sludge 
200 
µM 
28 d  
2
 
73 “ “ “ n.d. 
Not readily 
biodegradable 
Manometric 
Respirometry 
(OECD 301F) 
Activated 
Sludge 
120-
150 
mg/L 
28 d BOD 
2
 
74 
 
C4H9  0 
Not primarily 
biodegradable 
Primary 
Biodegradation 
by HPLC from 
modified OECD 
301 
Activated 
Sludge 
200 
µM 
28 d  
2
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74 “ “ “ n.d. 
Not readily 
biodegradable 
Manometric 
Respirometry 
(OECD 301F) 
Activated 
Sludge 
120-
150 
mg/L 
28 d BOD 
2
 
75 
 
C6H13  100 
primarily 
biodegradable 
Primary 
Biodegradation 
by HPLC from 
modified OECD 
301 
Activated 
Sludge 
200 
µM 
28 d  
2
 
75 “ “ “ 8 
Not readily 
biodegradable 
Manometric 
Respirometry 
(OECD 301F) 
Activated 
Sludge 
120-
150 
mg/L 
28 d BOD 
2
 
76 
 
 
C4H9  100 
primarily 
biodegradable 
Primary 
Biodegradation 
by HPLC from 
modified OECD 
301 
Activated 
Sludge 
200 
µM 
28 d  
2
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76 
 
C4H9  7 
Not readily 
biodegradable 
Manometric 
Respirometry 
(OECD 301F) 
Activated 
Sludge 
120-
150 
mg/L 
28 d BOD 
2
 
78 
 
CH2CONC4H8  0 
Not readily 
biodegradable 
CO2 Headspace 
test 
(ISO 14593) 
Activated 
sludge 
20 
mg/L 
28 d THCO2 
4
 
79 
 
CH2COOCH3  2 
Not readily 
biodegradable 
CO2 Headspace 
test 
(ISO 14593) 
Activated 
sludge 
20 
mg/L 
28 d THCO2 
4
 
80 
 
 
CH3  
 
30 
 
Not readily 
biodegradable 
CO2 Headspace 
test 
(ISO 14593) 
Activated 
sludge 
20 
mg/L 
28 d THCO2 
4
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81 
 
CH3 
 
35 
 
Not readily 
biodegradable 
CO2 Headspace 
test 
(ISO 14593) 
Activated 
sludge 
20 
mg/L 
28 d THCO2 
4
 
82 
 
CH2C6H5 
  
24 
Not readily 
biodegradable 
CO2 Headspace 
test 
(ISO 14593) 
Activated 
sludge 
20 
mg/L 
28 d THCO2 
4
 
83 
 
 
CH3 
 
 
31 
Not readily 
biodegradable 
CO2 Headspace 
test 
(ISO 14593) 
Activated 
sludge 
20 
mg/L 
28 d THCO2 
4
 
84 
 
CH2COOCH3  10 
Not readily 
biodegradable 
CO2 Headspace 
test 
(ISO 14593) 
Activated 
sludge 
20 
mg/L 
28 d THCO2 
4
 
A-12 
 
 
85 
 
CH2COOCH3 
 
5 
Not readily 
biodegradable 
CO2 Headspace 
test 
(ISO 14593) 
Activated 
sludge 
20 
mg/L 
28 d THCO2 
4
 
86 
 
CH2C6H5 
  
6 
Not readily 
biodegradable 
CO2 Headspace 
test 
(ISO 14593) 
Activated 
sludge 
20 
mg/L 
28 d THCO2 
4
 
87 
 
CH3 
  
12 
Not readily 
biodegradable 
CO2 Headspace 
test 
(ISO 14593) 
Activated 
sludge 
20 
mg/L 
28 d THCO2 
4
 
88 
 
CH3 
  
3 
Not readily 
biodegradable 
CO2 Headspace 
test 
(ISO 14593) 
Activated 
sludge 
20 
mg/L 
28 d THCO2 
4
 
A-13 
 
 
89 
 
CH2COOCH3  17 
Not readily 
biodegradable 
CO2 Headspace 
test 
(ISO 14593) 
Activated 
sludge 
20 
mg/L 
28 d THCO2 
4
 
90 
 
CH2CONC4H8  
12 
 
Not readily 
biodegradable 
CO2 Headspace 
test 
(ISO 14593) 
Activated 
sludge 
20 
mg/L 
28 d THCO2 
4
 
91 
 
CH2CONC4H8 
 
14 
 
Not readily 
biodegradable 
CO2 Headspace 
test 
(ISO 14593) 
Activated 
sludge 
20 
mg/L 
28 d THCO2 
4
 
92 
 
CH2C6H5 
  
2 
Not readily 
biodegradable 
CO2 Headspace 
test 
(ISO 14593) 
Activated 
sludge 
20 
mg/L 
28 d THCO2 
4
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93 
 
CH2COOCH3  10 
Not readily 
biodegradable 
CO2 Headspace 
test 
(ISO 14593) 
Activated 
sludge 
20 
mg/L 
28 d THCO2 
4
 
94 
 
CH2COOCH3 
 
14 
Not readily 
biodegradable 
CO2 Headspace 
test 
(ISO 14593) 
Activated 
sludge 
20 
mg/L 
28 d THCO2 
4
 
95 
 
CH2CONC4H8  3 
Not readily 
biodegradable 
CO2 Headspace 
test 
(ISO 14593) 
Activated 
sludge 
20 
mg/L 
28 d THCO2 
4
 
96 
 
CH2CONC4H8  3 
Not readily 
biodegradable 
CO2 Headspace 
test 
(ISO 14593) 
Activated 
sludge 
20 
mg/L 
28 d THCO2 
4
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97 
 
C2H5 
  
2.11 
Not readily 
biodegradable 
Closed Bottle 
Test (TG 301 D) 
Waste-
water 
organisms 
5 
mg/L 
28 d BOD 
5
 
98 
 
C2H5 
  
6.64 
Not readily 
biodegradable 
Closed Bottle 
Test (TG 301 D) 
Waste-
water 
organisms 
5 
mg/L 
28 d BOD 
5
 
99 
 
C2H5 
  
6.23 
Not readily 
biodegradable 
Closed Bottle 
Test (TG 301 D) 
Waste-
water 
organisms 
5 
mg/L 
28 d BOD 
5
 
100 
 
C6H13 
  
9.07 
Not readily 
biodegradable 
Closed Bottle 
Test (TG 301 D) 
Waste-
water 
organisms 
5 
mg/L 
28 d BOD 
5
 
A-16 
 
 
101 
 
CH3  61 
Readily 
biodegradable 
CO2 Headspace 
test 
(ISO 14593) 
Activated 
sludge 
20 
mg C 
L−1 
28 d ThCO2 
6
 
102 
 
CH3  64 
Readily 
biodegradable 
CO2 Headspace 
test 
(ISO 14593) 
Activated 
sludge 
20 
mg C 
L−1 
28 d ThCO2 
6
 
            
            
A-17 
 
 
IL Head Group Side Chain R Anion 
Biodegrad-
ation % 
Classification Test Method Inoculum 
IL 
Conc. 
Test 
Duration 
Measured 
Parameter 
Ref 
Bis-Imidazolium 
217 
 
CH3  <5 
Not readily 
biodegradable 
Primary 
Biodegradation 
by IC from 
modified OECD 
301 D 
Activated 
Sludge 
60-
100 
mg/L 
28 d  
7
 
218 
 
CH3  
<5 
Not readily 
biodegradable 
Primary 
Biodegradation 
by IC from 
modified OECD 
301 D 
Activated 
Sludge 
60-
100 
mg/L 
28 d  
7
 
A-18 
 
 
219 
 
CH3  
<5 
Not readily 
biodegradable 
Primary 
Biodegradation 
by IC from 
modified OECD 
301 D 
Activated 
Sludge 
60-
100 
mg/L 
28 d  
7
 
220 
 
CH3  
<5 
Not readily 
biodegradable 
Primary 
Biodegradation 
by IC from 
modified OECD 
301 D 
Activated 
Sludge 
60-
100 
mg/L 
28 d  
7
 
220 “ CH3  
0 ± 0.5 
Not readily 
biodegradable 
Manometric 
Respirometry 
(OECD 301F) 
Activated 
Sludge 
120-
150 
mg/L 
28 d BOD 
7
 
221 
 
C4H9  
<5 
Not readily 
biodegradable 
Primary 
Biodegradation 
by IC from 
modified OECD 
301 D 
Activated 
Sludge 
60-
100 
mg/L 
28 d  
7
 
A-19 
 
 
222 
 
C6H13  
<5 
Not readily 
biodegradable 
Primary 
Biodegradation 
by IC from 
modified OECD 
301 D 
Activated 
Sludge 
60-
100 
mg/L 
28 d  
7
 
222 
 
C6H13  
2 ± 2.5 
Not readily 
biodegradable 
Manometric 
Respirometry 
(OECD 301F) 
Activated 
Sludge 
120-
150 
mg/L 
28 d BOD 
7
 
223 
 
CH3  <5 
Not readily 
biodegradable 
Primary 
Biodegradation 
by IC from 
modified OECD 
301 D 
Activated 
Sludge 
60-
100 
mg/L 
28 d  
7
 
224 
 
CH3 
 
<5 
Not readily 
biodegradable 
Primary 
Biodegradation 
by IC from 
modified OECD 
301 D 
Activated 
Sludge 
60-
100 
mg/L 
28 d  
7
 
A-20 
 
 
IL Head Group Side Chain R Anion 
Biodegrad
ation % 
Classification Test Method Inoculum 
IL 
Conc. 
Test 
Duration 
Measured 
Parameter 
Ref 
Thiazolium 
103 
 
C2H5 
 
03 
Not readily 
biodegradable 
CO2 Headspace 
test 
(ISO 14593) 
Activated 
sludge 
20 
mg/L 
28 d THCO2 
8
 
104 “ C2H4OH 
 
07 
Not readily 
biodegradable 
CO2 Headspace 
test 
(ISO 14593) 
Activated 
sludge 
20 
mg/L 
28 d THCO2 
8
 
A-21 
 
 
IL Head Group Side Chain R Anion 
Biodegrad-
ation % 
Classification Test Method Inoculum 
IL 
Conc. 
Test 
Duration 
Measured 
Parameter 
Ref 
Pyridinium 
16 
 
 
C2H5  0 
Not readily 
biodegradable 
Primary 
Biodegradation 
Activated 
sludge 
50 
µmol
/L 
28 d  
9, 
10
 
105 
 
“ CH2CN  
Not 
reported 
Hydrolysis  
of cyano group 
detected 
Primary 
Biodegradation 
Activated 
sludge 
50 
µmol
/L 
28 d  
9
 
A-22 
 
 
105 
 
“ CH2CN  -2 ± 0 Inherently 
Manometric 
Respirometry 
(OECD 301F) 
Activated 
sludge 
 28 d BOD 
9
 
106 
 
 
C4H9  2 
Not readily 
biodegradable 
Manometric 
Respirometry 
(OECD 301F) 
Activated 
sludge 
 
28 d 
 
BOD 
9, 
11
 
107 
 
“ C3H7  1 ± 0 
Not readily 
biodegradable 
Manometric 
Respirometry 
(OECD 301F) 
Activated 
sludge 
 28 d BOD 
9
 
108 “ CH2C6H5  2 
Not readily 
biodegradable 
CO2 Headspace 
test 
(ISO 14593) 
 
20 
mg/L 
28 d THCO2 
4
 
A-23 
 
 
109 
 
“ C2H4OH  65 
Readily 
biodegradable 
CO2 Headspace 
test 
(ISO 14593, 
OECD 310) 
Activated 
sludge 
20 
mg/L 
28 d THCO2 
8
 
110 “ C2H4OH 
 
62 
Readily 
biodegradable 
CO2 Headspace 
test 
(ISO 14593, 
OECD 310) 
Activated 
sludge 
20 
mg/L 
28 d THCO2 
8
 
111 
 
 
C2H4OH  100 
Inherently, 
ultimately 
biodegradable 
Primary 
Biodegradation 
Activated 
sludge 
50 
µmol
/L 
28 d  
9
 
111 
 
“ C2H4OH  65 ± 10 Inherently 
Manometric 
Respirometry 
(OECD 301F) 
Activated 
sludge 
 
28 d 
 
BOD 
9
 
A-24 
 
 
112 
 
“ C2H4OH  51 ± 0 Inherently 
Manometric 
Respirometry 
(OECD 301F) 
Activated 
sludge 
 
28 d 
 
BOD 
9
 
113 
 
C2H4OH 
 
6 
Not readily 
biodegradable 
CO2 Headspace 
test 
(ISO 14593) 
Activated 
sludge 
20 
mg/L 
28 d THCO2 
8
 
114 “ C4H9 
 
01 
Not readily 
biodegradable 
CO2 Headspace 
test 
(ISO 14593) 
Activated 
sludge 
20 
mg/L 
28 d THCO2 
8
 
115 
 
C4H9 
 
36  
Not readily 
biodegradable 
CO2 Headspace 
test 
(ISO 14593) 
Activated 
sludge 
20 
mg/L 
28 d THCO2 
8
 
A-25 
 
 
116 
 
C4H9 
 
32 
Not readily 
biodegradable 
CO2 Headspace 
test 
(ISO 14593) 
Activated 
sludge 
20 
mg/L 
28 d THCO2 
8
 
117 “ C8H17 
 
31 
Not readily 
biodegradable 
CO2 Headspace 
test 
(ISO 14593) 
Activated 
sludge 
20 
mg/L 
28 d THCO2 
8
 
118 “ CH2C(O)OC2H5 
 
47 
Not readily 
biodegradable 
CO2 Headspace 
test 
(ISO 14593) 
Activated 
sludge 
20 
mg/L 
28 d THCO2 
8
 
119 “ CH2C(O)OC5H11 
 
51 
Not readily 
biodegradable 
CO2 Headspace 
test 
(ISO 14593) 
Activated 
sludge 
20 
mg/L 
28 d THCO2 
8
 
A-26 
 
 
120 
 
CH3  74 
Readily 
biodegradable 
CO2 Headspace 
test 
(ISO 14593) 
Waste-
water 
organisms 
40 
mg/L 
28 d THCO2 
11
 
121 
 
C4H9 
 
30 
Not readily 
biodegradable 
CO2 Headspace 
test 
(ISO 14593) 
Waste-
water 
organisms 
40 
mg/L 
28 d THCO2 
11
 
122 
 
C2H4OH 
 
71 
Readily 
biodegradable 
CO2 Headspace 
test 
(ISO 14593) 
Activated 
sludge 
20 
mg/L 
28 d THCO2 
8
 
123 
 
CH2C6H5  25 
Not readily 
biodegradable 
CO2 Headspace 
test 
(ISO 14593) 
Activated 
sludge 
20 
mg/L 
28 d THCO2 
4
 
A-27 
 
 
124 
 
N/A 
 
03 
Not readily 
biodegradable 
CO2 Headspace 
test 
(ISO 14593) 
Activated 
sludge 
20 
mg/L 
28 d THCO2 
8
 
IL Head Group Side Chain R Anion 
Biodegrad-
ation % 
Classification Test Method Inoculum 
IL 
Conc. 
Test 
Duration 
Measured 
Parameter 
Ref 
Bis-Pyridinium 
214 
 
N/A 
 
05 
Not readily 
biodegradable 
CO2 Headspace 
test 
(ISO 14593) 
Activated 
sludge 
20 
mg/L 
28 d THCO2 
8
 
A-28 
 
 
215 “ N/A 
 
04 
Not readily 
biodegradable 
CO2 Headspace 
test 
(ISO 14593) 
Activated 
sludge 
20 
mg/L 
28 d THCO2 
8
 
216 “ N/A 
 
03 
Not readily 
biodegradable 
CO2 Headspace 
test 
(ISO 14593) 
Activated 
sludge 
20 
mg/L 
28 d THCO2 
8
 
            
            
A-29 
 
 
IL Head Group Side Chain R Anion 
Biodegrad-
ation % 
Classification Test Method Inoculum 
IL 
Conc. 
Test 
Duration 
Measured 
Parameter 
Ref 
Morpholinium 
125 
 
C2H5  30 
Not readily 
biodegradable 
CO2 Headspace 
test 
(ISO 14593) 
Activated 
sludge 
20 
mg/L 
28 d THCO2 
12
 
126 
 
“ C4H9  10 
Not readily 
biodegradable 
CO2 Headspace 
test 
(ISO 14593) 
Activated 
sludge 
20 
mg/L 
28 d THCO2 
12
 
A-30 
 
 
126 
 
“ C4H9  -3±4 
Not readily 
biodegradable 
Primary 
Biodegradation 
Activated 
sludge 
50 
µmol
/L 
28 d  
9
 
127 
 
C6H13  04 
Not readily 
biodegradable 
CO2 Headspace 
test 
(ISO 14593) 
Activated 
sludge 
20 
mg/L 
28 d THCO2 
12
 
128 “ C8H17  06 
Not readily 
biodegradable 
CO2 Headspace 
test 
(ISO 14593) 
Activated 
sludge 
20 
mg/L 
28 d THCO2 
12
 
129 “ C10H21  07 
Not readily 
biodegradable 
CO2 Headspace 
test 
(ISO 14593) 
Activated 
sludge 
20 
mg/L 
28 d THCO2 
12
 
A-31 
 
 
130 
 
“ C2H4OH  17 ± 1  
Primary 
Biodegradation 
Activated 
sludge 
50 
µmol
/L 
28 d  
9
 
130 
 
“ C2H4OH  
-1 ± 1 
4 ± 1 
 
Not readily 
biodegradable 
Manometric 
Respirometry 
(OECD 301F) 
Activated 
sludge 
 
28 d 
60 d 
BOD 
9
 
131 
 
 
C3H6OH  12 ± 8  
Primary 
Biodegradation 
Activated 
sludge 
50 
µmol
/L 
28 d  
9
 
131 
 
“ C3H6OH  
31 ± 16 
59 ± 10 
Inherently 
Manometric 
Respirometry 
(OECD 301F) 
Activated 
sludge 
 
28 d 
41 d 
BOD 
9
 
A-32 
 
 
132 
 
“ CH2CN  54 ± 13 
Hydrolysis  
of cyano group 
detected 
Primary 
Biodegradation 
Activated 
sludge 
50 
µmol
/L 
28 d  
9
 
132 
 
“ CH2CN  0 
Not readily 
biodegradable 
Manometric 
Respirometry 
(OECD 301F) 
Activated 
sludge 
 
28 d 
 
BOD 
9
 
133 
 
“ CH2C6H5  0 
Not readily 
biodegradable 
Primary 
Biodegradation 
Modified OECD 
301 D 
Activated 
sludge 
45 
mg/L 
28 d  
13
 
133 
 
 
CH2C6H5  0 
Not readily 
biodegradable 
Manometric 
Respirometry 
(OECD 301F) 
Activated 
sludge 
20 
mg/L 
100 
mg/L 
28 d 
 
BOD  
A-33 
 
 
134 
 
“ C2H4OCH3  
-1 ± 4 
 
Not readily 
biodegradable 
Primary 
Biodegradation 
Activated 
sludge 
50 
µmol
/L 
28 d  
9
 
135 
 
“ CH2OC2H5  
-3 ± 4 
 
Not readily 
biodegradable 
Primary 
Biodegradation 
Activated 
sludge 
50 
µmol
/L 
28 d  
9
 
136 
 
“ C2H4OC2H5  
0 ± 8 
 
Not readily 
biodegradable 
Primary 
Biodegradation 
Activated 
sludge 
50 
µmol
/L 
28 d  
9
 
 
A-34 
 
 
IL Head Group Side Chain R Anion 
Biodegrad
ation % 
Classification Test Method Inoculum 
IL 
Conc. 
Test 
Duration 
Measured 
Parameter 
Ref 
1,4-Diazabicyclo[2.2.2]octanium (DABCO) 
137 
 
C2H5  40 
Not readily 
biodegradable 
CO2 Headspace 
test 
(ISO 14593) 
Activated 
sludge 
20 
mg/L 
28 d THCO2 
12
 
138 “ C4H9  36 
Not readily 
biodegradable 
CO2 Headspace 
test 
(ISO 14593) 
Activated 
sludge 
20 
mg/L 
28 d THCO2 
12
 
A-35 
 
 
139 “ C6H13  23 
Not readily 
biodegradable 
CO2 Headspace 
test 
(ISO 14593) 
Activated 
sludge 
20 
mg/L 
28 d THCO2 
12
 
140 
 
C8H17  34 
Not readily 
biodegradable 
CO2 Headspace 
test 
(ISO 14593) 
Activated 
sludge 
20 
mg/L 
28 d THCO2 
12
 
141 “ C10H21  34 
Not readily 
biodegradable 
CO2 Headspace 
test 
(ISO 14593) 
Activated 
sludge 
20 
mg/L 
28 d THCO2 
12
 
            
A-36 
 
 
IL Head Group Side Chain R Anion 
Biodegrad-
ation % 
Classification Test Method Inoculum 
IL 
Conc. 
Test 
Duration 
Measured 
Parameter 
Ref 
Piperidinium 
142 
 
 
C2H4OH  
29 ± 3 
85 ± 1 
Inherently 
biodegradable 
Manometric 
Respirometry 
(OECD 301F) 
Activated 
sludge 
 
28 d 
60 d 
BOD 
9
 
143 
 
 
C3H6OH  79 ± 2 
Inherently, 
ultimately 
biodegradable 
Manometric 
Respirometry 
(OECD 301F) 
Activated 
sludge 
 28 d BOD 
9
 
A-37 
 
 
144 
 
 
CH2CN  
Not 
reported 
Hydrolysis  
of cyano group 
detected 
Primary 
Biodegradation 
Activated 
sludge 
50 
µmol
/L 
28 d  
9
 
144 
 
 
CH2CN  5 ± 2 
Not readily 
biodegradable 
Manometric 
Respirometry 
(OECD 301F) 
Activated 
sludge 
 28 d BOD 
9
 
145 
 
 
CH2OC2H5  -2 ± 2 
Not readily 
biodegradable 
Primary 
Biodegradation 
Activated 
sludge 
50 
µmol
/L 
28 d BOD 
9
 
146 
 
 
C2H4OCH3  
1 ± 4 
 
Not readily 
biodegradable 
Primary 
Biodegradation 
Activated 
sludge 
50 
µmol
/L 
28 d BOD 
9
 
A-38 
 
 
147 
 
 
C4H9  -4 ± 3 
Not readily 
biodegradable 
Manometric 
Respirometry 
(OECD 301F) 
Activated 
sludge 
 
28 d 
 
BOD 
9, 
11
 
148 
 
 
C3H7 
 
3 ± 2 
Not readily 
biodegradable 
Manometric 
Respirometry 
(OECD 301F) 
Activated 
sludge 
 28 d BOD 
9
 
            
            
A-39 
 
 
IL Head Group Side Chain R Anion 
Biodegrad-
ation % 
Classification Test Method Inoculum 
IL 
Conc. 
Test 
Duration 
Measured 
Parameter 
Ref 
Pyrrolidinium 
149 
  
C4H9 
 
6/9 
Not readily 
biodegradable 
CO2 evolution 
test (OECD 
301B) 
Waste-
water 
organisms 
40 
mg/L 
28 d 
CO2 
Evolution 
14
 
149 “ “ “ 2/4 
Not readily 
biodegradable 
Manometric 
Respirometry 
(OECD 301F) 
Waste-
water 
organisms 
75 
mg/L 
28 d BOD 
14
 
A-40 
 
 
149 “ “ “ 0 
Not readily 
biodegradable 
Primary 
Biodegradation 
by ion 
chromatography 
(samples taken 
from OECD 
301B test) 
  28 d  
14
 
150 
 
C4H9  
14 ± 13 
70 ± 18 
Inherently, 
ultimately 
biodegradable 
Manometric 
Respirometry 
(OECD 301F) 
Activated 
sludge 
 
28 d 
42 d 
BOD 
9
 
151 
 
“ C3H6OH  
100 
 
Primarily 
biodegradable 
Primary 
Biodegradation 
Activated 
sludge 
50 
µmol
/L 
28 d  
9
 
151 
 
“ C3H6OH  
67 ± 3 
 
Readily 
biodegradable 
Manometric 
Respirometry 
(OECD 301F) 
Activated 
sludge 
 28 d BOD 
9
 
A-41 
 
 
152 
 
“ C2H5 
 
-2  ± 3 
-3  ± 8 
  
Not readily 
biodegradable 
Primary 
Biodegradation 
Activated 
sludge 
50 
µmol
/L 
28 d 
40 d 
 
9
 
153 
 
“ C2H4OH  
8 ± 5 
25 ± 21 
 
 
Not readily 
biodegradable, 
potentially 
inherently 
Primary 
Biodegradation 
Activated 
sludge 
50 
µmol
/L 
28 d 
43 d 
 
9
 
153 
  
C2H4OH  
6 ± 9 
42 ± 39 
 
Not readily 
biodegradable, 
potentially 
inherently 
Manometric 
Respirometry 
(OECD 301F) 
Activated 
sludge 
 
28 d 
60 d 
 
BOD 
9
 
154 
 
“ CH2CN  
Not 
reported 
Hydrolysis  
of cyano group 
detected 
Primary 
Biodegradation 
Activated 
sludge 
50 
µmol
/L 
28 d  
9
 
A-42 
 
 
154 
 
“ CH2CN  
2 ± 2 
 
Not readily 
biodegradable 
Manometric 
Respirometry 
(OECD 301F) 
Activated 
sludge 
 
28 d 
 
BOD 
9
 
155 
 
“ 
CH2CO-
OCH2CH3  
100 
 
Inherently, 
Ultimately 
Biodegradable 
 
Primary 
Biodegradation 
Activated 
sludge 
50 
µmol
/L 
28 d  
9
 
155 
 
“ 
CH2CO-
OCH2CH3 
 
34 ± 11 
74 ± 0.1 
 
 
Inherently, 
Ultimately 
Biodegradable 
 
Manometric 
Respirometry 
(OECD 301F) 
Activated 
sludge 
 
28 d 
38 d 
BOD 
9
 
156 
  
C8H17  
 
100 
 
Primarily 
biodegradable 
Primary 
Biodegradation 
Activated 
sludge 
50 
µmol
/L 
28 d  
9
 
A-43 
 
 
156 
 
“ C8H17  
 
69 ± 1 
 
Readily 
biodegradable 
Manometric 
Respirometry 
(OECD 301F) 
Activated 
sludge 
 28 d BOD 
9
 
IL Head Group Side Chain R Anion 
Biodegrad-
ation % 
Classification Test Method Inoculum 
IL 
Conc. 
Test 
Duration 
Measured 
Parameter 
Ref 
Bis-Pyrrolidinium 
225 
 
CH3  <5 
Not readily 
biodegradable 
Primary 
Biodegradation 
by IC from 
modified OECD 
301 D 
Activated 
Sludge 
60-
100 
mg/L 
28 d  
7
 
A-44 
 
 
226 
 
CH3 
 
<5 
Not readily 
biodegradable 
Primary 
Biodegradation 
by IC from 
modified OECD 
301 D 
Activated 
Sludge 
60-
100 
mg/L 
28 d  
7
 
226 
 
“ 
“ “ 2 ± 2.5 
Not readily 
biodegradable 
Manometric 
Respirometry 
(OECD 301F) 
Activated 
Sludge 
120-
150 
mg/L 
28 d BOD 
7
 
            
            
A-45 
 
 
IL 
Head Group (Cation) 
 
Anion 
Biodegrad-
ation % 
Classification Test Method Inoculum 
IL 
Conc. 
Test 
Duration 
Measured 
Parameter 
Ref 
Tetraalkyl Ammonium 
158  
  
59/62 
Readily 
biodegradable 
CO2 evolution 
test (OECD 
301B) 
Waste-
water 
organisms 
40 
mg/L 
28 d 
CO2 
Evolution 
14
 
158 “ “ 87/88 
Readily 
biodegradable 
Manometric 
Respirometry 
(OECD 301F) 
Waste-
water 
organisms 
75 
mg/L 
28 d BOD 
14
 
A-46 
 
 
158  
  
100±3 
Primarily 
biodegradable 
Primary 
Biodegradation 
by ion 
chromatography 
(samples taken 
from OECD 
301B test) 
  9 d  
14
 
159 
  
17/18 
Not readily 
biodegradable 
CO2 evolution 
test (OECD 
301B) 
Waste-
water 
organisms 
40 
mg/L 
28 d 
CO2 
Evolution 
14
 
159 “ “ 27/29 
Not readily 
biodegradable 
Manometric 
Respirometry 
(OECD 301F) 
Waste-
water 
organisms 
75 
mg/L 
28 d BOD 
14
 
159 “ “ 4±1  
Primary 
Biodegradation 
by ion 
chromatography 
  28 d  
14
 
A-47 
 
 
(samples taken 
from OECD 
301B test) 
173 
  
4/5 
Not readily 
biodegradable 
Manometric 
Respirometry 
(OECD 301F) 
Waste-
water 
organisms 
75 
mg/L 
28 d BOD 
14
 
56 
 
  
15.5 
Not readily 
biodegradable 
Closed Bottle 
Test (TG 301 D) 
Waste-
water 
organisms 
 28 d BOD 
15
 
57 
 
 
 
9.9 
Not readily 
biodegradable 
Closed Bottle 
Test (TG 301 D) 
Waste-
water 
organisms 
 28 d BOD 
15
 
A-48 
 
 
58 
 
 
 
18.6 
Not readily 
biodegradable 
Closed Bottle 
Test (TG 301 D) 
Waste-
water 
organisms 
 28 d BOD 
15
 
58 
 
  
15.5 
Not readily 
biodegradable 
Closed Bottle 
Test (TG 301 D) 
Waste-
water 
organisms 
 28 d BOD 
15
 
168 
 
  
14.2 
Not readily 
biodegradable 
Closed Bottle 
Test (TG 301 D) 
Waste-
water 
organisms 
 28 d BOD 
15
 
169 
 
  
12.2 
Not readily 
biodegradable 
Closed Bottle 
Test (TG 301 D) 
Waste-
water 
organisms 
 28 d BOD 
15
 
A-49 
 
 
170 
 
 
 
22.8 
Not readily 
biodegradable 
Closed Bottle 
Test (TG 301 D) 
Waste-
water 
organisms 
 28 d BOD 
15
 
67 
 
  
15-20 
Not readily 
biodegradable 
CO2 Headspace 
test 
(OECD 310) 
Activated 
sludge 
20 
mg/L 
28 d THCO2 
16
 
171 
 
  
15-20 
Not readily 
biodegradable 
CO2 Headspace 
test 
(OECD 310) 
Activated 
sludge 
20 
mg/L 
28 d THCO2 
16
 
172 
 
  
20-25 
Not readily 
biodegradable 
CO2 Headspace 
test 
(OECD 310) 
Activated 
sludge 
20 
mg/L 
28 d THCO2 
16
 
A-50 
 
 
323 
 
  
Nd 
Not 
determined 
Closed Bottle 
Test (TG 301 D) 
Waste-
water 
organisms 
 28 d BOD 
15
 
60 
 
  
72 
Readily 
biodegradable 
Manometric 
Respirometry 
(OECD 301F) 
Waste-
water 
organisms 
 28 d BOD 
17
 
174 
 
“  5 
Not readily 
biodegradable 
Manometric 
Respirometry 
(OECD 301F) 
Waste-
water 
organisms 
 28 d BOD 
17
 
175 
 
“ 
 
77 
Readily 
biodegradable 
Manometric 
Respirometry 
(OECD 301F) 
Waste-
water 
organisms 
 28 d BOD 
17
 
A-51 
 
 
176 
 
  
66 
Readily 
biodegradable 
Manometric 
Respirometry 
(OECD 301F) 
Waste-
water 
organisms 
 28 d BOD 
17
 
177 
 
“ 
 
45 
Not readily 
biodegradable 
Manometric 
Respirometry 
(OECD 301F) 
Waste-
water 
organisms 
 28 d BOD 
17
 
178 
 
“ 
 
69 
Readily 
biodegradable 
Manometric 
Respirometry 
(OECD 301F) 
Waste-
water 
organisms 
 28 d BOD 
17
 
179 “ 
 
54 
Not readily 
biodegradable 
Manometric 
Respirometry 
(OECD 301F) 
Waste-
water 
organisms 
 28 d BOD 
17
 
A-52 
 
 
180 
 
“ 
 
69 
Readily 
biodegradable 
Manometric 
Respirometry 
(OECD 301F) 
Waste-
water 
organisms 
 28 d BOD 
17
 
IL Cation Anion 
Biodegrad
ation % 
Classification Test Method Inoculum 
IL 
Conc. 
Test 
Duration 
Measured 
Parameter 
Ref 
Protic ILs – Ethanolaminium 
54 
 
 
 
 
86 
Readily 
biodegradable 
Manometric 
Respirometry 
(OECD 301 F) 
Activated 
Sludge 
100 
mg/L 
28 d BOD 
18
 
A-53 
 
 
54 “ “ 100 
Primarily 
biodegradable 
Primary 
Biodegradation 
by ion 
chromatography 
(samples taken 
from OECD 301 
F test) 
  5 d  
18
 
55 
   
95 
Readily 
biodegradable 
Manometric 
Respirometry 
(OECD 301F) 
Activated 
Sludge 
100 
mg/L 
28 d BOD 
18
 
55 
  
100 
Primarily 
biodegradable 
Primary 
Biodegradation 
by ion 
chromatography 
(samples taken 
from OECD 301 
F test) 
  5 d  
18
 
A-54 
 
 
160 
   
13 
Not readily 
biodegradable 
Manometric 
Respirometry 
(OECD 301F) 
Activated 
Sludge 
100 
mg/L 
28 d BOD 
18
 
160 “ “ 100 
Primarily 
biodegradable 
Primary 
Biodegradation 
by ion 
chromatography 
(samples taken 
from OECD 301 
F test) 
  5 d  
18
 
161 
   
69 
Readily 
biodegradable 
Manometric 
Respirometry 
(OECD 301F) 
Activated 
Sludge 
100 
mg/L 
28 d BOD 
18
 
161 
  
65/ 
100 
Primarily 
biodegradable 
Primary 
Biodegradation 
by ion 
chromatography 
  
5d/ 
28 d 
 
18
 
A-55 
 
 
(samples taken 
from OECD 301 
F test) 
162 
   
68 
Readily 
biodegradable 
Manometric 
Respirometry 
(OECD 301F) 
Activated 
Sludge 
100 
mg/L 
28 d BOD 
18
 
162 “ “ 100 
Primarily 
biodegradable 
Primary 
Biodegradation 
by ion 
chromatography 
(samples taken 
from OECD 301 
F test) 
  5 d  
18
 
163 
   
78 
Readily 
biodegradable 
Manometric 
Respirometry 
(OECD 301F) 
Activated 
Sludge 
100 
mg/L 
28 d BOD 
18
 
A-56 
 
 
163 
  
21/ 
100 
Primarily 
biodegradable 
Primary 
Biodegradation 
by ion 
chromatography 
(samples taken 
from OECD 301 
F test) 
  
5 d/ 
28 d 
 
18
 
164 
  
 
79 
Readily 
biodegradable 
Manometric 
Respirometry 
(OECD 301F) 
Activated 
Sludge 
100 
mg/L 
28 d BOD 
18
 
164 “ “ 
70/ 
100 
Primarily 
biodegradable 
Primary 
Biodegradation 
by ion 
chromatography 
(samples taken 
from OECD 301 
F test) 
  
5 d/ 
28d 
 
18
 
A-57 
 
 
165 
   
69 
Readily 
biodegradable 
Manometric 
Respirometry 
(OECD 301F) 
Activated 
Sludge 
100 
mg/L 
28 d BOD 
18
 
165 
  
16/ 
62 
Primarily 
biodegradable 
Primary 
Biodegradation 
by ion 
chromatography 
(samples taken 
from OECD 301 
F test) 
  
5 d/ 
28 d 
 
18
 
166 
 
 
 
59 
Not readily 
biodegradable 
Manometric 
Respirometry 
(OECD 301F) 
Activated 
Sludge 
100 
mg/L 
28 d BOD 
18
 
166 “ “ 
34/ 
100 
Primarily 
biodegradable 
Primary 
Biodegradation 
by ion 
chromatography 
  
5 d/ 
28 d 
 
18
 
A-58 
 
 
(samples taken 
from OECD 301 
F test) 
167 
 
“ 
 
57 
Not readily 
biodegradable 
Manometric 
Respirometry 
(OECD 301F) 
Activated 
Sludge 
100 
mg/L 
28 d BOD 
18
 
167 
 
 
33/ 
100 
Primarily 
biodegradable 
Primary 
Biodegradation 
by ion 
chromatography 
(samples taken 
from OECD 301 
F test) 
  
5 d/ 
28 d 
 
18
 
 
           
A-59 
 
 
IL Cation Anion 
Biodegrad
ation % 
Classification Test Method Inoculum 
IL 
Conc. 
Test 
Duration 
Measured 
Parameter 
Ref 
Cholinium 
157 
  
84/88 
Readily 
biodegradable 
CO2 evolution 
test (OECD 
301B) 
Waste-
water 
organisms 
40 
mg/L 
28 d 
CO2 
Evolution 
14
 
157 “ “ 88/90 
Readily 
biodegradable 
Manometric 
Respirometry 
(OECD 301F) 
Waste-
water 
organisms 
75 
mg/L 
28 d BOD 
14
 
A-60 
 
 
157 “ “ 100±2 
Primarily 
biodegradable 
Primary 
Biodegradation 
by ion 
chromatography 
(samples taken 
from OECD 
301B test) 
  5 d  
14
 
61 
   
76.4 ±  
1.1 
Readily 
biodegradable 
CO2 Headspace 
test 
(ISO 14593, 
OECD 310) 
Activated 
sludge 
20 
mg/L 
28 d THCO2 
19
 
61 
 
“ “ 82.6 ± 1.1 
Readily 
biodegradable 
Closed Bottle 
Test (TG 301 D) 
Waste-
water 
organisms 
3 
mg/L 
28 d BOD 
19
 
62 
 
“ 
 
70.5 ± 3.0 
Readily 
biodegradable 
CO2 Headspace 
test 
(OECD 310) 
Activated 
sludge 
20 
mg/L 
28 d THCO2 
19
 
A-61 
 
 
62 
 
“ “ 71.3 ± 0.1 
Readily 
biodegradable 
Closed Bottle 
Test (TG 301 D) 
Waste-
water 
organisms 
3 
mg/L 
28 d BOD 
19
 
63 
 
“ 
 
63.3 ± 1.2 
Readily 
biodegradable 
CO2 Headspace 
test 
(OECD 310) 
Activated 
sludge 
20 
mg/L 
28 d THCO2 
19
 
63 
  
 
65.3 ± 1.3 
Readily 
biodegradable 
Closed Bottle 
Test (TG 301 D) 
Waste-
water 
organisms 
3 
mg/L 
28 d BOD 
19
 
64 
 
“ 
 
63.6 ± 1.2 
Readily 
biodegradable 
CO2 Headspace 
test 
(OECD 310) 
Activated 
sludge 
20 
mg/L 
28 d THCO2 
19
 
A-62 
 
 
64 
 
“ “ 66.1 ± 0.9 
Readily 
biodegradable 
Closed Bottle 
Test (TG 301 D) 
Waste-
water 
organisms 
3 
mg/L 
28 d BOD 
19
 
65 
 
“ 
 
72.5 ± 0.3 
Readily 
biodegradable 
CO2 Headspace 
test 
(OECD 310) 
Activated 
sludge 
20 
mg/L 
28 d THCO2 
19
 
65 
 
“ “ 70.8 ± 0.1 
Readily 
biodegradable 
Closed Bottle 
Test (TG 301 D) 
Waste-
water 
organisms 
3 
mg/L 
28 d BOD 
19
 
66 
  
 
65.5 ± 1.2  
Readily 
biodegradable 
CO2 Headspace 
test 
(OECD 310) 
Activated 
sludge 
20 
mg/L 
28 d THCO2 
19
 
A-63 
 
 
66 
 
“ “ 67.6 ± 0.2 
Readily 
biodegradable 
Closed Bottle 
Test (TG 301 D) 
Waste-
water 
organisms 
3 
mg/L 
28 d BOD 
19
 
310 
 
“ 
 
76.2 ± 0.8 
Readily 
biodegradable 
CO2 Headspace 
test 
(OECD 310) 
Activated 
sludge 
20 
mg/L 
28 d THCO2 
19
 
310 
 
“ “ 80.0 ± 0.4 
Readily 
biodegradable 
Closed Bottle 
Test (TG 301 D) 
Waste-
water 
organisms 
3 
mg/L 
28 d BOD 
19
 
311 
 
“ 
 
67.5 ± 0.6 
Readily 
biodegradable 
CO2 Headspace 
test 
(OECD 310) 
Activated 
sludge 
20 
mg/L 
28 d THCO2 
19
 
A-64 
 
 
311 
  
 
69.4 ± 0.6 
Readily 
biodegradable 
Closed Bottle 
Test (TG 301 D) 
Waste-
water 
organisms 
3 
mg/L 
28 d BOD 
19
 
312 
 
“ 
 
71.4 ± 1.0 
Readily 
biodegradable 
CO2 Headspace 
test 
(OECD 310) 
Activated 
sludge 
20 
mg/L 
28 d THCO2 
19
 
312 
 
“ “ 72.4 ± 0.1 
Readily 
biodegradable 
Closed Bottle 
Test (TG 301 D) 
Waste-
water 
organisms 
3 
mg/L 
28 d BOD 
19
 
313 
 
“ 
 
70.5 ± 0.3 
Readily 
biodegradable 
CO2 Headspace 
test 
(OECD 310) 
Activated 
sludge 
20 
mg/L 
28 d THCO2 
19
 
A-65 
 
 
313 
 
“ “ 71.6 ± 0.8 
Readily 
biodegradable 
Closed Bottle 
Test (TG 301 D) 
Waste-
water 
organisms 
3 
mg/L 
28 d BOD 
19
 
314 
  
 
74.7 ± 0.3 
Readily 
biodegradable 
CO2 Headspace 
test 
(OECD 310) 
Activated 
sludge 
20 
mg/L 
28 d THCO2 
19
 
314 
 
“ “ 80.6 ± 1.5 
Readily 
biodegradable 
Closed Bottle 
Test (TG 301 D) 
Waste-
water 
organisms 
3 
mg/L 
28 d BOD 
19
 
315 
 
“ 
 
71.5 ± 0.8  
Readily 
biodegradable 
CO2 Headspace 
test 
(OECD 310) 
Activated 
sludge 
20 
mg/L 
28 d THCO2 
19
 
A-66 
 
 
315 
 
“ “ 74.3 ± 1.5 
Readily 
biodegradable 
Closed Bottle 
Test (TG 301 D) 
Waste-
water 
organisms 
3 
mg/L 
28 d BOD 
19
 
316 
 
“ 
 
82.4 ± 0.7 
Readily 
biodegradable 
CO2 Headspace 
test 
(OECD 310) 
Activated 
sludge 
20 
mg/L 
28 d THCO2 
19
 
316 
  
 
87.1 ± 0.6 
Readily 
biodegradable 
Closed Bottle 
Test (TG 301 D) 
Waste-
water 
organisms 
3 
mg/L 
28 d BOD 
19
 
317 
 
“ 
 
80.8 ± 0.5 
Readily 
biodegradable 
CO2 Headspace 
test 
(OECD 310) 
Activated 
sludge 
20 
mg/L 
28 d THCO2 
19
 
A-67 
 
 
317 
 
“ “ 86.3 ± 0.2 
Readily 
biodegradable 
Closed Bottle 
Test (TG 301 D) 
Waste-
water 
organisms 
3 
mg/L 
28 d BOD 
19
 
318 
 
“ 
 
85.2 ± 0.1 
Readily 
biodegradable 
CO2 Headspace 
test 
(OECD 310) 
Activated 
sludge 
20 
mg/L 
28 d THCO2 
19
 
318 
 
“ “ 87.1 ± 1.2 
Readily 
biodegradable 
Closed Bottle 
Test (TG 301 D) 
Waste-
water 
organisms 
3 
mg/L 
28 d BOD 
19
 
319 
  
 
81.4 ± 0.1 
Readily 
biodegradable 
CO2 Headspace 
test 
(OECD 310) 
Activated 
sludge 
20 
mg/L 
28 d THCO2 
19
 
A-68 
 
 
319 
 
“ “ 86.6 ± 1.4 
Readily 
biodegradable 
Closed Bottle 
Test (TG 301 D) 
Waste-
water 
organisms 
3 
mg/L 
28 d BOD 
19
 
320 
 
“ 
 
64.7 ± 0.5 
Readily 
biodegradable 
CO2 Headspace 
test 
(OECD 310) 
Activated 
sludge 
20 
mg/L 
28 d THCO2 
19
 
320 
 
“ “ 67.7 ± 1.0 
Readily 
biodegradable 
Closed Bottle 
Test (TG 301 D) 
Waste-
water 
organisms 
3 
mg/L 
28 d BOD 
19
 
321 
 
“ 
 
62.1 ± 0.3 
Readily 
biodegradable 
CO2 Headspace 
test 
(OECD 310) 
Activated 
sludge 
20 
mg/L 
28 d THCO2 
19
 
A-69 
 
 
321 
  
 
65.9 ± 0.2 
Readily 
biodegradable 
Closed Bottle 
Test (TG 301 D) 
Waste-
water 
organisms 
3 
mg/L 
28 d BOD 
19
 
322 
 
“ 
 
65.3 ± 0.1 
Readily 
biodegradable 
CO2 Headspace 
test 
(OECD 310) 
Activated 
sludge 
20 
mg/L 
28 d THCO2 
19
 
322 
 
“ 
 
“ 
68.1 ± 1.9 
Readily 
biodegradable 
Closed Bottle 
Test (TG 301 D) 
Waste-
water 
organisms 
3 
mg/L 
28 d BOD 
19
 
           
A-70 
 
 
IL Head Group Side Chain R Anion 
Biodegrad-
ation % 
Classification Test Method Inoculum 
IL 
Conc. 
Test 
Duration 
Measured 
Parameter 
Ref 
Phosphonium 
181 
 
C3H7 
 
4 
Not readily 
biodegradable 
CO2 Headspace 
test 
(ISO 14593) 
Activated 
sludge 
20 
mg/L 
28 d THCO2 
20
 
182 “ C5H11  3 
Not readily 
biodegradable 
CO2 Headspace 
test 
(ISO 14593) 
Activated 
sludge 
20 
mg/L 
28 d THCO2 
20
 
A-71 
 
 
183 “ C7H15  2 
Not readily 
biodegradable 
CO2 Headspace 
test 
(ISO 14593) 
Activated 
sludge 
20 
mg/L 
28 d THCO2 
20
 
184 
 
C3H7 
 
7 
Not readily 
biodegradable 
CO2 Headspace 
test 
(ISO 14593) 
Activated 
sludge 
20 
mg/L 
28 d THCO2 
20
 
185 “ C5H11 
 
2 
Not readily 
biodegradable 
CO2 Headspace 
test 
(ISO 14593) 
Activated 
sludge 
20 
mg/L 
28 d THCO2 
20
 
186 “ C7H15 
 
3 
Not readily 
biodegradable 
CO2 Headspace 
test 
(ISO 14593) 
Activated 
sludge 
20 
mg/L 
28 d THCO2 
20
 
A-72 
 
 
187 “ C3H7 
 
18 
Not readily 
biodegradable 
CO2 Headspace 
test 
(ISO 14593) 
Activated 
sludge 
20 
mg/L 
28 d THCO2 
20
 
188 “ C5H11 
 
22 
Not readily 
biodegradable 
CO2 Headspace 
test 
(ISO 14593) 
Activated 
sludge 
20 
mg/L 
28 d THCO2 
20
 
189 
 
C7H15 
 
21 
Not readily 
biodegradable 
CO2 Headspace 
test 
(ISO 14593) 
Activated 
sludge 
20 
mg/L 
28 d THCO2 
20
 
190 
 
(CH2)4O-
C(O)CH3 
  9 
Not readily 
biodegradable 
CO2 Headspace 
test 
(ISO 14593) 
Activated 
sludge 
20 
mg/L 
28 d THCO2 
20
 
A-73 
 
 
191 “  N/A 
 
9 
Not readily 
biodegradable 
CO2 Headspace 
test 
(ISO 14593) 
Activated 
sludge 
20 
mg/L 
28 d THCO2 
20
 
192 “ N/A 
 
22 
Not readily 
biodegradable 
CO2 Headspace 
test 
(ISO 14593) 
Activated 
sludge 
20 
mg/L 
28 d THCO2 
20
 
193 
 
C3H7 
 
12 
Not readily 
biodegradable 
CO2 Headspace 
test 
(ISO 14593) 
Activated 
sludge 
15 
mg/L 
28 d THCO2 
20
 
194 
 
C5H11  4 
Not readily 
biodegradable 
CO2 Headspace 
test 
(ISO 14593) 
Activated 
sludge 
15 
mg/L 
28 d THCO2 
20
 
A-74 
 
 
195 “ C7H15  10 
Not readily 
biodegradable 
CO2 Headspace 
test 
(ISO 14593) 
Activated 
sludge 
15 
mg/L 
28 d THCO2 
20
 
196 “ C3H7 
 
0 
Not readily 
biodegradable 
CO2 Headspace 
test 
(ISO 14593) 
Activated 
sludge 
15 
mg/L 
28 d THCO2 
20
 
197 “ C5H11 
 
2 
Not readily 
biodegradable 
CO2 Headspace 
test 
(ISO 14593) 
Activated 
sludge 
15 
mg/L 
28 d THCO2 
20
 
198 “ C7H15 
 
0 
Not readily 
biodegradable 
CO2 Headspace 
test 
(ISO 14593) 
Activated 
sludge 
15 
mg/L 
28 d THCO2 
20
 
A-75 
 
 
199 
 
C3H7 
 
15 
Not readily 
biodegradable 
CO2 Headspace 
test 
(ISO 14593) 
Activated 
sludge 
15 
mg/L 
28 d THCO2 
20
 
200 “ C5H11 
 
20 
Not readily 
biodegradable 
CO2 Headspace 
test 
(ISO 14593) 
Activated 
sludge 
15 
mg/L 
28 d THCO2 
20
 
201 “ C7H15 
 
30 
Not readily 
biodegradable 
CO2 Headspace 
test 
(ISO 14593) 
Activated 
sludge 
15 
mg/L 
28 d THCO2 
20
 
202 
 
(CH2)4O-
C(O)CH3 
  0 
Not readily 
biodegradable 
CO2 Headspace 
test 
(ISO 14593) 
Activated 
sludge 
15 
mg/L 
28 d THCO2 
20
 
A-76 
 
 
203 “  “ 
 
0 
Not readily 
biodegradable 
CO2 Headspace 
test 
(ISO 14593) 
Activated 
sludge 
15 
mg/L 
28 d THCO2 
20
 
204 
 
(CH2)4O-
C(O)CH3  
5 
Not readily 
biodegradable 
CO2 Headspace 
test 
(ISO 14593) 
Activated 
sludge 
15 
mg/L 
28 d THCO2 
20
 
205 
 
CH2CHCH2  8 
Not readily 
biodegradable 
CO2 Headspace 
test 
(ISO 14593) 
Activated 
sludge 
15 
mg/L 
28 d THCO2 
20
 
206 “ “ 
 
0 
Not readily 
biodegradable 
CO2 Headspace 
test 
(ISO 14593) 
Activated 
sludge 
15 
mg/L 
28 d THCO2 
20
 
A-77 
 
 
207 “ “ 
 
18 
Not readily 
biodegradable 
CO2 Headspace 
test 
(ISO 14593) 
Activated 
sludge 
15 
mg/L 
28 d THCO2 
20
 
208 
 
CH2OCH3  2 
Not readily 
biodegradable 
CO2 Headspace 
test 
(ISO 14593) 
Activated 
sludge 
15 
mg/L 
28 d THCO2 
20
 
209 
 
CH2OCH3 
 
0 
Not readily 
biodegradable 
CO2 Headspace 
test 
(ISO 14593) 
Activated 
sludge 
15 
mg/L 
28 d THCO2 
20
 
210 “ “ 
 
11 
Not readily 
biodegradable 
CO2 Headspace 
test 
(ISO 14593) 
Activated 
sludge 
15 
mg/L 
28 d THCO2 
20
 
A-78 
 
 
211 
 
CH2CH2OH  0 
Not readily 
biodegradable 
CO2 Headspace 
test 
(ISO 14593) 
Activated 
sludge 
15 
mg/L 
28 d THCO2 
20
 
212 “ “ 
 
0 
Not readily 
biodegradable 
CO2 Headspace 
test 
(ISO 14593) 
Activated 
sludge 
15 
mg/L 
28 d THCO2 
20
 
213 
 
CH2CH2OH 
 
9 
Not readily 
biodegradable 
CO2 Headspace 
test 
(ISO 14593) 
Activated 
sludge 
15 
mg/L 
28 d THCO2 
20
 
            
A-79 
 
 
Surfactant 
 
Head Group 
 
Anion 
Biodegrad-
ation % 
Classification Test Method Inoculum 
IL 
Conc. 
Test 
Duration 
Measured 
Parameter 
Ref 
Surfactants 
LAM 
 
 90 
Readily 
biodegradable 
Closed Bottle 
Test (TG 301 D) 
Waste-
water 
organisms 
 28 d BOD 
21
 
A-80 
 
 
C3(CA)2 
 
 
87 
Ultimately 
Biodegradable 
Closed Bottle 
Test (TG 301 D) 
Waste-
water 
organisms 
 28 d BOD 
21
 
1010R(4) 
 
 
 79 
Ultimately 
biodegradable 
Closed Bottle 
Test (TG 301 D) 
Waste-
water 
organisms 
  BOD 
21
 
A-81 
 
 
1010R(4) 
 
 
 20 
Not readily 
biodegradable 
Closed Bottle 
Test (TG 301 D) 
Waste-
water 
organisms 
 28 d BOD 
22
 
1212R 
 
 82 
Readily 
biodegradable 
Closed Bottle 
Test (TG 301 D) 
Waste-
water 
organisms 
 28 d BOD 
22
 
A-82 
 
 
1414R 
 
 61 
Readily 
biodegradable 
Closed Bottle 
Test (TG 301 D) 
Waste-
water 
organisms 
 28 d BOD 
22
 
HTAB 
 
 0.36 
Not readily 
biodegradable 
Closed Bottle 
Test (TG 301 D) 
Waste-
water 
organisms 
 28 d BOD 
22
 
           
A-83 
 
 
IL Head Group Side Chain R Anion 
Biodegrad
ation % 
Classification Test Method Inoculum 
IL 
Conc. 
Test 
Duration 
Measured 
Parameter 
Ref 
Tris-Imidazolium Surfactants 
286 
 
 
C4H9  
27 
Not readily 
biodegradable 
Closed Bottle 
Test (TG 301 D) 
Waste-
water 
organisms 
100 
mg/L 
16 d BOD 
23
 
287 “ C6H13  
36 
Not readily 
biodegradable 
Closed Bottle 
Test (TG 301 D) 
Waste-
water 
organisms 
100 
mg/L 
16 d BOD 
23
 
A-84 
 
 
288 “ C8H17  
47 
Not readily 
biodegradable 
Closed Bottle 
Test (TG 301 D) 
Waste-
water 
organisms 
100 
mg/L 
16 d BOD 
23
 
289 
 
C10H21  
45 
Not readily 
biodegradable 
Closed Bottle 
Test (TG 301 D) 
Waste-
water 
organisms 
100 
mg/L 
16 d BOD 
23
 
290 “ C12H25  
51 
Not readily 
biodegradable 
Closed Bottle 
Test (TG 301 D) 
Waste-
water 
organisms 
100 
mg/L 
16 d BOD 
23
 
291 “ CH2C6H5  
20 
Not readily 
biodegradable 
Closed Bottle 
Test (TG 301 D) 
Waste-
water 
organisms 
100 
mg/L 
16 d BOD 
23
 
A-85 
 
 
292 
 
C4H9  
22 
Not readily 
biodegradable 
Closed Bottle 
Test (TG 301 D) 
Waste-
water 
organisms 
100 
mg/L 
16 d BOD 
23
 
293 “ C6H13  
27 
Not readily 
biodegradable 
Closed Bottle 
Test (TG 301 D) 
Waste-
water 
organisms 
100 
mg/L 
16 d BOD 
23
 
294 
 
C8H17  
35.5 
Not readily 
biodegradable 
Closed Bottle 
Test (TG 301 D) 
Waste-
water 
organisms 
100 
mg/L 
16 d BOD 
23
 
295 “ C10H21  
40 
Not readily 
biodegradable 
Closed Bottle 
Test (TG 301 D) 
Waste-
water 
organisms 
100 
mg/L 
16 d BOD 
23
 
A-86 
 
 
296 “ C12H25  
45 
Not readily 
biodegradable 
Closed Bottle 
Test (TG 301 D) 
Waste-
water 
organisms 
100 
mg/L 
16 d BOD 
23
 
297 “ CH2C6H5  
16 
Not readily 
biodegradable 
Closed Bottle 
Test (TG 301 D) 
Waste-
water 
organisms 
100 
mg/L 
16 d BOD 
23
 
            
            
A-87 
 
 
IL Head Group Side Chain R Anion 
Biodegrad-
ation % 
Classification Test Method Inoculum 
IL 
Conc. 
Test 
Duration 
Measured 
Parameter 
Ref 
Tetrakis-Imidazolium Surfactants 
298 
 
C4H9  
35 
Not readily 
biodegradable 
Closed Bottle 
Test (TG 301 D) 
Waste-
water 
organisms 
100 
mg/L 
16 d BOD 
24
 
299 “ C6H13  
39 
Not readily 
biodegradable 
Closed Bottle 
Test (TG 301 D) 
Waste-
water 
organisms 
100 
mg/L 
16 d BOD 
24
 
A-88 
 
 
300 “ C8H17  
49 
Not readily 
biodegradable 
Closed Bottle 
Test (TG 301 D) 
Waste-
water 
organisms 
100 
mg/L 
16 d BOD 
24
 
301 
 
C10H21  
51.5 
Not readily 
biodegradable 
Closed Bottle 
Test (TG 301 D) 
Waste-
water 
organisms 
100 
mg/L 
16 d BOD 
24
 
302 “ C12H25  
56 
Not readily 
biodegradable 
Closed Bottle 
Test (TG 301 D) 
Waste-
water 
organisms 
100 
mg/L 
16 d BOD 
24
 
303 “ CH2C6H5  
22 
Not readily 
biodegradable 
Closed Bottle 
Test (TG 301 D) 
Waste-
water 
organisms 
100 
mg/L 
16 d BOD 
24
 
A-89 
 
 
304 
 
C4H9  
28 
Not readily 
biodegradable 
Closed Bottle 
Test (TG 301 D) 
Waste-
water 
organisms 
100 
mg/L 
16 d BOD 
24
 
305 “ C6H13  
33.5 
Not readily 
biodegradable 
Closed Bottle 
Test (TG 301 D) 
Waste-
water 
organisms 
100 
mg/L 
16 d BOD 
24
 
306 
 
C8H17  
42 
Not readily 
biodegradable 
Closed Bottle 
Test (TG 301 D) 
Waste-
water 
organisms 
100 
mg/L 
16 d BOD 
24
 
307 “ C10H21  
44 
Not readily 
biodegradable 
Closed Bottle 
Test (TG 301 D) 
Waste-
water 
organisms 
100 
mg/L 
16 d BOD 
24
 
A-90 
 
 
308 “ C12H25  
47 
Not readily 
biodegradable 
Closed Bottle 
Test (TG 301 D) 
Waste-
water 
organisms 
100 
mg/L 
16 d BOD 
24
 
309 “ CH2C6H5  
21.5 
Not readily 
biodegradable 
Closed Bottle 
Test (TG 301 D) 
Waste-
water 
organisms 
100 
mg/L 
16 d BOD 
24
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Appendix II 
 
Critical micelle concentration, tensiometry and 
HPLC curves for ILs examined in Chapter 4 
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Conductivity curves for linear alkyl pyridinium surfactants (432-434) 
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Conductivity curves for linear alkyl imidazolium surfactants (435-437) 
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Conductivity curves for linear alkyl cholinium surfactants (438-440) 
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Conductivity curves for bolaform pyridinium surfactants (444-446) 
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Conductivity curves for bolaform imidazolium surfactants (447-449) 
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Conductivity curves for bolaform cholinium surfactants (450-452) 
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Tensiometry curves for linear alkyl pyridinium surfactants (432-434) 
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Tensiometry curves for linear alkyl imidazolium surfactants (435-437) 
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Tensiometry curves for linear alkyl cholinium surfactants (438-440) 
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Tensiometry curves for bolaform pyridinium surfactants (444-446) 
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Tensiometry curves for bolaform imidazolium surfactants (447-449) 
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Tensiometry curves for bolaform cholinium surfactants (450-452) 
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HPLC/UV Traces for aqueous stability study for ILs (433, 436, 439). 
Conditions: pH 7, 50 °C 
 
 
IL (433), t = 0 h 
 
 
IL (433), t = 24 h 
 
 
B-15 
 
 
 
IL (433), t = 48 h 
 
 
 
IL (433), t = 72 h 
 
 
B-16 
 
 
 
IL (433), t = 96 h 
 
 
IL (433), t = 168 h 
 
 
 
 
 
B-17 
 
 
 
IL (436), t = 0 h 
 
 
IL (436), t = 24 h 
 
 
 
B-18 
 
 
 
IL (436), t = 48 h 
  
 
IL (436), t = 72 h 
 
 
 
B-19 
 
 
 
IL (436), t = 96 h 
 
 
 
IL (436), t = 168 h 
 
B-20 
 
 
 
IL (439), t = 0 h 
 
 
 
IL (439), t = 24 h 
 
 
 
 
B-21 
 
 
 
IL (439), t = 48 h 
 
 
IL (439), t = 72 h 
 
 
 
 
B-22 
 
 
 
IL (439), t = 96 h 
 
 
 
IL (439), t = 168 h 
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HPLC/UV Traces for aqueous stability study for ILs (433, 436, 439). 
Conditions: pH 2, 25 °C 
 
 
 
IL (433), t = 0 h
 
IL (433), t = 24 h 
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IL (433), t = 48 h 
 
 
IL (433), t = 72 h 
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IL (433), t = 96 h 
 
 
 
IL (433), t = 168 h 
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IL (436), t = 0 h 
 
 
 
IL (436), t = 24 h 
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IL (436), t = 48 h 
  
 
 
IL (436), t = 72 h 
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IL (436), t = 96 h 
 
 
IL (436), t = 168 h 
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IL (439), t = 0 h 
 
 
 
IL (439), t = 24 h 
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IL (439), t = 48 h 
 
 
IL (439), t = 72 h 
 
 
 
 
B-31 
 
 
 
IL (439), t = 96 h 
 
 
IL (439), t = 168 h 
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HPLC/UV Traces for aqueous stability study for ILs (433, 436, 439). 
Conditions: pH 10, 25 °C 
 
 
IL (433), t = 0 h 
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IL (433), t = 24 h 
 
IL (433), t = 48 h 
 
 
 
 
IL (433), t = 72 h 
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IL (433), t = 96 h 
 
 
IL (433), t = 168 h 
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IL (436), t = 0 h 
 
 
 
IL (436), t = 24 h 
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IL (436), t = 48 h 
 
 
 
IL (436), t = 72 h 
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IL (436), t = 96 h 
 
 
IL (436), t = 168 h 
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IL (439), t = 0 h 
 
 
 
IL (439), t = 24 h 
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IL (439), t = 48 h 
 
 
 
 
IL (439), t = 72 h 
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IL (439), t = 96 h 
 
 
 
IL (439), t = 168 h 
 
